<SEC-DOCUMENT>0001193125-21-017689.txt : 20210126
<SEC-HEADER>0001193125-21-017689.hdr.sgml : 20210126
<ACCEPTANCE-DATETIME>20210126160730
ACCESSION NUMBER:		0001193125-21-017689
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		7
FILED AS OF DATE:		20210126
DATE AS OF CHANGE:		20210126

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CATALYST BIOSCIENCES, INC.
		CENTRAL INDEX KEY:			0001124105
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				562020050
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-228970
		FILM NUMBER:		21554119

	BUSINESS ADDRESS:	
		STREET 1:		611 GATEWAY BLVD., SUITE 710
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		650-871-0761

	MAIL ADDRESS:	
		STREET 1:		611 GATEWAY BLVD., SUITE 710
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TARGACEPT INC
		DATE OF NAME CHANGE:	20000919
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>d260304d424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML><HEAD>
<TITLE>424B5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><FONT COLOR="#50748a"><B>Filed Pursuant to Rule 424(b)(5)<BR> Registration Numbers: 333-228970
</B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow"><FONT COLOR="#c6093b"><B>The information in this preliminary prospectus
supplement is not complete and may be changed. A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission. The preliminary prospectus supplement and the accompanying prospectus are not
an offer to sell these securities and we are not soliciting offers to buy these securities in any state or other jurisdiction where the offer or sale is not permitted. </B></FONT></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow" ALIGN="center"><FONT COLOR="#c6093b"><B>Subject to completion, dated January 26, 2021
</B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>PRELIMINARY PROSPECTUS SUPPLEMENT </B></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>(To Prospectus dated February&nbsp;14, 2019) </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>Shares </B></FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g260304g00a00.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>Common Stock </B></FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #50748a">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We are offering shares of
our common stock, par value $0.001 per share, in this offering. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Our common stock trades on the Nasdaq Capital Market under
the symbol &#147;CBIO.&#148; On January&nbsp;25, 2021, the last reported sale price of the common stock on the Nasdaq Capital Market was $6.83 per share. </FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:7.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #50748a;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>Investing
in our securities involves a high degree of risk. Before making an investment decision, please read the information under the heading &#147;<A HREF="#supptoc260304_4">Risk Factors</A>&#148; beginning on
<FONT STYLE="white-space:nowrap">page&nbsp;S-21</FONT> of this prospectus supplement and in the documents incorporated by reference into this prospectus supplement and the accompanying prospectus. </B></FONT></P>
<P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13" STYLE="BORDER-TOP:5.00pt solid #50748a">&nbsp;</TD>
<TD HEIGHT="13" COLSPAN="4" STYLE="BORDER-TOP:5.00pt solid #50748a">&nbsp;</TD>
<TD HEIGHT="13" COLSPAN="4" STYLE="BORDER-TOP:5.00pt solid #50748a">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#50748a"><B>Per&nbsp;Share</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#50748a"><B>Total</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Public offering price</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Underwriting discounts and commissions(1)</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:5.00pt solid #50748a"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Proceeds, before expenses, to
us</FONT></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:5.00pt solid #50748a">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:5.00pt solid #50748a"><FONT COLOR="#50748a">$</FONT> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:5.00pt solid #50748a" ALIGN="right"><FONT COLOR="#50748a">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:5.00pt solid #50748a"><FONT COLOR="#50748a">&nbsp;</FONT> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:5.00pt solid #50748a">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:5.00pt solid #50748a"><FONT COLOR="#50748a">$</FONT> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:5.00pt solid #50748a" ALIGN="right"><FONT COLOR="#50748a">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:5.00pt solid #50748a"><FONT COLOR="#50748a">&nbsp;</FONT> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">(1) See &#147;Underwriting&#148; beginning on page&nbsp;S-59 of this prospectus supplement for a
description of the compensation payable to the underwriters, including reimbursement of certain expenses. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We have granted
the underwriters an option for a period of 30&nbsp;days from the date of this prospectus supplement to purchase up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional shares of our common
stock at the public offering price less underwriting discounts and commissions. If the underwriters exercise the option in full, the total underwriting discounts and commissions payable by us will be
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and the total proceeds to us, before expenses, will be
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. See &#147;Underwriting&#148; for more information. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or
determined if this prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense. </B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#50748a"><I>The underwriters expect to deliver the shares of common stock against payment on or about &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021. </I></FONT></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><FONT COLOR="#50748a"><I>Sole&nbsp;Lead&nbsp;Active&nbsp;Bookrunner</I></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT COLOR="#50748a"><I>Bookrunner</I></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:18pt">
<TD VALIGN="top" ALIGN="center"><FONT COLOR="#50748a"><B>Piper&nbsp;Sandler</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT COLOR="#50748a"><B>Raymond&nbsp;James</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a"><B>The date of this prospectus supplement is , 2021 </B></FONT></P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></FONT></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #50748a"><FONT COLOR="#50748a"><B>Page</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Prospectus Supplement</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><A HREF="#supptoc260304_1">About This Prospectus
Supplement</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a"><FONT STYLE="white-space:nowrap">S-1</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><A HREF="#supptoc260304_2">Prospectus Supplement Summary</A></FONT></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a"><FONT STYLE="white-space:nowrap">S-2</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><A HREF="#supptoc260304_3">The Offering</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a"><FONT STYLE="white-space:nowrap">S-19</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><A HREF="#supptoc260304_4">Risk Factors</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a"><FONT STYLE="white-space:nowrap">S-21</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><A HREF="#supptoc260304_5">Cautionary Note Regarding Forward Looking Information
</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a"><FONT STYLE="white-space:nowrap">S-57</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><A HREF="#supptoc260304_6">Use of Proceeds</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a"><FONT STYLE="white-space:nowrap">S-57</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><A HREF="#supptoc260304_7">Dividend Policy</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a"><FONT STYLE="white-space:nowrap">S-58</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><A HREF="#supptoc260304_8">Dilution</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a"><FONT STYLE="white-space:nowrap">S-58</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><A HREF="#supptoc260304_9">Underwriting</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a"><FONT STYLE="white-space:nowrap">S-59</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><A HREF="#supptoc260304_10">Legal Matters</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a"><FONT STYLE="white-space:nowrap">S-65</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><A HREF="#supptoc260304_11">Experts</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a"><FONT STYLE="white-space:nowrap">S-65</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><A HREF="#supptoc260304_12">Where You Can Find More
Information</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a"><FONT STYLE="white-space:nowrap">S-65</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><A HREF="#supptoc260304_13">Incorporation of Certain Information By Reference
</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a"><FONT STYLE="white-space:nowrap">S-65</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Prospectus</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><A HREF="#toc260304_1">About This Prospectus</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><A HREF="#toc260304_2">Our Company</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><A HREF="#toc260304_3">Cautionary Note Regarding Forward-Looking
Information</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><A HREF="#toc260304_4">Risk Factors</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><A HREF="#toc260304_5">Use of Proceeds</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><A HREF="#toc260304_6">Description of Capital Stock</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><A HREF="#toc260304_7">Additional Information Concerning Our Capital
Stock</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">11</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><A HREF="#toc260304_8">Description of Debt Securities</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">14</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><A HREF="#toc260304_9">Description of Warrants</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">21</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><A HREF="#toc260304_10">Description of Units</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">23</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><A HREF="#toc260304_11">Plan of Distribution</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">25</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><A HREF="#toc260304_12">Legal Matters</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">27</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><A HREF="#toc260304_13">Experts</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">27</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><A HREF="#toc260304_14">Where You Can Find More
Information</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">28</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">-i-
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a"><B><A NAME="supptoc260304_1"></A>ABOUT THIS PROSPECTUS SUPPLEMENT
</B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">This document is in two parts. The first part is the prospectus supplement, including the documents incorporated by
reference herein, which describes the specific terms of this offering and also adds to and updates the information contained in the accompanying prospectus and the documents incorporated by reference therein. The second part, the accompanying
prospectus, including the documents incorporated by reference therein, provides more general information, some of which may not apply to this offering. Generally, when we refer to this prospectus, we are referring to both parts of this document
combined. Before you invest, you should carefully read this prospectus supplement, the accompanying prospectus and the information incorporated by reference herein and therein, as well as the additional information described in this prospectus
supplement under &#147;Where You Can Find More Information&#148; and &#147;Incorporation of Certain Information By Reference.&#148; This prospectus supplement may add, update or change information contained in the accompanying prospectus. To the
extent that any statement we make in this prospectus supplement is inconsistent with statements made in the accompanying prospectus or any documents incorporated by reference therein, the statements made in this prospectus supplement will be deemed
to modify or supersede those made in the accompanying prospectus and such documents incorporated by reference therein. However, if any statement in one of these documents is inconsistent with a statement in another document with a later date that is
incorporated by reference herein, the statement in the document having the later date modifies and supersedes the earlier statement. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#50748a">Neither we nor the underwriters have authorized anyone to provide you with any information or to make any representation, other than those contained or incorporated by reference in this prospectus supplement and the accompanying
prospectus, which together we sometimes refer to generally as the prospectus, or in any free writing prospectus prepared by us or on our behalf or to which we have referred you. Neither we nor the underwriters take any responsibility for, and
provide no assurance as to the reliability of, any other information that others may give you. You should assume that the information appearing in this prospectus supplement, the accompanying prospectus, the documents incorporated by reference in
this prospectus supplement and the accompanying prospectus, and any free writing prospectus is accurate only as of the date of those respective documents. Our business, financial condition, results of operations and prospects may have changed since
those dates. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We are offering to sell, and seeking offers to buy, shares of our common stock only in jurisdictions where
offers and sales are permitted. The distribution of this prospectus supplement and the offering of the common stock in certain jurisdictions may be restricted by law. Persons outside the United States who come into possession of this prospectus
supplement must inform themselves about, and observe any restrictions relating to, the offering of the common stock and the distribution of this prospectus supplement outside the United States. This prospectus supplement does not constitute, and may
not be used in connection with, an offer to sell, or a solicitation of an offer to buy, any securities offered by this prospectus supplement by any person in any jurisdiction in which it is unlawful for such person to make such an offer or
solicitation. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Unless the context indicates otherwise, as used in this prospectus supplement and the accompanying prospectus,
the terms &#147;Company,&#148; &#147;Catalyst,&#148; &#147;we,&#148; &#147;us&#148; and &#147;our&#148; refer to Catalyst Biosciences, Inc., a Delaware corporation, and its subsidiary, taken as a whole, unless otherwise noted. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">This prospectus supplement, the accompanying prospectus and the information incorporated herein and therein by reference includes
trademarks, service marks and trade names owned by us or other companies. All trademarks, service marks and trade names included or incorporated by reference into this prospectus supplement or the accompanying prospectus are the property of their
respective owners. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-1
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #50748a;BORDER-LEFT:1px solid #50748a;BORDER-RIGHT:1px solid #50748a;BORDER-TOP:1px solid #50748a;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a"><B><A NAME="supptoc260304_2"></A>PROSPECTUS SUPPLEMENT SUMMARY
</B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>Company Overview </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We are a research and clinical development biopharmaceutical company focused on addressing unmet medical needs in disorders of the
complement and coagulation systems. Proteases are the natural regulators of these biological systems. We engineer proteases to create both improved or novel molecules to improve treatment of diseases that result from dysregulation of the complement
and coagulation cascades. Our protease engineering platform has generated two late-stage clinical programs including marzeptacog alfa (activated) (&#147;MarzAA&#148;), a subcutaneously (&#147;SQ&#148;) administered next-generation engineered
coagulation Factor VIIa (&#147;FVIIa&#148;) for the treatment of episodic bleeding in subjects with rare bleeding disorders. Our complement pipeline includes a preclinical program partnered with Biogen International GmbH (&#147;Biogen&#148;) for dry
<FONT STYLE="white-space:nowrap">age-related</FONT> macular degeneration (&#147;AMD&#148;), an improved complement factor I protease for SQ prophylaxis in patients with complement factor I (&#147;CFI&#148;) deficiency and <FONT
STYLE="white-space:nowrap">C4b-degraders</FONT> designed to target disorders of the classical complement pathway as well as other complement programs in development. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">The product candidates generated by our protease engineering platform have improved functional properties such as longer half-life,
improved specificity, higher potency and increased bioavailability. These characteristics allow for the potential for improved efficacy, SQ administration of recombinant coagulation factors and complement inhibitors, or less frequently dosed
intravitreal therapeutics. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Our most advanced product candidate is MarzAA, a next-generation SQ FVIIa that is entering a
registrational Phase 3 trial <FONT STYLE="white-space:nowrap">(MAA-304)</FONT> in patients with Hemophilia A or B with inhibitors. We also plan to initiate a Phase 1/2 trial of MarzAA in Factor VII Deficiency, Glanzmann Thrombasthenia, and
Hemophilia A with inhibitor patients on prophylaxis Hemlibra for treatment of episodic bleeding <FONT STYLE="white-space:nowrap">(MAA-202).</FONT> </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Our complement portfolio is led by the development candidates CB 4332 and CB <FONT STYLE="white-space:nowrap">2782-PEG.</FONT> CB 4332
is a wholly-owned <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> improved CFI intended for lifelong prophylactic SQ administration in individuals with CFI deficiency. CB
<FONT STYLE="white-space:nowrap">2782-PEG</FONT> is a potential <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> C3 degrader product candidate in preclinical development for the treatment of dry AMD that
we have licensed to Biogen. We have several engineered protease programs in discovery or early <FONT STYLE="white-space:nowrap">non-clinical</FONT> development. These programs all target diseases caused by deficient regulation of the complement
system. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Our next most advanced hemophilia product candidate is dalcinonacog alfa (&#147;DalcA&#148;), a next-generation SQ
FIX, which has shown efficacy and safety in a Phase 2b clinical trial in individuals with Hemophilia B. We have a discovery stage Factor IX gene therapy construct, CB <FONT STYLE="white-space:nowrap">2679d-GT</FONT> for Hemophilia B, that has
demonstrated superiority compared with the Padua FIX variant in preclinical models. </FONT></P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-2
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #50748a;BORDER-LEFT:1px solid #50748a;BORDER-RIGHT:1px solid #50748a;BORDER-TOP:1px solid #50748a;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">The following table summarizes our current development programs. </FONT></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g260304g29d49.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Both MarzAA and DalcA have received orphan drug designation in the U.S. and in the European Union
(&#147;E.U.&#148;); MarzAA, for routine prophylaxis to prevent bleeding episodes in individuals with Hemophilia A and B with inhibitors, and DalcA, for routine prophylaxis to prevent bleeding episodes for Hemophilia B patients. In addition, the U.S.
Food and Drug Administration (the &#147;FDA&#148;) has granted Fast Track designation for MarzAA for the treatment of episodic bleeding in patients with Hemophilia A or Hemophilia B with inhibitors. We control worldwide development, manufacturing
and commercialization rights of both MarzAA and DalcA, except for the commercialization rights of DalcA in South Korea. We estimate the global market opportunity for MarzAA and DalcA to be approximately $4.0 billion: $2.2&nbsp;billion for the Factor
VIIa market and $1.8&nbsp;billion for the Factor IX (&#147;FIX&#148;) market. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">In the CB 4332, enhanced CFI program, we
intend to commence enrollment of an observational trial in <FONT STYLE="white-space:nowrap">mid-2021</FONT> to measure CFI activity and genotype patients who have diseases related to CFI deficiency in order to identify those who would benefit from
CB 4332 treatment. This will prepare us for a P1/2 clinical study of CB 4332 in 2022. CB 4332 is designed to restore the normal complement system in patients with dysregulated or aberrant CFI. There are currently no approved options for protein
replacement therapy in CFI deficiency, nor are there any in clinical development. We estimate that the market for CB 4332 in patients with atypical hemolytic uremic syndrome (&#147;aHUS&#148;), complement 3 glomerulopathy (&#147;C3G&#148;) and
immune complex mediated membranoproliferative glomerulonephritis <FONT STYLE="white-space:nowrap">(&#147;IC-MPGN&#148;)</FONT> is approximately $500&nbsp;million, with additional potential opportunities for patients who are CFI deficient with
indications outside of nephrology, such as to prevent severe infections and recurrent inflammatory histopathologies. The size of the market for these potential opportunities is estimated to be approximately $12.0&nbsp;billion by 2026. This patient
population is likely significantly underdiagnosed and appears to be growing as more awareness about the clinical manifestation of complete CFI deficiency emerge. There are a number of dry AMD patients who have genetic abnormalities in their CFI gene
that may be an important driver of their disease. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Additionally, we are currently developing a portfolio of next generation
specific complement degraders based on CB 4332 and designed to target disorders of the classical or alternative pathways. </FONT></P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-3
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #50748a;BORDER-LEFT:1px solid #50748a;BORDER-RIGHT:1px solid #50748a;BORDER-TOP:1px solid #50748a;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">There are currently no approved drugs for treating dry AMD. Dry AMD is estimated to
have a $5.0&nbsp;billion market opportunity which could grow to over $18.0&nbsp;billion by 2028 with no approved drugs on the market. We entered into an exclusive worldwide license and collaboration agreement with Biogen in late 2019 for the
development and commercialization of CB <FONT STYLE="white-space:nowrap">2782-PEG.</FONT> We received a $15.0&nbsp;million upfront payment from Biogen in January 2020 and are eligible to receive up to $340.0&nbsp;million in milestone payments and
tiered royalties for worldwide net sales of this product candidate up to low double-digits. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We are experiencing operational
and other challenges as a result of the novel coronavirus disease <FONT STYLE="white-space:nowrap">(&#147;COVID-19&#148;)</FONT> global pandemic, which have delayed our enrollment in <FONT STYLE="white-space:nowrap">MAA-304</FONT> and <FONT
STYLE="white-space:nowrap">MAA-202,</FONT> and which may delay or halt our development in our programs. See the section entitled &#147;Risk Factors&#148; for further discussion of the current and expected impact on our business and development
programs. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>Hemostasis </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><I>Background on Hemophilia.</I>&nbsp;&nbsp;&nbsp;&nbsp;Hemophilia is a rare and serious bleeding disorder that results from a genetic or
an acquired deficiency of a factor required for normal blood coagulation. There are two major types of hemophilia: Hemophilia A and Hemophilia B, caused by abnormalities in coagulation Factor VIII or Factor IX, respectively. Deficiencies in these
factors reduce the ability of the affected individuals to form clots and stop bleeding. The disease is X chromosome-linked, meaning that most people who inherit the disorder and suffer from bleeding are male; however, female carriers of mutations in
Factor VIII or Factor IX can also have reduced coagulation factor levels and resultant bleeding. Hemophilia A occurs in approximately 1 in 5,000 male births, and Hemophilia B in approximately 1 in 20,000 male births. The estimated number of patients
with hemophilia worldwide is 1.1&nbsp;million, of whom 418,000 are estimated to have severe hemophilia. The prevalence of severe Hemophilia A and Hemophilia B in the United States is approximately 20,000 patients. Patients with hemophilia suffer
from spontaneous and traumatic bleeding episodes that can become limb- or life-threatening. In cases of severe hemophilia, spontaneous bleeding into muscles or joints is frequent and often results in disabling irreversible joint damage. Currently
there is no cure for hemophilia. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><I>Hemophilia Management and Opportunities for a New Paradigm with SQ
Therapy.</I>&nbsp;&nbsp;&nbsp;&nbsp;Current hemophilia treatments involve <FONT STYLE="white-space:nowrap">on-demand</FONT> management of acute bleeding episodes or prophylactic treatment using factor replacement or bypassing therapy. Replacement
therapy involves frequent IV administration of the missing factors to prevent or stop bleeding. IV infusion is invasive, painful, time consuming and particularly challenging to administer to children. Often times, patients must seek assistance of a
health professional for the IV infusion. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Another significant challenge in managing patients with hemophilia is the risk for
development of inhibitors, which are neutralizing anti-drug-antibodies (&#147;nAbs&#148;) that reduce the efficacy of the factor replacement. This occurs in approximately 30% of Hemophilia A and <FONT STYLE="white-space:nowrap">5-10%</FONT> of
Hemophilia B patients. Inhibitor patients must be treated with bypassing agents to achieve coagulation in the absence of effective factor levels. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#50748a">Currently, two types of IV bypassing treatments exist: recombinant activated coagulation factor VII (rFVIIa: NovoSeven RT and SEVENFACT) and activated prothrombin complex concentrates (<I>e.g</I>., FEIBA). rFVIIa is currently the
leading bypassing agent for <FONT STYLE="white-space:nowrap">on-demand</FONT> treatment in inhibitor complicated hemophilia. rFVIIa has proven effective in multiple rare bleeding disorders, including Hemophilia A or B with inhibitors, Severe Factor
VII Deficiency, Glanzmann Thrombasthenia, and Acquired Hemophilia A. NovoSeven RT sales for 2019 were $1.2&nbsp;billion. FEIBA is also administered for acute bleeding but its effect is reduced by the need for frequent dosing and the risk of
anaphylaxis and renal side effects in Hemophilia B with inhibitor patients. All of these bypassing agents are administered intravenously, making them cumbersome to administer and have relatively short half-lives, often requiring multiple infusions
to treat a bleed. Although FEIBA is approved for prophylaxis, it must be administered by IV infusion every other day and the rFVIIa products are generally not used for routine prophylaxis. </FONT></P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-4
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #50748a;BORDER-LEFT:1px solid #50748a;BORDER-RIGHT:1px solid #50748a;BORDER-TOP:1px solid #50748a;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We believe SQ dosing is the future in hemophilia and other rare benign hematology
indications. Our nonclinical and clinical studies have shown that MarzAA is nine-fold more potent than NovoSeven RT and that DalcA is <FONT STYLE="white-space:nowrap">22-fold</FONT> more potent than BeneFIX. The enhanced potency of MarzAA and DalcA
allows for SQ dosing using a small volume, which we believe will provide the potential for more effective, durable and convenient treatments of spontaneous bleeds with MarzAA and prophylactic protection with MarzAA and DalcA, especially for children
and adults with difficult IV access. In late 2018 Hemlibra<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, a bispecific antibody mimicking FVIIIa, was approved for SQ prophylaxis in Hemophilia A with or without inhibitors but cannot treat
breakthrough bleeding. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B><I>MarzAA Clinical Development.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;We are initiating a registrational
Phase 3 trial <FONT STYLE="white-space:nowrap">(MAA-304)</FONT> for our most advanced product candidate, MarzAA, a potent, subcutaneously administered, next-generation Factor VIIa variant. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">The development program began with a Phase 1 clinical trial evaluating the pharmacokinetics and pharmacodynamics of MarzAA administered
IV in patients with severe Hemophilia A and B with and without inhibitors. In this study, we demonstrated that single IV administration of doses of MarzAA ranging from 0.5 &micro;g/kg/day to 30 &micro;g/kg/day were safe and well tolerated. Moreover,
there was a dose dependent increase in MarzAA antigen and activity levels with normalization of coagulation parameters at the higher dose levels. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#50748a">In 2019, we successfully completed a Phase 2 open-label SQ prophylaxis trial that met all primary and secondary end points. The Phase 2 trial was designed to evaluate the efficacy of MarzAA in preventing bleeding episodes. The
primary endpoint assessed the effect of MarzAA on the annualized bleed rate (&#147;ABR&#148;) at a subject&#146;s final dose level, with each patient&#146;s prior <FONT STYLE="white-space:nowrap">6-month</FONT> ABR serving as his own control. The
secondary endpoints included safety, tolerability and lack of anti-drug-antibody or neutralizing antibody formation. Daily SQ administration for 50 days at an individual&#146;s final dose of MarzAA significantly reduced the mean <FONT
STYLE="white-space:nowrap">6-month</FONT> <FONT STYLE="white-space:nowrap">pre-study</FONT> ABR from 19.8 to 1.6 during treatment (p&lt;0.01). Additionally, the Proportion of Days with Bleeding (&#147;PDB&#148;), was significantly reduced from a <FONT
STYLE="white-space:nowrap">6-month</FONT> <FONT STYLE="white-space:nowrap">pre-treatment</FONT> mean of 12.3% to 0.8% during treatment (p&lt;0.01). The median ABR and PDB were both reduced to zero during treatment, with seven of nine subjects
experiencing no bleeds, either traumatic or spontaneous, at their final dose level. Subcutaneous treatment with MarzAA demonstrated an acceptable safety profile and was well tolerated. No anti-drug antibodies or inhibitors to MarzAA or thrombotic
events were detected after administration of a total of 517 SQ doses. Subcutaneous administration prolonged the half-life of MarzAA to 16.6 hours so that trough levels of MarzAA before the next SQ dose are projected to be sufficient to provide bleed
prevention. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We completed a Phase 1/2 PK/PD study <FONT STYLE="white-space:nowrap">(MAA-102)</FONT> in 2020, to evaluate the
pharmacokinetics and pharmacodynamics of ascending single dose levels of MarzAA and twice and thrice dosing of 60 &micro;g/kg at <FONT STYLE="white-space:nowrap">3-hourly</FONT> intervals in individuals with Hemophilia A or B with or without
inhibitors. The purpose of the trial was to determine if the timing and peak levels achieved were sufficient to treat episodic or breakthrough bleeding with SQ dosing and determine if increasing dose levels resulted in dose proportional
pharmacokinetics. This trial, together with population pharmacokinetic simulations and preclinical studies of spontaneous joint bleeding, confirm that we have optimized dosing for the registrational Phase 3 trial
<FONT STYLE="white-space:nowrap">(MAA-304).</FONT> We reported final data from the trial at the International Society on Thrombosis and Haemostasis in July 2020, which demonstrated that MarzAA reaches target levels estimated to effectively treat
episodic and breakthrough bleeds. In addition to prophylaxis efficacy in patients, multiple preclinical studies suggest that MarzAA has the potential to be used for treatment of episodic bleeding and supports further clinical testing to assess
effectiveness to achieve hemostasis in the treatment of bleeding events in individuals with hemophilia with inhibitors or for other conditions. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#50748a">Across all clinical studies we have treated a total of 46 subjects ranging from single IV to <FONT STYLE="white-space:nowrap">44-97</FONT> days of daily SQ with no MarzAA anti-drug antibodies (ADAs) detected and an ISR rate of
&lt;1%. </FONT></P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-5
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #50748a;BORDER-LEFT:1px solid #50748a;BORDER-RIGHT:1px solid #50748a;BORDER-TOP:1px solid #50748a;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">In December 2020, we announced that the FDA had granted Fast Track designation for
MarzAA. The Fast Track program is designed to facilitate and expedite the development and review of drug candidates that have demonstrated the potential to address an unmet medical need in treating serious diseases or conditions. A drug candidate
with Fast Track designation is eligible for greater access to the FDA as well as a priority review and rolling review of the marketing application. We believe the FDA Fast Track designation validates MarzAA&#146;s potential to improve patient care.
As the only SQ delivered therapy in development for <FONT STYLE="white-space:nowrap">on-demand</FONT> treatment of bleeding events, MarzAA is uniquely positioned to become an important addition to the treatment landscape. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">The Phase 3 registration trial &#150; <FONT STYLE="white-space:nowrap">MAA-304</FONT> &#150; is an open-label, global, multi-center,
randomized, cross-over study, designed to evaluate the safety and efficacy of MarzAA for <FONT STYLE="white-space:nowrap">on-demand</FONT> treatment of spontaneous or traumatic bleeding episodes, in adolescents and adults with congenital Hemophilia
A or B with inhibitors, compared with Standard of Care, either IV rFVIIa or IV FEIBA. The study will enroll approximately 60 subjects to treat 244 eligible bleeding episodes with each treatment. The primary endpoint is hemostatic efficacy using a
standard <FONT STYLE="white-space:nowrap">4-point</FONT> assessment scale at the <FONT STYLE="white-space:nowrap">24-hour</FONT> timepoint. The study will assess the effectiveness of SQ MarzAA, using up to three doses to treat a bleeding episode,
compared with the Standard of Care. We plan to submit our first report to the Data and Safety Monitoring Board (&#147;DSMB&#148;) in 2021 and our final DSMB report in the first half of 2022. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We also plan to initiate a Phase 1/2 trial <FONT STYLE="white-space:nowrap">(MAA-202)</FONT> of MarzAA for treatment of bleeding in
Factor VII Deficiency, Glanzmann Thrombasthenia, and in individuals with Hemophilia A with inhibitors treated with Hemlibra in 2021 and to report interim PK data mid-year. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a"><B>Anticipated Milestones for our product candidates are listed below: </B></FONT></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g260304g10g27.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><I>Interplay of <FONT STYLE="white-space:nowrap">On-demand</FONT> Treatment of Bleed and Prophylaxis
for Hemophilia Management.</I>&nbsp;&nbsp;&nbsp;&nbsp;Our preclinical data has shown that SQ injections of MarzAA given one minute after injury, to mirror <FONT STYLE="white-space:nowrap">on-demand</FONT> therapy, significantly reduced bleeding in
animal models of Hemophilia A. In mice, reduction of bleeding after SQ administration of MarzAA was as efficient as NovoSeven RT administered IV. Moreover, bleeding was reduced in a dose-dependent manner when MarzAA was given 15 minutes prior to the
injury. Moreover, SQ MarzAA was efficacious as a stand-alone therapy for treating spontaneous bleeding in rats and dogs with congenital Hemophilia A. Rats and dogs with hemophilia A present with spontaneous unprovoked bleeding as is seen in humans
with hemophilia. These findings suggest that MarzAA has the potential to be used <FONT STYLE="white-space:nowrap">on-demand</FONT> by SQ administration for treatment of acute bleeding episodes and supports further clinical testing for <FONT
STYLE="white-space:nowrap">on-demand</FONT> treatment of bleeds in individuals with hemophilia or Factor VII deficiency or other rare bleeding disorders. </FONT></P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-6
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #50748a;BORDER-LEFT:1px solid #50748a;BORDER-RIGHT:1px solid #50748a;BORDER-TOP:1px solid #50748a;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Patients on prophylaxis with Hemlibra or other Factor replacement therapy may
experience breakthrough bleeds &#150; bleeding despite preventive treatment &#150; or require additional treatments for certain procedures or surgery. Our preclinical data showed that MarzAA is expected to have a similar safety profile as NovoSeven
when used in combination with Hemlibra. Specifically, when tested <I>in vit</I>ro by the thrombin-generation assay with Hemophilia A plasma, both MarzAA and NovoSeven were equally effective at triggering blood coagulation at their respective
clinically relevant concentrations without overshooting safe levels when combined with Hemlibra. Current therapies used with Hemlibra include FEIBA (a <FONT STYLE="white-space:nowrap">pro-coagulation</FONT> complex) and NovoSeven. However, the
concurrent administration of FEIBA with Hemlibra is associated with increased risk of thrombotic events (when a blood clot forms inside a blood vessel), requiring a boxed warning in the package insert. While NovoSeven is safe in patients on Hemlibra
prophylaxis, it is administered by an IV infusion to treat a bleeding event. Ideally, <FONT STYLE="white-space:nowrap">add-on</FONT> therapy for patients on SQ Hemlibra should be given subcutaneously. We believe MarzAA provides a potential SQ
solution to this problem as a SQ rescue therapy for hemophilia patients experiencing breakthrough bleeds while on prophylaxis with SQ agents such as Hemlibra. </FONT></P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-7
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #50748a;BORDER-LEFT:1px solid #50748a;BORDER-RIGHT:1px solid #50748a;BORDER-TOP:1px solid #50748a;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B><I>Complement.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;The complement system is a complex <FONT
STYLE="white-space:nowrap">enzyme-based</FONT> defense system depicted in the figure below, developed to protect the body from pathogens, such as viruses and bacteria. Similar to the coagulation system, the complement system employs a triggering
mechanism followed by a cascading system of enzymatic proteins (proteases) that, when functioning properly, ultimately leads to the destruction and removal of the pathogen. </FONT></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g260304g96y01.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">*</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left"><FONT COLOR="#50748a">Figure adapted from Mastellos <I>et</I> <I>al</I>., Clinical promise of next-generation
complement therapeutics. Nature Reviews. 2019 </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><I>Complement system
disorders.</I>&nbsp;&nbsp;&nbsp;&nbsp;Deficient or excessive activation of the complement system may lead to severe disorders, including micro thrombotic, autoimmune, and severe infectious diseases. Complement system disorders can be caused either
by defects in the complement system that prevent an appropriate response to </FONT></P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-8
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #50748a;BORDER-LEFT:1px solid #50748a;BORDER-RIGHT:1px solid #50748a;BORDER-TOP:1px solid #50748a;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">
threats, or by the lack of complement inhibitor activity, which can cause the complement system to become hyperactive and become self-destructive. Either imbalance can have severe or even fatal
consequences in affected individuals. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><I>Complement Factor I Deficiency and CB 4332.</I>&nbsp;&nbsp;&nbsp;&nbsp;CB 4332 is
an engineered version of the CFI protease with an extended half-life that was designed for SQ use in patients with CFI deficiency. Even partial CFI deficiency can lead to several diseases: </FONT></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="21%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="76%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #50748a; BORDER-TOP:1px solid #50748a; BORDER-BOTTOM:1px solid #50748a; padding-left:8pt"><FONT COLOR="#50748a"><I>Atypical Hemolytic<BR>Uremic Syndrome<BR>(&#147;aHUS&#148;)</I></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #50748a; BORDER-BOTTOM:1px solid #50748a">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #50748a; BORDER-RIGHT:1px solid #50748a; BORDER-BOTTOM:1px solid #50748a; padding-right:2pt"><FONT COLOR="#50748a">aHUS is a severe and life-threatening, ultra-rare disease characterized by chronic
uncontrolled complement activation and the formation of blood clots in small blood vessels throughout the body, causing a reduction in platelet count (thrombocytopenia) and life-threatening damage to the kidney, brain, heart and other vital organs.
In aHUS, clots in small vessels are common, and the disease is diagnosed based on a combination of hemolytic anemia, thrombocytopenia, and kidney impairment followed by testing for complement protein levels and/or aberrant genes. Disease
manifestation can occur at any age and is often caused by a combination of environmental and genetic factors. Not all aHUS patients are CFI deficient, however, and a definitive diagnosis of CFI deficiency requires measurement of CFI antigen and/or
activity eventually supplemented by genetic testing.</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #50748a; BORDER-BOTTOM:1px solid #50748a; padding-left:8pt"><FONT COLOR="#50748a"><I>C3 Glomerulonephritis<BR>(&#147;C3G&#148;) and<BR>Immune Complex<BR>Membranoproliferative<BR>Glomerulonephritis<BR><FONT
STYLE="white-space:nowrap">(&#147;IC-MPGN&#148;)</FONT></I></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #50748a">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #50748a; BORDER-BOTTOM:1px solid #50748a; padding-right:2pt"><FONT COLOR="#50748a">Glomerulonephritis is a group of diseases that affects the kidneys. Symptoms of glomerulonephritis are related to a
loss of normal kidney function, which includes vital functions such as removing wastes from the body, balancing body fluids, regulating blood pressure, and making the hormones that help make blood platelets and red blood cells. Signs can include
blood and excess protein in the urine, edema, gout, infections, high blood pressure, fatigue and reduced alertness, lack of appetite, nausea and vomiting, difficulty sleeping, dry and itchy skin and muscle cramps.</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #50748a; BORDER-BOTTOM:1px solid #50748a; padding-left:8pt"><FONT COLOR="#50748a"><I>Complete CFI<BR>Deficiency (&#147;CFID&#148;)</I></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #50748a">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #50748a; BORDER-BOTTOM:1px solid #50748a; padding-right:2pt"><FONT COLOR="#50748a">CFID may present with a variety of disease manifestations, such as recurrent invasive infections with encapsulated
bacteria, but patients are also at risk for developing noninfectious diseases such as chronic inflammation of the blood vessels of the brain and/or spinal cord. Clinical presentations include invasive bacterial infections, peritonitis, meningitis,
cutaneous IgA vasculitis and bacteremia. The heterogenous clinical presentation likely makes the disease significantly underdiagnosed and patients may experience life threatening emergencies that may have severe long-term impact on the quality of
life. No real prophylaxis exists and patients often receive lifelong antibiotic treatment, which may cause a range of additional problems.</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Currently, there are no therapeutic options approved to specifically replace the deficient CFI protein
with a well-functioning CFI to treat these disorders. While not specifically targeting CFI deficiency, eculizumab and ravulizumab are indicated for use in aHUS. Neither eculizumab nor ravulizumab address the root cause of the CFI deficiency;
instead, they are designed to prevent the downstream effects of uncontrolled complement activity. Patients with aberrant CFI may therefore still have uncontrolled complement activation downstream of CFI. This may cause deposition of complement
proteins, for example, on red blood cells, and some CFI patients may have a worse prognosis than others even when on <FONT STYLE="white-space:nowrap">non-replacement</FONT> therapy. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">CB 4332 is designed to address this unmet need by providing a therapeutic option that corrects the root problem of these diseases by
simple, fast and easy SQ administration. The total US and EU5 market potential in kidney </FONT></P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-9
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #50748a;BORDER-LEFT:1px solid #50748a;BORDER-RIGHT:1px solid #50748a;BORDER-TOP:1px solid #50748a;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">
disease caused by CFI deficiency such as aHUS, C3G, and <FONT STYLE="white-space:nowrap">IC-MPGN</FONT> is estimated to be around $500M with a potential to grow as genetic diagnostics gain more
widespread use. Similarly, diagnosis of complete CFI deficiency can be expected to grow in the future. The size of the market for these potential opportunities is estimated to be approximately $10.0&nbsp;billion. This would represent a further
upside to the market estimate as CFI deficiency may be significantly underdiagnosed at present. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><I>Diseases of the Classical
Complement Pathway.</I>&nbsp;&nbsp;&nbsp;&nbsp;In healthy individuals, the classical complement pathway is triggered by antibody-pathogen interactions. Specifically, antibodies bind to pathogens and mark them as targets for destruction by the
complement system. This lets the complement system know that an unwanted pathogen is present and needs to be destroyed and cleared. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#50748a">In disease, however, the antibody mediated targeting affects an individual&#146;s own cells and the classical complement system triggers an uncontrolled self-destructive process, which can have dire consequences. This response
involves complement proteins C1, C2, and C4, and modulating these factors could potentially treat disorders of the classical complement pathway in a way that leaves the alternative and lectin as well as common pathways intact to carry out their
normal physiological functions. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Examples of disorders related to the classical complement pathway for which limited
treatment options are available include the following: </FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #50748a; BORDER-TOP:1px solid #50748a; BORDER-BOTTOM:1px solid #50748a; padding-left:8pt"><FONT COLOR="#50748a"><I>Warm<BR>Autoimmune<BR>Hemolytic<BR>Anemia<BR>(&#147;wAIHA&#148;)</I></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #50748a; BORDER-BOTTOM:1px solid #50748a">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #50748a; BORDER-RIGHT:1px solid #50748a; BORDER-BOTTOM:1px solid #50748a; padding-right:2pt"><FONT COLOR="#50748a">wAIHA is a hemolytic anemia where destruction of red blood cells &#147;tagged&#148; by
antibodies may cause fatigue, shortness of breath, dizziness chest pain, decreased alertness, confusion, transient loss of consciousness and deregulation of heart rate and blood pressure. wAIHA is also associated with an increased risk of blood
clots. Even after treatment, approximately 70% are at risk of developing recurrent episodes of hemolysis. The majority of people with wAIHA survive, although mortality rates of about 5% have been reported. Children may develop wAIHA, but it is more
common among adults.</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #50748a; BORDER-BOTTOM:1px solid #50748a; padding-left:8pt"><FONT COLOR="#50748a"><I>Cold Agglutinin<BR>Disease (&#147;CAD&#148;)</I></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #50748a">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #50748a; BORDER-BOTTOM:1px solid #50748a; padding-right:2pt"><FONT COLOR="#50748a">Similar to wAIHA, CAD is a hemolytic anemia with similar symptoms. CAD is, however, triggered by cold temperatures. In
addition to symptoms mentioned above, patients with CAD may have cold and/or discolored feet or hands. CAD can also cause potentially fatal thrombotic events. Current treatments include blood transfusions, steroids or
<FONT STYLE="white-space:nowrap">off-label</FONT> rituximab often requiring patients to have recurring transfusions which may lead to iron overload. CAD can also be seen in association with some cancers.</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #50748a; BORDER-BOTTOM:1px solid #50748a; padding-left:8pt"><FONT COLOR="#50748a"><I>Generalized<BR>Myasthenia<BR>Gravis (&#147;gMG&#148;)</I></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #50748a">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #50748a; BORDER-BOTTOM:1px solid #50748a; padding-right:2pt"><FONT COLOR="#50748a">Myasthenia gravis is a neuromuscular disease caused by an antibody-mediated autoimmune response in which the complement
system inappropriately attacks receptors in muscles that receive nerve impulses. gMG patients suffer profound muscle weakness throughout the body, resulting in slurred speech, impaired swallowing and choking, double vision, upper and lower extremity
weakness, disabling fatigue, shortness of breath due to respiratory muscle weakness and episodes of respiratory failure. In 2017, eculizumab was approved for gMG in patients who are anti-acetylcholine receptor antibody-positive. As described
elsewhere in this prospectus supplement, eculizumab does not directly modulate the classical pathway hyperreactivity that is causing the disease.</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #50748a; BORDER-BOTTOM:1px solid #50748a; padding-left:8pt"><FONT COLOR="#50748a"><I>Guillain-Barr&eacute;<BR>Syndrome<BR>(&#147;GBS&#148;)</I></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #50748a">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #50748a; BORDER-BOTTOM:1px solid #50748a; padding-right:2pt"><FONT COLOR="#50748a">GBS is a severe disorder where the complement system triggered by an infection also attacks innocent bystander nerve
cells resulting in muscle weakness, inability to climb stairs or walk, double vision or inability to move eyes, severe cramp-like pain, lack of bladder control or bowel function as well as impaired ability to breathe. Although most people recover
from GBS, the mortality rate has been reported at about 5%.</FONT></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-10 </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #50748a;BORDER-LEFT:1px solid #50748a;BORDER-RIGHT:1px solid #50748a;BORDER-TOP:1px solid #50748a;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="84%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #50748a; BORDER-TOP:1px solid #50748a; BORDER-BOTTOM:1px solid #50748a; padding-left:8pt"><FONT COLOR="#50748a"><I>Amyotrophic<BR>Lateral<BR>Sclerosis<BR>(&#147;ALS&#148;)</I></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #50748a; BORDER-BOTTOM:1px solid #50748a">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #50748a; BORDER-RIGHT:1px solid #50748a; BORDER-BOTTOM:1px solid #50748a; padding-right:2pt"><FONT COLOR="#50748a">ALS is a motor neuron disease that can cause symptoms similar to those of gMG. The
weakness eventually affects chewing, swallowing, speaking and breathing. People with ALS are also at increased risk for acute inflammation of the lungs, caused by the inhalation of food or stomach contents due to loss of control of the muscles
normally preventing this whereas pain is uncommon as is the loss of bladder control and senses.</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #50748a; BORDER-BOTTOM:1px solid #50748a; padding-left:8pt"><FONT COLOR="#50748a"><I>Multifocal Motor<BR>Neuropathy<BR>(&#147;MMN&#148;)</I></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #50748a">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #50748a; BORDER-BOTTOM:1px solid #50748a; padding-right:2pt"><FONT COLOR="#50748a">MMN is a rare disease characterized by slowly progressive muscle weakness, primarily of the arms and legs due to
antibody-initiated complement activation. There is often asymmetric muscle weakness in the hands and lower arms as well as cramping, involuntary contractions or twitching, wrist or foot drop and wasting of affected muscles. Men are more frequently
affected than women and men tend to be diagnosed at a younger age.</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #50748a; BORDER-BOTTOM:1px solid #50748a; padding-left:8pt"><FONT COLOR="#50748a"><I>Systemic Lupus<BR>Erythematosus<BR>(&#147;SLE&#148;)</I></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #50748a">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #50748a; BORDER-BOTTOM:1px solid #50748a; padding-right:2pt"><FONT COLOR="#50748a">SLE is an autoimmune disorder causing widespread inflammation and tissue damage in the affected organs. It can affect
the joints, skin, brain, lungs, kidneys, and blood vessels. Accordingly, affected individuals can present with a variety of symptoms including fatigue, skin rashes, fevers, and pain or swelling in the joints. The symptoms may wax and wane and come
in &#147;flares&#148; that can be more or less frequent. Other symptoms of SLE can include sun sensitivity, ulcers in the mouth, joint and lung disease, heart and kidney problems, seizures, psychosis, and blood cell and immunological
abnormalities.</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #50748a; BORDER-BOTTOM:1px solid #50748a; padding-left:8pt"><FONT COLOR="#50748a"><I>Lupus Nephritis<BR>(&#147;LN&#148;)</I></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #50748a">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #50748a; BORDER-BOTTOM:1px solid #50748a; padding-right:2pt"><FONT COLOR="#50748a">LN is a nephritic complication of SLE induced by autoantibody-initiated complement activation in which the symptoms
share many similarities with those of other kidney disorders including blood and proteins in the urine, high blood pressure, edema and high levels of creatinine in the blood. Treatment is generally unspecific and may involve immunosuppressants,
dialysis, or kidney transplantation.</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #50748a; BORDER-BOTTOM:1px solid #50748a; padding-left:8pt"><FONT COLOR="#50748a"><I>Schizophrenia</I></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #50748a">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #50748a; BORDER-BOTTOM:1px solid #50748a; padding-right:2pt"><FONT COLOR="#50748a">Schizophrenia is a complex disorder. Growing evidence points to imbalances in the classical pathway, such as C4
hyperreactivity, that may be involved in aberrant pruning of nerve cell interactions.</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">In general, these disorders have large patient populations. For example, it is estimated that across the
US/EU5 markets there are: 32,000 patients with ALS; 76,000 with wAIHA; 129,000 with gMG; 13,000 with GBS; 22,000 with CAD; 4,000 with MMN, and 372,000 and 129,000 with SLE and LN, respectively. Taken together as a whole the classical pathway
disorders either have no approved therapies or severe unmet needs exists that if addressed by successful drug candidates could significantly improve patient outcomes and become great commercial successes. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><I>Catalyst protease programs in complement.</I>&nbsp;&nbsp;&nbsp;&nbsp;We believe that engineered proteases hold a unique potential to
address disorders driven by dysregulated biological processes and are differentiated by circumventing certain limitations of small molecule and antibody based therapeutics. Two examples of biological processes/systems that can be targeted by
engineered proteases are the coagulation and complement systems. In both systems one protease molecule can modulate tens, hundreds, thousands, or even more target molecules to either activate or inactivate them. This is because a protease
therapeutic does not become consumed in the process of engaging its target. Therefore, smaller amounts of protease-based drug molecules can have profound impact on biological regulatory pathways. In comparison, small molecule drugs normally only
inhibit a single target molecule per drug molecule and antibodies inhibit two at best. Proteases do not have this inherent limitation. Moreover, proteases lend themselves well to half-life extension allowing infrequent convenient administration.
</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We currently have several protease programs in preclinical discovery or early
<FONT STYLE="white-space:nowrap">non-clinical</FONT> development. Common to the programs is that they target diseases caused by deficient regulation of the complement system. One ocular program for dry AMD is partnered with Biogen; the remaining
complement programs are focused on systemic complement disorders and are wholly owned by Catalyst. </FONT></P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-11 </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #50748a;BORDER-LEFT:1px solid #50748a;BORDER-RIGHT:1px solid #50748a;BORDER-TOP:1px solid #50748a;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><I>CB <FONT STYLE="white-space:nowrap">2782-PEG</FONT> for dry AMD (Biogen
collaboration).</I>&nbsp;&nbsp;&nbsp;&nbsp;CB <FONT STYLE="white-space:nowrap">2782-PEG</FONT> is an engineered pegylated C3 degrader that we designed with a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> <FONT STYLE="white-space:nowrap">anti-C3</FONT> profile for dry AMD. Dry AMD is an ocular disease leading to vision loss and blindness for which there is
currently no approved therapies. Complement hyperreactivity plays an important role in dry AMD. Using the protease CB <FONT STYLE="white-space:nowrap">2782-PEG</FONT> to degrade C3 allows for the neutralization of C3 activity. It is expected that
maintaining low C3 in the eye can significantly slow disease progression in dry AMD in patients who would otherwise lose their vision over time. The global market potential in dry AMD has been estimated to be $8.6&nbsp;billion which could grow to
over $18.0&nbsp;billion by 2028. In December 2019, we entered into a License and Collaboration Agreement with Biogen for the development and commercialization of <FONT STYLE="white-space:nowrap">CB2782-PEG.</FONT> </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><I>C4b degraders for classical pathway disorders.</I>&nbsp;&nbsp;&nbsp;&nbsp;A key regulation of the classical pathway occurs at the
level of C2/C4. Specifically, CFI together with <FONT STYLE="white-space:nowrap">co-factors,</FONT> cleave and inactivate C4b to appropriately limit the downstream response. However, in diseases of the classical complement pathway, this regulatory
step can be overwhelmed by too much upstream activity leading to uncontrolled downstream complement activation, even in people with normal CFI, ultimately resulting in destruction of the patient&#146;s own cells. We are engineering specific and
potent C4b degraders to counteract this imbalance to alleviate disease in disorders of classical pathway hyperactivity by engineering an existing regulatory mechanism to become more effective and thereby applicable in individuals with normal CFI
levels. By taking this approach we leverage existing biological functions and aim to specifically address fundamental deficiencies in the way current and future antibody and small molecule-based therapeutics work. Our engineered C4b degrader program
aims to leverage the same SQ delivery and high-yield production process used for CB 4332. Notably, although we have not chosen a disorder for our first clinical trial with a C4b degrader, the concept is designed to work across disorders of the
classical pathway irrespective of the patients CFI genotype. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><I>Future programs currently in
discovery.</I>&nbsp;&nbsp;&nbsp;&nbsp;We have additional early stage complement targeted discovery programs that have not yet been disclosed. The programs target different proteins from C3b and C4b. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><I>Complement intellectual property.</I>&nbsp;&nbsp;&nbsp;&nbsp;The United States Patent and Trademark Offices issued a patent covering
Catalyst&#146;s portfolio of engineered proteases that selectively cleave and degrade complement Factor 3 (C3), including the lead candidate CB <FONT STYLE="white-space:nowrap">2782-PEG,</FONT> a potential <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">best-in-class</FONT></FONT> treatment for dry AMD currently in development and under a license and collaboration agreement with Biogen. These modified proteases inhibit complement activation and have the potential to treat
multiple diseases in which complement activation plays a role. The newly issued patent provides protection until at least 2038. Our portfolio encompasses additional issued IP and pending applications in the complement space across a range of targets
and protease scaffolds. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B><I>DalcA Clinical Development.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;DalcA is a next-generation SQ
Factor IX product candidate for the prophylactic treatment of individuals with Hemophilia B, which completed a Phase 2b study in 2020. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#50748a">We completed a Phase 1/2 SQ dosing trial that evaluated the safety and efficacy of DalcA in patients with severe Hemophilia B in a collaboration with ISU Abxis. The study objective was to demonstrate the feasibility of increasing
Factor IX activity levels from approximately 1% (severe hemophilia) to greater than 12% (mild hemophilia corresponding to a reduced risk of spontaneous joint bleeds) with daily SQ injections. DalcA maintained protective Factor IX activity levels of <FONT
STYLE="white-space:nowrap">12-30%.</FONT> Mild to moderate injection site reactions were reported and all resolved spontaneously without sequelae. Two subjects, who were cousins with the same rare Factor IX mutation, developed nAbs, one transiently.
The nAbs were specific to DalcA (did not bind to wild-type Factor IX) and therefore did not interfere with the patients&#146; ability to resume use of their prior Factor IX therapy. Thus, the nAbs to DalcA are not referred to as inhibitors. We
completed a comprehensive investigation of the root cause of the nAbs in 2018 and concluded that the immunogenic potential of DalcA was low and similar to that of commercial Factor IX products. Furthermore, the drug product quality of DalcA was
shown to be comparable to commercial Factor IX products. </FONT></P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-12 </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #50748a;BORDER-LEFT:1px solid #50748a;BORDER-RIGHT:1px solid #50748a;BORDER-TOP:1px solid #50748a;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">In 2020, we completed an open-label Phase 2b study to evaluate the ability of DalcA to
maintain steady state protective Factor IX levels above 12% in six individuals with severe hemophilia B. Each subject received a single intravenous dose, followed by daily SQ doses of DalcA for 28 days during which FIX activity levels, clotting
parameters, half-life, safety, tolerability and anti-drug antibody formation were monitored. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">At the World Federation of
Hemophilia Virtual Summit in June 2020, we reported that 28 days of daily SQ dosing of DalcA at 100 IU/kg achieved protective target FIX levels of &gt;12% in all participants, with FIX levels of up to 27% and a half-life of 2.5 to 5.1 days. No
bleeds were reported during the 28 days of dosing and the 5 day <FONT STYLE="white-space:nowrap">wash-out,</FONT> demonstrating effective prophylaxis and the potential for lower or less frequent dosing. Injection volumes were less than 1 mL. One
subject withdrew on day 7 after reporting injection site reactions (&#147;ISR&#148;) from the first 3 SQ doses. No neutralizing anti-drug antibodies were detected, and no serious adverse events were reported. A single
<FONT STYLE="white-space:nowrap">non-neutralizing</FONT> anti-drug antibody to DalcA was observed at the end of study time point and had no clinical effect. Some subjects reported mild ISR of pain and/or redness, primarily with the initial
injections. No thrombotic events occurred, and blood coagulation markers did not show any prothrombotic signals. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B><I>Factor IX Gene Therapy.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;Our Factor IX gene therapy construct CB
<FONT STYLE="white-space:nowrap">2679d-GT</FONT> has demonstrated a <FONT STYLE="white-space:nowrap">2-fold</FONT> to <FONT STYLE="white-space:nowrap">3-fold</FONT> higher activity resulting in improved clotting time and blood loss in a preclinical
Hemophilia B mouse model compared with the Padua variant of Factor IX. Fidanacogene elaparvovec (Pfizer/Spark), <FONT STYLE="white-space:nowrap">AMT-061</FONT> <FONT STYLE="white-space:nowrap">(uniQure),TAK-748</FONT> (Takeda) and FLT180A (Freeline)
use the Padua FIX variant as the transgene in their <FONT STYLE="white-space:nowrap">AAV-based</FONT> gene therapy clinical programs. Fidanacogene elaparvovec, <FONT STYLE="white-space:nowrap">AMT-061</FONT> and FLT180A have demonstrated encouraging
Factor IX levels in their respective Phase 1/2 and Phase 2/3 studies with median Factor IX activity levels in the upper end of the mild to normal ranges. By its increased activity, CB <FONT STYLE="white-space:nowrap">2679d-GT</FONT> has the
potential to reach higher Factor IX activity levels at lower vector doses which could improve tolerability of the vector as well as efficacy of the transgene, and ultimately lower manufacturing costs. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We have licensed AAV technology from The Board of Trustees of The Leland Stanford Junior University (&#147;Stanford&#148;) and are
currently optimizing the vector under a sponsored research agreement with Stanford. Data presented at European Association for Haemophilia and Allied disorders (&#147;EAHAD&#148;) in February 2020 show that the combination of our proprietary potency
enhanced CB <FONT STYLE="white-space:nowrap">2679d-GT</FONT> Factor IX construct with a novel chimeric AAV capsid may reduce the vector dose required in gene therapy while maintaining high Factor IX levels. We reported at the World Federation of
Hemophilia Virtual Summit in June 2020 that studies of CB <FONT STYLE="white-space:nowrap">2679d-GT</FONT> in Hemophilia B mice have demonstrated a <FONT STYLE="white-space:nowrap">4-fold</FONT> reduction in blood loss and an <FONT
STYLE="white-space:nowrap">8-fold</FONT> reduction in bleeding time when compared with the same dose of the Padua variant of FIX. We also reported that in a <FONT STYLE="white-space:nowrap">non-human</FONT> primate study evaluating expression and
tolerability, CB <FONT STYLE="white-space:nowrap">2679d-GT</FONT> in the novel chimeric capsid KP1 was well tolerated with high FIX expression that stabilized to approximately 25% to 50% FIX above baseline levels at the <FONT
STYLE="white-space:nowrap">6-week</FONT> interim data cutoff. The novel chimeric capsid had differentiated and superior response to anti-capsid neutralizing antibodies compared to that observed for the LK03 comparator during the screening of <FONT
STYLE="white-space:nowrap">non-human</FONT> primates for the study. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>Our Strategy </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We are building a protease medicines company. Our portfolio of engineered protease therapies is designed for individuals with disorders
of the complement and coagulation systems who need new or better treatment options. Our overall strategy builds on our belief that proteases can uniquely be engineered to improve their properties as potential drugs, for example by circumventing
limitations of small molecule and antibody-based therapies. We are focused on building a portfolio of closely linked, yet highly differentiated drug candidates that leverages the unique attributes of proteases. Key focus areas for us in the near and
longer term include: </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Complement Therapeutics: </FONT></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a"><FONT STYLE="font-family:ARIAL; font-size:6pt" COLOR="#50748a"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">Invest in multiple differentiated systemic complement regulation programs with our
proprietary protease engineering platform. </FONT></P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-13 </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #50748a;BORDER-LEFT:1px solid #50748a;BORDER-RIGHT:1px solid #50748a;BORDER-TOP:1px solid #50748a;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a"><FONT STYLE="font-family:ARIAL; font-size:6pt" COLOR="#50748a"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">Initiate clinical trial(s) with CB 4332 including an observational trial and a Phase 1/2
trial. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a"><FONT STYLE="font-family:ARIAL; font-size:6pt" COLOR="#50748a"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">Advance <FONT STYLE="white-space:nowrap">C4b-degraders</FONT> and other novel complement
programs into clinical development. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Hemostasis Therapeutics: </FONT></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a"><FONT STYLE="font-family:ARIAL; font-size:6pt" COLOR="#50748a"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">Initiate and complete a registrational Phase 3 trial for the treatment of acute bleeds.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a"><FONT STYLE="font-family:ARIAL; font-size:6pt" COLOR="#50748a"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">Expand clinical development of MarzAA in additional indications.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a"><FONT STYLE="font-family:ARIAL; font-size:6pt" COLOR="#50748a"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">Complete formulation studies of DalcA. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Leverage the protease engineering platform to develop novel differentiated therapeutics: </FONT></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a"><FONT STYLE="font-family:ARIAL; font-size:6pt" COLOR="#50748a"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">Focus on rare systemic disorders amenable to engagement by proteases and where clear unmet
needs exist. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a"><FONT STYLE="font-family:ARIAL; font-size:6pt" COLOR="#50748a"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">Engineer drug candidates that have applications across multiple indications.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a"><FONT STYLE="font-family:ARIAL; font-size:6pt" COLOR="#50748a"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">Utilize existing processes across candidates and programs to achieve platform benefits.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a"><FONT STYLE="font-family:ARIAL; font-size:6pt" COLOR="#50748a"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">Strategically develop candidates with a fast to clinic approach.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a"><FONT STYLE="font-family:ARIAL; font-size:6pt" COLOR="#50748a"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">Develop therapeutics with infrequent, convenient SQ administration.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>Collaborations </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><I>MarzAA.</I>&nbsp;&nbsp;&nbsp;&nbsp;In 2009, we licensed MarzAA to Wyeth Pharmaceuticals, Inc. (&#147;Wyeth&#148;). Wyeth was
subsequently acquired by Pfizer, Inc. (&#147;Pfizer&#148;) who terminated the license and collaboration agreement after completing a Phase 1 IV trial. Pursuant to the collaboration termination agreement, in exchange for the rights to certain Pfizer
technology, we agreed to make payments to Pfizer in an aggregate amount equal to up to $17.5&nbsp;million, payable upon the achievement of clinical, regulatory and commercial milestones. Following commercialization of any covered product, Pfizer
would also receive a single-digit royalty on net product sales on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis for a predefined royalty term. In February 2018, we paid Pfizer a
$1.0&nbsp;million milestone payment based on the dosing of the first patient in a Phase 2 study. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><I>DalcA.</I>&nbsp;&nbsp;&nbsp;&nbsp;We collaborated with ISU Abxis (&#147;ISU&#148;), in the early development of DalcA. Under the
collaboration agreement, ISU conducted the Phase I clinical trial of DalcA and was responsible for all manufacturing activities for the Phase 1 clinical trial. Pursuant to the agreement, as amended in December 2018, ISU is entitled to a low
single-digit royalty payment, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country&nbsp;basis,</FONT></FONT> for net product sales of DalcA by the Company or its affiliates in each country other than South Korea.
ISU is also entitled up to $19.5&nbsp;million in milestone payments, of which $2.5&nbsp;million are regulatory and development milestone payments and up to $17.0&nbsp;million in commercial milestone payments. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Under the original agreement with ISU, we received and recognized $2.7&nbsp;million from ISU through 2018. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><I>CB <FONT STYLE="white-space:nowrap">2782-PEG.</FONT></I>&nbsp;&nbsp;&nbsp;&nbsp;In 2019, we agreed to collaborate with Biogen to
develop and commercialize CB <FONT STYLE="white-space:nowrap">2782-PEG</FONT> and our other <FONT STYLE="white-space:nowrap">anti-C3</FONT> proteases for potential treatment of dry AMD and other disorders. We will perform preclinical and
manufacturing activities, and Biogen will be solely responsible for funding the preclinical and manufacturing activities and performing investigational new drug (&#147;IND&#148;)-enabling activities, worldwide clinical
</FONT></P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-14 </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #50748a;BORDER-LEFT:1px solid #50748a;BORDER-RIGHT:1px solid #50748a;BORDER-TOP:1px solid #50748a;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">
development, and commercialization. We received a $15.0&nbsp;million upfront payment from Biogen in January 2020 and are eligible to receive up to $340.0&nbsp;million in milestone payments, along
with tiered royalties for worldwide net sales of this product candidate up to low double-digits. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We also collaborated with
Mosaic Biosciences (&#147;Mosaic&#148;) in the development of our Complement product candidates including CB <FONT STYLE="white-space:nowrap">2782-PEG.</FONT> Under the collaboration agreement, as amended in December 2019, Mosaic will perform all
future services for an <FONT STYLE="white-space:nowrap">FTE-based</FONT> fee. Pursuant to a subsequent amendment in May 2020, Mosaic received a <FONT STYLE="white-space:nowrap">one-time</FONT> cash payment of $0.8&nbsp;million and is eligible to
receive up to $4.0&nbsp;million in potential future milestone payments for regulatory and clinical development milestones resulting from the development of CB <FONT STYLE="white-space:nowrap">2782-PEG</FONT> and an additional anti-complement product
candidate payable in cash or common stock at the Company&#146;s election. As a result, we now own one hundred percent of all future payment streams related to these product candidates. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>Competition </B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#50748a">Our product candidates will face competition from approved therapeutics. Competition for our product candidate pipeline comes primarily from large, well-established pharmaceutical companies, who have greater financial resources and
expertise in research and development, manufacturing, conducting clinical trials, and marketing approved products. Mergers and acquisitions within the pharmaceutical and biotechnology industries may further concentrate competitors&#146; resources.
We are not only competing with these companies in terms of technology, but also in recruiting and retaining qualified scientists and management personnel, in establishing partnerships with clinical trial sites, and in enrolling individuals into
clinical trials. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">In addition to current Standard of Care for individuals, clinical trials are being pursued by several
parties in the field of biologics and in our lead indications. These products in development may provide efficacy, safety, convenience, and other benefits that are not provided by currently marketed therapies. As a result, they may provide
significant competition for any of our product candidates for which we obtain marketing approval. Based on publicly available information, the following are some of the products currently on market or being developed by competitors in indications
overlapping with those of our programs. </FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a"><B><I>Factor VIIa Competition</I></B>: </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">Approved products </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a"><FONT STYLE="font-family:ARIAL; font-size:6pt" COLOR="#50748a"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">Novo Nordisk&#146;s NovoSeven RT is an intravenous recombinant Factor VIIa indicated for
treatment of bleeding episodes in individuals with Hemophilia A or B with an inhibitor to Factor VIII or Factor IX. NovoSeven was approved in 1999 and was approved in a room temperature formulation &#147;NovoSeven RT&#148; in 2008. The treatment has
since been approved for on demand use in individuals with Factor VII deficiency and Glanzmann thrombasthenia, but not for prophylaxis. It is also approved for treatment of bleeding episodes and peri-operative management in adults with Acquired
Hemophilia. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a"><FONT STYLE="font-family:ARIAL; font-size:6pt" COLOR="#50748a"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">Takeda&#146;s FEIBA is a plasma-based composition of coagulation factors indicated for
intravenous <FONT STYLE="white-space:nowrap">on-demand</FONT> and prophylactic use in the treatment of individuals with Hemophilia A or B with inhibitors. FEIBA has been on the market for more than 30 years. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="15%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a"><FONT STYLE="font-family:ARIAL; font-size:6pt" COLOR="#50748a"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">Roche&#146;s Hemlibra (emicizumab-kxwh), a bispecific Factor
<FONT STYLE="white-space:nowrap">IXa-Factor</FONT> X monoclonal antibody is indicated for routine SQ prophylaxis in adults and children with Hemophilia A with a Factor VIII inhibitor. Emicizumab received approval from the FDA in 2017. Emicizumab
cannot treat episodic bleeding. </FONT></P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-15 </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #50748a;BORDER-LEFT:1px solid #50748a;BORDER-RIGHT:1px solid #50748a;BORDER-TOP:1px solid #50748a;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a"><FONT STYLE="font-family:ARIAL; font-size:6pt" COLOR="#50748a"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">HEMA Biologics&#146; SEVENFACT is an intravenous recombinant Factor VIIa indicated for
treatment of bleeding episodes in individuals with Hemophilia A or B with an inhibitor to Factor VIII or Factor IX approved in 2020. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">In addition to currently approved products, several other companies including Novo Nordisk,
Pfizer, Genzyme and others are developing SQ agents for the treatment of Hemophilia A or B with or without inhibitors or Hemophilia B with inhibitors using a variety of technologies. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a"><B><I>Factor IX Competition: </I></B>BeneFIX, a recombinant Factor IX indicated for
treatment of individuals with Hemophilia B, was approved in 1997 and is marketed by Pfizer. In addition, Alprolix, a Factor <FONT STYLE="white-space:nowrap">IX-Fc</FONT> fusion product was approved in 2014 and is marketed by Sanofi Aventis and
Swedish Orphan Biovitrum (&#147;SOBI&#148;) in Europe, Russia, North Africa and the Middle East. Idelvion, a Factor <FONT STYLE="white-space:nowrap">IX-albumin</FONT> fusion product marketed by CSL Behring was approved by the FDA in 2016. Idelvion
is approved for weekly dosing for adolescents and adults and <FONT STYLE="white-space:nowrap">bi-weekly</FONT> at a higher dose for those same patients if well controlled on the original regimen. It is approved for weekly in patients &lt;12 years of
age. Novo Nordisk&#146;s glycopegylated-Factor IX product Rebinyn<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> was approved by the FDA in 2017 but is not indicated for routine prophylaxis in the U.S. Rebinyn is approved for <FONT
STYLE="white-space:nowrap">on-demand</FONT> treatment and control of bleeding episodes as well as Perioperative management of bleeding. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a"><B><I>Factor IX Gene Therapy Competition: </I></B>While there are no currently approved
Factor IX gene therapy treatments for Hemophilia B, several companies, are developing Factor IX gene therapy treatments in clinical studies. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a"><B><I>Dry AMD Competition:</I></B> While there are no currently approved treatments for dry
AMD, several companies are developing cyclic peptide, aptamer, antibody or gene therapy based anti-complement product candidates for the treatment of dry AMD that are currently in clinical studies: </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a"><FONT STYLE="font-family:ARIAL; font-size:6pt" COLOR="#50748a"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">Apellis is conducting two Phase 3 studies to compare the efficacy and safety of
intravitreal <FONT STYLE="white-space:nowrap">APL-2</FONT> therapy with sham injections in patients aged 60 years and older with GA secondary to AMD, which is scheduled to be completed in 2021. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a"><FONT STYLE="font-family:ARIAL; font-size:6pt" COLOR="#50748a"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">Iveric Bio (formerly Ophthotech) is developing two therapies to treat GA secondary to dry
AMD. Iveric Bio completed its Phase 2b clinical of Zimura<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (avacincaptad pegol) with positive data in patients with dry AMD. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a"><FONT STYLE="font-family:ARIAL; font-size:6pt" COLOR="#50748a"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">Gemini Therapeutics is developing &#147;GEM103&#148; a recombinant human complement
factor&nbsp;H (&#147;FH&#148;) for patients with genetically well-defined dry AMD and &#147;GEM104,&#148; a recombinant human complement factor&nbsp;I as well as additional molecules in preclinical development for other genetically defined
subpopulations of patients with dry AMD. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a"><FONT STYLE="font-family:ARIAL; font-size:6pt" COLOR="#50748a"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">Gyroscope Therapeutics is developing &#147;GT005&#148; a gene therapeutic approach to
expressing additional CFI in the patient&#146;s eye after subretinal delivery. GT005 is being developed for a genetically well-defined subpopulation of patients with dry AMD. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B><I>Systemic Complement Factor I Deficiency Competition:</I></B> There are currently no approved agents specifically targeting
systemic factor I deficiency patients irrespective of the resultant disease phenotype being aHUS, C3G, <FONT STYLE="white-space:nowrap">IC-MPGN,</FONT> invasive infections or any other. There are no approved therapies for C3G and <FONT
STYLE="white-space:nowrap">IC-MPGN.</FONT> There are, however, less specific treatment options on the market or in clinical development which may be applicable to some disease manifestations of systemic CFI deficiency, for instance aHUS and C3G.
</FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a"><FONT STYLE="font-family:ARIAL; font-size:6pt" COLOR="#50748a"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">Alexion Pharmaceuticals (to be acquired by AstraZeneca) markets eculizumab and ravulizumab
for use in aHUS irrespective of the patients&#146; CFI status. </FONT></P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-16 </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #50748a;BORDER-LEFT:1px solid #50748a;BORDER-RIGHT:1px solid #50748a;BORDER-TOP:1px solid #50748a;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a"><FONT STYLE="font-family:ARIAL; font-size:6pt" COLOR="#50748a"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">Apellis is conducting clinical development for
<FONT STYLE="white-space:nowrap">APL-2</FONT> (pegcetacoplan), a pegylated peptide based C3 inhibitor, in IgA Nephropathy (&#147;IgAN&#148;), LN, Membranous Nephropathy (&#147;MN&#148;), C3G, and Dense Deposit Disease irrespective of the
patients&#146; CFI status. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a"><FONT STYLE="font-family:ARIAL; font-size:6pt" COLOR="#50748a"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">ChemoCentryx is developing CCX168 (avacopan), a twice daily oral small molecule inhibitor
of the complement 5a receptor (&#147;C5aR&#148;) in C3G &#150; currently in phase 2. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a"><FONT STYLE="font-family:ARIAL; font-size:6pt" COLOR="#50748a"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">Novartis is conducting clinical development for iptacopan (&#147;LNP023&#148;), a small
peptide complement factor B inhibitor. Iptacopan is in development for PNH, as well as C3G and several other rare renal diseases including IgAN, aHUS, and membranous nephropathy. Novartis expect first FDA filings in 2023. Iptacopan has received Rare
Pediatric Disease Designation in C3G. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a"><FONT STYLE="font-family:ARIAL; font-size:6pt" COLOR="#50748a"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">Omeros is developing OMS721 (&#147;narsoplimab&#148;). Narsoplimab is a human monoclonal
antibody targeting mannan-binding lectin-associated serine <FONT STYLE="white-space:nowrap">protease-2</FONT> <FONT STYLE="white-space:nowrap">(&#147;MASP-2&#148;),</FONT> the effector enzyme of the lectin pathway of the complement system. Clinical
activities have been initiated in IgAN, LN, MN, &amp; C3G and a phase 3 clinical program is underway in aHUS. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#50748a">Our commercial opportunity in different indications could be reduced or eliminated if our competitors develop and market products that are safer, more effective, more convenient to use, or less expensive to use than our products.
Furthermore, if competitors gain FDA approval faster than we do, we may be unable to establish a strong market presence or to gain market share. The key competitive factors affecting the success of all our product candidates, if approved, are likely
to be their efficacy, safety, convenience, price, the level of generic competition, and the availability of reimbursement from government and other third-party payors. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B><FONT STYLE="white-space:nowrap">COVID-19</FONT> Business Impact </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">The current <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic has presented a substantial public health and economic challenge
around the world and is affecting our employees, potential trial participants, communities and business operations, as well as the U.S. economy and financial markets. The full extent to which the <FONT STYLE="white-space:nowrap">COVID-19</FONT>
pandemic will directly or indirectly impact our business, results of operations and financial condition will depend on future developments that are highly uncertain and cannot be accurately predicted, including new information that may emerge
concerning <FONT STYLE="white-space:nowrap">COVID-19,</FONT> the actions taken to contain it or treat its impact and the economic impact on local, regional, national and international markets. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">To date, we have instructed our employees to work from home except as needed to ensure continuity of our operations. As we continue to
actively advance our clinical programs, we are in close contact with our principal investigators, clinical sites and contractors, including manufacturers, and are assessing the impact of <FONT STYLE="white-space:nowrap">COVID-19</FONT> on our
current and planned trials, expected timelines and costs on an ongoing basis. We are continuing study <FONT STYLE="white-space:nowrap">start-up</FONT> activities where possible to allow rapid site activation and enrollment of our registrational
Phase&nbsp;3 trial <FONT STYLE="white-space:nowrap">(MAA-304)</FONT> at the appropriate time, although we may experience delays. We have experienced some supply chain disruptions as the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT>
pandemic has impacted the ability of some of our suppliers to deliver certain raw materials on a timely basis. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Given the
focus of healthcare providers and hospitals on fighting <FONT STYLE="white-space:nowrap">COVID-19,</FONT> and the reluctance of potential trial participants to visit hospitals or other clinical trial sites, we have experienced delays in the
enrollment of patients in our upcoming clinical trials. We will continue to evaluate the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on our business and will reevaluate the timing of our anticipated clinical milestones as
we learn more and the impact of <FONT STYLE="white-space:nowrap">COVID-19</FONT> on our industry becomes clearer. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">For
additional information on the various risks posed by the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, please read the section entitled &#147;Risk Factors&#148; included in this prospectus supplement. </FONT></P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-17 </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #50748a;BORDER-LEFT:1px solid #50748a;BORDER-RIGHT:1px solid #50748a;BORDER-TOP:1px solid #50748a;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>Recent Developments </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>Certain Preliminary Financial Results as of December&nbsp;31, 2020 </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Although we have not finalized our full financial results for the fourth quarter and fiscal year ended December&nbsp;31, 2020, we expect
to report that we had approximately $81.9&nbsp;million in cash, cash equivalents and investments as of December&nbsp;31, 2020. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#50748a">The information above is based on preliminary unaudited information and management estimates for the year ended December&nbsp;31, 2020, is not a comprehensive statement of our financial results, and is subject to completion of our
financial closing procedures. Our independent registered public accounting firm has not conducted an audit or review of, and does not express an opinion or any other form of assurance with respect to, these preliminary estimates. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>Company Information </B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#50748a">We commenced operations in 2002 and are a Delaware corporation. On August&nbsp;20, 2015, we merged with Targacept, Inc. Our corporate headquarters are located at 611 Gateway Blvd., Suite 710, South San Francisco, California 94080.
Our telephone number is (650) <FONT STYLE="white-space:nowrap">871-0761,</FONT> and our website address is www.catalystbiosciences.com. The information contained on, or that can be accessed through, our website is not part of this prospectus
supplement, and you should not consider information on our website to be part of this prospectus supplement. </FONT></P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-18 </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a"><B><A NAME="supptoc260304_3"></A>THE OFFERING </B></FONT></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="41%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>Common stock offered by us </B></FONT></P></TD>
<TD><FONT COLOR="#50748a">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shares of common stock, par value $0.001 per share. </FONT></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="41%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>Option to purchase additional shares </B></FONT></P></TD>
<TD><FONT COLOR="#50748a">We have granted the underwriters an option to purchase up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional shares of common stock. This option is exercisable, in
whole or in part, for a period of 30&nbsp;days from the date of this prospectus supplement. </FONT></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="41%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>Common stock to be outstanding after this offering </B></FONT></P></TD>
<TD><FONT COLOR="#50748a">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares (or approximately &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares if the underwriters exercise their option to purchase additional shares of common stock in full). </FONT></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="41%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>Use of proceeds </B></FONT></P></TD>
<TD><FONT COLOR="#50748a">We expect the net proceeds from this offering to us, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us, will be approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million if the underwriters exercise their option to purchase additional shares in full). We currently expect to use the net
proceeds primarily for general corporate purposes, including research, development and manufacturing activities in our hemophilia and complement programs, specifically for MarzAA (FVIIa), CB 4332 (enhanced complement Factor I) and others, capital
expenditures, selling, general and administrative costs, facilities expansion, and to meet working capital needs. We expect from time to time to evaluate the acquisition of businesses, products and technologies for which a portion of the net
proceeds may be used, although we currently are not planning or negotiating any such transactions. See &#147;Use of Proceeds&#148; on <FONT STYLE="white-space:nowrap">page&nbsp;S-57</FONT> of this prospectus supplement. </FONT></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="41%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>Risk factors </B></FONT></P></TD>
<TD><FONT COLOR="#50748a">Investing in our common stock involves significant risks. See &#147;Risk Factors,&#148; beginning on <FONT STYLE="white-space:nowrap">page&nbsp;S-21</FONT> as well as the other information included in or incorporated by
reference in this prospectus supplement and the accompanying prospectus, for a discussion of risks you should carefully consider before investing in our securities. </FONT></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="41%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>Nasdaq Capital Market symbol </B></FONT></P></TD>
<TD><FONT COLOR="#50748a">&#147;CBIO&#148; </FONT></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">The number of shares of our common stock to be outstanding
immediately after this offering as shown above is based on 22,082,924&nbsp;shares of common stock outstanding as of September&nbsp;30, 2020, and excludes: </FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">2,264,141&nbsp;shares of common stock issuable upon exercise of options outstanding as of
September&nbsp;30, 2020, with a weighted average exercise price of $8.841 per share; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">83,000&nbsp;shares of common stock issuable upon exercise of options granted after
September&nbsp;30, 2020, with a weighted average exercise price of $5.946 per share; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">722&nbsp;shares of common stock issuable upon exercise of warrants outstanding as of
September&nbsp;30, 2020, with a weighted average exercise price of $90.26 per share; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-19 </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">1,674,278&nbsp;shares of common stock reserved and available for future issuance as of
September&nbsp;30, 2020, under our equity incentive plans, consisting of (1)&nbsp;1,373,834&nbsp;shares of common stock reserved and available for issuance under our 2018 Omnibus Incentive Plan as of September&nbsp;30, 2020, and
(2)&nbsp;300,444&nbsp;shares of common stock reserved for issuance under our 2018 Employee Stock Purchase Plan as of September&nbsp;30, 2020; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">1,275,938 additional shares of common stock reserved and available for future issuance
after September&nbsp;30, 2020 under our 2018 Omnibus Incentive Plan. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Except as otherwise indicated, all
information in this prospectus supplement assumes no exercise of outstanding options and warrants and no exercise of the underwriters&#146; option to purchase additional shares of common stock. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-20 </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a"><B><A NAME="supptoc260304_4"></A>RISK FACTORS </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><I>An investment in our securities involves a high degree of risk. Prior to making a decision about investing in our securities, you
should carefully consider the risk factors described below, together with all of the other information included in this prospectus, including the risks described in our reports and other documents, which are incorporated herein by reference, and may
be amended, supplemented or superseded from time to time by other reports we file with the Securities and Exchange Commission (the &#147;SEC&#148;), in the future. </I></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><I>If any of the risks incorporated by reference or set forth below occurs, our business, operations and financial condition could
suffer significantly. As a result, you could lose some or all of your investment in our common stock. The risks and uncertainties we have described are not the only ones we face. Additional risks and uncertainties not presently known to us or that
we currently deem immaterial may also affect our business, operations and financial condition, or cause the value of our common stock to decline. </I></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>Summary of Risk Factors </B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#50748a">Investing in our securities involves a high degree of risk. Below please find a summary of the principal risks we face. These risks are discussed more fully below. </FONT></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">We are experiencing operational and other challenges as a result of the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> global pandemic, which have delayed our enrollment in <FONT STYLE="white-space:nowrap">MAA-304</FONT> and <FONT STYLE="white-space:nowrap">MAA-202</FONT> and which may delay or halt our development in these
or other programs. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">CB 4332, one of our complement product candidates, is in the early stages of development
and its commercial viability remains subject to preclinical studies, clinical trials, regulatory approvals and the risks generally inherent in the development of a pharmaceutical product candidate. If we are unable to advance or develop our
complement product candidates, our business may be materially harmed. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">If we experience delays or difficulties in the enrollment of patients in clinical trials,
our regulatory approvals could be delayed or prevented. Competitive products or products that reduce the frequency of bleeding among patients treated with our drugs have reduced the likelihood that patients will enroll in our clinical trials.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">The operations of our third-party manufacturers may be requisitioned by government orders
such as under emergency, disaster and civil defense declarations in connection with the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a"><FONT STYLE="white-space:nowrap">COVID-19</FONT> may impact our third-party supply of the
raw materials needed for our product candidates, which increases the risk that we will not have sufficient quantities of such product candidates or quantities at an acceptable cost, which could delay, prevent or impair our development efforts.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">We have incurred significant losses since our inception and are expected to continue to
incur significant losses for the foreseeable future. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">We will need additional capital. If we are unable to raise sufficient capital, we will be
forced to delay, reduce or eliminate product development programs. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">Raising additional funds by issuing securities or through licensing arrangements may cause
dilution to stockholders, restrict our operations or require us to relinquish proprietary rights. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">We are focused on the clinical development of MarzAA and our complement product candidates.
Any adverse events, trial failures or material delays in these programs could materially harm our business. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-21 </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">DalcA has caused and MarzAA or our complement product candidates may cause the generation
of neutralizing antibodies, which could prevent their further development. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">MarzAA and DalcA are in late-stage clinical trials, and all of our other product candidates
are still in preclinical development. If we are unable to obtain regulatory clearance and commercialize our product candidates or experience significant delays in doing so, our business will be materially harmed. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">Results from our trials may not be confirmed, and if serious adverse side effects are
identified during development of product candidates, we may need to abandon or limit development of some product candidates. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">Fast Track designation by the FDA may not actually lead to a faster development or
regulatory review or approval process. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">Our collaboration with Biogen may not result in successful product development or payments
to us. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">We expect to seek to establish additional collaborations, and, if we are not able to
establish them on commercially reasonable terms, we may have to alter our development and commercialization plans. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">We contract with third parties for the manufacture of our product candidates. This reliance
on third parties increases the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">We and our contract manufacturers will be subject to significant regulation with respect to
manufacturing our products. The manufacturing facilities on which we will rely may not continue to meet regulatory requirements and have limited capacity. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">We rely on third parties to conduct our clinical trials, and those third parties may not
perform satisfactorily, including failing to meet deadlines for the completion of such trials. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">Our employees, principal investigators and commercial partners may engage in misconduct or
other improper activities, including <FONT STYLE="white-space:nowrap">non-compliance</FONT> with regulatory standards and insider trading. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">If we are unable to obtain, protect or enforce intellectual property rights related to our
product candidates, we may not be able to compete effectively in our markets. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">Third-party claims of intellectual property infringement or challenging the inventorship or
ownership of our patents may prevent or delay our development and commercialization efforts. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">We may need to license certain intellectual property from third parties, and such licenses
may not be available or may not be available on commercially reasonable terms. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">If we are not able to obtain, or if there are delays in obtaining, required regulatory
approvals, we will not be able to commercialize our products, and our ability to generate revenue will be materially impaired. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">The FDA may disagree with our regulatory plan and we may fail to obtain regulatory approval
of our product candidates. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-22 </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">Our results of operations may be adversely affected by current and potential future
healthcare legislative and regulatory actions. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">If we fail to protect personal information or comply with existing or future data
protection regulations, our business, financial condition, results of operations and prospects may be materially adversely affected. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">If we fail to comply with environmental, health and safety laws and regulations, we could
become subject to fines or penalties or incur costs that could harm our business. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">Even if any of our product candidates receives marketing approval, we may fail to achieve
the degree of market acceptance necessary for commercial success. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">Our product candidates are years away from regulatory approval.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">If we are unable to establish sales, marketing and distribution capabilities, we may not be
successful in commercializing our product candidates if they are approved. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">We face substantial competition that may result in others discovering, developing or
commercializing products before or more successfully than we do. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">If the market opportunities for our product candidates are smaller than expected, our
revenues may be adversely affected and our business may suffer. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">Sales of a significant number of shares of our common stock in the public markets, or the
perception that such sales could occur, could depress the market price of our common stock. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">We have broad discretion in the use of the net proceeds from this offering and may not use
them effectively. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">If you purchase shares of common stock sold in this offering you will experience immediate
and substantial dilution in your investment. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B></B><B><I>Risks related to our financial condition and
capital requirements</I></B><B> </B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>The outbreak of the novel coronavirus disease,
<FONT STYLE="white-space:nowrap">COVID-19,</FONT> could adversely impact our business, including our preclinical studies and clinical trials. </B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#50748a">The global coronavirus pandemic has resulted in widespread requirements for individuals to work from their homes, strained medical facilities worldwide and is causing disruptions to certain pharmaceutical manufacturing and product
supply chains. We are experiencing operational and other challenges as a result of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> global pandemic, which have delayed our enrollment in <FONT STYLE="white-space:nowrap">MAA-304</FONT> and <FONT
STYLE="white-space:nowrap">MAA-202,</FONT> and which may delay or halt our development in these or other programs. In particular, as a result of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, we may experience disruptions that could
severely impact our business, preclinical studies, drug manufacturing and clinical trials including: </FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">additional delays or difficulties in enrolling potential trial participants in our clinical
trials; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">delays or difficulties in clinical site initiation, including difficulties in recruiting
clinical site investigators and clinical site staff; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-23 </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">diversion of healthcare resources away from the conduct of clinical trials, including the
diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">delays in manufacturing of our product candidates as third-party manufacturing capacity is
shifted towards the production of <FONT STYLE="white-space:nowrap">COVID-19</FONT> vaccines; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">interruption of key clinical trial activities, such as clinical trial site data monitoring,
due to limitations on travel imposed or recommended by federal or state governments, employers and others or interruption of clinical trial subject visits and study procedures, which may impact the integrity of subject data and clinical study
endpoints; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">interruption or delays in the operations of the FDA, European Medicines Agency (the
&#147;EMA&#148;) or other regulatory authorities, which may impact review and approval timelines; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">interruption of, or delays in receiving, supplies of our product candidates from our
contract manufacturing organizations due to staffing shortages, production slowdowns or stoppages and disruptions in delivery systems; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">interruptions in preclinical studies due to restricted or limited operations at laboratory
facilities; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">suspension or termination of our clinical trials for various reasons, such as a finding
that the participants are being exposed to infectious diseases like <FONT STYLE="white-space:nowrap">COVID-19</FONT> or the participants involved in our clinical trials have become infected with <FONT STYLE="white-space:nowrap">COVID-19;</FONT>
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">limitations on employee resources that would otherwise be focused on the conduct of our
preclinical studies and clinical trials, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">material delays and complications with respect to our research and development programs.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">In addition, the trading prices for our common stock and other biopharmaceutical companies have been
highly volatile as a result of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. Furthermore, a recession or market correction resulting from the spread of <FONT STYLE="white-space:nowrap">COVID-19</FONT> could materially affect our
operations and the value of our common stock. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>CB 4332, one of our complement product candidates, is in the early stages
of development and its commercial viability remains subject to current and future preclinical studies, clinical trials, regulatory approvals and the risks generally inherent in the development of a pharmaceutical product candidate. If we are unable
to successfully advance or develop our complement product candidates, our business may be materially harmed. </B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Failure to
successfully advance the development of our complement product candidates, including CB 4332, may have a material adverse effect on us. To date, we have not successfully commercially marketed, distributed or sold any product candidate. The success
of our business depends primarily upon our ability to successfully advance the development of our product candidates through preclinical studies and clinical trials, have the product candidates approved for sale by the FDA or regulatory authorities
in other countries, and ultimately have the product candidates successfully commercialized by us or a strategic partner. We cannot assure you that the results of our ongoing preclinical studies or future clinical trials will support or justify the
continued development of CB 4332, or that we will receive approval from the FDA, or similar regulatory authorities in other countries, to advance the development of CB 4332. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-24 </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Our product candidates, including MarzAA, CB 4332 and DalcA, must satisfy rigorous
regulatory standards of safety and efficacy before we can advance or complete their clinical development or can be approved for sale. To satisfy these standards, we must engage in expensive and lengthy preclinical studies and clinical trials,
develop acceptable manufacturing processes, and obtain regulatory approval of our complement product candidates. Despite these efforts, our complement product candidates, including MarzAA, CB 4332 and DalcA, may not: </FONT></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">offer therapeutic or other medical benefits over existing drugs or other product candidates
in development to treat the same patient population; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">be proven to be safe and effective in current and future preclinical studies or clinical
trials; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">have the desired effects; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">be free from undesirable or unexpected effects; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">meet applicable regulatory standards; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">be capable of being formulated and manufactured in commercially suitable quantities and at
an acceptable cost; or </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">be successfully commercialized by us or by collaborators. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Even if we demonstrate favorable results in preclinical studies and early-stage clinical trials, we cannot assure you that the results
of late-stage clinical trials will be favorable enough to support the continued development of our product candidates. A number of companies in the pharmaceutical and biopharmaceutical industries have experienced significant delays, setbacks and
failures in all stages of development, including late-stage clinical trials, even after achieving promising results in preclinical testing or early-stage clinical trials. Accordingly, results from completed preclinical studies and early-stage
clinical trials of our complement product candidates, including MarzAA, CB 4332 and DalcA, may not be predictive of the results we may obtain in later-stage trials. Furthermore, even if the data collected from preclinical studies and clinical trials
involving our complement product candidates, demonstrate a favorable safety and efficacy profile, such results may not be sufficient to support the submission of a new drug application or biologics license application (&#147;BLA&#148;) to obtain
regulatory approval from the FDA in the United States or other similar regulatory agencies in other jurisdictions, which is required to market and sell the products. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">MarzAA, CB 4332 and DalcA will require significant additional research and development efforts, the commitment of substantial financial
resources, and regulatory approvals prior to advancing into clinical development or being commercialized by us or collaborators. We cannot assure you that CB 4332 will successfully progress into clinical development or that CB 4332, MarzAA or DalcA
will progress through the drug development process or will result in a commercially viable product. We do not expect CB 4332 or any of our other complement product candidates to be commercialized by us or collaborators for at least several years.
</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>If we experience delays or difficulties in the enrollment of patients in clinical trials, our regulatory approvals could
be delayed or prevented. </B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We or our collaborators may not be able to initiate or continue clinical trials for our product
candidates if we are unable to locate, enroll and maintain enrollment of a sufficient number of eligible patients to participate in these trials as required by the FDA or similar regulatory authorities outside the United States. In particular, there
is a relatively small number of individuals with hemophilia, which may cause delays in enrollment of clinical trials of MarzAA in individuals with hemophilia A and B with an inhibitor, and there are a limited number of individuals with CFI
deficiency for whom CB 4332 can be used in clinical trials. Competitive products or products that reduce the frequency of bleeding among patients treated with our drugs have reduced the likelihood that patients
</FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-25 </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">
will enroll in our clinical trials. Some of our competitors have ongoing clinical trials for product candidates that treat the same indications as our product candidates and thus compete with us
to enroll patients in their clinical trials. The availability of other approved products and other products in clinical trials may limit the number of patients willing to participate in our clinical trials. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Patient enrollment is affected by other factors including: </FONT></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">the severity of the disease under investigation; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">the eligibility criteria for the study in question; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">the perceived risks and benefits of the product candidate under study;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">the efforts to facilitate timely enrollment in clinical trials;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">laboratory testing and turnaround time for samples needed for eligibility assessments;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">the patient referral practices of physicians; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">the ability to monitor patients adequately during and after treatment; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">the proximity and availability of clinical trial sites for prospective patients.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Our inability to enroll a sufficient number of patients for our clinical trials will result in significant
delays and could require us to abandon one or more clinical trials altogether. Enrollment delays in clinical trials conducted by us may also result in increased development costs for our product candidates, which would cause the value of the Company
to decline and limit our ability to obtain additional financing. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>The operations of our third-party manufacturers may be
requisitioned, diverted or allocated by U.S. or foreign government orders such as under emergency, disaster and civil defense declarations in connection with the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic or otherwise. </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Our third-party manufacturers of MarzAA have advised us that they could be required under orders of the U.S. government to allocate
manufacturing capacity to the manufacture or distribution of <FONT STYLE="white-space:nowrap">COVID-19</FONT> vaccines. If any of our third-party manufacturers become subject to acts or orders of U.S. or foreign government entities to allocate
manufacturing capacity to the manufacture or distribution of <FONT STYLE="white-space:nowrap">COVID-19</FONT> vaccines or medical supplies needed to treat <FONT STYLE="white-space:nowrap">COVID-19</FONT> patients, this could delay or interrupt,
perhaps substantially, our supply of clinical trial material for MarzAA which could materially and adversely affect our business. Refer to the risk factor entitled &#147;The outbreak of the novel coronavirus disease,
<FONT STYLE="white-space:nowrap">COVID-19,</FONT> could adversely impact our business, including our preclinical studies and clinical trials.&#148; </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>The coronavirus disease, <FONT STYLE="white-space:nowrap">COVID-19,</FONT> may impact our third-party supply of the raw materials and
components needed for our product candidates, which increases the risk that we will not have sufficient quantities of such product candidates or products or such quantities at an acceptable cost, which could delay, prevent or impair our development
efforts. </B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">If supplies of the raw materials for our product candidates are significantly delayed, or if the third parties
that we engage to supply any materials or to manufacture any products for our preclinical tests and clinical trials should cease to continue to do so for any reason, including due to the effects of the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and the actions undertaken by governments and private enterprises to contain <FONT STYLE="white-space:nowrap">COVID-19,</FONT> we likely would experience delays in advancing these tests and
trials while we identify and qualify replacement suppliers or manufacturers and we may be unable to obtain replacement supplies on terms that are favorable to us. In addition, if we are not able to
</FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-26 </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">
obtain adequate supplies of our product candidates or the substances used to manufacture them, it will be more difficult for us to develop our product candidates and compete effectively.
</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Our current and anticipated dependence upon third-party suppliers may adversely affect our ability to develop product
candidates and could delay our clinical trials and development programs, and otherwise harm our operations and financial condition and increase our costs and expenses. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>We have incurred significant losses since our inception and are expected to continue to incur significant losses for the foreseeable
future. </B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We are a clinical-stage biotechnology company, and we have not yet generated significant revenues. We have
incurred net losses in each year since our inception in August 2002, including net losses of $55.2&nbsp;million and $30.1&nbsp;million for the years ended December&nbsp;31, 2019 and 2018, respectively. In addition, our net loss was
$37.3&nbsp;million for the nine months ended September&nbsp;30, 2020. As of September&nbsp;30, 2020, we had an accumulated deficit of $295.9&nbsp;million. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We are still in the early stages of development of our product candidates, and have no products approved for commercial sale. To date,
we have financed our operations primarily through issuances of shares of common stock, from private placements of convertible preferred stock, and from payments under collaboration agreements. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We have devoted most of our financial resources to research and development, including our preclinical and clinical development
activities. We expect to continue to incur significant expenses and operating losses over the next several years as we continue clinical development of MarzAA, our complement product candidates and DalcA. Our operating losses may fluctuate
significantly from quarter to quarter and year to year. We are expected to continue to incur significant expenses and increasing operating losses for at least the next several years, and our expenses will increase substantially if and as we:
</FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">continue clinical development of MarzAA and DalcA; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">continue preclinical development and begin clinical development of CB 4332 and our other
complement product candidates; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">further develop the manufacturing process for our product candidates;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">attract and retain skilled personnel; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">seek regulatory and marketing approvals for any of our product candidates that successfully
complete clinical studies; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> other product candidates and
technologies; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">make milestone or other payments under collaboration agreements, or any <FONT
STYLE="white-space:nowrap">in-license</FONT> agreements we may enter; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">maintain, protect and expand our intellectual property portfolio;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">create additional infrastructure to support operations as a public company and our product
development and planned future commercialization efforts; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">experience any delays or other issues with any of the above. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-27 </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">In connection with the license granted to us by Pfizer, we agreed to make contingent
cash payments to Pfizer in an aggregate amount equal to up to $17.5&nbsp;million, payable upon the achievement of clinical, regulatory and commercial milestones, the timing of which is uncertain. Following commercialization of any Factor VIIa
products, Pfizer would also receive a single-digit royalty on net product sales on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis for a predefined royalty term. See the section entitled
&#147;Collaborations&#148; in this prospectus supplement. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">In connection with the license agreement with ISU, the Company
will also make up to an aggregate of $19.5&nbsp;million in milestone payments to ISU, inclusive of $2.5&nbsp;million in regulatory and development milestone payment and up to $17.0&nbsp;million in commercial milestone payment, if the applicable
milestones are met. See the section entitled &#147;Collaborations&#148; in this prospectus supplement. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">In connection with
our collaboration with Mosaic regarding our anti-complement program, we have agreed to pay Mosaic a double-digit percentage of funds we receive from Biogen or other sublicensees, or certain milestone payments and royalties if we develop and
commercialize products from the collaboration ourselves. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Further, in connection with the development and manufacturing
agreement that we have with AGC, we have firm work orders with AGC to manufacture MarzAA and DalcA to support our clinical trials totaling $12.4&nbsp;million and the payment obligations remaining as of December&nbsp;31, 2019 was $4.6&nbsp;million.
Furthermore, in connection with the clinical supply services agreement we have with Catalent, we have firm work orders with Catalent to manufacture DalcA to support clinical trials totaling $0.5&nbsp;million and all outstanding amounts were paid
during the nine months ended September&nbsp;30, 2020. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">To become and remain profitable, we must succeed in developing and
eventually commercializing products that generate significant revenue. This will require us to be successful in a range of challenging activities, including completing preclinical testing and clinical trials of product candidates, obtaining
regulatory approval for these product candidates and manufacturing, marketing and selling any products for which regulatory approval is obtained. We are only in the preliminary stages of most of these activities. We may never succeed in these
activities and, even if we do, we may never generate revenues that are significant enough to achieve profitability. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Because
of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. Even if we do
achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Failure to become and remain profitable would depress the value of our common stock and could impair our ability to raise capital, expand
our business, maintain research and development efforts, diversify product offerings or even continue operations. A decline in the value of our common stock could also cause you to lose all or part of your investment. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>We will need additional capital. If we are unable to raise sufficient capital, we will be forced to delay, reduce or eliminate
product development programs. </B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Developing pharmaceutical products, including conducting preclinical studies and clinical
trials, is expensive. We expect our research and development expenses to increase with our ongoing activities, particularly activities related to the continued clinical development of MarzAA, the preclinical and clinical development of our
complement product candidates, and the clinical development of DalcA. We believe that our available cash, cash equivalents and investments will be sufficient to fund our operations for at least the next 12 months. However, we may need to raise
substantial additional capital to complete the development and commercialization of MarzAA, DalcA, or other product candidates, and depending on the availability of capital, may need to delay or cease development of some of our product candidates.
Even if we raise additional capital, we may elect to focus our efforts on one or more development programs and delay or cease other development programs. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Until we can generate sufficient revenue from our product candidates, if ever, we expect to finance future cash needs through public or
private equity offerings, debt financings, corporate collaborations and/or licensing </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-28 </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">
arrangements. Additional funds may not be available when we need them on terms that are acceptable, or at all. If adequate funds are not available, we may be required to delay, reduce the scope
of or eliminate one or more of our research or development programs. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Because successful development of our product
candidates is uncertain, we are unable to estimate the actual funds required to complete research and development and commercialize our products under development. Our future funding requirements, both near and long-term, will depend on many
factors, including, but not limited to: </FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">the initiation, progress, timing, costs and results of clinical trials for our product
candidates in hemophilia, including MarzAA and DalcA; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">the costs and results of preclinical studies or clinical trials of CB 4332 or our other
complement product candidates, and expenses related to potential clinical development of such candidates; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">the number and characteristics of product candidates that we pursue;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">the terms and timing of any future collaboration, licensing or other arrangements that we
may establish; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">the outcome, timing and cost of regulatory approvals; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">the cost of obtaining, maintaining, defending and enforcing intellectual property rights,
including patent rights; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">the effect of competing technological and market developments;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">the cost and timing of completing outsourced manufacturing activities;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">market acceptance of any product candidates for which we may receive regulatory approval;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">the cost of establishing sales, marketing and distribution capabilities for any product
candidates for which we may receive regulatory approval; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">the extent to which we acquire, license or invest in businesses, products or technologies.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>Raising additional funds by issuing securities or through licensing arrangements may cause dilution to
stockholders, restrict our operations or require us to relinquish proprietary rights. </B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">To the extent that we raise
additional capital through the sale of equity or convertible debt securities, stockholders will be diluted, and the terms of these new securities may include liquidation or other preferences that adversely affect the rights of common stockholders.
</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Debt financing, if available at all, may involve agreements that include covenants limiting or restricting our ability to
take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to
relinquish valuable rights to our technologies, product candidates or future revenue streams or grant licenses on terms that are not favorable to us. We may also seek to access the public or private capital markets whenever conditions are favorable,
even if we do not have an immediate need for additional capital at that time. There can be no assurance that we will be able to obtain additional funding if, and when necessary. If we are unable to obtain adequate financing on a timely basis, we
could be required to delay, curtail or eliminate one or more, or all, of our development programs or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-29 </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We currently have an effective registration statement on Form <FONT
STYLE="white-space:nowrap">S-3</FONT> that allows us to offer up to $140&nbsp;million of securities in one or more offerings. Any additional sales in the public market of our common stock or other securities under this shelf registration statement
could adversely affect prevailing market prices for our common stock. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>We have no history of commercialization of
pharmaceutical products, which may make it difficult to evaluate the Company&#146;s prospects. </B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We began operations in
August 2002. Our operations to date have been limited to financing and staffing the Company, developing our technology and product candidates, establishing collaborations and conducting Phase 2 clinical trials on small numbers of patients. We have
not yet demonstrated an ability to successfully conduct a Phase 3 clinical trial, obtain marketing approvals, manufacture a product at commercial scale repeatedly, or conduct sales and marketing activities necessary for successful product
commercialization. Consequently, predictions about the Company&#146;s future product development timelines, clinical trial plans, expenses, success or viability may not be as accurate as they could be if we had a longer operating history or a
history of successfully developing and commercializing pharmaceutical products. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B><I>Risks related to the discovery,
development and commercialization of our product candidates </I></B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>We are focused on the clinical development of MarzAA
and our complement product candidates. Any adverse events, trial failures or material delays in these programs could materially harm our business. </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">The failure of MarzAA to achieve successful clinical trial endpoints, delays in clinical development, unanticipated adverse side
effects, the cessation of clinical development or any other adverse developments or information related to MarzAA, CB 4332 or our other product candidates would significantly harm our business, its prospects and the value of the Company&#146;s
common stock. There is no guarantee that the results of further clinical trials of MarzAA will be positive or will not generate unanticipated safety concerns. If neutralizing antibodies or other adverse events in patients receiving either MarzAA
lead to concerns about patient safety, the long-term efficacy, or commercial viability of MarzAA could be halted. Depending on the availability of additional capital, we may also delay or terminate clinical development of MarzAA. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">MarzAA is not expected to be commercially available in the near term, if at all. Further, its commercial success will depend upon its
acceptance by physicians, patients, third-party payors and other key decision-makers as a therapeutic and cost-effective alternative to currently available products. If we are unable to successfully develop, obtain regulatory approval for and
commercialize MarzAA, our ability to generate revenue from product sales will be significantly delayed and our business will be materially and adversely affected, and we may not be able to earn sufficient revenues to continue as a going concern.
</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Even if the FDA or other regulatory agency approves MarzAA or our other product candidates, the approval may impose
significant restrictions on the indicated uses, conditions for use, labeling, advertising, promotion, marketing and/or production of such product and may impose ongoing commitments or requirements for post-approval studies, including additional
research and development and clinical trials. The FDA and other agencies also may impose various civil or criminal sanctions for failure to comply with regulatory requirements, including withdrawal of product approval. Regulatory approval from
authorities in foreign countries will be needed to market MarzAA or our other product candidates in those countries. Approval by one regulatory authority does not ensure approval by regulatory authorities in other jurisdictions. If we fail to obtain
approvals from foreign jurisdictions, the geographic market for MarzAA or our other product candidates would be limited. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>DalcA has caused and MarzAA or our complement product candidates may cause the generation of neutralizing antibodies, which could
prevent their further development. </B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">MarzAA, CB 4332 and DalcA are protein molecules which may cause the generation of
antibodies in individuals who receive them. Two patients who received DalcA subcutaneously following intravenous dosing developed </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-30 </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">
neutralizing antibodies that inhibit the activity of DalcA. There can be no assurance that such antibodies will not be observed in the future, either in the patients who have already received
DalcA or MarzAA, or in new patients with those products or CB 4332 or our other complement product candidates. If clinical trials demonstrate a treatment-related neutralizing immunological response in individuals that causes safety concerns or would
limit the efficacy of either product candidate, development of the product candidate could be halted. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>MarzAA and DalcA
are in late-stage clinical trials, and all of our other product candidates are still in preclinical development. The regulatory path for MarzAA and DalcA is uncertain. If we are unable to obtain regulatory clearance and commercialize our product
candidates or experience significant delays in doing so, our business will be materially harmed. </B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">MarzAA and DalcA have
completed Phase 2 clinical trials. All our other product candidates are still in preclinical development. Engineered protease biopharmaceuticals are a relatively new class of therapeutics. There can be no assurance as to the length of the trial
period, the number of individuals the FDA or EMA will require to be enrolled in the trials to establish the safety, efficacy, purity and potency of the engineered protease products, or that the data generated in these trials will be acceptable to
the FDA, EMA or other foreign regulatory agencies to support marketing approval. Our ability to generate product revenues, which we do not expect will occur for many years, if ever, will depend heavily on the successful development and eventual
commercialization of our product candidates. The success of our product candidates will depend on several factors, including the following: </FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">successful completion of preclinical studies and clinical trials;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">receipt of marketing approvals from applicable regulatory authorities;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">obtaining and maintaining patent and trade secret protection and regulatory exclusivity for
our product candidates; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">making arrangements with third-party manufacturers for, or establishing, commercial
manufacturing capabilities; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">launching commercial sales of the products, if and when approved, whether alone or in
collaboration with others; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">acceptance of the products, if and when approved, by patients, the medical community and
third-party payors; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">effectively competing with other therapies; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">obtaining and maintaining healthcare coverage and adequate reimbursement;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">protecting our rights in our intellectual property portfolio; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">maintaining a continued acceptable safety profile of the products following approval.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">If we do not achieve one or more of these factors in a timely manner or at all, we could experience
significant delays or an inability to successfully commercialize our product candidates, which would materially harm our business. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#50748a"><B>Clinical drug development involves a lengthy and expensive process with an uncertain outcome. Results from our successful Phase 1 or Phase 2 trials may not be confirmed in later trials, and if serious adverse or unacceptable side
effects are identified during the development of our product candidates, we may need to abandon or limit our development of some of our product candidates. </B></FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-31 </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Clinical testing is expensive, time consuming and uncertain as to outcome. We cannot
guarantee that any preclinical studies and clinical trials will be conducted as planned or completed on schedule, if at all. The clinical development of our product candidates is susceptible to the risk of failure at any stage of drug development,
including failure to demonstrate efficacy in a clinical trial or across a suitable population of patients, the occurrence of severe or medically or commercially unacceptable adverse events, failure to comply with protocols or applicable regulatory
requirements and determination by the FDA or any comparable foreign regulatory authority that a drug product is not approvable. It is possible that even if one or more of our product candidates has a beneficial effect, that effect will not be
detected during clinical evaluation as a result of one or more of a variety of factors, including the size, duration, design, measurements, conduct or analysis of our clinical trials. Conversely, as a result of the same factors, our clinical trials
may indicate an apparent positive effect of a product candidate that is greater than the actual positive effect, if any. Similarly, in our clinical trials we may fail to detect toxicity of or intolerability caused by our product candidates, or
mistakenly believe that our product candidates are toxic or not well tolerated when that is not in fact the case. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">In
addition, the outcome of preclinical studies and early clinical trials may not be predictive of the success of later clinical trials. Our Phase 2 trial of MarzAA was conducted in eleven patients, and DalcA has been dosed repeatedly in a subcutaneous
prophylaxis trial in only six patients. Trials of these product candidates in larger numbers of patients may not have similar efficacy results and could result in adverse effects that were not observed in the earlier trials with smaller numbers of
patients. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage
clinical trials after achieving positive results in earlier development, and we may face similar setbacks. The design of a clinical trial can determine whether our results will support approval of a product and flaws in the design of a clinical
trial may not become apparent until the clinical trial is well advanced. We have limited experience in designing clinical trials and may be unable to design and execute a clinical trial to support marketing approval. In addition, preclinical and
clinical data are often susceptible to varying interpretations and analyses. Many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing
approval for the product candidates. Even if we believe that the results of clinical trials for our product candidates warrant marketing approval, the FDA or comparable foreign regulatory authorities may disagree and may not grant marketing approval
of our product candidates. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">In some instances, there can be significant variability in safety or efficacy results between
different clinical trials of the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the dosing
regimen and other clinical trial protocols and the rate of dropout among clinical trial participants. Any Phase 2, Phase 3 or other clinical trials that we may conduct may not demonstrate the efficacy and safety necessary to obtain regulatory
approval to market our product candidates. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">If our product candidates are associated with undesirable side effects in
clinical trials or have characteristics that are unexpected, we may need to abandon development or limit development of the product candidate to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are
less prevalent, less severe or more acceptable from a risk-benefit perspective. Any such limitations could adversely affect the value of our product candidates or common stock. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>Fast Track designation by the FDA may not actually lead to a faster development or regulatory review or approval process.
</B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">The FDA grants Fast Track designation to therapies that are considered capable of addressing unmet medical needs and
possess the potential to treat serious or life-threatening disease conditions in order to facilitate its development and expedite the review procedure. The FDA has broad discretion in granting Fast Track designation, so even if we believe that a
particular product candidate is eligible for such designation, the FDA </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-32 </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">
could decide not to grant it. Even though Marzeptacog alfa (activated)&#151;or MarzAA has received Fast Track designation in certain indications, we may not experience a faster development
process, review or approval, or receive FDA approval at all, in any of those indications compared to conventional FDA procedures. A Fast Track designation does not change the standards for approval. The FDA may also withdraw Fast Track designation
if it believes that the designation is no longer supported by data from our clinical development program. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B></B><B><I>Risks
related to our reliance on third parties</I></B><B> </B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>Our collaboration with Biogen may not result in successful
product development or payments to us. </B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We have entered into a collaboration and license agreement with Biogen to develop
and commercialize <FONT STYLE="white-space:nowrap">CB&nbsp;2782-PEG</FONT> and our other <FONT STYLE="white-space:nowrap">anti-C3</FONT> proteases for potential treatment of dry AMD and other disorders. We will perform preclinical and manufacturing
activities, and Biogen will be solely responsible for funding the preclinical and manufacturing activities and performing <FONT STYLE="white-space:nowrap">IND-enabling</FONT> activities, worldwide clinical development, and commercialization. Future
revenues from this collaboration depend upon the achievement of milestones and payment of royalties based on product sales after successful product development and regulatory approval. Biogen can terminate this agreement on 60 days&#146; prior
written notice. If Biogen terminates the agreement, our reputation in the business and scientific community may suffer and we will not receive payments from them after termination. If milestones are not achieved or Biogen is unable to successfully
develop and commercialize products from which milestones and royalties are payable, we will not earn the revenues contemplated by the collaboration. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We have limited or no control over the resources that Biogen may devote to the development and commercialization of products under our
agreement. Biogen may not perform its obligations as expected or may breach or terminate the agreement with us or otherwise fail to conduct research, development or commercialization activities successfully or in a timely manner. Further, Biogen may
elect not to develop pharmaceutical products arising out of our collaborative arrangement or may not devote sufficient resources to the development, regulatory approval, manufacture, marketing or sale of these products. If any of these events
occurs, we may not receive collaboration revenue or otherwise realize anticipated benefits from such collaborations, our product development efforts may be delayed and our business, operating results and financial condition could be adversely
affected. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>We expect to seek to establish additional collaborations, and, if we are not able to establish them on
commercially reasonable terms, we may have to alter our development and commercialization plans. </B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Our drug development
programs and the potential commercialization of our product candidates will require substantial additional cash to fund expenses. We have previously relied on collaborators, such as Pfizer and ISU, to contribute to the development of our product
candidates, and we are currently working with Biogen and Mosaic to support the development of our dry AMD product candidates. We may seek one or more additional collaborators for the development and commercialization of one or more of our product
candidates. For example, we may seek a new collaborator to develop MarzAA and might also seek collaborators for DalcA or our earlier stage programs. In addition, full development efforts on the use of our novel proteases for the treatment of other
complement mediated diseases will likely involve significant cost, and we do not expect to conduct any such efforts except in collaboration with one or more partners who are willing to pay for such costs. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We face significant competition in seeking appropriate collaborators. Whether we can reach a definitive agreement with a collaborator
will depend, among other things, upon our assessment of the collaborator&#146;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#146;s evaluation of a number of factors. Those factors may
include the design or results of preclinical trials, the likelihood of approval by the FDA or comparable foreign regulatory authorities and the regulatory pathway for any such approval, the potential market for the product candidate, the costs and
complexities of manufacturing and delivering the product to patients and the potential of competing products. The collaborator may also </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-33 </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">
consider alternative product candidates or technologies for similar indications that may be available for collaboration and whether such a collaboration could be more attractive than the one with
us. There can also be no assurance that any collaboration agreements will be on favorable terms. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Collaborations are complex
and time consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. We may not
be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of the product candidate for which we are seeking to collaborate, reduce or delay our
development program or one or more of our other development programs, delay our potential commercialization or reduce the scope of any sales or marketing activities, and increase our expenditures and undertake development or commercialization
activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we
do not have sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate product revenue. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#50748a"><B>We contract with third parties for the manufacture of our product candidates for preclinical testing and expect to continue to do so for clinical testing and commercialization. This reliance on third parties increases the risk
that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts. </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We currently have no internal capabilities to manufacture our product candidates for clinical use or for preclinical trials following
good manufacturing practices (&#147;GMP&#148;), or good laboratory practices (&#147;GLP&#148;). We expect to rely on one or more third-party contractors to manufacture, package, label and distribute clinical supplies and commercial quantities of any
product candidate that we commercialize following approval for marketing by applicable regulatory authorities. We also expect to rely on one or more third-party contractors to manufacture our product candidates for use in our clinical trials.
Reliance on such third-party contractors entails risks, including: </FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">our inability to identify and negotiate manufacturing and supply agreements with suitable
manufacturers; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">manufacturing delays if our third-party contractors give greater priority to the supply of
other products over our product candidates or otherwise do not satisfactorily perform according to the terms of the agreements between us and them; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">the possible termination or nonrenewal of agreements by our third-party contractors at a
time that is costly or inconvenient for us; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">the possible breach by the third-party contractors of our agreements with them;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">the failure of third-party contractors to comply with applicable regulatory requirements;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">the possible mislabeling of clinical supplies, potentially resulting in the wrong dose
amounts being supplied or active drug or placebo not being properly identified; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">the possibility of clinical supplies not being delivered to clinical sites on time, leading
to clinical trial interruptions, or of drug supplies not being distributed to commercial vendors in a timely manner, resulting in lost sales; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">the possible misappropriation of our proprietary information, including our trade secrets
and <FONT STYLE="white-space:nowrap">know-how.</FONT> </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-34 </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We may incur delays in product development resulting from the need to identify or
qualify manufacturers for our product candidates. Our current and anticipated future dependence upon others for the manufacture of our product candidates may adversely affect our future profit margins and our ability to commercialize any products
that receive marketing approval on a timely and competitive basis. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>We are subject to many manufacturing risks, any of
which could substantially increase our costs and limit supply of our product candidates and any future products. </B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">To
date, our product candidates have been manufactured by third-party manufacturers solely for preclinical studies and relatively small clinical trials. The process of manufacturing MarzAA, DalcA, CB 4332 and our other Complement associated therapeutic
product candidates is complex, highly regulated and subject to several risks, including: </FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">the process of manufacturing biologics is susceptible to product loss due to contamination,
equipment failure, improper installation or operation of equipment, vendor or operator error and improper storage conditions. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects and
other supply disruptions. If microbial, viral or other contaminations are discovered in our products or in the manufacturing facilities in which our products are made, the manufacturing facilities may need to be closed for an extended period of time
to investigate and eliminate the contamination; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">the manufacturing facilities in which our products are made could be adversely affected by
equipment failures, labor and raw material shortages, financial difficulties of our contract manufacturers, including as a result of the evolving effects of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, natural disasters, power
failures, local political unrest and numerous other factors; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">any adverse developments affecting manufacturing operations or the scale up of
manufacturing operations for our products may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls or other interruptions in the supply of our product candidates. We may also have to record inventory
write-offs and incur other charges and expenses for product candidates or drug substances that fail to meet specifications, undertake costly remediation efforts or seek costlier manufacturing alternatives. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Specifically, we have entered into various development, manufacturing and clinical supply services agreements with third-party
manufacturers for drug substance and drug product manufacturing of MarzAA, DalcA and CB 4332. If any of our third-party manufacturers is not able to provide us with sufficient quantities of (i)&nbsp;MarzAA or DalcA for our clinical trials or
(ii)&nbsp;CB 4332 for our preclinical trials on a timely basis, or at all, whether due to production shortages or other supply delays or interruptions resulting from the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic or otherwise,
our preclinical trials, clinical trials or regulatory approval, as applicable, may be delayed. Significant portions of our research and development resources are focused on manufacturing. If any of our third-party manufacturers experiences
difficulties in scaling production or experiences product loss due to contamination, equipment failure, improper installation or operation of equipment, vendor or operator error or improper storage conditions, the potential trials of the affected
product candidate would be delayed, perhaps substantially, which could materially and adversely affect our business. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We have
minimal process development capabilities and have access only to external manufacturing capabilities. We do not have, and we do not currently plan to acquire or develop, the facilities or capabilities to manufacture bulk drug substance or filled
drug product for use in clinical trials or commercialization. Any delay or interruption in the supply of clinical trial material or preclinical trial material could delay the completion of clinical trials or preclinical trials, increase the costs
associated with maintaining such trial programs and, depending upon the period of delay, require us to commence new clinical trials or preclinical trials at additional expense or terminate the trials completely. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-35 </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>We and our contract manufacturers will be subject to significant regulation with
respect to manufacturing our products. The manufacturing facilities on which we will rely may not continue to meet regulatory requirements and have limited capacity. </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">All entities involved in the preparation of therapeutics for clinical studies or commercial sale, including any contract manufacturers
for our product candidates, are subject to extensive regulation. Components of a finished therapeutic product approved for commercial sale or used in late-stage clinical studies must be manufactured in accordance with GMP. These regulations govern
manufacturing processes and procedures (including record keeping) and the implementation and operation of quality systems to control and assure the quality of investigational products and products approved for sale. Poor control of production
processes can lead to the introduction of adventitious agents or other contaminants, or to inadvertent changes in the properties or stability of our product candidates that may not be detectable in final product testing. We or our contract
manufacturers must supply all necessary documentation in support of a BLA on a timely basis and must adhere to the FDA&#146;s GLP and GMP regulations enforced by the FDA through its facilities inspection program. Our facilities and quality systems
and the facilities and quality systems of some or all our third-party contractors must pass a <FONT STYLE="white-space:nowrap">pre-approval</FONT> inspection for compliance with the applicable regulations as a condition of regulatory approval of our
product candidates. In addition, the regulatory authorities may, at any time, audit or inspect a manufacturing facility involved with the preparation of our product candidates or the associated quality systems for compliance with the regulations
applicable to the activities being conducted. If these facilities do not pass a <FONT STYLE="white-space:nowrap">pre-approval</FONT> plant inspection or do not have a GMP compliance status acceptable for the FDA, FDA approval of the products will
not be granted. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">The regulatory authorities also may, at any time following approval of a product for sale, audit our
manufacturing facilities or those of our third-party contractors. If any such inspection or audit identifies a failure to comply with applicable regulations or if a violation of our product specifications or applicable regulations occurs independent
of such an inspection or audit, we or the relevant regulatory authority may require remedial measures that may be costly and/or time-consuming for us or a third-party to implement and that may include the temporary or permanent suspension of a
clinical study or commercial sales or the temporary or permanent closure of a facility. Any such remedial measures imposed upon us or third parties with whom we contract could materially harm our business. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">If we or any of our third-party manufacturers fail to maintain regulatory compliance, the FDA can impose regulatory sanctions including,
among other things, refusal to approve a pending application for a new drug product or biologic product, or revocation of a <FONT STYLE="white-space:nowrap">pre-existing</FONT> approval. As a result, our business, financial condition and results of
operations may be materially harmed. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Additionally, if supply from one approved manufacturer is interrupted, there could be a
significant disruption in commercial supply. An alternative manufacturer would need to be qualified through a BLA supplement which could result in further delay. The regulatory agencies may also require additional studies if a new manufacturer is
relied upon for commercial production. Switching manufacturers may involve substantial costs and is likely to result in a delay in our desired clinical and commercial timelines. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">These factors could cause the delay of clinical studies, regulatory submissions, required approvals or commercialization of our product
candidates, cause us to incur higher costs and prevent us from commercializing our products successfully. Furthermore, if our suppliers fail to meet contractual requirements, and we are unable to secure one or more replacement suppliers capable of
production at a substantially equivalent cost, our clinical studies may be delayed, or we could lose potential revenue. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>We rely on third parties to conduct our clinical trials, and those third parties may not perform satisfactorily, including failing to
meet deadlines for the completion of such trials. </B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We rely on third parties such as contract research organizations
(&#147;CROs&#148;), medical institutions and clinical investigators to enroll qualified patients and conduct, supervise and monitor clinical trials. Our reliance on these </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-36 </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">
third parties for clinical development activities will reduce our control over these activities. Our reliance on these third parties, however, will not relieve us of our regulatory
responsibilities, including ensuring that our clinical studies are conducted in accordance with good clinical practices, and the investigational plan and protocols contained in the relevant regulatory application, such as an investigational new drug
application, or IND. In addition, the CROs with whom we contract may not complete activities on schedule or may not conduct our preclinical studies or clinical studies in accordance with regulatory requirements or our clinical study design. If these
third parties do not successfully carry out their contractual duties or meet expected deadlines, our efforts to obtain regulatory approvals for, and to commercialize, our product candidates may be delayed or prevented. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B><I>Risks related to employee matters, managing growth and our business operations </I></B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel.
</B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Our ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon our ability to
attract and retain highly qualified managerial, scientific and medical personnel. We are highly dependent on our executive management and scientific personnel. We do not maintain &#147;key man&#148; insurance policies on the lives of these
individuals or the lives of any of our other employees. In addition, we will need to add personnel to achieve our business objectives. The loss of the services of any of our executive officers, other key employees, and our inability to find suitable
replacements, or our inability to hire new clinical development and manufacturing personnel, could result in delays in product development and harm our business. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We conduct operations at our facility in the San Francisco Bay Area. This region is headquarters to many other biopharmaceutical
companies and many academic and research institutions. Competition for skilled personnel in our market is intense and may limit our ability to hire and retain highly qualified personnel on acceptable terms or at all. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">To induce valuable employees to remain at Catalyst, in addition to salary and cash incentives, we have provided stock options that vest
over time. The value to employees of stock options that vest over time may be significantly affected by movements in the Company&#146;s stock price that are beyond our control and may at any time be insufficient to counteract more lucrative offers
from other companies. Despite our efforts to retain valuable employees, members of management and scientific and development teams may terminate their employment with the Company on short notice. Our employees are under <FONT
STYLE="white-space:nowrap">at-will</FONT> employment arrangements, which means that any of our employees can leave employment with Catalyst at any time, with or without notice. Failure to retain, replace or recruit personnel could harm our business.
</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>Our employees, principal investigators, consultants and commercial partners may engage in misconduct or other improper
activities, including <FONT STYLE="white-space:nowrap">non-compliance</FONT> with regulatory standards and requirements and insider trading. </B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#50748a">We are exposed to the risk of fraud or other misconduct by our employees, principal investigators, consultants and collaborators. Misconduct by these parties could include intentional failures to comply with the regulations of the
FDA and <FONT STYLE="white-space:nowrap">non-US</FONT> regulators, to provide accurate information to the FDA and <FONT STYLE="white-space:nowrap">non-US</FONT> regulators, to comply with healthcare fraud and abuse laws and regulations in the United
States and abroad, to report financial information or data accurately or to disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations
intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive
programs and other business arrangements. Such misconduct could also involve the improper use of information obtained during clinical studies that could result in regulatory sanctions and cause serious harm to our reputation. It is not always
possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us
</FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-37 </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">
from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us and we are not
successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>We will continue to incur significant costs as a result of operating as a public company, and our management is required to devote
substantial time to compliance initiatives. </B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">As a public company, we have and will continue to incur significant legal,
accounting and other expenses that we did not incur as a private company, including costs associated with public company reporting and corporate governance requirements, in order to comply with the rules and regulations imposed by the Sarbanes-Oxley
Act and the Dodd-Frank Wall Street Reform and Consumer Protection (the &#147;Dodd-Frank Act&#148;), as well as rules implemented by the SEC and Nasdaq. Stockholder activism, the political environment and the current high level of government
intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways that are not currently anticipated.
Our management and other personnel need to devote a substantial amount of time to these compliance initiatives. In addition, these rules and regulations make it difficult and expensive for us to obtain director and officer liability insurance, and
we may be required to incur substantial costs to maintain our current levels of such coverage. We expect that we will annually incur significant expenses to comply with the requirements imposed on us as a public company. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>We or the third parties upon whom we depend may be adversely affected by earthquakes or other natural disasters and our business
continuity and disaster recovery plans may not adequately protect us from a serious disaster. </B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Our offices are located in
the San Francisco Bay Area, which is prone to earthquakes. Earthquakes or other natural disasters could severely disrupt our operations, and have a material adverse effect on our business, results of operations, financial condition and prospects. If
a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure, such as the manufacturing facilities of our third-party contract
manufacturers, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. The disaster recovery and business continuity plans we have in place
currently are limited and are unlikely to prove adequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans that,
particularly when taken together with our lack of earthquake insurance, could have a material adverse effect on our business. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B><I>Risks related to our intellectual property </I></B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>If we are unable to obtain, protect or enforce intellectual property rights related to our product candidates, we may not be able to
compete effectively in our markets. </B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We rely upon a combination of patents, trade secret protection and confidentiality
agreements to protect the intellectual property related to our product candidates. The strength of patents in the biotechnology and pharmaceutical field involves complex legal and scientific questions and can be uncertain. Third parties may
challenge the validity, enforceability or scope of our patents, which may result in those patents being narrowed or invalidated. The patent applications that we own may fail to result in issued patents with claims that cover our product candidates
in the United States or in other foreign countries. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property, provide exclusivity for our product candidates or prevent
others from designing around our claims. Certain of our patents also cover processes, for which enforcement can be difficult. Any of these outcomes could impair our ability to prevent competition from third parties that may have an adverse impact on
our business. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-38 </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">If the patents or patent applications we hold or have
<FONT STYLE="white-space:nowrap">in-licensed</FONT> for our programs or product candidates are invalidated or fail to issue, if their breadth or strength of protection is threatened, or if they fail to provide meaningful exclusivity for our product
candidates, it could threaten our ability to commercialize future products. Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product candidate under patent protection could be reduced. In
addition, patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years after it is filed. Various extensions may be available; however the life of a patent, and the protection it affords, is
limited. Once the patent life has expired for a product, we may be open to competition from generic medications. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">In addition
to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary <FONT STYLE="white-space:nowrap">know-how</FONT> that is not patentable or that we elect not to patent and other elements
of our product candidate discovery and development processes that involve proprietary <FONT STYLE="white-space:nowrap">know-how,</FONT> information or technology that is not covered by patents. However, trade secrets can be difficult to protect. We
seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with our employees, consultants, scientific advisors and contractors. We also seek to preserve the integrity and confidentiality of our
data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security
measures may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Although we expect all of our employees and consultants to assign their inventions to us, and all of our employees, consultants,
advisors and any third parties who have access to our proprietary <FONT STYLE="white-space:nowrap">know-how,</FONT> information or technology to enter into confidentiality agreements, we cannot provide any assurances that all such agreements have
been duly executed or that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information
and techniques. Misappropriation or unauthorized disclosure of our trade secrets could impair our competitive position and may have a material adverse effect on our business. Additionally, if the steps taken to maintain our trade secrets are deemed
inadequate, we may have insufficient recourse against third parties for misappropriating the trade secret. In addition, others may independently discover our trade secrets and proprietary information. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Further, filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively
expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect proprietary rights to the same extent
or in the same manner as the laws of the United States. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and abroad. If we are unable to prevent material disclosure of
the <FONT STYLE="white-space:nowrap">non-patented</FONT> intellectual property related to our technologies to third parties, and there is no guarantee that we will have any such enforceable trade secret protection, we may not be able to establish or
maintain a competitive advantage in our market, which could materially adversely affect our business, results of operations and financial condition. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>Third-party claims of intellectual property infringement or challenging the inventorship or ownership of our patents may prevent or
delay our development and commercialization efforts. </B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Our commercial success depends in part on avoiding infringement of
the patents and proprietary rights of third parties. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries,
including patent infringement lawsuits, interferences, oppositions and <I>inter partes </I>reexamination proceedings before the USPTO, and corresponding foreign patent offices. Numerous U.S. and foreign issued patents and pending patent
applications, which are owned by third parties, exist in the fields in which we are pursuing development candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product
candidates may be subject to claims of infringement of the patent rights of third parties. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-39 </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Third parties may assert that the manufacture, use or sale of our product candidates
infringes patents held by such third parties, or that we are employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims to compositions of matter, materials, formulations,
methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued
patents that our product candidates may infringe. There is a patent family pending in the U.S. and Europe in which claims that may read on MarzAA have been filed. We, however, do not believe such claims are patentable. If they were to issue, we
would take appropriate action to challenge their enforceability and/or validity. We are also aware of additional patents that have been issued in the United States and Europe that have claims related to Factor VII. We do not believe that MarzAA does
or will infringe any valid claims in such patents. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We are aware of a patent family that includes issued patents in the
United States, Australia, Israel, Malaysia, New Zealand and Japan, and pending applications in Europe and Canada. The patents and pending applications may include claims that may read on a contemplated FXa clinical candidate. There is prior art that
we believe discloses subject matter on which a challenge to the patentability of such claims can be based. In the event that development of the FXa candidate is pursued we would, if necessary, consider appropriate action to challenge such claims.
</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">In addition, we have received confidential and proprietary information from third parties, and we employ individuals who
were previously employed at other biotechnology or pharmaceutical companies. We may be subject to claims that our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed confidential information of these
third parties or our employees&#146; former employers. Litigation may be necessary to defend against these claims. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Parties
making claims against us may obtain injunctive or other equitable relief that could effectively block our ability to further develop and commercialize one or more of our product candidates unless we redesigned infringing products (which may be
impossible) or obtained a license under the applicable patents (which may not be available on commercially reasonable terms or at all), or until such patents expire. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>We may be involved in lawsuits to protect or enforce our patents. </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Competitors may infringe our patents. To counter infringement or unauthorized use, we or our collaborators may be required to file
infringement claims that can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that one of our patents is not valid, is unenforceable and/or is not infringed, or may refuse to stop the other party from
using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated or interpreted
narrowly and could put our patent applications at risk of not issuing. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Interference proceedings provoked by third parties or
brought by us may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of our licensors. An unfavorable outcome could require us to cease using the related technology or to attempt to
license rights from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. We may not be able to prevent, alone or with our licensors, misappropriation of our
intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#50748a">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type
of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse
effect on the price of our common stock. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-40 </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>Intellectual property litigation could cause us to spend substantial resources and
distract our personnel from their normal responsibilities. </B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Even if resolved in our favor, litigation or other legal
proceedings relating to intellectual property claims, regardless of their merit, would cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. In the event of a successful
claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#146; fees for willful infringement, in addition to paying royalties, redesign infringing products or obtain one or more licenses from
third parties, which may be impossible or require substantial time and monetary expenditure. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts
or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for
development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs
of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to
compete in the marketplace. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>We may need to license certain intellectual property from third parties, and such licenses
may not be available or may not be available on commercially reasonable terms. </B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">A third-party may hold intellectual
property, including patent rights, that is important or necessary to the development of our products. It may be necessary for us to use the patented or proprietary technology of third parties to commercialize our products, in which case we would be
required to obtain a license from these third parties on commercially reasonable terms, or our business could be harmed, possibly materially. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#50748a"><B><I>Risks related to regulatory approval of our product candidates and other legal compliance matters </I></B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#50748a"><B>If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals, we will not be able to commercialize our product candidates, and our ability to generate revenue will be materially impaired.
</B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">While we have multiple drug candidates in clinical and advanced preclinical development for a range of diseases, we have
not yet submitted BLAs for our engineered human proteases to the FDA, or similar approval filings to comparable foreign authorities. Submission of a BLA requires extensive preclinical and clinical data and supporting information that demonstrates
the product candidate&#146;s safety, purity, and potency, also known as safety and effectiveness, for each desired indication. A BLA must also include significant information regarding the chemistry, manufacturing and controls for the product.
MarzAA has completed a Phase 2 clinical trial, and DalcA is completing a Phase 2 clinical trial. However, failure of one or more clinical trials can occur at any stage in the clinical trial process. Accordingly, the regulatory pathway for our
product candidates is still uncertain, complex, and lengthy, and ultimately, approval may not be obtained. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We may experience
delays in completing planned clinical trials for a variety of reasons, including delays related to: </FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">the availability of financial resources to commence and complete the planned trials;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">inability to reach agreement on acceptable terms with prospective CROs and clinical trial
sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">obtaining approval at each clinical trial site by an independent institutional review board
(&#147;IRB&#148;); </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-41 </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">recruiting suitable patients to participate in trials; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">having patients complete a trial or return for post-treatment <FONT
STYLE="white-space:nowrap">follow-up;</FONT> </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">clinical trial sites deviating from trial protocol or dropping out of a trial;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">adding new clinical trial sites; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">manufacturing sufficient quantities of qualified materials under Current Good Manufacturing
Practice (&#147;cGMPs&#148;) regulations and applying them on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">subject-by-subject</FONT></FONT> basis for use in clinical trials. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We could also experience delays in obtaining approval if physicians encounter unresolved ethical issues associated with enrolling
patients in clinical trials of our product candidates in lieu of prescribing existing treatments that have established safety and efficacy profiles given the serious nature of the diseases for the core indications for our product candidates.
Additionally, a clinical trial may be suspended or terminated by us, the IRBs for the institutions in which the trials are being conducted, the Data Monitoring Committee for the trial, or by the FDA or other regulatory authorities for a number of
reasons, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the
imposition of a clinical hold, unforeseen safety issues, or adverse side effects, failure to demonstrate a benefit from using a product candidate, changes in governmental regulations or administrative actions or lack of adequate funding to continue
the clinical trial. In addition, the FDA review and approval process could be delayed by any future shutdown of the U.S. government, and our development activities could be harmed or delayed as a result. If we experience termination of, or delays in
the completion of, any clinical trial of our product candidates, our ability to commercialize our product candidates will be harmed and our ability to generate revenue will be materially impaired. Additionally, delays in completing trials will
increase costs, slow down our product development and approval process, and impair our ability to commence product sales and generate revenue. Many of the factors that could create or lead to a delay in the commencement or completion of clinical
trials may lead to the denial of regulatory approval for our product candidates. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>The FDA may disagree with our regulatory
plan and we may fail to obtain regulatory approval of our product candidates. </B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">The results of clinical trials we conduct
may not support regulatory approval of our product candidates. Our product candidates could fail to receive regulatory approval for many reasons, including the following: </FONT></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">the FDA or comparable foreign regulatory authorities may disagree with the design or
implementation of our clinical trials; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">We may be unable to demonstrate to the satisfaction of the FDA or comparable foreign
authorities that our product candidates are safe and effective for any of their proposed indications; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">the results of clinical trials may not meet the level of statistical significance required
by the FDA or comparable foreign regulatory authorities for approval; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">We may be unable to demonstrate that our product candidates&#146; clinical and other
benefits outweigh their safety risks; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">the FDA or comparable foreign regulatory authorities may disagree with our interpretation
of data from preclinical studies or clinical trials; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-42 </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">the data collected from clinical trials of our product candidates may not be sufficient to
the satisfaction of the FDA or comparable foreign regulatory authorities to support the submission of a BLA or other comparable submission in foreign jurisdictions or to obtain regulatory approval in the United States or elsewhere;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing
processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">the approval policies or regulations of the FDA or comparable foreign regulatory
authorities may significantly change in a manner rendering our clinical data insufficient for approval. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>Our relationships with customers and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other
healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings. </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Healthcare providers, physicians and third-party payors will play a primary role in the recommendation and prescription of any product
candidates for which we obtain marketing approval. Our future arrangements with third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or
financial arrangements and relationships through which we would market, sell and distribute our products. As a pharmaceutical company, even though we do not and may not control referrals of healthcare services or bill directly to Medicare, Medicaid
or other third-party payors, federal and state healthcare laws and regulations pertaining to fraud and abuse and patients&#146; rights are and will be applicable to our business. These regulations include: </FONT></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">the Federal Healthcare Anti-Kickback Statute that prohibits, among other things, persons
from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or
recommendation of, any good or service, for which payment may be made under a federal healthcare program such as Medicare and Medicaid, and which will constrain our marketing practices and the marketing practices of our licensees, educational
programs, pricing policies, and relationships with healthcare providers or other entities; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">the federal physician self-referral prohibition, commonly known as the Stark Law, which
prohibits physicians from referring Medicare or Medicaid patients to providers of &#147;designated health services&#148; with whom the physician or a member of the physician&#146;s immediate family has an ownership interest or compensation
arrangement, unless a statutory or regulatory exception applies; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">federal false claims laws that prohibit, among other things, individuals or entities from
knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other government reimbursement programs that are false or fraudulent, and which may expose entities that provide coding and billing advice to customers
to potential criminal and civil penalties, including through civil whistleblower or qui tam actions, and including as a result of claims presented in violation of the Federal Healthcare Anti-Kickback Statute, the Stark Law or other
healthcare-related laws, including laws enforced by the FDA; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">the federal Health Insurance Portability and Accountability Act of 1996
(&#147;HIPAA&#148;), which imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program and also created federal criminal laws that prohibit knowingly and willfully falsifying, concealing or covering up a
material fact or making any materially false statements in connection with the delivery of or payment for healthcare benefits, items or services that, as amended by the Health Information
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-43 </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">
Technology for Economic and Clinical Health Act (&#147;HITECH&#148;), also imposes obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and
transmission of individually identifiable health information; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">federal physician sunshine requirements under the ACA, which requires manufacturers of
approved drugs, devices, biologics and medical supplies to report annually to the U.S. Department of Health and Human Services or HHS, information related to payments and other transfers of value to physicians, other healthcare providers, and
teaching hospitals, and ownership and investment interests held by physicians and other healthcare providers and their immediate family members and applicable group purchasing organizations; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">the Federal Food, Drug, and Cosmetic Act, which, among other things, strictly regulates
drug product marketing, prohibits manufacturers from marketing drug products for <FONT STYLE="white-space:nowrap">off-label</FONT> use and regulates the distribution of drug samples; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">state and foreign law equivalents of each of the above federal laws, such as anti-kickback
and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by <FONT STYLE="white-space:nowrap">non-governmental</FONT> third-party payors, including private insurers, state
laws requiring pharmaceutical companies to comply with the pharmaceutical industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government and which may require drug manufacturers to report
information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures, and state and foreign laws governing the privacy and security of health information in specified circumstances, many
of which differ from each other in significant ways and often are not preempted by federal laws such as HIPAA, thus complicating compliance efforts. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will
involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws
and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines,
imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations. If any physicians or other healthcare providers or entities with whom we expect to do business
are found to not be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>Our results of operations may be adversely affected by current and potential future healthcare legislative and regulatory actions.
</B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Legislative and regulatory actions affecting government prescription drug procurement and reimbursement programs occur
relatively frequently. In the United States, the ACA was enacted in 2010 to expand healthcare coverage. Since then, numerous efforts have been made to repeal, amend or administratively limit the ACA in whole or in part. For example, the Tax Cuts and
Jobs Act, signed into law by President Trump in 2017, repealed the individual health insurance mandate, which is considered a key component of the ACA. In December 2018, a Texas federal district court struck down the ACA on the grounds that the
individual health insurance mandate is unconstitutional, although this ruling has been stayed pending appeal. The ongoing challenges to the ACA and new legislative proposals have resulted in uncertainty regarding the ACA&#146;s future viability and
destabilization of the health insurance market. The resulting impact on our business is uncertain and could be material. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Efforts to control prescription drug prices could also have a material adverse effect on our business. For example, in 2018, President
Trump and the Secretary of the U.S. Department of Health and Human Services (&#147;HHS&#148;) </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-44 </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">
released the &#147;American Patients First Blueprint&#148; and have begun implementing certain portions. The initiative includes proposals to increase generic drug and biosimilar competition,
enable the Medicare program to negotiate drug prices more directly and improve transparency regarding drug prices and ways to lower consumers&#146; <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs.
The Trump administration also proposed to establish an &#147;international pricing index&#148; that would be used as a benchmark to determine the costs and potentially limit the reimbursement of drugs under Medicare Part B. Among other
pharmaceutical manufacturer industry-related proposals, Congress has proposed bills to change the Medicare Part D benefit to impose an inflation-based rebate in Medicare Part D and to alter the benefit structure to increase manufacturer
contributions in the catastrophic phase. The volume of drug pricing-related bills has dramatically increased under the current Congress, and the resulting impact on our business is uncertain and could be material. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">In addition, many states have proposed or enacted legislation that seeks to indirectly or directly regulate pharmaceutical drug pricing,
such as by requiring biopharmaceutical manufacturers to publicly report proprietary pricing information or to place a maximum price ceiling on pharmaceutical products purchased by state agencies. For example, in 2017, California&#146;s governor
signed a prescription drug price transparency state bill into law, requiring prescription drug manufacturers to provide advance notice and explanation for price increases of certain drugs that exceed a specified threshold. Both Congress and state
legislatures are considering various bills that would reform drug purchasing and price negotiations, allow greater use of utilization management tools to limit Medicare Part D coverage, facilitate the import of lower-priced drugs from outside the
United States and encourage the use of generic drugs. Such initiatives and legislation may cause added pricing pressures on our products. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#50748a">Changes to the Medicaid program at the federal or state level could also have a material adverse effect on our business. Proposals that could impact coverage and reimbursement of our products, including giving states more
flexibility to manage drugs covered under the Medicaid program and permitting the <FONT STYLE="white-space:nowrap">re-importation</FONT> of prescription medications from Canada or other countries, could have a material adverse effect by limiting our
products&#146; use and coverage. Furthermore, state Medicaid programs could request additional supplemental rebates on our products as a result of an increase in the federal base Medicaid rebate. To the extent that private insurers or managed care
programs follow Medicaid coverage and payment developments, they could use the enactment of these increased rebates to exert pricing pressure on our products, and the adverse effects may be magnified by their adoption of lower payment schedules.
</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Other proposed regulatory actions affecting manufacturers could have a material adverse effect on our business. It is
difficult to predict the impact, if any, of any such proposed legislative and regulatory actions or resulting state actions on the use and reimbursement of our products in the United States, but our results of operations may be adversely affected.
</FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>We are subject to evolving privacy and data protection laws, including HIPAA and the EU General Data Protection
Regulation (&#147;GDPR&#148;). If we fail to protect personal information or comply with existing or future data protection regulations, our business, financial condition, results of operations and prospects may be materially adversely affected.
</B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Numerous state and federal laws and regulations govern the collection, dissemination, use, privacy, confidentiality,
security, availability, integrity, and other processing of personal information. HIPAA establishes a set of national privacy and security standards for the protection of protected health information (as defined in HIPAA) (&#147;PHI&#148;) by health
plans, healthcare clearinghouses and certain healthcare providers, referred to as covered entities, and the business associates with whom such covered entities contract for services. HIPAA requires covered entities and business associates, such as
us, to develop and maintain policies with respect to the protection of, use and disclosure of electronic PHI, including the adoption of administrative, physical and technical safeguards to protect such information, and certain notification
requirements in the event of a data breach. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-45 </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">By virtue of our clinical trial activities in Europe, we are also subject to European
data protection laws, including the GDPR (as implemented in the European Economic Area (the &#147;EEA&#148;) and the United Kingdom). The GDPR which came into effect on May&nbsp;25, 2018, establishes stringent requirements applicable to the
processing of personal data (<I>i.e</I>., data which identifies an individual or from which an individual is identifiable), affords various data protection rights to individuals (e.g., the right to erasure of personal data) and imposes potential
penalties for serious breaches of up to 4.0% annual worldwide turnover or &#128;20&nbsp;million, whichever is greater. Individuals (<I>e.g</I>., study subjects) also have a right to compensation for financial or
<FONT STYLE="white-space:nowrap">non-financial</FONT> losses (<I>e.g</I>., distress). There may be circumstances under which a failure to comply with the GDPR, or the exercise of individual rights under the GDPR, would limit our ability to utilize
clinical trial data collected on study subjects. The GDPR imposes additional responsibility and liability in relation to our processing of personal data. This may be onerous and materially adversely affect our business, financial condition, results
of operations and prospects. The GDPR also prohibits the international transfer of personal data from the EEA/UK to countries outside of the EEA/United Kingdom unless made to a country deemed to have adequate data privacy laws by the European
Commission or a data transfer mechanism has been put in place. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">In addition, the interpretation and application of consumer,
health-related and data protection laws in the United States, Europe and elsewhere are often uncertain, contradictory and in flux. It is possible that these laws may be interpreted and applied in a manner that is inconsistent with our practices. If
so, this could result in government-imposed fines or orders requiring that we change our practices, which could adversely affect our business. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#50748a">In addition, we are subject to various U.S. state laws which may require us to modify our data processing practices and policies and to incur substantial costs and expenses in an effort to comply. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or
incur costs that could harm our business. </B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We are subject to numerous environmental, health and safety laws and
regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. From time to time and in the future, our operations may involve the use of hazardous and flammable
materials, including chemicals and biological materials, and may also produce hazardous waste products. Even if we contract with third parties for the disposal of these materials and waste products, we cannot completely eliminate the risk of
contamination or injury resulting from these materials. In the event of contamination or injury resulting from the use or disposal of our hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our
resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We maintain workers&#146; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees
resulting from the use of hazardous materials, but this insurance may not provide adequate coverage against potential liabilities. However, we do not maintain insurance for environmental liability or toxic tort claims that may be asserted against
us. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">In addition, we may incur substantial costs to comply with current or future environmental, health and safety laws and
regulations. Current or future environmental laws and regulations may impair our research, development or production efforts that could adversely affect our business, financial condition, results of operations or prospects. In addition, failure to
comply with these laws and regulations may result in substantial fines, penalties or other sanctions. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-46 </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>We face potential product liability, and, if successful claims are brought against
us, we may incur substantial liability and costs. If the use of our product candidates harms patients or is perceived to harm patients even when such harm is unrelated to our product candidates, regulatory approvals could be revoked or otherwise
negatively impacted and we could be subject to costly and damaging product liability claims. </B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">The use of our product
candidates in clinical trials and the sale of any products for which we obtain marketing approval exposes us to the risk of product liability claims. Product liability claims might be brought against us by consumers, healthcare providers,
pharmaceutical companies or others selling or otherwise coming into contact with our products. There is a risk that our product candidates may induce adverse events. If we cannot successfully defend against product liability claims, we could incur
substantial liability and costs. In addition, regardless of merit or eventual outcome, product liability claims may result in: </FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">impairment of our business reputation; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">withdrawal of clinical trial participants; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">costs due to related litigation; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">distraction of management&#146;s attention from our primary business;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">substantial monetary awards to patients or other claimants; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">the inability to commercialize our product candidates; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">decreased demand for our product candidates, if approved for commercial sale.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We carry product liability insurance of $10,000,000 per occurrence and $10,000,000 aggregate limit. We
believe our product liability insurance coverage is sufficient for our current clinical programs; however, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability.
If we obtain marketing approval for product candidates, we intend to expand our insurance coverage to include the sale of commercial products; however, we may be unable to obtain product liability insurance on commercially reasonable terms or in
adequate amounts. On occasion, large judgments have been awarded in class action lawsuits based on drugs or medical treatments that had unanticipated adverse effects. A successful product liability claim or series of claims brought against us could
cause our stock price to decline and, if judgments exceed insurance coverage, could adversely affect our results of operations and business. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#50748a">Patients with the diseases targeted by our product candidates are often already in severe and advanced stages of disease and have both known and unknown significant <FONT STYLE="white-space:nowrap">pre-existing</FONT> and
potentially life-threatening health risks. During treatment, patients may suffer adverse events, including death, for reasons that may be related to our product candidates. Such events could subject us to costly litigation, require us to pay
substantial amounts of money to injured patients, delay, negatively impact or end our opportunity to receive or maintain regulatory approval to market our products, or require us to suspend or abandon our commercialization efforts. Even in a
circumstance in which we do not believe that an adverse event is related to our products, the investigation into the circumstance may be time-consuming or inconclusive. These investigations may interrupt our sales efforts, delay our regulatory
approval process in other countries, or impact and limit the type of regulatory approvals our product candidates receive or maintain. As a result of these factors, a product liability claim, even if successfully defended, could have a material
adverse effect on our business, financial condition, results of operations, or cash flows. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-47 </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B><I>Risks related to commercialization of our product candidates </I></B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>Even if any of our product candidates receives marketing approval, we may fail to achieve the degree of market acceptance by
physicians, patients, third-party payors and others in the medical community necessary for commercial success. </B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">If any of
our product candidates receives marketing approval, we may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. For example, current hemophilia treatments like
intravenous NovoSeven RT are well established in the medical community, and doctors may continue to rely on these treatments. If our product candidates do not achieve an adequate level of acceptance, we may not generate significant product revenues
and we may not become profitable. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on several factors, including: </FONT></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">the subcutaneous efficacy and potential advantages compared with alternative treatments;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">our ability to offer our products for sale at competitive prices;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">the convenience and ease of subcutaneous administration compared with alternative
treatments; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">the willingness of the target patient population to try new therapies and of physicians to
prescribe these therapies; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">the strength of marketing and distribution support; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">the availability of third-party coverage and adequate reimbursement;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">the prevalence and severity of any side effects; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">any restrictions on the use of our products together with other medications.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>Our product candidates are years away from regulatory approval. </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">MarzAA and DalcA are not expected to be commercially available for several years, if at all. Further, the commercial success of either
product candidate will depend upon its acceptance by physicians, individuals, third-party payors and other key decision-makers as a therapeutic and cost-effective alternative to products available at the time, which may include competing products
currently under development by others. See &#147;We face substantial competition that may result in others discovering, developing or commercializing products before or more successfully than we do.&#148; If we are unable to successfully develop,
obtain regulatory approval in a timely manner (including due to reasons that are beyond our control, such as changes in regulations or a shutdown of the federal government, including the FDA) for and commercialize MarzAA or DalcA, our ability to
generate revenue from product sales will be significantly delayed and our business will be materially and adversely affected, and we may not be able to earn sufficient revenues to continue as a going concern. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Even if the FDA or other regulatory agency approves MarzAA or DalcA, the approval may impose significant restrictions on the indicated
uses, conditions for use, labeling, advertising, promotion, marketing and/or production of such product and may impose ongoing commitments or requirements for post-approval studies, including additional research and development and clinical trials.
The FDA and other agencies also may impose various civil or criminal sanctions for failure to comply with regulatory requirements, including withdrawal of product approval. Regulatory approval from authorities in foreign countries will be needed to
market MarzAA or DalcA in those countries. Approval by one regulatory authority does not ensure approval by regulatory authorities in other jurisdictions. If we fail to obtain approvals from foreign jurisdictions, the geographic market for MarzAA or
DalcA would be limited. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-48 </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>If we are unable to establish sales, marketing and distribution capabilities, we
may not be successful in commercializing our product candidates if they are approved. </B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We have not yet established a
sales, marketing or product distribution infrastructure for our other product candidates, which are still in preclinical or early clinical development. Except for ISU Abxis&#146; rights to commercialize DalcA in South Korea, we generally expect to
retain commercial rights for the Company&#146;s hemophilia product candidates. We believe that it will be possible to access the United States hemophilia market through a focused, specialized sales force. However, we have not yet developed a
commercial strategy for hemophilia products outside of the United States, or for any other of our product candidates. To achieve commercial success for any product for which we obtain marketing approval, we will need to establish a sales and
marketing organization within the United States and to develop a strategy for sales outside of the United States. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">There are
risks involved with establishing internal sales, marketing and distribution capabilities. For example, recruiting and training a sales force is expensive and time consuming and could delay any product launch. If the commercial launch of a product
candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our
investment would be lost if we cannot retain or reposition our sales and marketing personnel. If we are unable to establish sales, marketing and distribution capabilities and enter into additional arrangements with third parties to perform these
services, then our product revenues and profitability, if any, are likely to be lower than if we were to market, sell and distribute any products that we develop ourselves. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>We face substantial competition that may result in others discovering, developing or commercializing products before or more
successfully than we do. </B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">The biotechnology and pharmaceutical industries are characterized by rapidly advancing
technologies, intense competition, and a strong emphasis on proprietary products. We face potential competition from many different sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions
and governmental agencies, and public and private research institutions. Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future.
</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Specifically, there are a large number of companies developing or marketing treatments for hemophilia, including many major
pharmaceutical and biotechnology companies, including Novo Nordisk, which has developed NovoSeven RT, an intravenous recombinant Factor VIIa indicated for treatment of bleeding episodes that has been approved for use in treatment of
(i)&nbsp;hemophilia A or B individuals with inhibitors to Factor VIII or Factor IX and in individuals with Factor VII deficiency and Glanzmann&#146;s thrombasthenia but not for prophylaxis and (ii)&nbsp;peri-operative management in adults with
Acquired Hemophilia; HEMA Biologics, which has developed SEVENFACT, an intravenous recombinant Factor VIIa indicated for treatment of bleeding episodes in individuals with Hemophilia A or B with an inhibitor to Factor VIII or Factor IX;
Takeda&#146;s FEIBA, a plasma-based composition of coagulation factors indicated for intravenous <FONT STYLE="white-space:nowrap">on-demand</FONT> and prophylactic use in the treatment of individuals with Hemophilia A or B inhibitors; Roche, which
is marketing Hemlibra (emicizumab-kxwh), a recombinant humanized bispecific antibody that binds to activated Factor IX and Factor X mimicking the cofactor function of Factor VIIIa, that has been approved by the FDA to treat hemophilia A with
inhibitors and is administered subcutaneously; several companies including Novo Nordisk, Pfizer and Genzyme are developing SQ agents for the treatment of Hemophilia A or B with or without inhibitors or Hemophilia with inhibitors using a variety of
technologies. There are numerous marketed factor <FONT STYLE="white-space:nowrap">IX-based</FONT> products that are used to replace Factor IX intravenously. BeneFIX, a recombinant Factor IX indicated for treatment of individuals with Hemophilia B,
was approved in 1997 and is marketed by Pfizer. In addition, Alprolix, a Factor <FONT STYLE="white-space:nowrap">IX-Fc</FONT> fusion product was approved in 2014 and is marketed by Sanofi Aventis and Swedish Orphan Biovitrum (SOBI&#151;in Europe,
Russia, North Africa and the Middle East). Idelvion, a Factor <FONT STYLE="white-space:nowrap">IX-albumin</FONT> fusion product marketed by </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-49 </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">
CSL Behring was approved by the FDA in 2016. Idelvion is approved for weekly dosing for adolescents and adults and <FONT STYLE="white-space:nowrap">bi-weekly</FONT> at a higher dose for those
same patients if well controlled on the original regimen. It is approved for weekly in patients &lt;12 years of age. Novo Nordisk&#146;s glycopegylated-Factor IX product Rebinyn was approved by the FDA in 2017 but is not indicated for routine
prophylaxis in the U.S. Rebinyn is approved for <FONT STYLE="white-space:nowrap">on-demand</FONT> treatment and control of bleeding episodes as well as Perioperative management of bleeding. CSL&nbsp;Behring is developing its marketed product
Idelvion an albumin-linked Factor IX for subcutaneous administration. We are also aware of many companies focused on developing gene therapies that may compete with our planned hemophilia B indication, as well as several companies addressing other
methods for modifying genes and regulating gene expression. Although there are no currently approved treatments for dry AMD, several companies are developing cyclic peptide, aptamer, antibody or gene therapy based anti-complement product candidates
in clinical studies. Apellis is conducting two Phase&nbsp;3 studies to compare the efficacy and safety of intravitreal <FONT STYLE="white-space:nowrap">APL-2</FONT> therapy with sham injections in patients aged 60 years and older with GA secondary
to AMD; Iveric Bio (formerly Ophthotech) is developing two therapies to treat GA secondary to dry AMD, iveric Bio completed its Phase 2b clinical of Zimura<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (avacincaptad pegol) with positive
data in patients with dry AMD; Gemini Therapeutics is developing &#147;GEM103&#148; a recombinant human complement factor H (&#147;FH&#148;) for patients with genetically well-defined dry AMD and &#147;GEM104,&#148; a recombinant human complement
factor&nbsp;I as well as additional molecules in preclinical development for other genetically defined subpopulations of patients with dry AMD and Gyroscope Therapeutics is developing &#147;GT005&#148; a gene therapeutic approach to expressing
additional CFI in the patient&#146;s eye after subretinal delivery. In addition, there are currently no approved agents specifically targeting systemic factor I deficiency patients irrespective of the resultant disease phenotype being aHUS, C3G, <FONT
STYLE="white-space:nowrap">IC-MPGN,</FONT> invasive infections or any other or any approved therapies for C3G and <FONT STYLE="white-space:nowrap">IC-MPGN.</FONT> However, there are less specific treatment options on the market or in clinical
development which may be applicable to some disease manifestations of systemic CFI deficiency, for instance aHUS and C3G. These treatment options include: eculizumab and ravulizumab marketed by Alexion Pharmaceuticals (to be acquired by AstraZeneca)
for use in aHUS irrespective of the patients&#146; CFI status; <FONT STYLE="white-space:nowrap">APL-2</FONT> (pegcetacoplan), a pegylated peptide based C3 inhibitor, in IgA Nephropathy (&#147;IgAN&#148;), LN, Membranous Nephropathy (&#147;MN&#148;),
C3G, and Dense Deposit Disease which is in clinical development by Apellis; CCX168 (avacopan), a twice daily oral small molecule inhibitor of the complement 5a receptor (&#147;C5aR&#148;) in C3G&#151;currently in phase 2 being developed by
ChemoCentryx; iptacopan (&#147;LNP023&#148;), a small peptide complement factor B inhibitor which is currently in development by Novartis for PNH, C3G and several other rare renal diseases including IgAN, aHUS, and membranous nephropathy; and Omeros
has initiated clinical activities in igAN, LN, MN, &amp; C3G and a phase 3 clinical program in aHUS with OMS721 (&#147;narsoplimab&#148;), a human monoclonal antibody targeting mannan-binding lectin-associated serine
<FONT STYLE="white-space:nowrap">protease-2</FONT> <FONT STYLE="white-space:nowrap">(&#147;MASP-2&#148;),</FONT> the effector enzyme of the lectin pathway of the complement system. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Our commercial opportunity in different indications could be reduced or eliminated if competitors develop and market products or
therapies that are more convenient to use, more effective, less expensive, and safer to use than our products. Furthermore, if competitors gain FDA approval earlier than we do, we may be unable to establish a strong market presence or to gain market
share. The key competitive factors affecting the success of all our product candidates, if approved, are likely to be their efficacy, safety, convenience, price, the level of generic competition, and the availability of reimbursement from government
and other third-party payors. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Many of the companies against which we are competing or against which we may compete in the
future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Mergers and
acquisitions in the pharmaceutical, biotechnology and diagnostic industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant
competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites
and individual registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-50 </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Although we believe that MarzAA could be a SQ rescue therapy for hemophilia A
(congenital factor VIII deficiency) patients with inhibitors experiencing breakthrough bleeds while on prophylaxis with other agents such as Hemlibra, nevertheless, branded products such as Hemlibra, present a potentially significant competitive
risk to the wide-spread use of MarzAA, due to bleeding prophylaxis with Hemlibra requiring less frequent administration while decreasing the risk of breakthrough bleeds. Consequently, MarzAA, if approved, may compete with existing drugs such as
Hemlibra, NovoSeven RT, and other therapies, and to the extent it is ultimately used in combination with or as an adjunct to these therapies, MarzAA may not be competitive. The FDA first approved Hemlibra in 2017 for patients with hemophilia A with
factor VIII (&#147;FVIII&#148;) inhibitors and in 2018, the FDA approved Hemlibra for prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A with or without FVIII inhibitors. As a
result, obtaining market acceptance of, and gaining significant market share for MarzAA may pose challenges. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>Even if we
commercialize any product candidates, the products may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives that would harm our business. </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">The regulations that govern marketing approvals, pricing, coverage and reimbursement for new drug products vary widely from country to
country. Current and future legislation may significantly change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries require approval of the sale price of a drug before it can
be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after
initial approval is granted. As a result, we may obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods, and
negatively impact the revenues we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if our product candidates obtain
marketing approval. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Our ability to commercialize any product candidates successfully also will depend in part on the extent
to which coverage and adequate reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers and other organizations. Government authorities and third-party
payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. A primary trend in the U.S. healthcare industry and elsewhere is cost containment.
Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for certain medications. Increasingly, third-party payors are requiring that drug companies provide them with
predetermined discounts from list prices and are challenging the prices charged for medical products. Coverage and reimbursement may not be available for any product that we or our collaborators commercialize and, even if these are available, the
level of reimbursement may not be satisfactory. Reimbursement may affect the demand for, or the price of, any product candidate that receives marketing approval. Obtaining and maintaining adequate reimbursement for our products may be difficult. We
may be required to conduct expensive pharmaco-economic studies to justify coverage and reimbursement or the level of reimbursement relative to other therapies. If coverage and adequate reimbursement are not available or reimbursement is available
only to limited levels, we may not be able to successfully commercialize any product candidate for which we obtain marketing approval. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#50748a">There may be significant delays in obtaining reimbursement for newly approved drugs, and coverage may be more limited than the purposes for which the drug is approved by the FDA or similar regulatory authorities outside the United
States. Moreover, eligibility for reimbursement does not imply that a drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Interim reimbursement levels for new
drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-51 </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Reimbursement rates may vary according to the use of the drug and the clinical setting
in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by
government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Third-party payors often rely upon
Medicare coverage policy and payment limitations in setting their own reimbursement policies. Our inability to promptly obtain coverage and adequate reimbursement rates from both government-funded and private payors for any approved products that we
develop could have a material adverse effect on our operating results, ability to raise capital needed to commercialize products and overall financial condition. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>The insurance coverage and reimbursement status of newly approved products is uncertain. Failure to obtain or maintain adequate
coverage and reimbursement for new or current products could limit our ability to market those products and decrease our ability to generate revenue. </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">The availability and extent of reimbursement by governmental and private payors is essential for most patients to be able to afford
expensive treatments. Sales of our product candidates will depend substantially, both domestically and abroad, on the extent to which the costs of our product candidates will be paid by health maintenance, managed care, pharmacy benefit and similar
healthcare management organizations, or reimbursed by government health administration authorities, private health coverage insurers and other third-party payors. If reimbursement is not available, or is available only to limited levels, we may not
be able to successfully commercialize our product candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a sufficient return on our
investment. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products.
Moreover, increasing efforts by governmental and third-party payors, in the United States and abroad, to cap or reduce healthcare costs may cause such organizations to limit both coverage and level of reimbursement for new products approved and, as
a result, they may not cover or provide adequate payment for our product candidates. We expect to experience pricing pressures in connection with the sale of any of our product candidates, due to the trend toward managed healthcare, the increasing
influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general has become very intense. As a result, increasingly high barriers are being erected to the entry of new products.
</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>If the market opportunities for our product candidates are smaller than expected, our revenues may be adversely affected
and our business may suffer. </B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We focus our research and product development on hemostasis and inflammation treatment. Our
projections of both the number of people who suffer from related conditions, as well as the subset of people with these conditions who have the potential to benefit from treatment with our product candidates, are based on estimates. These estimates
may prove to be incorrect and new studies may change the estimated incidence or prevalence of these diseases. The number of patients in the United States, Europe and elsewhere may turn out to be lower than expected or may not be otherwise amenable
to treatment with our products, or new patients may become increasingly difficult to identify or gain access to, all of which would adversely affect our results of operations and our business. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B><I>Risks related to our common stock </I></B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>The market price of our common stock has historically been highly volatile. </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">The trading price of our common stock has historically been highly volatile and there have been significant periods of time in which the
trading volume of our common stock has been low, which can contribute to volatility in price. Additionally, the stock market in general has experienced extreme price and volume </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-52 </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">
fluctuations. The market prices of securities of pharmaceutical, biopharmaceutical and biotechnology companies in particular have been extremely volatile and have experienced fluctuations that
have often been unrelated or disproportionate to operating performance. Factors giving rise to this volatility may include: </FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">disclosure of clinical trial results; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">regulatory or political developments in both the United States and abroad;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">developments concerning proprietary rights, including patents and litigation matters;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">disclosure of new collaborations or other strategic transactions;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">public concern about the safety or efficacy of product candidates or technology, their
components, or related technology or new technologies generally; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">public announcements by competitors or others regarding new products or new product
candidates; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">general market conditions and comments by securities analysts and investors.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>Fluctuations in operating results could adversely affect the price of our common stock. </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Our operating results are likely to fluctuate significantly from quarter to quarter and year to year. These fluctuations could cause our
stock price to decline. Some of the factors that may cause operating results to fluctuate on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">period-to-period</FONT></FONT> basis include the scope, progress, duration results and
costs of preclinical and clinical development programs, as well as <FONT STYLE="white-space:nowrap">non-clinical</FONT> studies and assessments of product candidates and programs, restructuring costs, implementation or termination of collaboration,
licensing, manufacturing or other material agreements with third parties, <FONT STYLE="white-space:nowrap">non-recurring</FONT> revenue or expenses under any such agreement, the cost, timing and outcomes of regulatory compliance, approvals or other
regulatory actions and general and industry-specific economic conditions, particularly as affects the pharmaceutical, biopharmaceutical or biotechnology industries in the United States.
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Period-to-period</FONT></FONT> comparisons of our historical and future financial results may not be meaningful, and investors should not rely on them as an indication of future
performance. Fluctuating losses may fail to meet the expectations of securities analysts or investors. Failure to meet these expectations may cause the price of our common stock to decline. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>Sales of a significant number of shares of our common stock in the public markets, or the perception that such sales could occur,
could depress the market price of our common stock. </B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Our current trading volumes are modest, and sales of a substantial
number of shares of our common stock in the public market, or the perception that these sales could occur, could cause the market price to decline. We have an effective registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> that
enables us to sell up to $140.0&nbsp;million in securities. Any additional sales in the public market of our common stock or other securities under these shelf registration statements could adversely affect prevailing market prices for our common
stock. In addition, we have outstanding options to purchase 2,264,141 shares of common stock at a weighted average exercise price of $8.84 as of September&nbsp;30, 2020. If such options are exercised and the shares are sold into the open market,
such sales also might make it more difficult for us to sell equity securities in the future at a time and at a price that we deem appropriate. Conversion or exercise of these securities into shares of our common stock will cause dilution to the
other holders of our common stock, and all such stock may be sold in the public market after conversion or exercise, subject to restrictions under the securities laws, which may lead to a decline in the market price of our common stock. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-53 </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>Anti-takeover provisions in our charter documents and provisions of Delaware law
may make an acquisition more difficult and could result in the entrenchment of management. </B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We are incorporated in
Delaware. Anti-takeover provisions of Delaware law and our charter documents may make a change in control or efforts to remove management more difficult. Also, under Delaware law, our board of directors may adopt additional anti-takeover measures.
The existence of the following provisions of Delaware law and our restated certificate of incorporation and amended and restated bylaws could limit the price that investors might be willing to pay in the future for shares of our common stock.
</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Our restated certificate of incorporation authorizes our board of directors to issue up to 5,000,000 shares of preferred
stock and to determine the terms of those shares of stock without any further action by our stockholders. If the board of directors exercises this power to issue preferred stock, it could be more difficult for a third-party to acquire a majority of
our outstanding voting stock and vote the stock they acquire to remove management or directors. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Our restated certificate
also provides staggered terms for the members of our board of directors, and that directors may be removed by stockholders only by vote of the holders of 66 2/3% of voting shares then outstanding. In addition, our amended and restated bylaws do not
permit stockholders to call special or annual meetings of stockholders, or to act by written consent without a meeting. These provisions may prevent stockholders from replacing the entire board in a single proxy contest, making it more difficult for
a third party to acquire control without the consent of our board of directors. These provisions could also delay the removal of management by the board of directors with or without cause. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">As a Delaware corporation, we are also subject to certain Delaware anti-takeover provisions. Under Delaware law, a publicly-held
corporation may not engage in a business combination with any holder of 15% or more of our voting stock unless the holder has held the stock for three years or, among other things, the board of directors has approved the transaction. Our board of
directors could rely on Delaware law to prevent or delay an acquisition. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>Our business could be negatively affected as a
result of actions of activist stockholders, and such activism could impact the trading value of our securities. </B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Two of
our stockholders have requested that we add one or more individuals to our board of directors. Although we have entered into a cooperation agreement with one such stockholder and appointed two new members to our board of directors, one or more other
stockholders could engage in proxy solicitations or advance stockholder proposals, or otherwise attempt to effect changes and assert influence on our board of directors and management. Such an activist campaign could conflict with our strategic
direction or seek changes in the composition of our board of directors and could have an adverse effect on our operating results and financial condition. A proxy contest would require us to incur significant legal and advisory fees, proxy
solicitation expenses and administrative and associated costs, and require significant time and attention by our board of directors and management, diverting their attention from the pursuit of our business strategy. Any perceived uncertainties as
to our future direction and control, our ability to execute on our strategy, or changes to the composition of our board of directors or senior management team arising from a proxy contest could lead to the perception of a change in the direction of
our business or instability which may result in the loss of potential business opportunities, make it more difficult to pursue our strategy, or limit our ability to attract and retain qualified personnel, any of which could adversely affect our
business and operating results. If individuals are ultimately elected to our board of directors with a specific agenda, it may adversely affect our ability to effectively implement our business strategy and create additional value for our
stockholders. We may choose to initiate, or may become subject to, litigation as a result of the proxy contest or matters arising from the proxy contest, which would serve as a further distraction to our board of directors and management and would
require us to incur significant additional costs. In addition, actions such as those described above could cause significant fluctuations in our stock price based upon temporary or speculative market perceptions or other factors that do not
necessarily reflect the underlying fundamentals and prospects of our business. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-54 </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>We are a smaller reporting company and we cannot be certain if the reduced
disclosure requirements applicable to smaller reporting companies will make our common stock less attractive to investors. </B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#50748a">We have been a &#147;smaller reporting company&#148; as defined in the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), and thus have been allowed to provide simplified executive compensation disclosures
in our filings. We have also had certain other decreased disclosure obligations in our SEC filings. We cannot predict whether investors find our common stock less attractive because of our reliance on any of these exemptions. If some investors find
our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B><I>Risks related to this offering </I></B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>We have broad discretion in the use of the net proceeds from this offering and may not use them effectively. </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Our management has broad discretion in the application of the net proceeds from this offering, and you will not have the opportunity as
part of your investment decision to assess whether the net proceeds are being used appropriately. Our management could spend the net proceeds from this offering in ways that do not improve our results of operations or enhance the value of our common
stock. The failure by our management to apply these funds effectively could result in financial losses that could have a material adverse effect on our business, cause the price of our common stock to decline and delay the development of our product
candidates. Pending their use, we may invest the net proceeds from this offering in a manner that does not produce income or that loses value. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#50748a"><B>If you purchase shares of common stock sold in this offering you will experience immediate and substantial dilution in your investment. You will experience further dilution if we issue additional equity securities in the future.
</B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Since the price per share of our common stock being offered is higher than the net tangible book value per share of our
common stock, you will suffer dilution with respect to the net tangible book value of the shares of common stock you purchase in this offering. Based on a public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share and our net tangible book value as of September&nbsp;30, 2020, if you purchase shares of common stock in this offering, you will suffer
immediate dilution of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share with respect to the net tangible book value of the common stock. Furthermore, if outstanding options or warrants are
exercised, you could experience further dilution. See &#147;Dilution&#148; for a more detailed discussion of the dilution you will incur if you purchase shares of common stock in this offering. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>Future sales of our common stock in the public market could cause the market price of our common stock to drop significantly, even if
our business is doing well. </B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Sales of a substantial number of shares of our common stock in the public market, or the
perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock and make it more difficult for you to sell your common stock at a time and price that you deem
appropriate. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We may raise money through additional public or private offerings of our equity securities or equity-linked
securities. Any sales of our equity or equity-linked securities could have a material adverse effect on the market price of our common stock. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#50748a">In connection with this offering, we and our directors and executive officers have entered into <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements for a period of 90&nbsp;days following this offering. The <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreements are subject to various exceptions, and we and our directors and executive officers may be released from the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements prior to the expiration of
the <FONT STYLE="white-space:nowrap">lock-up</FONT> period at the sole discretion of the representative. See &#147;Underwriting.&#148; Upon </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-55 </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">
expiration or earlier release of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements, we and our directors and executive officers may sell shares into the market, which could adversely
affect the market price of shares of our common stock. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We have registered under the Securities Act of 1933, as amended (the
&#147;Securities Act&#148;) shares of common stock that we may issue under our equity compensation plans. In addition, we have a significant number of stock options outstanding, and may also choose to issue additional common stock, or securities
convertible into or exchangeable for common stock, in the future in connection with a financing, an acquisition, a litigation settlement, employee arrangements or otherwise. In the event that the outstanding options are exercised, or that we make
additional issuances of common stock or other convertible or exchangeable securities, you could experience additional dilution. Furthermore, we cannot assure you that we will be able to issue shares or other securities in any other offering at a
price per share that is equal to or greater than the price per share paid by investors in this offering, and investors purchasing our securities in the future may have rights superior to investors purchasing shares in this offering. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B>We do not anticipate paying dividends on our common stock in the foreseeable future. </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We currently plan to invest all available funds, including the proceeds from this offering and future earnings, if any, in the
development and growth of our business. We currently do not anticipate paying any cash dividends on our common stock in the foreseeable future. As a result, a rise in the market price of our common stock, which is uncertain and unpredictable, will
be your sole source of potential gain in the foreseeable future, and you should not rely on an investment in our common stock for dividend income. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-56 </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a"><B><A NAME="supptoc260304_5"></A>CAUTIONARY NOTE REGARDING FORWARD
LOOKING INFORMATION </B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">This prospectus supplement, the accompanying prospectus, and documents incorporated by reference
herein and therein contain &#147;forward-looking statements&#148; within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a number of risks and uncertainties. We caution readers that any
forward-looking statement is not a guarantee of future performance and that actual results could differ materially from those contained in the forward-looking statement. These statements are based on current expectations of future events. Such
statements include, but are not limited to, statements about future financial and operating results, plans, objectives, expectations and intentions, costs and expenses, outcome of contingencies, financial condition, results of operations, liquidity,
objectives of management, business strategies, financing, the timing, plans and expected results of our current and future clinical trials, the extent to which we will be able to advance development of our product candidates using the proceeds of
this offering together with our existing cash resources; our focus on specific product candidates, the progress, outcomes, scope or duration of the development of product candidates or programs, the benefits that may be derived from product
candidates or the commercial or market opportunity in any target indication, the progress of our third-party collaborations, including estimated milestones, the advancement of our technologies and our product candidates, approvals and
commercialization of product candidates, the impacts of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and other statements that are not historical facts. You can find many of these statements by looking for words like
&#147;believes,&#148; &#147;expects,&#148; &#147;anticipates,&#148; &#147;estimates,&#148; &#147;may,&#148; &#147;might,&#148; &#147;should,&#148; &#147;will,&#148; &#147;could,&#148; &#147;plan,&#148; &#147;intend,&#148; &#147;project,&#148;
&#147;seek&#148; or similar expressions in this prospectus supplement, the accompanying prospectus and the documents incorporated by reference herein and therein and any free writing prospectus. We intend that such forward-looking statements be
subject to the safe harbors created thereby. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">These forward-looking statements are based on the current beliefs and
expectations of our management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results may differ materially from current expectations and
projections. Factors that might cause such a difference include those discussed in the Risk Factors sections of our Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> for the year ended December&nbsp;31, 2019 and our Quarterly
Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-Q</FONT> for the quarter ended September&nbsp;30, 2020, as well as those discussed in this prospectus supplement, the accompanying prospectus and the documents incorporated by reference herein
and therein and any free writing prospectus. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date made. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">All subsequent written or oral forward-looking statements attributable to us or any person acting on our behalf are expressly qualified
in their entirety by the cautionary statements contained or referred to in this section. We do not undertake any obligation to release publicly any revisions to these forward-looking statements to reflect events or circumstances after the date of
this prospectus supplement or to reflect the occurrence of unanticipated events, except as may be required under applicable U.S. securities laws. If we do update one or more forward-looking statements, no inference should be drawn that we will make
additional updates with respect to those or other forward-looking statements. </FONT></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a"><B><A NAME="supptoc260304_6"></A>USE OF PROCEEDS </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We expect that the net proceeds of this offering, after deducting underwriting discounts and commissions and estimated offering
expenses, will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, or approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million if the underwriters exercise their over-allotment option in full. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We intend to use the net proceeds from the sale of the shares of common stock under this prospectus supplement for general corporate
purposes including research, development and manufacturing activities in our hemophilia and complement programs, specifically MarzAA (FVIIa), CB 4332 (enhanced complement Factor I) and others, capital expenditures, selling, general and
administrative costs, facilities expansion, and to meet working capital </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-57 </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">
needs. We expect from time to time to evaluate the acquisition of businesses, products and technologies for which a portion of the net proceeds may be used, although we currently are not planning
or negotiating any such transactions. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">As of the date of this prospectus supplement, we cannot specify with certainty all of
the particular uses of the proceeds from this offering. The amounts and timing of our actual expenditures will depend on numerous factors, including the progress of our clinical trials and other development efforts and other factors described under
&#147;Risk factors&#148; in this prospectus supplement and the documents incorporated by reference herein. As a result, our management will have broad discretion over the uses of the net proceeds, if any, we receive in connection with securities
offered pursuant to this prospectus supplement. Investors will be relying on the judgment of our management regarding the application of the proceeds, and will not have the opportunity to evaluate the economic, financial or other information on
which we base our decisions on how to use the proceeds from this offering. Pending these uses, we intend to invest the net proceeds in short-term, interest-bearing obligations, investment-grade instruments, certificates of deposit or guaranteed
obligations of the U.S. government. </FONT></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a"><B><A NAME="supptoc260304_7"></A>DIVIDEND POLICY </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We have never paid cash dividends on our common stock and we do not anticipate paying cash dividends in the foreseeable future, but
intend to retain our capital resources for reinvestment in our business. Any future determination to pay cash dividends on our common stock will be at the discretion of our Board of Directors and will be dependent upon our financial condition,
results of operations, capital requirements and other factors as the Board of Directors deems relevant. </FONT></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a"><B><A NAME="supptoc260304_8">
</A>DILUTION </B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">If you invest in our common stock, your interest will be diluted immediately to the extent of the
difference between the public offering price per share of our common stock and the as adjusted net tangible book value per share of common stock after this offering. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Our net tangible book value as of September&nbsp;30, 2020 was approximately $92.5&nbsp;million, or approximately $4.19 per share. Net
tangible book value per share is determined by dividing our total tangible assets, less total liabilities, by the number of shares of our common stock outstanding as of September&nbsp;30, 2020. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">After giving effect to our sale of shares of our common stock in this offering at the public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, and after deducting the underwriting discount and commissions and the estimated offering expenses payable by us, our as adjusted net
tangible book value as of September&nbsp;30, 2020 would have been approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, or
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share of common stock. This represents an immediate decrease in net tangible book value of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share to existing stockholders and an immediate dilution in net tangible book value of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share to investors participating in this offering. The following table illustrates this dilution on a per share basis: </FONT></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Public offering price per share of common stock</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Net tangible book value per share as of September&nbsp;30,
2020</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">4.19</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Increase in net tangible book value per share attributable to investors in
this offering</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">As adjusted net tangible book value per share as of September&nbsp;30, 2020
after giving effect to the offering</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Dilution in net tangible book value per share to new
investors</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">If the underwriters exercise in full their option to purchase additional shares of common stock at the
public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the as adjusted net tangible book value after this offering would be
</FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-58 </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">
approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, representing a decrease in net tangible book value of approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share to existing stockholders and immediate dilution in net tangible book value of approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share to investors participating in this offering at the public offering price. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">The above discussion and table are based on 22,082,924&nbsp;shares of common stock outstanding as of September&nbsp;30, 2020, and
excludes as of such date: </FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">2,264,141&nbsp;shares of common stock issuable upon exercise of options outstanding as of
September&nbsp;30, 2020, with a weighted average exercise price of $8.841 per share; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">83,000&nbsp;shares of common stock issuable upon exercise of options granted after
September&nbsp;30, 2020, with a weighted average exercise price of $5.946 per share; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">722&nbsp;shares of common stock issuable upon exercise of warrants outstanding as of
September&nbsp;30, 2020, with a weighted average exercise price of $90.26 per share; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">1,674,278&nbsp;shares of common stock reserved and available for future issuance as of
September&nbsp;30, 2020, under our equity incentive plans, consisting of (1) 1,373,834&nbsp;shares of common stock reserved and available for issuance under our 2018 Omnibus Incentive Plan as of September&nbsp;30, 2020, and
(2)&nbsp;1,373,834&nbsp;shares of common stock reserved for issuance under our 2018 Employee Stock Purchase Plan as of September&nbsp;30, 2020; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">1,275,938 additional shares of common stock reserved and available for future issuance
after September&nbsp;30, 2020 under our 2018 Omnibus Incentive Plan. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">To the extent that outstanding
options have been or may be exercised or other shares are issued, investors purchasing our common stock in this offering may experience further dilution. In addition, we may choose to issue additional common stock, or securities convertible into or
exchangeable for common stock, in the future. The issuance of these securities could result in further dilution for investors purchasing our common stock in this offering. </FONT></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a"><B><A NAME="supptoc260304_9"></A>UNDERWRITING </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We have entered into an underwriting agreement, dated as of the date of this prospectus supplement, with respect to the shares being
offered. Piper Sandler&nbsp;&amp;&nbsp;Co. (&#147;Piper Sandler&#148;), is acting as the sole lead active bookrunner and as representative of the underwriters. The underwriting agreement provides for the purchase of a specific number of shares of
common stock by each of the underwriters. The underwriters&#146; obligations are several, which means that each underwriter is required to purchase a specified number of shares of common stock, but is not responsible for the commitment of any other
underwriter to purchase shares of common stock. Subject to the terms and conditions of the underwriting agreement, each underwriter has severally agreed to purchase the number of shares of common stock set forth opposite its name below: </FONT></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><FONT COLOR="#50748a"><B>Underwriters</B></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#50748a"><B>Number<BR>of&nbsp;Shares</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Piper Sandler&nbsp;&amp; Co.</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Raymond James&nbsp;&amp; Associates, Inc.</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Total</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">The underwriters have agreed to purchase all of the shares of common stock offered by this prospectus
supplement (other than those covered by the over-allotment option described below), if any are purchased. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-59 </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">The shares of common stock offered hereby should be ready for delivery on or
about&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021 against payment in immediately available funds. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">The underwriters are offering the shares of common stock subject to various conditions (including approval of legal matters by the
representatives&#146; legal counsel and other conditions specified in the underwriting agreement) and may reject all or part of any order. The representatives of the underwriters have advised us that the underwriters propose to offer the common
stock directly to the public at the applicable public offering price that appears on the cover page of this prospectus supplement. In addition, the underwriters may offer some of the securities to other securities dealers at such price less a
concession of up to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share of common stock. After the shares of common stock are released for sale to the public, the representatives may change the
offering price and other selling terms at various times. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We have granted the underwriters the right to purchase up to an
aggregate of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional shares of our common stock. The underwriters may exercise this right, in whole or in part, at any time within 30&nbsp;days
following the date of this prospectus supplement. If the underwriters exercise the option in full, the total underwriting discount payable by us will be
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and the total proceeds to us, before expenses, will be
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">The following table
provides information regarding the amount of the discounts and commissions to be paid to the underwriters by us, before expenses: </FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#50748a"><B>Per Share</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#50748a"><B>Total</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><FONT COLOR="#50748a"><B>Underwriters</B></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#50748a"><B>Without<BR>Option</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#50748a"><B>With<BR>Option</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#50748a"><B>Without<BR>Option</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT COLOR="#50748a"><B>With<BR>Option</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Public offering price of common stock</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Underwriting discounts and commissions</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Proceeds before expenses, to us</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#50748a">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#50748a">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We estimate that our total expenses of the offering, excluding underwriting discounts and commissions,
will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, which includes up to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; that we
have agreed to reimburse the underwriters for the fees and expenses incurred by them in connection with the offering. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We
have agreed to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We
and our officers and directors have agreed to a <FONT STYLE="white-space:nowrap">90-day</FONT> <FONT STYLE="white-space:nowrap">&#147;lock-up&#148;</FONT> with respect to shares of our common stock and other of our securities that they beneficially
own, including securities that are convertible into shares of common stock and securities that are exchangeable or exercisable for shares of common stock. This means that, subject to certain exceptions, for a period of 90&nbsp;days following the
date of this prospectus supplement, we and such persons may not offer, sell, pledge or otherwise dispose of these securities without the prior written consent of Piper Sandler. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Rules of the SEC may limit the ability of the underwriters to bid for or purchase shares before the distribution of the shares is
completed. However, the underwriters may engage in the following activities in accordance with the rules: </FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">Stabilizing transactions&nbsp;&#151; The underwriters may make bids or purchases for the
purpose of pegging, fixing or maintaining the price of the shares, so long as stabilizing bids do not exceed a specified maximum. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">Over-allotments and syndicate covering transactions&nbsp;&#151; The underwriters may sell
more shares of our common stock in connection with this offering than the number of shares that they have committed to </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-60 </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">
purchase. This over-allotment creates a short position for the underwriters. This short sales position may involve either &#147;covered&#148; short sales or &#147;naked&#148; short sales. Covered
short sales are short sales made in an amount not greater than the underwriters&#146; over-allotment option to purchase additional shares in this offering described above. The underwriters may close out any covered short position either by
exercising its over-allotment option or by purchasing shares in the open market. To determine how they will close the covered short position, the underwriters will consider, among other things, the price of shares available for purchase in the open
market, as compared to the price at which they may purchase shares through the over-allotment option. Naked short sales are short sales in excess of the over-allotment option. The underwriters must close out any naked short position by purchasing
shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that, in the open market after pricing, there may be downward pressure on the price of the shares that could adversely affect investors
who purchase shares in this offering. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">Penalty bids&nbsp;&#151; If the representatives purchase shares in the open market in a
stabilizing transaction or syndicate covering transaction, they may reclaim a selling concession from the underwriters and selling group members who sold those shares as part of this offering. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">Passive market making&nbsp;&#151; Market makers in the shares who are underwriters or
prospective underwriters may make bids for or purchases of shares, subject to limitations, until the time, if ever, at which a stabilizing bid is made. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Similar to other purchase transactions, the underwriters&#146; purchases to cover the syndicate short sales or to stabilize the market
price of our common stock may have the effect of raising or maintaining the market price of our common stock or preventing or mitigating a decline in the market price of our common stock. As a result, the price of the shares of our common stock may
be higher than the price that might otherwise exist in the open market. The imposition of a penalty bid might also have an effect on the price of the shares if it discourages resales of the shares. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Neither we nor the underwriters make any representation or prediction as to the effect that the transactions described above may have on
the price of our common stock. These transactions may occur on the Nasdaq Capital Market or otherwise. If such transactions are commenced, they may be discontinued without notice at any time. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Electronic Delivery of Prospectus Supplement: A prospectus supplement in electronic format may be delivered to potential investors by
one or more of the underwriters participating in this offering. The prospectus supplement in electronic format will be identical to the paper version of such preliminary prospectus supplement. Other than the prospectus supplement in electronic
format, the information on any underwriter&#146;s website and any information contained in any other website maintained by an underwriter is not part of this prospectus supplement, the accompanying prospectus or the registration statement of which
this prospectus supplement and the accompanying prospectus form&nbsp;a part. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">From time to time in the ordinary course of its
businesses, one or more of the representatives and certain affiliates have engaged, and may in the future engage, in commercial banking or investment banking transactions with us and our affiliates. They have received, or may in the future receive,
customary fees and commissions for these transactions. In the ordinary course of its various business activities, they may make or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and
financial instruments (including bank loans) for their own account and for the accounts of their customers, and such investment and securities activities may involve our securities and/or instruments. They may also make investment recommendations
and/or publish or express independent research views in respect of such securities or instruments and may at any time hold, or recommend to clients that they acquire, long and/or short positions in such securities and instruments. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-61 </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B><I>NOTICE TO <FONT STYLE="white-space:nowrap">NON-U.S.</FONT> INVESTORS
</I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Investors are advised to contact their legal, financial or tax advisers to obtain an independent assessment of the
financial and tax consequences of an investment in the shares being sold in this offering. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B><I>European Economic
Area.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;In relation to each Member State of the European Economic Area which has implemented the Prospectus Regulation (each, a &#147;Relevant Member State&#148;) an offer to the public of any shares of our common stock
may not be made in that Relevant Member State, except that an offer to the public in that Relevant Member State of any shares of our common stock may be made at any time under the following exemptions under the Prospectus Regulation, if they have
been implemented in that Relevant Member State: </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">(a)&nbsp;to any legal entity which is a qualified investor
as defined in the Prospectus Regulation; </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">(b)&nbsp;to fewer than 150, natural or legal persons (other than
qualified investors as defined in the Prospectus Regulation), as permitted under the Prospectus Regulation, subject to obtaining the prior consent of the representatives for any such offer; or </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">(c)&nbsp;in any other circumstances falling within Article&nbsp;1(4) of the Prospectus Regulation, provided that no such
offer of shares of our common stock shall result in a requirement for the publication by us or any underwriter of a prospectus pursuant to Article&nbsp;3 of the Prospectus Regulation or supplement a prospectus pursuant to Article&nbsp;23 of the
Prospectus Regulation. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">For the purposes of this provision, the expression an &#147;offer to the public&#148; in relation to
any shares of our common stock in any Relevant Member State means the communication in any form and by any means of sufficient information on the terms of the offer and any shares of our common stock to be offered so as to enable an investor to
decide to purchase any shares of our common stock, as the same may be varied in that Member State by any measure implementing the Prospectus Regulation in that Member State, the expression &#147;Prospectus Regulation&#148; means
Regulation&nbsp;(EU)&nbsp;2017/1129. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B><I>United Kingdom.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;Each underwriter has represented
and agreed that: </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">(a)&nbsp;it has only communicated or caused to be communicated and will only communicate or
cause to be communicated an invitation or inducement to engage in investment activity (within the meaning of Section&nbsp;21 of the Financial Services and Markets Act 2000 (the &#147;FSMA&#148;)) received by it in connection with the issue or sale
of the shares of our common stock in circumstances in which Section&nbsp;21(1) of the FSMA does not apply to us; and </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#50748a">(b)&nbsp;it has complied and will comply with all applicable provisions of the FSMA with respect to anything done by it in relation to the shares of our common stock in, from or otherwise involving the United Kingdom. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B><I>Canada.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;The common stock may be sold only to purchasers purchasing as principal that are both
&#147;accredited investors&#148; as defined in National <FONT STYLE="white-space:nowrap">Instrument&nbsp;45-106</FONT> Prospectus and Registration Exemptions and &#147;permitted clients&#148; as defined in National
<FONT STYLE="white-space:nowrap">Instrument&nbsp;31-103</FONT> Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the common stock must be made in accordance with an exemption from the prospectus requirements and
in compliance with the registration requirements of applicable securities laws. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B><I>Germany.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;Each person who is in possession of this prospectus is aware of the fact that no German
securities prospectus (wertpapierprospekt) within the meaning of the German Securities Prospectus Act (&#147;Wertpapier-prospektgesetz&#148; or the &#147;Act&#148;) of the Federal Republic of Germany has been or will be published with respect to the
shares of our common stock. In particular, each underwriter has represented that it has not engaged and has agreed that it will not engage in a public offering in the Federal Republic of Germany within the meaning of the Act with respect to any of
the shares of our common stock otherwise than in accordance with the Act and all other applicable legal and regulatory requirements. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-62 </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B><I>Hong Kong.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;The common stock may not be offered or
sold in Hong Kong by means of any document other than (i)&nbsp;in circumstances which do not constitute an offer to the public within the meaning of the Companies Ordinance (Cap. 32, Laws of Hong Kong), or (ii)&nbsp;to &#147;professional
investors&#148; within the meaning of the Securities and Futures Ordinance (Cap. 571, Laws of Hong Kong) and any rules made thereunder, or (iii)&nbsp;in other circumstances which do not result in the document being a &#147;prospectus&#148; within
the meaning of the Companies Ordinance (Cap. 32, Laws of Hong Kong) and no advertisement, invitation or document relating to the shares may be issued or may be in the possession of any person for the purpose of issue (in each case whether in Hong
Kong or elsewhere), which is directed at, or the contents of which are likely to be accessed or read by, the public in Hong Kong (except if permitted to do so under the laws of Hong Kong) other than with respect to common stock which are or are
intended to be disposed of only to persons outside Hong Kong or only to &#147;professional investors&#148; within the meaning of the Securities and Futures Ordinance (Cap. 571, Laws of Hong Kong) and any rules made thereunder. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B><I>Singapore.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;This prospectus has not been registered as a prospectus with the Monetary Authority of
Singapore. Accordingly, this prospectus and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the common stock may not be circulated or distributed, nor may the common stock be
offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i)&nbsp;to an institutional investor under Section&nbsp;274 of the Securities and Futures Act,
Chapter&nbsp;289 of Singapore (the &#147;SFA&#148;), (ii)&nbsp;to a relevant person pursuant to Section&nbsp;275(1), or any person pursuant to Section&nbsp;275(1A), and in accordance with the conditions specified in Section&nbsp;275 of the SFA or
(iii)&nbsp;otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA, in each case subject to compliance with conditions set forth in the SFA. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Where the common stock are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant person which is: </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">(a)&nbsp;a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole
business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">(b) a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each
beneficiary of the trust is an individual who is an accredited investor, </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">shares, debentures and units of shares and
debentures of that corporation or the beneficiaries&#146; rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the common stock pursuant to an offer made
under Section&nbsp;275 of the SFA except: </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">(a) to an institutional investor (for corporations, under
Section&nbsp;274 of the SFA) or to a relevant person defined in Section&nbsp;275(2) of the SFA, or to any person pursuant to an offer that is made on terms that such shares, debentures and units of shares and debentures of that corporation or such
rights and interest in that trust are acquired at a consideration of not less than $200,000 (or its equivalent in a foreign currency) for each transaction, whether such amount is to be paid for in cash or by exchange of securities or other assets,
and further for corporations, in accordance with the conditions specified in Section&nbsp;275 of the SFA; </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">(b) where no consideration is or will be given for the transfer; or </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">(c) where the transfer is by operation of law. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B><I>Switzerland.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;The common stock may not be publicly offered in Switzerland and will not be listed on
the SIX Swiss Exchange (the &#147;SIX&#148;) or on any other stock exchange or regulated trading facility in Switzerland. This document has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art.
1156 of the Swiss Code of Obligations or the disclosure standards for listing prospectuses under art. 27 ff. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-63 </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">
of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither this document nor any other offering or marketing material relating
to the common stock or the offering may be publicly distributed or otherwise made publicly available in Switzerland. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Neither
this document nor any other offering or marketing material relating to the offering, or the common stock have been or will be filed with or approved by any Swiss regulatory authority. In particular, this document will not be filed with, and the
offer of common stock will not be supervised by, the Swiss Financial Market Supervisory Authority FINMA, and the offer of common stock has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes
(&#147;CISA&#148;). Accordingly, no public distribution, offering or advertising, as defined in CISA, its implementing ordinances and notices, and no distribution to any <FONT STYLE="white-space:nowrap">non-qualified</FONT> investor, as defined in
CISA, its implementing ordinances and notices, shall be undertaken in or from Switzerland, and the investor protection afforded to acquirers of interests in collective investment schemes under CISA does not extend to acquirers of common stock.
</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B><I>United Arab Emirates.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;This offering has not been approved or licensed by the Central
Bank of the United Arab Emirates (the &#147;UAE&#148;), Securities and Commodities Authority of the UAE and/or any other relevant licensing authority in the UAE including any licensing authority incorporated under the laws and regulations of any of
the free zones established and operating in the territory of the UAE, in particular the Dubai Financial Services Authority (&#147;DFSA&#148;), a regulatory authority of the Dubai International Financial Centre (&#147;DIFC&#148;). The offering does
not constitute a public offer of securities in the UAE, DIFC and/or any other free zone in accordance with the Commercial Companies Law, Federal Law No 8 of 1984 (as amended), DFSA Offered Securities Rules and NASDAQ Dubai Listing Rules,
accordingly, or otherwise. The common stock may not be offered to the public in the UAE and/or any of the free zones. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">The
common stock may be offered and issued only to a limited number of investors in the UAE or any of its free zones who qualify as sophisticated investors under the relevant laws and regulations of the UAE or the free zone concerned. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a"><B><I>France.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;This prospectus (including any amendment, supplement or replacement thereto) is not being
distributed in the context of a public offering in France within the meaning of Article&nbsp;L. <FONT STYLE="white-space:nowrap">411-1</FONT> of the French Monetary and Financial Code (Code mon&eacute;taire et financier). </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">This prospectus has not been and will not be submitted to the French Autorit&eacute; des march&eacute;s financiers (the &#147;AMF&#148;)
for approval in France and accordingly may not and will not be distributed to the public in France. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Pursuant to <FONT
STYLE="white-space:nowrap">Article&nbsp;211-3</FONT> of the AMF General Regulation, French residents are hereby informed that: </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#50748a">1. the transaction does not require a prospectus to be submitted for approval to the AMF; </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">2. persons or entities referred to in Point 2&deg;, Section&nbsp;II of
<FONT STYLE="white-space:nowrap">Article&nbsp;L.411-2</FONT> of the Monetary and Financial Code may take part in the transaction solely for their own account, as provided in Articles&nbsp;D. <FONT STYLE="white-space:nowrap">411-1,</FONT> D. <FONT
STYLE="white-space:nowrap">734-1,</FONT> D. <FONT STYLE="white-space:nowrap">744-1,</FONT> D. <FONT STYLE="white-space:nowrap">754-1</FONT> and D. <FONT STYLE="white-space:nowrap">764-1</FONT> of the Monetary and Financial Code; and </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">3. the financial instruments thus acquired cannot be distributed directly or indirectly to the public otherwise than in
accordance with Articles&nbsp;L. <FONT STYLE="white-space:nowrap">411-1,</FONT> L. <FONT STYLE="white-space:nowrap">411-2,</FONT> L. <FONT STYLE="white-space:nowrap">412-1</FONT> and <FONT STYLE="white-space:nowrap">L.&nbsp;621-8</FONT> to <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">L.&nbsp;621-8-3</FONT></FONT> of the Monetary and Financial Code. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">This prospectus is not to be further distributed or reproduced (in whole or in part) in France by the recipients of this prospectus.
This prospectus has been distributed on the understanding that such recipients will only participate in the issue or sale of our common stock for their own account and undertake not to transfer, directly or indirectly, our common stock to the public
in France, other than in compliance with all applicable laws and regulations and in particular with Articles&nbsp;L. <FONT STYLE="white-space:nowrap">411-1</FONT> and <FONT STYLE="white-space:nowrap">L.&nbsp;411-2</FONT> of the French Monetary and
Financial Code. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-64 </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a"><B><A NAME="supptoc260304_10"></A>LEGAL MATTERS </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">The validity of the securities being offered by this prospectus will be passed upon by Orrick, Herrington&nbsp;&amp; Sutcliffe LLP, New
York, New York. The underwriters are being represented in connection with this offering by Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., New York, New York. </FONT></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a"><B><A NAME="supptoc260304_11"></A>EXPERTS </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">The consolidated balance sheets of Catalyst Biosciences, Inc. as of December&nbsp;31, 2019 and 2018, and the related consolidated
statements of operations, comprehensive loss, stockholders&#146; equity, and cash flows for each of the years then ended, have been audited by EisnerAmper LLP, independent registered public accounting firm, as stated in their reports which are
incorporated herein by reference, which reports (i)&nbsp;express an unqualified opinion on financial statements which report includes an explanatory paragraph that refers to a change in the method of accounting for leases, and (ii)&nbsp;express an
unqualified opinion on the effectiveness of internal control over financial reporting as of December&nbsp;31, 2019. Such financial statements have been incorporated herein by reference in reliance on the reports of such firm given upon their
authority as experts in accounting and auditing. </FONT></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a"><B><A NAME="supptoc260304_12"></A>WHERE YOU CAN FIND MORE
INFORMATION </B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We have filed with the SEC a registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT>
under the Securities Act with respect to the securities offered hereby. This prospectus supplement, which constitutes a part of the registration statement, does not contain all of the information set forth in the registration statement or the
exhibits filed therewith. For further information about us and the securities offered hereby, reference is made to the accompanying prospectus and registration statement of which it is a part and the exhibits filed therewith. Statements contained in
this prospectus supplement regarding the contents of any contract or any other document that is filed as an exhibit to the accompanying prospectus and the registration statement of which it is a part are not necessarily complete, and in each
instance we refer you to the copy of such contract or other document filed as an exhibit to the registration statement or the exhibits to the reports or other documents incorporated by reference in this prospectus for a copy of such contract or
other document. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">We are subject to the informational requirements of the Exchange Act and are required to file annual,
quarterly and other reports, proxy statements and other information with the SEC. The SEC maintains an Internet site (http://www.sec.gov) that contains reports, proxy and information statements, and various other information about us. You may also
inspect the documents described herein at our principal executive offices, 611&nbsp;Gateway Blvd., Suite&nbsp;710, South San Francisco, California 94080, during normal business hours. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Information about us is also available at our website at www.catalystbiosciences.com. However, the information on our website is not a
part of this prospectus supplement and is not incorporated by reference into this prospectus supplement. </FONT></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a"><B><A NAME="supptoc260304_13">
</A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">The SEC allows us to &#147;incorporate by reference&#148; the
information we file with the SEC, which means we can disclose important information to you by referring you to those documents. The information we incorporate by reference is an important part of this prospectus, and certain information that we will
later file with the SEC will automatically update and supersede this information. We incorporate by reference the documents listed below as well as any future filings made with the SEC under Sections&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange
Act after the date of this prospectus until we sell all of the securities under this prospectus, except that we do not </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-65 </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">
incorporate any document or portion of a document that is &#147;furnished&#148; to the SEC, but not deemed &#147;filed.&#148; The following documents filed with the SEC are incorporated by
reference in this prospectus: </FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">our Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> for the year
ended December&nbsp;31, 2019 filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1124105/000156459020005546/cbio-10k_20191231.htm">February<U></U>&nbsp;20, 2020</A>; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">our Quarterly Reports on <FONT STYLE="white-space:nowrap">Form&nbsp;10-Q</FONT> for the
quarters ended March&nbsp;31, 2020, June&nbsp;30, 2020 and September&nbsp;30, 2020 filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1124105/000156459020023982/cbio-10q_20200331.htm">May<U></U>&nbsp;
11, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1124105/000156459020037483/cbio-10q_20200630.htm">August<U></U>&nbsp;
6, 2020</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1124105/000156459020023982/cbio-10q_20200331.htm">November&nbsp;5, 2020</A>, respectively; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">our Current Reports on <FONT STYLE="white-space:nowrap">Form&nbsp;8-K</FONT> filed with the
SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1124105/000119312520009556/d847025d8k.htm">January&nbsp;17, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1124105/000119312520018373/d879446d8k.htm">January&nbsp;
29, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1124105/000119312520027476/d879910d8k.htm">February&nbsp;7, 2020 (Item 8.01)</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1124105/000119312520036011/d870581d8k.htm">February&nbsp;
14, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1124105/000119312520080653/d832615d8k.htm">March&nbsp;20, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1124105/000119312520169647/d944481d8k.htm">June&nbsp;
16, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1124105/000119312520171303/d932103d8k.htm">June&nbsp;17, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1124105/000119312520174052/d946598d8k.htm">June&nbsp;
19, 2020</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1124105/000119312520308422/d23700d8k.htm">December&nbsp;2, 2020</A>; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT COLOR="#50748a">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#50748a">the description of our common stock in our Registration Statement on <FONT
STYLE="white-space:nowrap">Form&nbsp;8-A</FONT> (Commission File <FONT STYLE="white-space:nowrap">No.&nbsp;000-51173),</FONT> filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1124105/000119312506074852/d8a12g.htm">April&nbsp;
6, 2006</A>, including any subsequent amendment or any report filed for the purpose of updating such description. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#50748a">We will furnish without charge to you, on written or oral request, a copy of any or all of such documents that has been incorporated herein by reference (other than exhibits to such documents unless such exhibits are specifically
incorporated by reference into the documents that this prospectus incorporates). Written or oral requests for copies should be directed Catalyst Biosciences, Inc., Attn: Investor Relations, 611&nbsp;Gateway Blvd., Suite&nbsp;710, South San
Francisco, California 94080, telephone number <FONT STYLE="white-space:nowrap">(650)&nbsp;871-0761.</FONT> See the section of this prospectus supplement entitled &#147;Where You Can Find More Information&#148; for information concerning how to read
and obtain copies of materials that we file with the SEC. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#50748a">Any statement contained in this prospectus supplement, or in a
document all or a portion of which is incorporated by reference, shall be modified or superseded for purposes of this prospectus supplement to the extent that a statement contained in this prospectus supplement or any document incorporated by
reference modifies or supersedes such statement. Any such statement so modified or superseded shall not, except as so modified or superseded, constitute a part of this prospectus. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a">S-66 </FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>$200,000,000 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g260304g47o32.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Preferred Stock </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Debt
Securities </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Warrants </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Units </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time, we may offer
and sell, in one or more offerings, in amounts, at prices and on terms determined at the time of any such offering, common stock, preferred stock, debt securities, warrants, either individually or in units, with a total value of up to $200,000,000.
We refer to our common stock, preferred stock, debt securities, warrants and units in this prospectus as &#147;securities.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock trades
on The Nasdaq Capital Market under the symbol &#147;CBIO.&#148; On December&nbsp;20, 2018, the last reported sale price of the common stock on The Nasdaq Capital Market was $7.10 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus provides you with a general description of the securities we may offer. Each time we offer securities using this prospectus, we will provide
the specific terms of the securities and the offering in one or more supplements to this prospectus. We may also authorize one or more free writing prospectuses to be provided to you in connection with these offerings. The prospectus supplement and
any related free writing prospectus will also describe the specific manner in which we will offer the securities and may also supplement, update or amend information contained in this prospectus. You should read this prospectus, any accompanying
prospectus supplement and any related free writing prospectus carefully before you purchase any of our securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may offer the securities in
amounts, at prices and on terms determined at the time of offering. We may sell the securities directly to you, through agents designated from time to time or to or through underwriters or dealers, on a continuous or delayed basis. If we use agents,
underwriters or dealers to sell the securities, we will name them and describe their compensation in a prospectus supplement. You can find additional information about our plan of distribution for the securities under the heading &#147;Plan of
Distribution&#148; in this prospectus. We will also describe the plan of distribution for any particular offering of these securities in the prospectus supplement. This prospectus may not be used to offer and sell securities unless accompanied by a
prospectus supplement. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>INVESTING IN OUR SECURITIES INVOLVES A HIGH DEGREE OF RISK. YOU SHOULD CAREFULLY READ AND CONSIDER THE RISKS AND UNCERTAINTIES DESCRIBED IN THIS
PROSPECTUS, ANY ACCOMPANYING PROSPECTUS SUPPLEMENT AND ANY RELATED FREE WRITING PROSPECTUS AND IN THE DOCUMENTS INCORPORATED BY REFERENCE INTO THIS PROSPECTUS, ANY ACCOMPANYING PROSPECTUS SUPPLEMENT AND ANY RELATED FREE WRITING PROSPECTUS. SEE
&#147;</B><B><I><A HREF="#toc260304_4">RISK FACTORS</A></I></B><B>&#148; BEGINNING ON PAGE 5. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor
any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus is&nbsp;February&nbsp;14, 2019 </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Caption</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc260304_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc260304_2">OUR COMPANY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc260304_3">CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc260304_4">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc260304_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc260304_6">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc260304_7">ADDITIONAL INFORMATION CONCERNING OUR CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc260304_8">DESCRIPTION OF DEBT SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc260304_9">DESCRIPTION OF WARRANTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc260304_10">DESCRIPTION OF UNITS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc260304_11">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc260304_12">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc260304_13">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc260304_14">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>You should rely only on the information contained or incorporated by reference in this prospectus, in any accompanying
prospectus supplement or in any related free writing prospectus filed by us with the U.S. Securities and Exchange Commission (the &#147;SEC&#148;). We have not authorized any other person to provide you with different information. If anyone provides
you with additional, different or inconsistent information, you should not rely on it. You should not assume that the information appearing in this prospectus, any applicable prospectus supplement, any related free writing prospectus or any
documents incorporated by reference herein or therein is accurate as of any date other than the dates of those documents. Our business, financial condition, results of operations and prospects may have changed since those dates. Any information
contained on or accessible through our Internet site is not incorporated herein and does not constitute part of this prospectus. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc260304_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> that we filed with the U.S. Securities and Exchange
Commission, or the SEC, using a &#147;shelf&#148; registration process. Under this shelf registration process, we may, from time to time, issue, offer and sell to the public any part of the securities described in this prospectus, together or
separately, in one or more offerings, for a maximum aggregate offering price not to exceed $200,000,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus provides you with a general
description of the securities we may offer. Each time we sell any securities under this prospectus, we will provide a prospectus supplement containing more specific information about the terms of that offering, including the specific amounts, prices
and terms of the securities offered. Any such prospectus supplement may include a discussion of risks or other special considerations applicable to us or the securities offered thereby. Any such prospectus supplement may also add, update or change
information in this prospectus or in documents incorporated by reference in this prospectus. To the extent that any statement that we make in a prospectus supplement is inconsistent with statements made in this prospectus or in documents
incorporated by reference in this prospectus, the statements made or incorporated by reference in this prospectus will be deemed modified or superseded by those made in the prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus and any applicable prospectus supplement contain and incorporate by reference market data, industry statistics and other data that have been
obtained or compiled from information made available by third parties. These data, to the extent they contain estimates or projections, involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates
or projections. Industry publications and other reports we have obtained from independent parties generally state that the data contained in these publications or other reports have been obtained in good faith or from sources considered to be
reliable, but they do not guarantee the accuracy or completeness of such data. We urge you to carefully read this prospectus, any applicable prospectus supplement and any related free writing prospectus, any documents that we incorporate by
reference in this prospectus, any applicable prospectus supplement and any related free writing prospectus, and the additional information described below under &#147;Where You Can Find More Information&#148; before making an investment decision.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This document may only be used where it is legal to sell these securities. This prospectus is not an offer to sell these securities and it is not
soliciting an offer to buy these securities in any jurisdiction whether the offer or sale is not permitted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THIS PROSPECTUS MAY NOT BE USED TO OFFER
AND SELL SECURITIES UNLESS IT IS ACCOMPANIED BY A PROSPECTUS SUPPLEMENT. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of this prospectus, references to the terms
&#147;Catalyst,&#148; the &#147;Company,&#148; &#147;we,&#148; &#147;us&#148; and &#147;our&#148; refer to Catalyst Biosciences, Inc., a Delaware corporation, unless the context otherwise requires. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The registration statement containing this prospectus, including exhibits to the registration statement, provides additional information about us and the
securities offered under this prospectus. The registration statement can be read at the SEC&#146;s website or at the SEC offices mentioned under the heading &#147;Where You Can Find More Information.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc260304_2"></A>OUR COMPANY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a clinical-stage biopharmaceutical company focused on developing novel medicines to address serious medical conditions for individuals who need new or
better treatment options. We are focusing our product development efforts in the field of hemostasis (the process that regulates bleeding) and have a mission to develop valuable therapies for individuals with hemophilia. We used a scientific
approach to engineer several protease-based therapeutic candidates that regulate blood clotting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additional details of our development or clinical
programs and related strategic agreements are contained in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2017 and our Quarterly Reports on Form
<FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarterly periods ended March&nbsp;31, 2018, June&nbsp;30, 2018 and September&nbsp;30, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We
commenced operations in 2002 and are a Delaware corporation. Our corporate headquarters are located at South San Francisco, California 94080. Our telephone number is (650) <FONT STYLE="white-space:nowrap">871-0761,</FONT> and our website address is
www.catalystbiosciences.com. The information on or accessible through our website does not constitute part of this prospectus or any accompanying prospectus supplement and should not be relied upon in connection with making any investment in our
securities. Further, our reference to the URL for the website is intended to be an inactive textual reference only. We make our annual reports on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> quarterly reports on Form <FONT
STYLE="white-space:nowrap">10-Q,</FONT> current reports on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> and amendments to these reports available free of charge on our website as soon as reasonably practicable after we file these reports with
the SEC. Our Code of Ethics can be found on our website. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc260304_3"></A>CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus and any accompanying prospectus supplement, as well as the documents we incorporate by reference herein or therein, contains forward-looking
statements within the meaning of Section&nbsp;27A of the Securities Act and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;). All statements, other than statements of historical facts, included or
incorporated in this prospectus regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans, intentions and objectives of management are forward-looking statements. We may, in some cases,
use words such as &#147;believe,&#148; &#147;anticipate,&#148; &#147;should,&#148; &#147;could,&#148; &#147;intend,&#148; &#147;plan,&#148; &#147;may,&#148; &#147;will,&#148; &#147;seek,&#148; &#147;estimate,&#148; &#147;predict,&#148;
&#147;project,&#148; &#147;potentially,&#148; &#147;continue,&#148; &#147;expect&#148; or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. These statements are based on
our management&#146;s assumptions and assessments in light of information currently available to our management, its experience and its perception of historical trends, current conditions, expected future developments and other factors our
management believes to be appropriate. These forward-looking statements are subject to a number of risks and uncertainties, including those risks described under &#147;Risk Factors&#148; and in other sections in this prospectus and in our current
and periodic reports, and other filings, filed from time to time with the SEC that are incorporated by reference into this prospectus, that could cause actual results to differ materially from those anticipated in the forward-looking statements. See
&#147;Where You Can Find More Information&#148; below and for information about how to obtain copies of those documents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Forward-looking statements
included or incorporated by reference in this prospectus include, for example, statements about: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the strategies, prospects, plans, expectations or objectives of management for future operations;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our focus on specific product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the progress, scope or duration of the development of product candidates or programs, clinical trial plans,
timelines and potential results; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the benefits that may be derived from product candidates or the commercial or market opportunity in any target
indication; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to protect intellectual property rights; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our anticipated operations, financial position, revenues, costs or expenses, statements regarding future economic
conditions or performance, statements of belief and any statement of assumptions underlying any of the foregoing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential regulatory filings for or approval of any of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the progress of our third-party collaborations, including estimated milestones; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our intention to seek, and the ability to enter into, strategic alliances and collaborations;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the responsibilities of our collaborators, including the responsibility to make cost reimbursement, milestone,
royalty and other payments to us, and our expectations regarding our collaborators&#146; plans with respect to our products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our responsibilities to our collaborators, including our responsibilities to conduct research and development,
clinical trials and manufacture products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the results and timing of clinical trials and the possible commencement of future clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conditions for obtaining regulatory approval of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">submission and timing of applications for regulatory approval; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of the U.S. Food and Drug Administration (FDA) and other government regulations on our business;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">uncertainties associated with obtaining and protecting patents and other intellectual property rights, as well as
avoiding the intellectual property rights of others; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">products and companies that will compete with the products we license to third-party collaborators;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the possibility we may commercialize our own products and build up our commercial, sales and marketing
capabilities and other required infrastructure; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our employees, including the number of employees and the continued service of key management, technical and
scientific personnel; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our future performance and obligations under agreements we have entered into, such as the definitive agreement
related to the termination of the Pfizer Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our future performance and our expectations regarding our ability to achieve profitability;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">requirements for us to purchase supplies and raw materials from third parties, and the ability of third parties
to provide us with required supplies and raw materials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sufficiency of our cash resources, anticipated capital requirements and capital expenditures and our need for
additional financing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the composition of future revenues; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">accounting policies and estimates, including revenue recognition policies; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">statements of belief and any statement of assumptions underlying any of the foregoing. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any such forward-looking statements are not guarantees of future performance and are subject to certain risks and uncertainties that could cause actual
results to differ materially from those contemplated by such forward-looking statements. All such forward-looking statements are made only as of the date of the document in which they are contained, based on our management&#146;s beliefs and
assumptions and information available to us as of the date of that document, and we caution you not to place undue reliance on forward-looking statements in light of the risks and uncertainties associated with them. We undertake no obligation, and
disclaim any duty, to update or revise any forward-looking statements in light of future developments. You should also carefully consider other information set forth in reports or other documents that we file with the SEC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc260304_4"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our business is subject to certain risks and uncertainties. Before you invest in our securities, in addition to the other information, documents or reports
incorporated by reference in this prospectus and any prospectus supplement or other offering materials, you should carefully consider the risk factors in this section, the section entitled &#147;Risk Factors&#148; in any prospectus supplement as
well as our most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> and in our Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> filed subsequent to the Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K,</FONT> which are incorporated by reference into this prospectus and any prospectus supplement in their entirety, as the same may be amended, supplemented or superseded from time to time by other reports we file with
the SEC in the future. Each of the risks described in these sections and documents could materially and adversely affect our business, financial condition, results of operations and prospects, and could result in a partial or complete loss of your
investment. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc260304_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated in a prospectus supplement, the net proceeds from the sale of securities offered by this prospectus will be used for general
corporate purposes, which may include clinical trials, research and development activities, capital expenditures, selling, general and administrative costs, facilities expansion, and to meet working capital needs. We expect from time to time to
evaluate the acquisition of businesses, products and technologies for which a portion of the net proceeds may be used, although we currently are not planning or negotiating any such transactions. Pending such uses, we may invest the net proceeds in
investment grade interest-bearing securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amounts actually expended for each purpose may vary significantly depending upon numerous factors,
including the amount and timing of the proceeds from this offering and progress with the commercial development of our products as well as our clinical development programs. Expenditures will also depend upon the establishment of collaborative
arrangements with other companies, the availability of additional financing and other factors. Investors will be relying on the judgment of our management regarding the application of the proceeds of any sale of securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc260304_6"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following description of our common stock and preferred stock, together with the additional information we include in any applicable prospectus
supplements, summarizes the material terms and provisions of the common stock and preferred stock that we may offer under this prospectus. It may not contain all the information that is important to you. For the complete terms of our common stock
and preferred stock, please refer to our Fourth Amended and Restated Certificate of Incorporation, as amended (the &#147;restated certificate of incorporation&#148;) and our amended and restated bylaws, which are incorporated by reference into the
registration statement which includes this prospectus. The Delaware General Corporation Law (&#147;DGCL&#148;) may also affect the terms of these securities. While the terms we have summarized below will apply generally to any future common stock
and preferred stock that we may offer, we will describe the particular terms of these securities in more detail in the applicable prospectus supplement. If we so indicate in a prospectus supplement, the terms of any security we offer under that
prospectus supplement may differ from the terms we describe below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under our restated certificate of incorporation, we have authority to issue 100,000,000 shares of our common stock, par value $0.001 per share. As of
December&nbsp;20, 2018, 11,947,738 shares of our common stock were issued and outstanding. All shares of our common stock will, when issued, be duly authorized, fully paid and nonassessable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Dividends. </I>Subject to preferential dividend rights of any other class or series of stock, the holders of shares of our common stock are entitled to
receive dividends, including dividends of our stock, as and when declared by our board of directors, subject to any limitations imposed by law and to the rights of the holders, if any, of our preferred stock. We have never paid cash dividends on our
common stock, except with respect to a cash dividend paid in connection with the closing of our business combination with Targacept, Inc. We do not anticipate paying periodic cash dividends on our common stock for the foreseeable future. Any future
determination about the payment of dividends will be made at the discretion of our board of directors and will depend upon our earnings, if any, capital requirements, operating and financial conditions and on such other factors as the board of
directors deems relevant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Liquidation.</I> In the event we are liquidated, dissolved or our affairs are wound up, after we pay or make adequate
provision for all of our known debts and liabilities, each holder of our common stock will be entitled to share ratably in all assets that remain, subject to any rights that are granted to the holders of any class or series of preferred stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Voting Rights.</I> For all matters submitted to a vote of stockholders, each holder of our common stock is entitled to one vote for each share registered
in his or her name. Except as may be required by law and in connection with some significant actions, such as mergers, consolidations, or amendments to our restated certificate of incorporation that affect the rights of stockholders, holders of our
common stock vote together as a single class. There is no cumulative voting in the election of our directors, which means that, subject to any rights to elect directors that are granted to the holders of any class or series of preferred stock, a
plurality of the votes cast at a meeting of stockholders at which a quorum is present is sufficient to elect a director. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other Rights and
Restrictions.</I> Subject to the preferential rights of any other class or series of stock, all shares of our common stock have equal dividend, distribution, liquidation and other rights, and have no preference, appraisal or exchange rights, except
for any appraisal rights provided by Delaware law. Furthermore, holders of our common stock have no conversion, sinking fund or redemption rights, or preemptive rights to subscribe for any of our securities. Our restated certificate of incorporation
and our bylaws do not restrict the ability of a holder of our common stock to transfer his or her shares of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The rights, powers,
preferences and privileges of holders of our common stock are subject to, and may be adversely affected by, the rights of holders of shares of any series of preferred stock which we may designate and issue in the future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Listing.</I> Our common stock is listed on the Nasdaq Capital Market under the symbol &#147;CBIO.&#148;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Transfer Agent and Registrar. </I>The transfer agent for our common stock is American Stock Transfer&nbsp;&amp;Trust Company, LLC. Its address is 6201
15th Avenue, Brooklyn, NY 11219. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under our restated certificate of incorporation, we have authority, subject to any limitations prescribed by law and without further stockholder approval, to
issue from time to time up to 5,000,000 shares of preferred stock, par value $0.001 per share, in one or more series. As of December&nbsp;20, 2018, the Company had no shares of preferred stock issued and outstanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to our restated certificate of incorporation, we are authorized to issue &#147;blank check&#148; preferred stock, which may be issued from time to
time in one or more series upon authorization by our board of directors. Our board of directors, without further approval of the stockholders, is authorized to fix the designation, powers, preferences, relative, participating optional or other
special rights, and any qualifications, limitations and restrictions applicable to each series of the preferred stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes
could, among other things, adversely affect the voting power or rights of the holders of our common stock and, under certain circumstances, make it more difficult for a third party to gain control of us, discourage bids for our common stock at a
premium or otherwise adversely affect the market price of the common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preferred stock will have the terms described below unless otherwise
provided in the prospectus supplement relating to a particular series of the preferred stock. You should read the prospectus supplement relating to the particular series of the preferred stock being offered for specific terms, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the designation and stated value per share of the preferred stock and the number of shares offered;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the amount of liquidation preference per share; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the price at which the preferred stock will be issued; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the dividend rate, or method of calculation of any dividend, the dates on which dividends will be payable,
whether dividends will be cumulative or noncumulative and, if cumulative, the dates from which dividends will accumulate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any redemption or sinking fund provisions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if other than the currency of the United States, the currency or currencies, including composite currencies, in
which the preferred stock is denominated and/or in which payments will or may be payable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any conversion provisions; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other rights, preferences, privileges, qualifications, limitations and restrictions on the preferred stock.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preferred stock will, when issued, be duly authorized, fully paid and nonassessable. Unless otherwise specified in the prospectus
supplement, each series of the preferred stock will rank equally as to dividends and liquidation rights in all respects with any other series of preferred stock. The rights of holders of shares of each series of preferred stock will be subordinate
to those of our general creditors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Rank. </I>Unless otherwise specified in the prospectus supplement, the preferred stock will, with respect to
dividend rights and rights upon our liquidation, dissolution or winding up of our affairs, rank: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">senior to all classes or series of our common stock and to all equity securities ranking junior to such preferred
stock with respect to dividend rights or rights upon our liquidation, dissolution or winding up of our affairs; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on a parity with all equity securities issued by us, the terms of which specifically provide that such equity
securities rank on a parity with the preferred stock with respect to dividend rights or rights upon our liquidation, dissolution or winding up of our affairs; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">junior to all equity securities issued by us, the terms of which specifically provide that such equity securities
rank senior to the preferred stock with respect to dividend rights or rights upon our liquidation, dissolution or winding up of our affairs. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;equity securities&#148; does not include convertible debt securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Dividends.</I> Holders of the preferred stock of each series will be entitled to receive, when, as and if declared by our board of directors, cash
dividends at such rates and on such dates described in the prospectus supplement. Different series of preferred stock may be entitled to dividends at different rates or based on different methods of calculation. The dividend rate may be fixed or
variable or both. Dividends will be payable to the holders of record as they appear on our stock books on record dates fixed by our board of directors, as specified in the applicable prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dividends on any series of the preferred stock may be cumulative or noncumulative, as described in the applicable prospectus supplement. If our board of
directors does not declare a dividend payable on a dividend payment date on any series of noncumulative preferred stock, then the holders of that noncumulative preferred stock will have no right to receive a dividend for that dividend payment date,
and we will have no obligation to pay the dividend accrued for that period, whether or not dividends on that series are declared payable on any future dividend payment dates. Dividends on any series of cumulative preferred stock will accrue from the
date we initially issue shares of such series or such other date specified in the applicable prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Liquidation Preference. </I>Upon
any voluntary or involuntary liquidation, dissolution or winding up of our affairs, before we make any distribution or payment to the holders of any common stock or any other class or series of our capital stock ranking junior to the preferred stock
in the distribution of assets upon any liquidation, dissolution or winding up of our affairs, the holders of each series of preferred stock shall be entitled to receive out of assets legally available for distribution to stockholders, liquidating
distributions in the amount of the liquidation preference per share set forth in the applicable prospectus supplement, plus any accrued and unpaid dividends thereon. Such dividends will not include any accumulation in respect of unpaid noncumulative
dividends for prior dividend periods. Unless otherwise specified in the prospectus supplement, after payment of the full amount of their liquidating distributions, the holders of preferred stock will have no right or claim to any of our remaining
assets. Upon any such voluntary or involuntary liquidation, dissolution or winding up, if our available assets are insufficient to pay the amount of the liquidating distributions on all outstanding preferred stock and the corresponding amounts
payable on all other classes or series of our capital stock ranking on parity with the preferred stock and all other such classes or series of shares of capital stock ranking on parity with the preferred stock in the distribution of assets, then the
holders of the preferred stock and all other such classes or series of capital stock will share ratably in any such distribution of assets in proportion to the full liquidating distributions to which they would otherwise be entitled. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Redemption.</I> If so provided in the applicable prospectus supplement, the preferred stock will be subject to mandatory redemption or redemption at our
option, as a whole or in part, in each case upon the terms, at the times and at the redemption prices set forth in such prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Voting
Rights.</I> Holders of preferred stock will have voting rights as required by law or as indicated in the applicable prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Conversion
Rights. </I>The terms and conditions, if any, upon which any series of preferred stock is convertible into common stock will be set forth in the applicable prospectus supplement relating thereto. Such terms will include the number of shares of
common stock into which the shares of preferred stock are convertible, the conversion </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
price, rate or manner of calculation thereof, the conversion period, provisions as to whether conversion will be at our option or at the option of the holders of the preferred stock, the events
requiring an adjustment of the conversion price and provisions affecting conversion in the event of the redemption. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Transfer Agent and Registrar.</I>
Any transfer agent and registrar for the preferred stock will be set forth in the applicable prospectus supplement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Series A Convertible Preferred
Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;20, 2018, the Company had no shares of preferred stock issued and outstanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Liquidation Preference</I>. In the event of a liquidation, the holders of Series A Convertible Preferred Stock will be entitled to participate on an <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">as-converted-to-common-stock</FONT></FONT></FONT> basis with holders of the common stock in any distribution of assets of the Company to the holders of the
common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Dividends</I>. The Series A Certificate of Designation provides, among other things, that we shall not pay any dividends on shares of
common stock (other than dividends in the form of common stock) unless and until such time as we pay dividends on each share of Series A Convertible Preferred Stock on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis. Other than as set
forth in the previous sentence, the Series A Certificate of Designation provides that no other dividends shall be paid on shares of Series A Convertible Preferred Stock and that we shall pay no dividends (other than dividends in the form of common
stock) on shares of common stock unless we simultaneously comply with the previous sentence. The Series A Certificate of Designation does not provide for any restriction on the repurchase of Series A Convertible Preferred Stock by us while there is
any arrearage in the payment of dividends on the Series A Convertible Preferred Stock. There are no sinking fund provisions applicable to the Series A Convertible Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Voting Rights</I>. With certain exceptions, as described in the Series A Certificate of Designation, the Series A Convertible Preferred Stock has no voting
rights. However, as long as any shares of Series A Convertible Preferred Stock remain outstanding, the Series A Certificate of Designation provides that we shall not, without the affirmative vote of holders of a majority of the then-outstanding
shares of Series A Convertible Preferred Stock, (a)&nbsp;alter or change adversely the powers, preferences or rights given to the Series A Convertible Preferred Stock or alter or amend the Series A Certificate of Designation, (b)&nbsp;increase the
number of authorized shares of Series A Convertible Preferred Stock or (c)&nbsp;effect a stock split or reverse stock split of the Series A Convertible Preferred Stock or any like event. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Conversion</I>. Each share of Series A Convertible Preferred Stock is convertible at any time at the holder&#146;s option into a number of shares of Common
Stock equal to $1,000.00 per share divided by the Conversion Price. The &#147;Conversion Price&#148; is initially $5.00, subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations and other similar transactions
as specified in the Certificate of Designation. Notwithstanding the foregoing, the Series A Certificate of Designation provides further that we shall not effect any conversion of the Series A Convertible Preferred Stock, with certain exceptions, to
the extent that, after giving effect to an attempted conversion, the holder of Series A Convertible Preferred Stock (together with such holder&#146;s affiliates, and any persons acting as a group together with such holder or any of such
holder&#146;s affiliates) would beneficially own a number of shares of Common Stock in excess of 4.99% (or, at the election of the purchaser, 9.99%) of the shares of our common stock then outstanding after giving effect to such exercise (the
&#147;Preferred Stock Beneficial Ownership Limitation&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Call Right</I>. Additionally, subject to certain exceptions, at any time prior to the
three year anniversary of the issuance of the Series A Convertible Preferred Stock, subject to the Preferred Stock Beneficial Ownership Limitation, we will have the right to cause each holder of the Series A Convertible Preferred Stock to convert
all or part of such holder&#146;s Series A Convertible Preferred Stock in the event that (i)&nbsp;the volume weighted average price of our common stock for 30 consecutive trading days (the &#147;Measurement Period&#148;) exceeds 300% of the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
conversion price of the Series A Convertible Preferred Stock issued (subject to adjustment for forward and reverse stock splits, recapitalizations, stock dividends and similar transactions), (ii)
the average daily trading volume for such Measurement Period exceeds $500,000 per trading day and (iii)&nbsp;the holder is not in possession of any information that constitutes or might constitute, material
<FONT STYLE="white-space:nowrap">non-public</FONT> information which was provided by the Company and subject to the Preferred Beneficial Ownership Limitation. Our right to cause each holder of the Series A Convertible Preferred Stock to convert all
or part of such holder&#146;s Series A Convertible Preferred Stock shall be exercised ratably among the holders of the then outstanding Series A Convertible Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Listing</I>. We have not applied for listing of the Series A Convertible Preferred Stock on any securities exchange or other trading system. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Transfer Agent</I>. The transfer agent for our Series A Convertible Preferred Stock is American Stock Transfer&nbsp;&amp; Trust Company, LLC. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain Effects of Authorized but Unissued Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have
shares of common stock and preferred stock available for future issuance without stockholder approval. We may issue these additional shares for a variety of corporate purposes, including future public or private offerings to raise additional capital
or to facilitate corporate acquisitions or for payment as a dividend on our capital stock. The existence of unissued and unreserved preferred stock may enable our board of directors to issue shares of preferred stock with terms that could render
more difficult or discourage a third-party attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise, thereby protecting the continuity of our management. In addition, if we issue preferred stock, the issuance
could adversely affect the voting power of holders of common stock and the likelihood that holders of common stock will receive dividend payments or payments upon liquidation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc260304_7"></A>ADDITIONAL INFORMATION CONCERNING OUR CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-Takeover Effects of Provisions of Our Charter Documents </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our restated certificate of incorporation provides for our board of directors to be divided into three classes serving staggered terms. Approximately <FONT
STYLE="white-space:nowrap">one-third</FONT> of our board of directors will be elected each year. The provision for a classified board could prevent a party who acquires control of a majority of the outstanding voting stock from obtaining control of
the board of directors until the second annual stockholders meeting following the date the acquirer obtains the controlling stock interest. The classified board provision could discourage a potential acquirer from making a tender offer or otherwise
attempting to obtain control of Catalyst and could increase the likelihood that incumbent directors will retain their positions. Our restated certificate of incorporation provides that directors may be removed with or without cause by the
affirmative vote of the holders of at least 66 2/3% of the voting power of all outstanding stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our restated certificate of incorporation requires that
certain amendments to the restated certificate of incorporation and amendments by the stockholders of our bylaws require the affirmative vote of at least 66 2/3% of the voting power of all outstanding stock. These provisions could discourage a
potential acquirer from making a tender offer or otherwise attempting to obtain control of the Company and could delay changes in management. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our amended
and restated bylaws establish an advance notice procedure for stockholder proposals to be brought before an annual stockholders meeting, including proposed nominations of persons for election to our board of directors. At an annual stockholders
meeting, stockholders may only consider proposals or nominations specified in the notice of meeting or brought before the meeting by or at the direction of our board of directors. Stockholders may also consider a proposal or nomination by a person
who was a stockholder of record on the record date for the meeting, who is entitled to vote at the meeting and who has given to the Secretary of the Company timely written notice, in proper form, of his or her intention to bring that business before
the annual stockholders meeting. The amended and restated bylaws do not give our board of directors the power to approve or disapprove stockholder nominations of candidates or proposals regarding other business to be conducted at a special or annual
meeting of the stockholders. However our bylaws may have the effect of precluding the conduct of business at a meeting if the proper procedures are not followed. These provisions may also discourage or deter a potential acquirer from conducting a
solicitation of proxies to elect the acquirer&#146;s own slate of directors or otherwise attempting to obtain control of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our amended and
restated bylaws provide that only our board of directors, the chairperson of the board, the President or the Chief Executive Officer may call a special meeting of stockholders. Because our stockholders do not have the right to call a special
meeting, a stockholder could not force stockholder consideration of a proposal over the opposition of our board of directors by calling a special meeting of stockholders prior to such time as a majority of our board of directors, the chairperson of
the board, the President or the Chief Executive Officer believed the matter should be considered or until the next annual meeting provided that the requestor met the notice requirements. The restriction on the ability of stockholders to call a
special meeting means that a proposal to replace the board also could be delayed until the next annual stockholders meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our restated certificate of
incorporation does not allow stockholders to act by written consent without a meeting. Without the availability of stockholder&#146;s actions by written consent, a holder controlling a majority of our capital stock would not be able to amend our
bylaws or remove directors without holding a stockholders&#146; meeting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-Takeover Effects of Provisions of Delaware Law </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are subject to the provisions of Section&nbsp;203 of the DGCL, or Section&nbsp;203. Under Section&nbsp;203, we would generally be prohibited from engaging
in any business combination with any interested stockholder for a period of three years following the time that this stockholder became an interested stockholder unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prior to this time, our board of directors approved either the business combination or the transaction that
resulted in the stockholder becoming an interested stockholder; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the
interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding shares owned by persons who are directors and also officers, and by employee stock plans in which employee
participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at or subsequent to such time, the business combination is approved by our board of directors and authorized at a
special or annual stockholders meeting, and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting stock that is not owned by the interested stockholder. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Section&nbsp;203, a &#147;business combination&#148; includes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any merger or consolidation involving the corporation and the interested stockholder; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any sale, transfer, pledge or other disposition of 10% or more of the assets of the corporation involving the
interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to
the interested stockholder, subject to limited exceptions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any transaction involving the corporation that has the effect of increasing the proportionate share of the stock
of any class or series of the corporation beneficially owned by the interested stockholder; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other
financial benefits provided by or through the corporation. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In general, Section&nbsp;203 defines an interested stockholder as an entity
or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by such entity or person. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitation of Liability and Indemnification </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our restated
certificate of incorporation provides that our directors shall not be personally liable to us or our stockholders for monetary damages for any breach of fiduciary duty as a director, except for liability for breach of the director&#146;s duty of
loyalty to us or our stockholders, for acts or omissions not in good faith or involving intentional misconduct or a knowing violation of law, for payment of dividends or approval of stock purchases or redemptions that are prohibited by the DGCL, or
for any transaction from which the director derived an improper personal benefit. Under the DGCL, our directors have a fiduciary duty to us that is not eliminated by this provision of the restated certificate of incorporation and, in appropriate
circumstances, equitable remedies such as injunctive or other forms of <FONT STYLE="white-space:nowrap">non-monetary</FONT> relief will remain available. This provision also does not affect our directors&#146; responsibilities under any other laws,
such as federal securities laws or state or federal environmental laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;145 of the DGCL empowers a corporation to indemnify its directors
and officers against expenses (including attorneys&#146; fees), judgments, fines and amounts paid in settlements actually and reasonably incurred by them in connection with any action, suit or proceeding brought by third parties by reason of the
fact that they were or are directors or officers of the corporation, if they acted in good faith, in a manner they reasonably believed to be in or not opposed to the best interests of the corporation and, with respect to any criminal action or
proceeding, had no reasonable cause to believe that their conduct was unlawful. The DGCL provides further that the indemnification permitted thereunder shall not be deemed exclusive of any other rights to which the directors and officers may be
entitled under the corporation&#146;s bylaws, any agreement, a vote of stockholders or otherwise. Our restated certificate of incorporation provides that, to the fullest extent permitted by Section&nbsp;145 of the DGCL, we shall indemnify any person
who is or was a director or officer of us, or is or was serving at our request as a director, officer or trustee of another corporation, partnership, joint venture, trust, employee benefit </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
plan or other enterprise, against the expenses, liabilities or other matters referred to in or covered by Section&nbsp;145 of the DGCL. Our amended and restated bylaws provide that we will
indemnify any person who was or is a party or threatened to be made a party to any proceeding by reason of the fact that such person is or was a director or officer of us or is or was serving at our request as a director, officer or trustee of
another corporation, partnership, joint venture, trust, employee benefit plan or other enterprise to the fullest extent permitted by the DGCL. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
addition, we have entered into indemnification agreements with each of our directors and with certain of our executive officers. Pursuant to the indemnification agreements, we has agreed to indemnify and hold harmless these directors and officers to
the fullest extent permitted by the DGCL. The agreements generally cover expenses that a director or officer incurs or amounts that a director or officer becomes obligated to pay because of any proceeding to which he or she is made or threatened to
be made a party or participant by reason of his or her service as a current or former director, officer, employee or agent of the Company. The agreements also provide for the advancement of expenses to the directors and officers subject to specified
conditions. There are certain exceptions to our obligation to indemnify the directors and officers, including any intentional malfeasance or act where the director or officer did not in good faith believe he or she was acting in our best interests,
with respect to &#147;short-swing&#148; profit claims under Section&nbsp;16(b) of the 1934 Act and, with certain exceptions, with respect to proceedings that he or she initiates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;145 of the DGCL also empowers a corporation to purchase insurance for its officers and directors for such liabilities. We maintain liability
insurance for our officers and directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc260304_8"></A>DESCRIPTION OF DEBT SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following description, together with the additional information we include in any applicable prospectus supplements, summarizes the material terms and
provisions of the debt securities that we may offer under this prospectus. While the terms we have summarized below will apply generally to any future debt securities we may offer under this prospectus, we will describe the particular terms of any
debt securities that we may offer in more detail in the applicable prospectus supplement. The terms of any debt securities we offer under a prospectus supplement may differ from the terms we describe below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following summary description, together with the additional information we may include in any applicable prospectus supplements does not purport to be
complete and is subject to, and qualified in its entirety by reference to, the form of indenture filed as an exhibit to the registration statement of which this prospectus is part, as it may be supplemented, amended or modified from time to time, as
well as the notes and supplemental agreements relating to each series of debt securities that will be incorporated by reference as exhibits to the registration statement that includes this prospectus or as exhibits to a current report on Form <FONT
STYLE="white-space:nowrap">8-K</FONT> if we offer debt securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will issue senior debt securities under one or more senior indentures that we will
enter into with a trustee named in the relevant senior indenture. We will issue subordinated debt securities under one or more subordinated indentures that we will enter into with a trustee named in the relevant subordinated indenture. We have filed
a form of indenture as an exhibit to the registration statement of which this prospectus is a part. We use the terms &#147;indenture&#148; and &#147;indentures&#148; in this prospectus to refer to both the senior indenture and the subordinated
indenture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The indentures will be qualified under the Trust Indenture Act of 1939, as amended. We use the term &#147;debenture trustee&#148; to refer to
either the trustee under the senior indenture or the trustee under the subordinated indenture, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following summaries of material
provisions of the senior debt securities, the subordinated debt securities and the indentures are subject to, and qualified in their entirety by reference to, all the provisions of the indenture applicable to a particular series of debt securities.
We urge you to read the applicable prospectus supplements related to the debt securities that we sell under this prospectus, as well as the indenture that would contain the terms of the debt securities. Except as we may otherwise indicate, the terms
of the senior indenture and the subordinated indenture would be identical. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will describe in each prospectus supplement the following terms relating to a series of debt securities: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the principal amount being offered, and if a series, the total amount authorized and the total amount
outstanding; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any limit on the amount that may be issued; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether or not we will issue the series of debt securities in global form, the terms and who the depositary will
be; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the maturity date; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether and under what circumstances, if any, we will pay additional amounts on any debt securities held by a
person who is not a U.S. person for tax purposes, and whether we can redeem the debt securities if we have to pay such additional amounts; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the annual interest rate, which may be fixed or variable, or the method for determining the rate and the date
interest will begin to accrue, the dates interest will be payable and the regular record dates for interest payment dates or the method for determining such dates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether or not the debt securities will be secured or unsecured, and the terms of any secured debt;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms of the subordination of any series of subordinated debt; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the place where payments will be payable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on transfer, sale or other assignment, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our right, if any, to defer payment of interest and the maximum length of any such deferral period;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date, if any, after which, and the price at which, we may, at our option, redeem the series of debt
securities pursuant to any optional or provisional redemption provisions and the terms of those redemptions provisions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date, if any, on which, and the price at which we are obligated, pursuant to any mandatory sinking fund or
analogous fund provisions or otherwise, to redeem, or at the holder&#146;s option to purchase, the series of debt securities and the currency or currency unit in which the debt securities are payable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the indenture will restrict our ability and/or the ability of our subsidiaries to: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">incur additional indebtedness; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issue additional securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">create liens; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pay dividends and make distributions in respect of our capital stock and the capital stock of our subsidiaries;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">redeem capital stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">place restrictions on our subsidiaries&#146; ability to pay dividends, make distributions or transfer assets;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make investments or other restricted payments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sell or otherwise dispose of assets; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enter into sale-leaseback transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">engage in transactions with stockholders and affiliates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issue or sell stock of our subsidiaries; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">effect a consolidation or merger; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the indenture will require us to maintain any interest coverage, fixed charge, cash flow-based,
asset-based or other financial ratios; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a discussion of any material or special U.S. federal income tax considerations applicable to the debt securities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">information describing any book-entry features; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provisions for a sinking fund purchase or other analogous fund, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the debt securities are to be offered at a price such that they will be deemed to be offered at an
&#147;original issue discount&#148; as defined in paragraph (a)&nbsp;of Section&nbsp;1273 of the Internal Revenue Code; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the denominations in which we will issue the series of debt securities, if other than denominations of $1,000 and
any integral multiple thereof; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other specific terms, preferences, rights or limitations of, or restrictions on, the debt securities,
including any additional events of default or covenants provided with respect to the debt securities, and any terms that may be required by us or advisable under applicable laws or regulations. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conversion or Exchange Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will set forth in the
prospectus supplement the terms on which a series of debt securities may be convertible into or exchangeable for our common stock or our other securities. We will include provisions as to whether conversion or exchange is mandatory, at the option of
the holder or at our option. We may include provisions pursuant to which the number of shares of our common stock or our other securities that the holders of the series of debt securities receive would be subject to adjustment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Consolidation, Merger or Sale </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any successor to or
acquiror of the indentures must assume all of our obligations under the indentures or the debt securities, as appropriate. If the debt securities are convertible for our other securities or securities of other entities, the person with whom we
consolidate or merge or to whom we sell all of our property must make provisions for the conversion of the debt securities into securities that the holders of the debt securities would have received if they had converted the debt securities before
the consolidation, merger or sale. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Events of Default Under the Indenture </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise provided in any applicable prospectus supplement, documents incorporated by reference or free writing prospectus, the following will be events
of default under the indenture with respect to each series of debt securities issued thereunder: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if we fail to pay interest when due and payable and our failure continues for 30 days, or within such other
time period as may be specified in the applicable indenture, and the time for payment has not been extended or deferred; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if we fail to pay the principal, premium or sinking fund payment, if any, when due and payable and the time for
payment has not been extended or delayed; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if specified events of bankruptcy, insolvency or reorganization occur; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if we fail to observe or perform any other covenant contained in the debt securities or the indentures, other
than a covenant specifically relating to another series of debt securities, and our failure continues for 60 days, or within such other time period as may be specified in the applicable indenture, after we receive notice from the debenture trustee
or holders of at least a majority in principal amount of the outstanding debt securities of an affected series, or such other percentage as may be specified in the applicable indenture, in aggregate principal amount of the outstanding debt
securities of the applicable series. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an event of default with respect to debt securities of any series occurs and is continuing,
other than an event of default specified in the last bullet point above, the debenture trustee or the holders of at least 25%, or such other percentage as may be specified in the applicable indenture, in aggregate principal amount of the outstanding
debt securities of that series, by notice to us in writing, and to the debenture trustee if notice is given by such holders, may declare the unpaid principal of, premium, if any, and accrued interest, if any, due and payable immediately. If an event
of default specified in the last bullet point above occurs with respect to us, the principal amount of and accrued interest, if any, of each issue of debt securities then outstanding shall be due and payable without any notice or other action on the
part of the debenture trustee or any holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The holders of a majority in principal amount of the outstanding debt securities of an affected series may
waive any default or event of default with respect to the series and its consequences, except defaults or events of default regarding payment of principal, premium, if any, or interest, unless we have cured the default or event of default in
accordance with the indenture. Any waiver shall cure the default or event of default. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the terms of the indentures, if an event of default under an indenture shall occur and be
continuing, the debenture trustee will be under no obligation to exercise any of its rights or powers under such indenture at the request or direction of any of the holders of the applicable series of debt securities, unless such holders have
offered the debenture trustee reasonable indemnity. The holders of a majority in principal amount of the outstanding debt securities of any series will have the right to direct the time, method and place of conducting any proceeding for any remedy
available to the debenture trustee, or exercising any trust or power conferred on the debenture trustee, with respect to the debt securities of that series, provided that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the direction so given by the holder is not in conflict with any law or the applicable indenture; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to its duties under the Trust Indenture Act of 1939, the debenture trustee need not take any action that
might involve it in personal liability or might be unduly prejudicial to the holders not involved in the proceeding. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A holder of the
debt securities of any series will only have the right to institute a proceeding under the indentures or to appoint a receiver or trustee, or to seek other remedies if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the holder has given written notice to the debenture trustee of a continuing event of default with respect to
that series; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the holders of at least 25% (or, in the case of a default of the type described under subsection (d), above, a
majority in principal amount of the outstanding debt securities of an affected series), or such other percentage as may be specified in the applicable indenture, in aggregate principal amount of the outstanding debt securities of that series have
made written request, and such holders have offered reasonable indemnity to the debenture trustee to institute the proceeding as trustee; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the debenture trustee does not institute the proceeding, and does not receive from the holders of a majority in
aggregate principal amount of the outstanding debt securities of that series other conflicting directions within 60 days, or within such other time period as may be specified in the applicable indenture, after the notice, request and offer of
indemnity. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These limitations do not apply to a suit instituted by a holder of debt securities if we default in the payment of the
principal, premium, if any, or interest on, the debt securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will periodically file statements with the debenture trustee regarding our compliance
with specified covenants in the indentures. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Modification of Indenture; Waiver </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We and the debenture trustee may change an indenture without the consent of any holders with respect to specific matters: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to evidence the succession of another corporation to us and the assumption by any such successor of our covenants
in such indenture and in the debt securities issued thereunder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to add to our covenants or to surrender any right or power conferred on us pursuant to the indenture;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to establish the form and terms of debt securities issued thereunder; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to evidence and provide for a successor trustee under such indenture with respect to one or more series of debt
securities issued thereunder or to provide for or facilitate the administration of the trusts under such indenture by more than one trustee; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to cure any ambiguity, to correct or supplement any provision in the indenture that may be defective or
inconsistent with any other provision of the indenture or to make any other provisions with respect to matters or questions arising under such indenture; provided that no such action adversely affects the interests of the holders of any series of
debt securities issued thereunder in any material respect; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to add to, delete from or revise the conditions, limitations and restrictions on the authorized amount, terms or
purposes of issue, authentication and delivery of securities under the indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to add any additional events of default with respect to all or any series of debt securities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to supplement any of the provisions of the indenture as may be necessary to permit or facilitate the defeasance
and discharge of any series of debt securities, provided that such action does not adversely affect the interests of any holder of an outstanding debt security of such series or any other security in any material respect; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to make provisions with respect to the conversion or exchange rights of holders of debt securities of any series;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to pledge to the trustee as security for the debt securities of any series any property or assets;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to add guarantees in respect of the debt securities of one or more series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to change or eliminate any of the provisions of the indenture, provided that any such change or elimination
becomes effective only when there is no security of any series outstanding created prior to the execution of such supplemental indenture which is entitled to the benefit of such provision; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to provide for certificated securities in addition to or in place of global securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to qualify such indenture under the Trust Indenture Act of 1939, as amended; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">with respect to the debt securities of any series, to conform the text of the indenture or the debt securities of
such series to any provision of the description thereof in our offering memorandum or prospectus relating to the initial offering of such debt securities, to the extent that such provision, in our good faith judgment, was intended to be a verbatim
recitation of a provision of the indenture or such securities; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to make any other change that does not adversely affect the rights of holders of any series of debt securities
issued thereunder in any material respect. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, under the indentures, the rights of holders of a series of debt securities may
be changed by us and the debenture trustee with the written consent of the holders of at least a majority in aggregate principal amount of the outstanding debt securities of each series that is affected. However, we and the debenture trustee may
only make the following changes with the consent of each holder of any outstanding debt securities affected: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">extending the fixed maturity of the series of debt securities; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reducing the principal amount, reducing the rate of or extending the time of payment of interest, or reducing any
premium payable upon the redemption of any debt securities; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reducing the percentage of debt securities, the holders of which are required to consent to any amendment,
supplement, modification or waiver; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make any change that adversely affects the right to convert or exchange any security into or for common stock or
other securities, cash or other property in accordance with the terms of the applicable debt security. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each indenture provides that we
can elect to be discharged from our obligations with respect to one or more series of debt securities, except for specified obligations, including obligations to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">register the transfer or exchange of debt securities of the series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">replace stolen, lost or mutilated debt securities of the series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintain paying agencies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">hold monies for payment in trust; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recover excess money held by the debenture trustee; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compensate and indemnify the debenture trustee; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">appoint any successor trustee. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to exercise our rights to be discharged, we must deposit with the debenture trustee money or government obligations sufficient to pay all the
principal of, any premium, if any, and interest on, the debt securities of the series on the dates payments are due. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Form, Exchange and Transfer
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each debt security will be represented by either one or more global securities registered in the name of The Depository Trust Company, as depositary,
or a nominee (which we refer to, in the case of any debt security represented by a global debt security, as a &#147;book-entry debt security&#148;), or a certificate issued in definitive registered form (which we refer to, in the case of any debt
security represented by a certificated security, as a &#147;certificated debt security&#148;) as set forth in the applicable prospectus supplement. Except as set forth in the applicable prospectus supplement, book-entry debt securities will not be
issuable in certificated form. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You may transfer or exchange certificated debt securities at any office we maintain for this purpose in accordance with
the terms of the indenture. No service charge will be made for any registration of transfer or exchange of certificated debt securities, but we may require payment of a sum sufficient to cover all taxes, assessments or other governmental charges
that may be imposed in connection with a transfer or exchange. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You may effect the transfer of certificated debt securities and the right to receive the
principal of, and any premium and interest on, certificated debt securities only by surrendering the certificate representing those certificated debt securities and either execution by us, and authentication and delivery by the debenture trustee, of
the certificate to the new holder or execution by us, and authentication and delivery by the debenture trustee, of a new certificate to the new holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we elect to redeem the debt securities of any series, we will not be required to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issue, register the transfer of, or exchange any debt securities of that series during a period beginning at the
opening of business 15 days, or within such other time period as may be specified in the applicable indenture, before the day of mailing of a notice of redemption of any debt securities that may be selected for redemption and ending at the close of
business on the day of the mailing; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">register the transfer of or exchange any debt securities so selected for redemption, in whole or in part, except
the unredeemed portion of any debt securities we are redeeming in part. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Repurchases on the Open Market </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We, or an affiliate of ours, may at any time or from time to time repurchase any debt security in the open market or otherwise. Such debt securities may, at
our option (or our affiliate&#146;s option), be held, resold or surrendered to the trustee for cancellation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Discharge of Debt Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When all outstanding debt securities of any series will become due and payable within one year of their stated maturity and we have deposited with the
debenture trustee cash sufficient to pay and discharge all outstanding debt securities of such series on the date of their stated maturity, then we may discharge our obligations under the relevant indenture with respect to such debt securities while
they remain outstanding. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Information Concerning the Debenture Trustee </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The debenture trustee, other than during the occurrence and continuance of an event of default under an indenture, undertakes to perform only those duties as
are specifically set forth in the applicable indenture. Upon an event of default under an indenture, the debenture trustee must use the same degree of care as a prudent person would exercise or use in the conduct of his or her own affairs. Subject
to this provision, the debenture trustee is under no obligation to exercise any of the powers given him or her by the indentures at the request of any holder of debt securities unless he or she is offered reasonable security and indemnity against
the costs, expenses and liabilities that he or she might incur. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Payment and Paying Agents </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless we otherwise indicate in the applicable prospectus supplement, we will make payment of the interest on any debt securities on any interest payment date
to the person in whose name the debt securities, or one or more predecessor securities, are registered at the close of business on the regular record date for the interest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will pay principal of and any premium and interest on the debt securities of a particular series at the office of the paying agents designated by us,
except that unless we otherwise indicate in the applicable prospectus supplement, we will make interest payments by check that we will mail to the holder or by wire transfer to certain holders. Unless we otherwise indicate in a prospectus
supplement, we will designate the corporate trust office of the debenture trustee in the City of New York as our sole paying agent for payments with respect to debt securities of each series. We will name in the applicable prospectus supplement any
other paying agents that we initially designate for the debt securities of a particular series. We will maintain a paying agent in each place of payment for the debt securities of a particular series. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All money we pay to a paying agent or the debenture trustee for the payment of the principal of or any premium or interest on any debt securities that remains
unclaimed at the end of two years after such principal, premium or interest has become due and payable will be repaid to us, and the holder of the debt security thereafter may look only to us for payment thereof. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Governing Law </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The indentures and the debt securities
will be governed by and construed in accordance with the laws of the State of New York, except to the extent that the Trust Indenture Act of 1939 is applicable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Subordination of Subordinated Debt Securities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
subordinated debt securities will be unsecured and will be subordinate and junior in priority of payment to certain of our other indebtedness to the extent described in a prospectus supplement. The subordinated indenture does not limit the amount of
subordinated debt securities that we may issue. It also does not limit us from issuing any other secured or unsecured debt. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Outstanding Debt
Securities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;20, 2018, the Company had no outstanding debt securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc260304_9"></A>DESCRIPTION OF WARRANTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following description, together with the additional information we may include in any applicable prospectus supplements, summarizes the material terms and
provisions of the warrants that we may offer under this prospectus and the related warrant agreements and warrant certificates. While the terms summarized below will apply generally to any warrants that we may offer, we will describe the particular
terms of any series of warrants in more detail in the applicable prospectus supplement. The terms of any warrants offered under that prospectus supplement may differ from the terms described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following summary description, together with the additional information we may include in any applicable prospectus supplements does not purport to be
complete and is subject to, and qualified in its entirety by reference to, the form of warrant agreement and form of warrant certificate relating to each series of warrants that will be incorporated by reference as an exhibit to the registration
statement that includes this prospectus or as an exhibit to a current report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> if we offer warrants. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will describe in the applicable prospectus
supplement the terms of the series of warrants, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the offering price and aggregate number of warrants offered; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the currency for which the warrants may be purchased; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the designation and terms of the securities with which the warrants are issued and the number of
warrants issued with each such security or each principal amount of such security; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the date on and after which the warrants and the related securities will be separately
transferable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of warrants to purchase common stock, the number of shares of common stock purchasable upon the
exercise of one warrant and the price at which these shares may be purchased upon such exercise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effect of any merger, consolidation, sale or other disposition of our business on the warrant agreements and
the warrants; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms of any rights to redeem or call the warrants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any provisions for changes to or adjustments in the exercise price or number of securities issuable upon exercise
of the warrants; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the dates on which the right to exercise the warrants will commence and expire; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the manner in which the warrant agreements and warrants may be modified; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">federal income tax consequences of holding or exercising the warrants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms of the securities issuable upon exercise of the warrants; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other specific terms, preferences, rights or limitations of or restrictions on the warrants.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Before exercising their warrants, holders of warrants will not have any of the rights of holders of the securities purchasable upon
such exercise, including the right to receive dividends, if any, or, payments upon our liquidation, dissolution or winding up or to exercise voting rights, if any. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exercise of Warrants </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each warrant will entitle the
holder to purchase the securities that we specify in the applicable prospectus supplement at the exercise price that we describe in the applicable prospectus supplement. Unless we otherwise </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
specify in the applicable prospectus supplement, holders of the warrants may exercise the warrants at any time up to 5:00 P.M. Eastern Time on the expiration date that we set forth in the
applicable prospectus supplement. After the close of business on the expiration date, unexercised warrants will become void. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holders of the warrants may
exercise the warrants by delivering the warrant certificate representing the warrants to be exercised together with specified information, and paying the required amount to the warrant agent in immediately available funds, as provided in the
applicable prospectus supplement. We will set forth on the reverse side of the warrant certificate and in the applicable prospectus supplement the information that the holder of the warrant will be required to deliver to the warrant agent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon receipt of the required payment and the warrant certificate properly completed and duly executed at the corporate trust office of the warrant agent or
any other office indicated in the applicable prospectus supplement, we will issue and deliver the securities purchasable upon such exercise. If fewer than all of the warrants represented by the warrant certificate are exercised, then we will issue a
new warrant certificate for the remaining amount of warrants. If we so indicate in the applicable prospectus supplement, holders of the warrants may surrender securities as all or part of the exercise price for warrants. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Enforceability of Rights by Holders of Warrants </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any
warrant agent will act solely as our agent under the applicable warrant agreement and will not assume any obligation or relationship of agency or trust with any holder of any warrant. A single bank or trust company may act as warrant agent for more
than one issue of warrants. A warrant agent will have no duty or responsibility in case of any default by us under the applicable warrant agreement or warrant, including any duty or responsibility to initiate any proceedings at law or otherwise, or
to make any demand upon us. Any holder of a warrant may, without the consent of the related warrant agent or the holder of any other warrant, enforce by appropriate legal action its right to exercise, and receive the securities purchasable upon
exercise of, its warrants. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Form, Exchange, and Transfer </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may issue the warrants in registered form or bearer form. Warrants issued in registered form, i.e., book-entry form, will be represented by a global
security registered in the name of a depository, which will be the holder of all the warrants represented by the global security. Those investors who own beneficial interests in a global warrant will do so through participants in the
depository&#146;s system, and the rights of these indirect owners will be governed solely by the applicable procedures of the depository and its participants. In addition, we may issue warrants in <FONT STYLE="white-space:nowrap">non-global</FONT>
form, i.e., bearer form. If any warrants are issued in <FONT STYLE="white-space:nowrap">non-global</FONT> form, warrant certificates may be exchanged for new warrant certificates of different denominations, and holders may exchange, transfer, or
exercise their warrants at the warrant agent&#146;s office or any other office indicated in the applicable prospectus supplement or other offering material. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Outstanding Warrants </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;20, 2018, we
have outstanding warrants to purchase common stock as follows: (i)&nbsp;at any time until the <FONT STYLE="white-space:nowrap">5-year</FONT> anniversary of the original date of issuance in 2014, warrants to purchase an aggregate of 2,313 shares of
our common stock at an exercise price of $499.05 per share, (ii)&nbsp;at any time until the <FONT STYLE="white-space:nowrap">5-year</FONT> anniversary of the original date of issuance in 2015, as applicable, warrants to purchase an aggregate of
7,772 shares of our common stock at an exercise price of $49.91 per share and warrants to purchase an aggregate of 24 shares of our common stock at an exercise price of $499.05 per share, and (iii)&nbsp;at any time until the <FONT
STYLE="white-space:nowrap">7-year</FONT> anniversary of the original date of issuance in 2012, warrants to purchase an aggregate of 85 shares of our common stock at an exercise price of $392.70 per share. Effective November&nbsp;13, 2018, Healthcare
Ventures VIII, L.P. agreed to cancel outstanding warrants representing the right to purchase up to an aggregate 1,845 shares of the Company&#146;s common stock (as adjusted for the 15:1 reverse stock split effected February&nbsp;10, 2017). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc260304_10"></A>DESCRIPTION OF UNITS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following description, together with the additional information we may include in any applicable prospectus supplements, summarizes the material terms and
provisions of the units that we may offer under this prospectus. While the terms we have summarized below will apply generally to any units that we may offer under this prospectus, we will describe the particular terms of any series of units in more
detail in the applicable prospectus supplement. The terms of any units offered under a prospectus supplement may differ from the terms described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following summary description, together with the additional information we may include in any applicable prospectus supplements does not purport to be
complete and is subject to, and qualified in its entirety by reference to, the form of unit agreement and form of unit certificate relating to each series of units that will be incorporated by reference as an exhibit to the registration statement
that includes this prospectus or as an exhibit to a current report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> if we offer units. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may issue units comprised of common stock, preferred stock, debt securities, debt obligations of third parties, including U.S. treasury securities,
warrants or any combination thereof. Each unit will be issued so that the holder of the unit is also the holder of each security included in the unit. Thus, the holder of a unit will have the rights and obligations of a holder of each included
security. The unit agreement under which a unit is issued may provide that the securities included in the unit may not be held or transferred separately, at any time or at any time before a specified date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will describe in the applicable prospectus supplement the terms of the series of units, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the designation and terms of the units and of the securities comprising the units, including whether and under
what circumstances those securities may be held or transferred separately; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any provisions of the governing unit agreement that differ from those described below; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any provisions for the issuance, payment, settlement, transfer or exchange of the units or of the securities
comprising the units. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The provisions described in this section, as well as those described under &#147;Description of Capital
Stock,&#148; &#147;Description of Debt Securities&#148; and &#147;Description of Warrants&#148; will apply to each unit and to any common stock, preferred stock, debt security or warrants included in each unit, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Issuance in Series </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may issue units in such amounts
and in such numerous distinct series as we determine. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Enforceability of Rights by Holders of Units </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any unit agent will act solely as our agent under the applicable unit agreement and will not assume any obligation or relationship of agency or trust with any
holder of any unit. A single bank or trust company may act as unit agent for more than one series of units. A unit agent will have no duty or responsibility in case of any default by us under the applicable unit agreement or unit, including any duty
or responsibility to initiate any proceedings at law or otherwise, or to make any demand upon us. Any holder of a unit may, without the consent of the related unit agent or the holder of any other unit, enforce by appropriate legal action its rights
as holder under any security included in the unit. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Title </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We, any unit agents and any of their agents may treat the registered holder of any unit certificate as an absolute owner of the units evidenced by that
certificate for any purpose and as the person entitled to exercise the rights attaching to the units so requested, despite any notice to the contrary. See &#147;Legal Ownership of Securities&#148; below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Outstanding Units </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have no outstanding units. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc260304_11"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may sell the securities being offered by this prospectus separately or together through any of the following methods: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to or through one or more underwriters or dealers in a public offering and sale by them; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">directly to investors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through agents; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through block trades in which the broker or dealer engaged to handle the block trade will attempt to sell the
securities as agent, but may position and resell a portion of the block as principal to facilitate the transaction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through any combination if these methods of sale; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in any manner, as provided in the applicable prospectus supplement. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may distribute securities from time to time in one or more transactions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at a fixed price or prices, which may be changed; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at market prices prevailing at the times of sale; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at prices related to such prevailing market prices; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at negotiated prices. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will describe the method of distribution of the securities in the applicable prospectus supplement. We may also determine the price or other terms of the
securities offered under this prospectus by use of an electronic auction. We will describe how any auction will determine the price or any other terms, how potential investors may participate in the auction and the nature of the obligations of the
underwriter, dealer or agent in the applicable prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise specified in the applicable prospectus supplement, each class or
series of securities will be a new issue with no established trading market, other than our common stock, which is traded on The Nasdaq Capital Market. We may elect to list any other class or series of securities on any exchange, but we are not
obligated to do so. It is possible that one or more underwriters may make a market in a class or series of securities, but the underwriters will not be obligated to do so and may discontinue any market making at any time without notice. We cannot
give any assurance as to the liquidity of the trading market for any of the securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Underwriters, dealers or agents may receive compensation in the
form of discounts, concessions or commissions from us or our purchasers (as their agents in connection with the sale of the securities). In addition, underwriters may sell the securities to or through dealers, and those dealers may receive
compensation in the form of discounts, concessions or commissions from the underwriters and/or commissions from the purchasers for whom they act as agent. These underwriters, dealers or agents may be considered to be underwriters under the
Securities Act. As a result, discounts, commissions, or profits on resale received by the underwriters, dealers or agents may be treated as underwriting discounts and commissions. The prospectus supplement will identify any such underwriter, dealer
or agent, and describe any compensation received by them from us. Only underwriters named in the prospectus supplement are underwriters of the securities offered by the prospectus supplement. Any initial public offering price and any discounts or
concessions allowed or reallowed or paid to dealers may be changed from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may sell the securities directly or through agents we designate
from time to time. We will name any agent involved in the offering and sale of securities and we will describe any commissions we will pay the agent in the prospectus supplement. Unless the prospectus supplement states otherwise, our agent will act
on a best-efforts basis for the period of its appointment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may authorize agents or underwriters to solicit offers by certain types of institutional investors to
purchase securities from us at the public offering price set forth in the prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified date in the future. We will describe the conditions to these
contracts and the commissions we must pay for solicitation of these contracts in the prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Underwriters, dealers and agents may be
entitled to indemnification by us against certain civil liabilities, including liabilities under the Securities Act, or to contribution with respect to payments made by the underwriters, dealers or agents, under agreements between us and the
underwriters, dealers and agents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any person participating in the distribution of common stock registered under the registration statement that includes
this prospectus will be subject to applicable provisions of the Exchange Act, and the applicable SEC rules and regulations, including, among others, Regulation M, which may limit the timing of purchases and sales of any of our common stock by any
such person. Furthermore, Regulation M may restrict the ability of any person engaged in the distribution of our common stock to engage in market-making activities with respect to our common stock. These restrictions may affect the marketability of
our common stock and the ability of any person or entity to engage in market-making activities with respect to our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may grant
underwriters who participate in the distribution of the securities an option to purchase additional securities to cover overallotments, if any, in connection with the distribution. Any underwriter may engage in overallotment, stabilizing
transactions, short-covering transactions and penalty bids in accordance with Regulation M that stabilize, maintain or otherwise affect the price of the offered securities. Overallotment involves sales in excess of the offering size, which create a
short position. Stabilizing transactions permit bids to purchase the underlying security so long as the stabilizing bids do not exceed a specified maximum. Short covering transactions involve purchases of the common stock in the open market after
the distribution is completed to cover short positions. Penalty bids permit the underwriters to reclaim a selling concession from a dealer when the common stock originally sold by the dealer is purchased in a covering transaction to cover short
positions. Those activities may cause the price of the common stock to be higher than it would otherwise be. If commenced, the underwriters may discontinue any of the activities at any time. If any such activities will occur, they will be described
in the applicable prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Underwriters or agents and their associates may be customers of, engage in transactions with or perform services
for us in the ordinary course of business and any such relationships will be described in the applicable prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent required,
this prospectus may be amended or supplemented from time to time to describe a specific plan of distribution. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc260304_12"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The validity of the securities being offered by this prospectus will be passed upon by Morrison&nbsp;&amp; Foerster LLP of Palo Alto, California. Additional
legal matters may be passed upon for us or any underwriters, dealers or agents, by counsel that we will name in an applicable prospectus supplement. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc260304_13"></A>EXPERTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
consolidated balance sheets of Catalyst Biosciences, Inc. as of December&nbsp;31, 2017 and 2016, and the related consolidated statements of operations, comprehensive loss, convertible preferred stock and stockholders&#146; equity and cash flows for
each of the years then ended, have been audited by EisnerAmper LLP, independent registered public accounting firm, as stated in their report which is incorporated herein by reference. Such financial statements have been incorporated herein by
reference in reliance on the report of such firm given upon their authority as experts in accounting and auditing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc260304_14"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a reporting company and file annual, quarterly and current reports, proxy statements and other information with the Securities and Exchange Commission,
or the SEC. You may read and copy these reports, proxy statements and other information at the SEC&#146;s public reference rooms at 100 F Street, N.E., Room 1580, Washington, D.C. 20549. You can request copies of these documents by writing to the
SEC and paying a fee for the copying cost. Please call the SEC at <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-800-SEC-0330</FONT></FONT></FONT> for more information about the operation of the
public reference rooms. Our SEC filings are also available at the SEC&#146;s website at www.sec.gov and our website at www.catalystbiosciences.com. We have not incorporated by reference into this prospectus the information contained on our website
and you should not consider it to be part of this prospectus. In addition, you can read and copy our SEC filings at the office of the National Association of Securities Dealers, Inc. at 1735 K Street, Washington, D.C. 20006. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have filed a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> with the SEC relating to the securities covered by this prospectus.
This prospectus is a part of the registration statement and does not contain all of the information in the registration statement. You may review a copy of the registration statement at the SEC&#146;s public reference room in Washington, D.C., as
well as through the SEC&#146;s Internet site at www.sec.gov. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The SEC allows us to &#147;incorporate by reference&#148; the information we file with it,
which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is considered to be part of this prospectus. In addition, information we file with the SEC in the future
will automatically update and supersede information contained in this prospectus and any accompanying prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus incorporates
by reference the documents set forth below that we have previously filed with the SEC: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1124105/000156459018006216/cbio-10k_20171231.htm">Form
 <FONT STYLE="white-space:nowrap">10-K</FONT></A> for the fiscal year ended December&nbsp;31, 2017 filed with the SEC on March&nbsp;19, 2018; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarterly periods ended <A HREF="http://www.sec.gov/Archives/edgar/data/1124105/000156459018010740/cbio-10q_20180331.htm">March&nbsp;31,
 2018</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1124105/000156459018018950/cbio-10q_20180630.htm">June&nbsp;30, 2018 </A>and <A HREF="http://www.sec.gov/Archives/edgar/data/1124105/000156459018026288/cbio-10q_20180930.htm">September&nbsp;
30, 2018</A> filed with the SEC on May&nbsp;3, 2018, August&nbsp;2, 2018 and November&nbsp;1, 2018, respectively; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1124105/000119312518116963/d570062d8k.htm">April&nbsp;13,
 2018</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1124105/000119312518193006/d609717d8k.htm">June&nbsp;14, 2018</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1124105/000119312518195617/d608034d8k.htm">June&nbsp;
18, 2018</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1124105/000119312518220636/d559464d8k.htm">July&nbsp;18, 2018</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1124105/000119312518249889/d610054d8k.htm">August&nbsp;
15, 2018</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1124105/000119312518265035/d612321d8k.htm">August&nbsp;31, 2018</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1124105/000119312518352172/d639117d8k.htm">December&nbsp;18,
2018</A>. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All filings filed by us pursuant to the Exchange Act after the date of the initial filing of the registration statement of
which this prospectus is a part and prior to effectiveness of the registration statement shall be deemed to be incorporated by reference into this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also incorporate by reference into this prospectus additional documents that we may file with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the
Exchange Act, excluding, in each case, information deemed furnished and not filed until we sell all of the securities we are offering. Any statements contained in a previously filed document incorporated by reference into this prospectus is deemed
to be modified or superseded for purposes of this prospectus to the extent that a statement contained in this prospectus, or in a subsequently filed document also incorporated by reference herein, modifies or supersedes that statement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will provide to you at no cost a copy of any and all of the information incorporated by reference into
the registration statement of which this prospectus is a part. You may make a request for copies of this information in writing or by telephone. Requests should be directed to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Catalyst Biosciences, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">611
Gateway Blvd. Suite 710 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">South San Francisco, CA 94080 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attn: Fletcher Payne, Chief Financial Officer </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(650) <FONT STYLE="white-space:nowrap">871-0761</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a"><B>SHARES </B></FONT></P>
<P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g260304g99a99.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a"><B>Catalyst Biosciences, Inc. </B></FONT></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a"><B>Common Stock </B></FONT></P> <P STYLE="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #50748a;width:47%">&nbsp;</P></center> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#50748a"><B>PROSPECTUS SUPPLEMENT </B></FONT></P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #50748a;width:47%">&nbsp;</P></center>
<P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a"><B><I>Sole Lead Active Bookrunner </I></B></FONT></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a"><B>Piper Sandler </B></FONT></P>
<P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a"><B><I>Bookrunner </I></B></FONT></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a"><B>Raymond James </B></FONT></P>
<P STYLE="margin-top:48pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#50748a"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021 </B></FONT></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g260304g00a00.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g260304g00a00.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_X4+T:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ
M-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z>&UP1TEM9STB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O:6UG+R(^"B @(" @(" @(#QX
M;7 Z0W)E871E1&%T93XR,#(Q+3 Q+3(U5#$X.C0U.C Y*S U.C,P/"]X;7 Z
M0W)E871E1&%T93X*(" @(" @(" @/'AM<#I#<F5A=&]R5&]O;#Y!9&]B92!)
M;&QU<W1R871O<B!#4S8@*%=I;F1O=W,I/"]X;7 Z0W)E871O<E1O;VP^"B @
M(" @(" @(#QX;7 Z36]D:69Y1&%T93XR,#(Q+3 Q+3(U5#$X.C0U.C$P*S U
M.C,P/"]X;7 Z36]D:69Y1&%T93X*(" @(" @(" @/'AM<#I-971A9&%T841A
M=&4^,C R,2TP,2TR-50Q.#HT-3HQ,"LP-3HS,#PO>&UP.DUE=&%D871A1&%T
M93X*(" @(" @(" @/'AM<#I4:'5M8FYA:6QS/@H@(" @(" @(" @(" \<F1F
M.D%L=#X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.G=I9'1H/C(U
M-CPO>&UP1TEM9SIW:61T:#X*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z
M:&5I9VAT/C@P/"]X;7!'26UG.FAE:6=H=#X*(" @(" @(" @(" @(" @(" @
M/'AM<$=);6<Z9F]R;6%T/DI014<\+WAM<$=);6<Z9F]R;6%T/@H@(" @(" @
M(" @(" @(" @(" \>&UP1TEM9SII;6%G93XO.6HO-$%!45-K6DI29T%"06=%
M05-!0DE!040O-U%!<U5':'9D1SEZ84<Y=TE$375-04$T46ML3D$K,$%!04%!
M04)!05-!04%!045!)B-X03M!44))04%!04%104(O*S1!1&M&:V(R2FQ!1U1!
M04%!04%F+V)!25%!0F=114)!545"9U5&0F=K1T)164I#=V='0F=G3$1!;TM#
M=V]+)B-X03M$0D%-1$%W341!=U%$031014$X3T1"351&0E%417AW8D=X<V-(
M>#AF2'@X9DAX.&9(=T5(0G=C3D1!,%E%0D%91VA54D92;V9(>#AF)B-X03M(
M>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX
M.&9(>#AF2'@X9DAX.&8O.$%!15%G055!14%!=T52)B-X03M!04E205%-4D%F
M+T5!84E!04%!2$%114)!445!04%!04%!04%!05%&07=)1T%104A#06M+0W=%
M04%G241!445"05%%04%!04%!04%!)B-X03M!44%#07=11D)G8TE#46],14%!
M0T%1341!9U%#0F=C1$)!24=!;DU"06=-4D)!049)4DEX459%1T4R16EC6455
M37!':$)X5WA1:5!")B-X03M5=$AH37A::3A#4GEG=D5L47I25&MQ2WE9,U!#
M3E51;FLV3WI.:&156DA41#!U24E*;TU*0VAG6FA*4D92<5,P5G1.5DM"<GDT
M+U!%)B-X03LQ3U0P6EA71FQA5S%X9%AL.5=:,FAP86UT<V)7-799,U(Q9&YD
M-&58<#=F2#$K9C-/16A984AI26U+:31Y3FIO*T-K-5-6;'!E66U:)B-X03MQ
M8FY*,F5N-4MJ<$M7;7 V:7!Q<75S<F$V=F]204%)0T%1241"455%0E%914-!
M341B445!06A%1$)#15--545&55).:$EG6GAG6D5Y)B-X03MO8DAW1DU(4C13
M3D-&5DII8W9%>DI$4D1G:&%357E7:5DW3$-",U!33F5*16=X9%5K=V=*0VAG
M6DIJ6D9':61K9$95,SAQ3WIW>6=P)B-X03LP*U!Z:$I3:W1-5%4U4%)L9%E7
M5G!B6$8Q95@Q4FQ:;61O85=P<F)',75B,E(Q9&YD-&58<#=F2#$K9C-/16A9
M84AI26U+:31Y3FIO)B-X03LK1&Q*5U=L-6E:;7!U8VY:-F9K<4]K<&%A;G%+
M;7%Q-GET<G$K=B]A04%W1$%104-%44U2040X03E5-'$W1EA9<3=&6%EQ-T98
M67$W)B-X03M&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T98
M67$T:T%63W=(531Q>$17.55.-6-C15 K:GAM:41X4&1V-EIY=F%')B-X03MS
M.%=61#92*TQD-7!.4#1C8E Q1DQ344)5-T%D5&UV8W0U.35M,35T47541$-X
M1FY%84M",&,O>D@K1U933G9184Q3*TA'>CE26G8K)B-X03M4+VU"-4DW:E)*
M,TI-63EE,#5'=$8R1&]+*T)O86903V<W1C%.,VI0=D@V6%$K,%=J04EY9V,Y
M:BMJ.&4U-EAM+V579&ER<U9D:7)S)B-X03M69&ER<U9D:7)S5F1I<G-69&ER
M<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5E-,>DAQ;D)$
M6GA(-#)(-S1J<W O)B-X03M:*VY.3#)R<DM(:'@U;FTW2%$V97IX;C1-8GIN
M,V)*<G!'9W<V:D9),31N2S!91D]&4W9/=7@S1D116G1E>G1#379Q;CE0,W5&
M<717)B-X03MC4D%H.51X>EAD2FPP;E8W<E1P86LR.&A65T\S2D1U:F8W2E-$
M;7 Q1T4T-6U*-E!:-E151$YJ:DUD43-O1W)3-E)R1G!Q35<U=#-$)B-X03M-
M;R]A43=/=C!Q4TUD4&U/3UEM3VDV=E1J3FEL03E2+UDK:31*-')I0T]E1F<X
M57%Q.&)J;U995D(K-T\U:DE304DU1C@P;D5X2D(U)B-X03MH9FMM3'-69&ER
M04QZ>DPU;SAY-C5D-DXU5&MJ<W)$5#(Y2R\Q<5922695<5%5:%4Q0C9(*V\R
M<5986%!L9CA!3694;VID85@U;D]P)B-X03M80V)M>79)559*04XK26%R8U-F
M;RM9>%909DI8;7E,>DIP5%1T16)A+W18348O84XQ:FQ8<E-U.40R<CAU,D)5
M9C5J,6E,4G1#=G15)B-X03MK;U)A=W,V<65J4#!29CA!6D]13599;"M6;FUF
M5SE2:G9D33$K4FXQ4S-%5C%'>FA66G)E-6I6,3)5069$6"]H<TI63TYE.'5E
M83<O)B-X03M!1D)R:E1F37HV6&%L5E57:3)Q5$%%9%<U<S9N9D%R14QY,C@O
M5S-N1W<X="]W0TQ:2"MV5S<S2#%R-G!%3TA$;CA01&MA,31D95=&)B-X03M$
M2TY,.')E8W)854E,:3@X,E-8=')',TM7,$YP2$=*1B]L-6AY4FEL=CAY3F4Q
M2%,Y1FAT.4IF:G)/<5A%9'!9531L9WI.5FU!86\V)B-X03MF1#E/259%9FPW
M-6AM,3-Y=F)85C Q8BM!=&)8,5%!9E=I3D-30E%66F%..4]!<7(K96(K.# O
M>6QQ;#=:>4='-F=H3%)39T%L5%5B)B-X03LW9VI%2VEV3$8Q8UAF;')38G4U
M8WE81GA:5SAS,&AO0WIV17)-9'1T>6-64U0X>#=R6&1-,#(R,3-36FY#-EI-
M<VPO6F<O0DYB<U%')B-X03LU1"]*.75X2C=947)*=%!V-V)53$<S=G)6*V1V
M8WAR3$4S:7)#;W(W*T]"5TDK63E9,5154$]U;6573DEU6'0P='@Y9#%Q94DP
M65)#)B-X03MN1TMV8FM$+T%-375&54Q0<DAM<GI8<C$O<&YL*SA84V1','51
M=UAM<$)"3$Q,34YM4TU(64%5-V9/=31'2W$X,VLW>GI:<6)J4W9.)B-X03MC
M,7AC<E9V<3DY1W)X3V4V,2M,:5!K35948U=V;6I79DQ-360U361!,6QM0FUE
M,4EM<'=*1S(Y2T].-F-J5'AW2WA0>EIO4&Y$469,)B-X03LQ-7%Y96)R=31A
M,59714IJ5E$S2C%8-UA),"LQ:%%J9$PX;RMB-S=43$\Y4&Y'.&I.,4)(355%
M4VYJ-FE"<58U9'$T<%IV<%9P8S)E)B-X03MN45<Q>F1.97IX3'AK=6Y(1G!$
M+T%$14%N07%+>%9"-G!Q0U=.<5I$=DDR,%,K2B]O37A.6G%H:&AF6&\S-F9#
M8VMQ-DU-:VME4C)K)B-X03MC.&Y9,5EN=51N2E-K6D=Z>DQV-&=!5454<'1H
M2F4S4WA,<V<S:V9W6$PY2G!J;6YW:FPQ87,K65DT,GI32TM/2TY9-'AX4D)2
M45!!)B-X03M:,3A)0TE!2$E/9VQ)>4YL-6PK8U=H9C=Y-C-%=B],=&1%9E,P
M8D@X4CDR841T=E0X<V<Y>"]1.50W3V%R-G-2.30O4SAX>FXS<6YS)B-X03MN
M-51A-SED,$HY3VQA<RMN3GA7=E5W=E5R.7AQ4'5Z<65X=%)X-"M!.#0O8SA4
M-U%A6&=Z8UDU5"LX335Z8T]G9&ER<U991"M384%E)B-X03M3>DPO04QS;G4U
M<$I'-W,S=W)8+T%)6$-66CEG5DQD3CAU-E9P=6\S*V]78U)J=6146EAV1'E9
M<7I,5V@T:S!"*TDY3599<"M:3&Y6)B-X03MT53!,>6A%9'12=4)C,S%/;W1O
M2VMG+S8Q1TDY,7=H5W9.=UA14%!'9V59:TAP,E8U6%-T44DR54(Y-%-F:V0O
M:W5+<RMW2W=,5U O)B-X03M!0V-E9R\X06)0;2]63&A6;G5"5T%K+S1G+TY5
M3#EU=SAR,CEF1F9R9'@O469I=497.4-0-D(O3796=$AB-&)06%EX<59K3S-R
M0W9Q)B-X03MQ4&,O150W05EQ;E U:R\X;TQR4"]-3V8K2D1!1E)N:S,O;$5.
M1"\W6CER+T%-;49X5DY,:3-H=4QE5S-N45-1>DDP8W-:-DUR0VI!)B-X03LO
M34A&6&Y(;%!862]*>#$S>3-Q.&@Y2%)W.3=P<G-D-6)6>E5)=F)L>5EB94I0
M:&A63G9Y>#!I-5A4<FYZ1G%++W=#-518-41D4U8V)B-X03MP0U-416=R,F]E
M6'EP-%EL56TX<F$W6F53.6(Q:GDO<C5.;D9D,W-L-W Y.#9N,'!5;$%&0S1R
M5%I2-U9Q1&ER,$]Y,6I33#<O94LK)B-X03MT-W%V5#!:56LY+S)38T-O=D97
M2R]M;B]!36]$<2\X07AJ:B]!3U1Y65%Q8V574"M58C!N+VU$="]W1&LP=4)5
M>7A68DQ+:U5B4U-()B-X03MI:4-R12M!>4TU:4E*4$E*:D5K,$=&-FYF=F4S
M5%-N6D)T1W9G=6-J<3E38S K3' P96<P*T59-#$Q46)U<4E863!64E5K*T=9
M.$E')B-X03M204A-='-P04-Y;$UV;7)5:T)I<U@K<7<Q<5-O2$YZ,DQ-4BM!
M>G(Y2'!2:&A86'$X+W%--7E3=F]O3C5S.'=+3C<K6#)&4B]436)T)B-X03M$
M=%1(<'A83V9D*W1Y9$8R9%!/8C51-R]!3E-(=5!-;7)8='106C,Y=S%X85A+
M.$I),V]A9#%D9CAP5T%)>FLU.7):<VA);6)I96XV)B-X03MV8SE2:#=0>%EI
M2E%&4VHQ+TAE=W%21U(R4G9T2V%(24$R-S!'>&%F95)D9"]1,VU3,G5(8FIB
M5$@P3&UV5# U0TYZ+T%+<E5B-DUZ)B-X03MD0G%00WEG.4]29&8R<G!02'='
M22MO8FHS:#<Y;F%0;F)S5F1I<D$O>55C=#5(:E%M<&IU6FQP-&)H<68X3FA+
M<SAW2V]1-FA95#--)B-X03LQ<D1C>%,S5G14-GA!:G$P:V9,8V,Q0G%T9F9&
M6&Q':BME=DMY+VU"<FUU-GAF0T%29U=/;' V8W-O35-':G5$1W)G8VEL4B]R
M2$-H)B-X03M(*V4O4&XU9F$O-5=V=%!I,4U.9$9F5G1!64QG9G9O>GE506U-
M06-Q8V%N>'A3>D1Y2G)W,3-Y<G Y*WIC<'I'27)R=697:BM">68Y)B-X03M9
M:FPY3T)5:#%J+WEC96<O.7,K8CE5=4976F%V<55';#989#9J3V8S5G!%.')$
M>#1#=%!P-EE&95AF;'HU.#AN-E1P5C%C87AQ4517)B-X03MD5'5P3'$Y2&]Z
M=5%73D98:W-B2V4W8DAV:$MQ9FXO>CDU4W9*.4<Q:E)B+T%.9E9.2G5G-&DY
M2V%0;D$O=T1E3'ED1D@W24A8=6-5)B-X03M-,S@O,TU.,2M8;7 S341C-%HW
M45-23T]H5BM,2V9U3TE3;5!K,R]L14Y$+T%/,F9A+SA!2FAC0W!X:7)Z5#@R
M=$8P*SDQ<GEQ,#AD)B-X03M7=7(V3WAN64=H84(U1DI5+TMP<#@X258V56E+
M:6A%059604-Q0E%!1&]!34-O92\P>E1D4F@Y0R]T67)U2"]F8WE,24%F14)G
M8U99)B-X03MX<4@U5&533'1'359I8DLT-G@S1G1)-DUH-T5,57 O=W5',55V
M>3(Q8E9N3W-A0G%S-74W=E%B:%E6=D<K,4I%+TPP>7A.86XT1#$S)B-X03MX
M2V]V.# O*U5",68O:DA(+W=!;FMX0W!X-5DO-5)V4V8K64\S+S5.3&=637-6
M67HU:3%4,5I$85%N.3!H+V5K9#)(8C5$3V0W53%N)B-X03M%9D1J>4A0,W4S
M,%=N-%)X2&U5:WI4=7=34%=R+VTS,6%-+T%P+V5%9'HT9E)N4CEL85!H2&E3
M-6YL-VY583=55V5!8W5Q9&57=DES)B-X03LQ,7=U.55":71J=6QV,&1X+VQF
M>6HX8S-&=75:1C5L.'%7;6\V44E,4TI)8FDR0DYP>$%5939(,F(Y96%V=%!S
M.&%J2'0Y635F<2M,)B-X03MS97IT8V-%.2]O4$XU33901S=)-FQ846Q753=%
M16)%2$]"24E.1C=51457178Q1S$U<C9Y1#1L*S!0168R6F1H;E=X8CA5-C)3
M>DUP)B-X03MY6'9(-64V-RML+TQ6=3AJ5G5B6"]2-VIX2E%$:3,K>5=N,#%Z
M<V5Z3E(T=458>FIS*V9D<V%8=V,U<C9:8FHX93EK=6)",6)S5F5B)B-X03M2
M>&$S-4$Q92MK9W-*9%4X<6%H2V)K<F%J;$YA>4XY<C1/-'!T-%5!,T(V;%5:
M8R]M>F%815)H,$13<C=59%-C56EH34Q):7-E:&MA)B-X03MP3D(W9F5-859#
M4C9:<3-L3'E4<F5R6&Y+-#AZ87=3.#-O9W-5;&QQ<4MV1W8Y,WI:=D1S359:
M2C5'.'-7,FHK5F10<W!O14YY27A*)B-X03MC;#%"8C%:9FI913 O6G)X*VI!
M<69F56),+VQN:B\T0F8V67%W9GE00F-A1C5X.'=E6%1'>39D3S0Q1%1N0VXP
M=TI+8S!"-F)";$90)B-X03LX;D-Q<G$Y=D\S-74V2$]S8D=&8D-93DM&4$5%
M:5A9=#!X5C,U<6TK=G),5&9,;&MR.#E:=6M3-&Q64U930TYG5TQ%8D0T:7 K
M9S1H)B-X03M76#(K;&%B8G=2=U)7,&%X46]S8UDT2V%+;V]/,VAG5E$Q6%%D
M3S%(5$QQ=VMG:E9,<4HT:7=287)Z56IK3G5O-C1Q.#8P,F)5-69Y)B-X03ML
M,6Y2<GE#46%H<$EK<RM"5G%U9V-&0W4R-$<V:6YH:%%J+TPS-6UA4G K9V%:
M650V9'%2;G1,4T-#57)B17)Z:6I61V]E43)Q36%3)B-X03MM2"]+,CE#+S9T
M,G%F.4EV+TXR3DMO96942F8S=FMQ-W0T6D1'*W R.#=!;V5327I),WAG5C0P
M-S1Q>C=!<D%F.%EE8U!,,3=00C5N)B-X03LP<5,O<UAK6G)B53E-:C5+14HK
M1D=J<G14+TM.9CEB<FA69DPK8D]N,T-'4%)D2C%$57(Q:"LW:%=!;V]9.4]B
M9D514&]/3DMJ=GDK)B-X03LX=#9P<&M';V%N<DI8.4TV,5 X05=,=4Y+1EEW
M2SA).7$Y3UHO5FE65F9Z3VEL;#AI871(16I34TY';D9&0EEN.39N441!1E1F
M>3)R)B-X03M*-60P<%="5FQS-$%Y;EEG:4ID:FEQ:')E=$I!:E<Y=3%B9S=-
M=R]92#EC,6UV,5IG3T=!2FPY>FTV6%1I4C1P8VU,8C5Z;FA4-VDW)B-X03MJ
M:FHS:'0W1%=,:&93<W):,F0Y=E=98TDQ2&IY86=0,%IS=$0R9$M5=4M9<5 S
M=49Q=%E):6]N9%!03'9K=7HP,')C,U)&>F9$8TXK)B-X03MW:"]Y465P.7IN
M4W5N6DIG5C)+=E O>D4X=&-73W,R<2]#84,X461J,$5N,#E$;DLY=F1N,2LK
M:B]N9G(O5SE*,DYR=CAL3"]!1&8Q)B-X03M-1'IL,V]K;W8W6#!:3U-J.3(O
M5#)0:&U::6Y9.#-+>%1S37 O2W989C!F-6A&;$DQ3&9544EJ6&]*5G%9>CE.
M4W8P-75U>4Y2=UIE)B-X03M%.'!B9DAO-FIT-U-E2F@T:#E53B]H,2]8.$AT
M5V19.$TW1E5N+WAL-5$O-G9M;B]!4%-60B]Z5FEQ2W-.9#!055A-96XV:F)8
M:VEI)B-X03MR2D).2$M14$5H0V-65C<S54Q#=V=.>&98359P04-&33 W<D=L
M5#!(2FE":7%S<DMY:&Q)2VM60D<T24]+<%1D*V(O2S%N8VTQ=717)B-X03MT
M26)H5%)O,VU11E17;$<S*T@V8U944T=A1V5*6EE85U=*>%9*14E:4U!%16)(
M1E50<5=S859P:U%L,4<X:',T,C)6<&Y63U)(6F52)B-X03M&9F]X5E$P,WI,
M-64Q3U%X869Q5G1D4VEP.4M+5D=E9S<X465635943$95;6TX-2M5;TQG,CAU
M<S)A5$$X5U%Z>#=(=T\K,S T<6TX)B-X03M5<U5S87EX3W-K8F=-:G%1>6M(
M;U%2,7A646DQ5%1P<BMF5#1R:4XW,C)#=&-7-%E&,$1G1E-Y.7%G:D951&8K
M8B]+*VXS8C)L.7%L)B-X03MT8EA55E!5:&MK5E=8:T%W<40T9V<T<6@O=T1(
M,VMR+T%+=F1N+WE.6"MU3DMJ<&9-96=X86)&<6-L+T%M;GI.>&EU,F-#3FIU
M2T)U)B-X03MN-TIX5DU147="0G%$=4-/;$U643)O87!P,FUW3%!F,T5D=$-Z
M:4Y:2E=#9W4S4F%N=6%9<6EC5E-79GIT-5%T-V<R.#)S,F%403!:)B-X03M4
M36UX1S%'3F%$-F-65&E'84MA2EI96%=32GAY4U)#1U5G.7=2<V-64VDW.#4K
M5DQ/-6MT8G)6<E='-&E01U=*-49$2V9!9S1Q;R\T)B-X03LK.&QF.5AU>B]W
M0U)Q+S%X<%4V:G4W5U<P4SA35D=T6D5%<50Q2$%X<T]18FPP<%1E=4MP3B]J
M,WE8-B]O9G!Q>CE4<%@Q5C0K2#(V)B-X03LX9GAX5E!9-4DU15=33F<V3T%6
M9%1514AO45)I<F5+<EI9;S5O;FEL55!(27!6,$\T2VM524]2;$530D(U1DU:
M1TIS8W<X93@P*U@U)B-X03M.1C%.;U)5,G-T6'1P1#-8*U4K-CE-."\W4S!*
M,"M3=C14>2](:SEV;TY932M/+S1H>E-/5TI*67EJ9$1M1$=61S-0:DMJ851-
M2G)7)B-X03LT0D)+>5)S1U)X-&<Q0D=:,$HS=4A-,FM0279O6'EZ<DMA>F]D
M<'%+,#542BLK569S>4PX3&HO9VAN9&%44#1U35,O1G9M*W4P>'=:)B-X03M:
M43=U6'4V2FYM431J>6HX;B]+,VPS5E!+8C-/;S9D8C-D=TQQ4D),2V=:=4E6
M0T)5+U!#54DS.'@O2F9L+U-V3#AU=C90075L86YP)B-X03MR4GEW5#)X35E*
M36EP>$MG.&8R='-1;'8X,')Y5SDO2S8P=DIL-'DS4#%385)E;$=K6&M2.35X
M0V\S.'E.6C%#>3AS85IP*VY3;4,X)B-X03LQ:5='>E=91VA61U@T:40R2C)(
M>4]+<&QP9C59*U1,2%1X6G9P<TXR-55#5S5U1D1Y=3-D=5(K>%@O2G!G=%5H
M,$,R8GEJ*UDS*T<W)B-X03M34FTP5%=,9')Q,71N670V37%C:5%T9"MK8F9-
M57(P=W%P959.2# W>E8U<CAX871R<UEV6F)#-V%Z<S=+8C1O-&]K2D-K>&Y9
M,30Y)B-X03LY<3%X5FME<2]L;C53=FYH;6=T0G!L,4$V>5(S3VXP=#-(13%P
M.$$T-RM.2S1,5DQV>E%V=%)984PU8G-*;70R,38U344X-C%,0T)/)B-X03M)
M8U8V-RMO0V9965%Q8E=V-6)E4TQE=RMP1%-92E4T.%=M;%50369F,50X65 K
M<5)G=%5R.&UA2G)0;')Z3'%':7AP3$XU66U4-GAP)B-X03LX-VYK25I#4GEI
M<EAV52]C1#-/1E90>3DO=T-48S@Q+SAW.7 O=T%M67-64S(P,&)3=%8O3TAZ
M2$1Q5G!&9'A*87=/:51+1T%B,&]")B-X03M502MX>%9M2"M!9DI8+U9K<R\X
M06M5=CE-1G%X:C@S.4]S-UAY4&%71FY%='1B3&91<$A&1T%&54U*0V%!935W
M:%56*UA/=#,Q<&-8)B-X03M0:WI7,B\S2V%6+W9*2S-393$O64LQ-CA25"]9
M+TDT;%=V>FXO=T-55W10*S)H8B]!2VYX0VQF*V%M;V%G671).'9737AT<$YE
M=6AB)B-X03M45$MA34E15D1J>' K.$9A9'1U*TE63G)0.'502DYR64-Y1VLR
M.'EC94Q45$E(;6)X2FQ)-4%N+T%#4TU&<6Q0;$11.5HX<RMA8C=2)B-X03LT
M235:9DMT>$@Y67-:6%!*64I34GEJ<60Y.2]W.3A+<&(U6#!$4F17.#@K8R]W
M0DHR54XU-D9X8BMJ-GE"*U!-4SAQ5CAE27A6;'8K)B-X03M!9DI8+U9K<R]W
M1&M5=CA!5$)A<V(O36U"2DQN>7(U6%)J86%0<4YW66)I3TDX4#-C2'!R2$50
M8C0Y:#0P=VA75&8T1#AM9E9"869O)B-X03M7>CE)1&E$-E,K<#@O57 V;&1U
M=DMU0E9B>7HU63 O>3594%DR1'ET8G1+.'%R335F:'HO04=%.$9(*S-I<6(T
M<3=&57(X>#9&1')/)B-X03MM4&%V4EIL*T\S:U W3&=B9E%E:'I#-U$P43%'
M37A04&]F3GDY1G%Z9WE#435D9F,X8G5B96$R=4I,961#:S!41DA1.5%2;FYU
M5$=9)B-X03M335IB15!C46U*05-(26]'*W1F5VHU2U S:3E08V5'4WA4;RM4
M9FIN4EIH*U0R=2ML9#-/:7ET4DIW6C=92"]F:6EJ<CE+:78P6C%0)B-X03M9
M;6]Q4GAN<G50>"M/5'!085!3,T5:4C R4'4V9F(Y-S%B3VME465++VQJ<%!N
M>3<X='9,;U=U4F%D6F972D9.=DI"2$MF54-R5G54)B-X03M)>#-&3RM%;U)F
M;DA1=D\Y<$9B86XU;G9L.'=A0EI3<$IF5TU&3%DX83!$1D5207=&9CA!84<K
M2W S*V)L,V$S;C5C4C-D<5%B831K)B-X03MT<%E#0E0T2$96,C=B2$5*9"M9
M1$MT,35'6FE!;S%/,DI*,D%!365+=E)-0W-!.'=&4#A!;&-(;%E$*SA&<F1&
M='0V1TMA;2\S-%92)B-X03M7=&9L-61.<DTR=6583E=K,&)5<FYE-E%+2DE*
M5TAD:TI!.7I52&9T:F%P9'%'<V9M9C56='IQ3W)F571A,&U):C9Y,$%-539)
M5%1N)B-X03MS<4M.>C1(*T]+<G9.,3EB6"]M=CAV-S8R8FQB,U5K.'-49$MQ
M-G=K9G)X5C9*9U8R2W-#.'9F*U1C.#$O=T1-4&%F.&U9<TMP2$QA)B-X03ME
M63=N.#-F34MA1&925T9Y3&%!>7E44FE536YO=V9#05%D-C!X47E23D8O3E5/
M<&9Z1EIL05)Y0716,TAF.6Y&2T@O3V8O;$9R5"]T)B-X03MO5R\V;GA#;$5F
M;50U8W9:-$QF>DAO=S0V.6]P.5=)<4MM5T5B=D=2*S$S24AF8V0X47%1969F
M36QN-6DO3'949%5T9'95=C1&;6DV)B-X03MM3U969FUH*UAB>$9$:45*;BM9
M;D5E9&9)>%E62#%U66)E2F%#;C0T:$PP2$%R<U9E4V%:<#-M-C@X."MB=CA!
M1#)Q>#9:-F1X1#EA)B-X03LY4T9*9E5Q2D]&3V%V5&I2=G9W<7EB5#E#+TY#
M2R]T<$PS>DQ"4%IP2VI834,R<U-L-&=W3&]'15E)-4Q55GA63R].9FQ45&9-
M=6Y#)B-X03MZ=E,X8GA.-G1T8WA':VM59T9!>6XY67=+>'1F3%@U<#9A;D14
M=DUS1V]1>"]9:G9O84UF67935GHO=U=&53$X:V5B-WI7;79T3S%7)B-X03LQ
M5WDQ>E,S0UAK0T5L1T16-'5L4V1T=D4Y=#DX0W-P>%8R2W5X5FAF-6<K5V9R
M34HQ83%7='A#2UA31#EQ369T9DYF,69,3V,W9#=/)B-X03LT>#1S9G%(4#-D
M+W<K-3,S62MU-%0T5752-64O.7)Z9D]196Y1<7I4-EAQ9'9Q;')S.$5I>54W
M5D(S0CEM1WAZ3S!M;TU*06IM1WE5)B-X03M";'AN2$QQ2'8Y:&5W6#%L0F57
M-V-O8FA&:VI0<W=R=C<U-D1J>4-C4DEC:2MD6F-2>'I-6F-W86519FQB*UE8
M;&9Y+S5A97@Q3S1E)B-X03M+-4YZ2DM&5THS2$9L441D45(K>FQH86LR.#%F
M;5!995DY2FXP1'EV8EA'<%@K;W(V2EE21E5J4FHX5$YY;V5N,$1R6$=K<B]!
M37ET)B-X03M-8E-V>7!S.4YD9S<R:'196&-D0WEI:D5D3G$Y35%Q8RMF4$QE
M;V$Q-5=S<$Y-04]Q86$X3C5A2V%$;5589$%4,U!5931X5D17;C5X)B-X03LK
M5VMT4W5S<&-A6G%K47!C5TUK36AB;4]O46=D4#EA;4Y+;RM6;V16.'IE9$<X
M-%AD<$I9-EIA44<Q,&E'66-:2D$Q87E&9FLW9F5!)B-X03M#85EQ<G8X06UD
M3&\K<#-.;#5S,'E85$5%:F95<GE%3DY"2D8K>E9G2VLK-FHU9UDP<4$X,&9M
M1G O;5!3-VIY+W=#5F]:=%5V.5%8)B-X03LP0S9X3VM585!S>G-80VMB5C9I
M;F,T<6E032]K>E=)4$Q(;#)84W%83W(K5U!4:U-)1&%8:48Y44HO<VM&0C-(
M=FEQ=D0K8S-L35<Q)B-X03MB-6)M>C%"3G!T4&5&:DE(<'5O3D]06'!5:C59
M,')F:VE(6'19.'<S,VUZ5DEP8D=Z;6I&=G!7;GE%9VE)145Y<VYI86)(=E4Y
M<5EQ)B-X03MT.'9F*U1C.#$O.$%-4&%F.&U9<U933U1Z5&\S;#,X,V9-3C%Q
M<W)247I7,$5337%--4QE:D$S4E%E=WA6:U@O04-U6'E$+WDR4V8X)B-X03MI
M2F8K86-A5DQF>E Q87@Q9GE*<#)O,DQM4S!U3"M%>$]62VMG96]P,D\O55EH
M1#!N06PT8BM:=FQQ-SAV-FQZ<TYV3"MS6%55-W=!)B-X03MF0D9D4FLW1"M8
M:T=9<CE)+UI'14EE:&9M5#5E,5A58DMW,4Q2=T@Q6%)B9UAD=D-F.3)!54Q+
M0C-.5E4P-SE-46Q!>&9N4#584S-))B-X03LQ0T<V<W125&%B5#-H67E">#%5
M2%EF.$%"57AP5R]*9'1R971E6G)V>FAQ;'9*63)R=VDQ,&UX:W%'159A;5)L
M4%-V-#%086U+<$1P)B-X03MN;F)1+TQ(;FYZ9"ML5VM8-C-C42MJ-F%C+S=O
M4V-Q*T@R>&EQ9F8X<G,X:F8W.'50*U)*+W)J4W!H-6@X,S9X63)7;#9Z<%=L
M='%7)B-X03MH,U5A>EAJ4C$K<TI(2V]:0W-9.6UQ979H=#%X5D%N.#902E!O
M.&QE-6%F=&%I0G95-69Y+W=!;&8Y;&I3="]L.7 R<C-7<S8Q-7,Q)B-X03M3
M,6%X8E9J1VQP85-B4TQ$14])6GAT4V]64G8W;G=X5FY70EA9<3=&6$5!:6@S
M0C9J1EAL6&YB>74R;%AN,7$R5"]C9F-(-&%D23-/)B-X03LU42LS.'5C4#)V
M,F%C12M+22]D>2MW.3,V;G-/>3EF-#!E1U@Q:C=F4#EB1C-26%5Q=W%P1D--
M,#1"1'1G85IP*UA0;6E/>&E':#9G)B-X03LO1T5-5W-B:'9S:FMA;4YZ*WIV
M=40P>G%U>'4P;V=E2%!B=61$,C%O1&M0:7<U+WA$.4EF+SEK/3PO>&UP1TEM
M9SII;6%G93X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @
M(#PO<F1F.D%L=#X*(" @(" @(" @/"]X;7 Z5&AU;6)N86EL<SX*(" @(" @
M/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F
M.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.G!D9CTB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]P9&8O,2XS+R(^"B @(" @(" @(#QP9&8Z2V5Y=V]R9',O/@H@
M(" @(" @(" \<&1F.E!R;V1U8V5R/DUI8W)O<V]F=,*N(%!O=V5R4&]I;G3"
MKB R,#$V/"]P9&8Z4')O9'5C97(^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N
M/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @
M(" @("!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N
M,2\B/@H@(" @(" @(" \9&,Z8W)E871O<CX*(" @(" @(" @(" @/')D9CI3
M97$^"B @(" @(" @(" @(" @(#QR9&8Z;&D^2V%M86P@1&AA;6]D:&%R86X\
M+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+V1C
M.F-R96%T;W(^"B @(" @(" @(#QD8SIF;W)M870^87!P;&EC871I;VXO<&]S
M='-C<FEP=#PO9&,Z9F]R;6%T/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*
M(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @
M(" @>&UL;G,Z>&UP5%!G/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O
M="]P9R\B"B @(" @(" @(" @('AM;&YS.G-T1&EM/2)H='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C O<U1Y<&4O1&EM96YS:6]N<R,B"B @(" @(" @(" @
M('AM;&YS.GAM<$<](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]G+R(^
M"B @(" @(" @(#QX;7!44&<Z36%X4&%G95-I>F4@<F1F.G!A<G-E5'EP93TB
M4F5S;W5R8V4B/@H@(" @(" @(" @(" \<W1$:6TZ=SXQ-3@R+CDX,#0V.3PO
M<W1$:6TZ=SX*(" @(" @(" @(" @/'-T1&EM.F@^.#DP+C4R,# R,#PO<W1$
M:6TZ:#X*(" @(" @(" @(" @/'-T1&EM.G5N:70^4&]I;G1S/"]S=$1I;3IU
M;FET/@H@(" @(" @(" \+WAM<%109SI-87A086=E4VEZ93X*(" @(" @(" @
M/'AM<%109SI.4&%G97,^,3PO>&UP5%!G.DY086=E<SX*(" @(" @(" @/'AM
M<%109SI(87-6:7-I8FQE5')A;G-P87)E;F-Y/D9A;'-E/"]X;7!44&<Z2&%S
M5FES:6)L951R86YS<&%R96YC>3X*(" @(" @(" @/'AM<%109SI(87-6:7-I
M8FQE3W9E<G!R:6YT/D9A;'-E/"]X;7!44&<Z2&%S5FES:6)L94]V97)P<FEN
M=#X*(" @(" @(" @/'AM<%109SI0;&%T94YA;65S/@H@(" @(" @(" @(" \
M<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:3Y#>6%N/"]R9&8Z;&D^
M"B @(" @(" @(" @(" @(#QR9&8Z;&D^36%G96YT83PO<F1F.FQI/@H@(" @
M(" @(" @(" @(" \<F1F.FQI/EEE;&QO=SPO<F1F.FQI/@H@(" @(" @(" @
M(" @(" \<F1F.FQI/D)L86-K/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F
M.E-E<3X*(" @(" @(" @/"]X;7!44&<Z4&QA=&5.86UE<SX*(" @(" @(" @
M/'AM<%109SI3=V%T8VA'<F]U<',^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@
M(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E
M(CX*(" @(" @(" @(" @(" @(" @/'AM<$<Z9W)O=7!.86UE/D1E9F%U;'0@
M4W=A=&-H($=R;W5P/"]X;7!'.F=R;W5P3F%M93X*(" @(" @(" @(" @(" @
M(" @/'AM<$<Z9W)O=7!4>7!E/C \+WAM<$<Z9W)O=7!4>7!E/@H@(" @(" @
M(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @
M(" @(" \+WAM<%109SI3=V%T8VA'<F]U<',^"B @(" @(#PO<F1F.D1E<V-R
M:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@
M(" @(" @(" @("!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+VUM+R(*(" @(" @(" @(" @>&UL;G,Z<W12968](FAT=' Z+R]N
M<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B"B @(" @
M(" @(" @('AM;&YS.G-T179T/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q
M+C O<U1Y<&4O4F5S;W5R8V5%=F5N=",B/@H@(" @(" @(" \>&UP34TZ1&5R
M:79E9$9R;VT@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @
M(" \<W12968Z:6YS=&%N8V5)1#YX;7 N:6ED.C<X13<T048Y,$,U1D5",3$Y
M0C@Y1$,V.#9%-T5&,T5%/"]S=%)E9CII;G-T86YC94E$/@H@(" @(" @(" @
M(" \<W12968Z9&]C=6UE;G1)1#YX;7 N9&ED.C<X13<T048Y,$,U1D5",3$Y
M0C@Y1$,V.#9%-T5&,T5%/"]S=%)E9CID;V-U;65N=$E$/@H@(" @(" @(" @
M(" \<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD:60Z-S=%-S1!1CDP
M0S5&14(Q,3E".#E$0S8X-D4W148S144\+W-T4F5F.F]R:6=I;F%L1&]C=6UE
M;G1)1#X*(" @(" @(" @(" @/'-T4F5F.G)E;F1I=&EO;D-L87-S/F1E9F%U
M;'0\+W-T4F5F.G)E;F1I=&EO;D-L87-S/@H@(" @(" @(" \+WAM<$U-.D1E
M<FEV961&<F]M/@H@(" @(" @(" \>&UP34TZ1&]C=6UE;G1)1#YX;7 N9&ED
M.C<Y13<T048Y,$,U1D5",3$Y0C@Y1$,V.#9%-T5&,T5%/"]X;7!-33I$;V-U
M;65N=$E$/@H@(" @(" @(" \>&UP34TZ26YS=&%N8V5)1#YX;7 N:6ED.C<Y
M13<T048Y,$,U1D5",3$Y0C@Y1$,V.#9%-T5&,T5%/"]X;7!-33I);G-T86YC
M94E$/@H@(" @(" @(" \>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD
M:60Z-S=%-S1!1CDP0S5&14(Q,3E".#E$0S8X-D4W148S144\+WAM<$U-.D]R
M:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.DAI<W1O<GD^"B @
M(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T
M179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C<W13<T048Y,$,U1D5"
M,3$Y0C@Y1$,V.#9%-T5&,T5%/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(Q+3 Q+3(U5#$X.C0Q.C(X*S U
M.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F
M='=A<F5!9V5N=#Y!9&]B92!);&QU<W1R871O<B!#4S8@*%=I;F1O=W,I/"]S
M=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D
M9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V
M960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN
M<W1A;F-E240^>&UP+FEI9#HW.44W-$%&.3!#-49%0C$Q.4(X.41#-C@V13=%
M1C-%13PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T
M179T.G=H96X^,C R,2TP,2TR-50Q.#HT-3HQ,"LP-3HS,#PO<W1%=G0Z=VAE
M;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O
M8F4@26QL=7-T<F%T;W(@0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!
M9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%
M=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @
M(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!-33I(:7-T;W)Y/@H@(" @
M(" @(" \>&UP34TZ4F5N9&ET:6]N0VQA<W,^9&5F875L=#PO>&UP34TZ4F5N
M9&ET:6]N0VQA<W,^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" \+W)D
M9CI21$8^"CPO>#IX;7!M971A/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @"CP_
M>'!A8VME="!E;F0](G<B/S[_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_VP!#
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  O )<# 1$  A$! Q$!_\0 '0
M @(# 0$!            !P@ "04&"@,$ ?_$ "\0  $% 0 !! (" @$"!P
M  0! @,%!@<( !$2$PD4%2$6(C$7&",X07%WL;C_Q  = 0 " @,! 0$
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MD223OS],?.I)QC;E_BC9Z5.JG?R(^,W\H%-WW%5_O8U@\,'2*X2+W>;5P,;
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%'4(__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g260304g10g27.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g260304g10g27.jpg
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M<AEP9/<).4$3,1\<F(F?AFOY^/VQ,-.:VWCV:C^#-I[0L6HZS#TU-^_([56
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M:08/(R?E#U]BYFR:"*DW4,;!J1#6T].G2)G]XCKTC]<F(Z]?6(_:9Z=?^_\
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M&VVFT'JD#/%UJ=_*G=.TVN%=AN:@!-(HJD)Q.S1K$\6);!59=FWBP+G]ANV
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MCA'#^B X&*8R&88X/"4(L6:7QV_'G]*'6$=BE+[03)A"K<9(I1=LBDS)QWN
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MMM5I](T;4*(L[_;[/97=;W^YY9J]10)-=PS7,4AB.*.22&M2O5>OALL&",Y
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MG-KY-Y?PF6DV3)VI5@]1D6FEAR6UZQW=)S?\EXFAR58@V#.K-?E[NN6;5?V
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MLBNI\=A(,*$:;< R:J1-&_H7%=6P762\@%M9^['EFW=L@HRNK":0%0PK-&>
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MGMG6-:;+MFT[+9Y8Q%N<TG0-[S0UP99@<2;TP8V78@C#(V+ A?\ <E1>P,"
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M4MK=MLC:G6'TVL/L-@K<9RE3U;;:=;"D$,5:9.[#39R,6R2O3NO4=!M>LT:
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M"P*=HS',8Y.Z8@(+T"(96&;@7$0M=(6;_P!<NCD\2DML<F=XU^(6WQ*"L*K
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M6LY8DC)10U9YMKF^P5W3J11:X0DMYH-/9$B^QEF\;A'1,G8G=4M.H#90FX-
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M+X"EIUK*5,BP,YGI'3I$]>D3$ST].OMZ>OM__61'6>O6?3K,3^_3^OIU]O\
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METQ+7I!1^64%0*XK^+WR6!"'2E9+-[=*Q,S,^N90BHU0N$4<JL5XF &4B<*
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M>'%K1)2-T3H7Q[1/4U(J@MX5"=U136TTB)M.8(]1KQ[ NSJL/SA0++^)-:S
MAJW<N/P*S'0-[2^SXMQ]LEBU8OUBL9GY*A4YLFN<M7KLN;[ F-YG(E6YY.<#
M,!<"\&N60W?;' K $+ G$SN;J? ,7&7K+H>+K#'AUVL!BK;40M-97B&"Q )I
M-YI(8B_^5-)(2:S3MFLWO,=.Z>N3*2=I--E%IEB+P>9 *9/%XI%X-,T_S8O
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M4:\T6B:^#9:E 0,,R*?6O"=+2T%K;9^8'.M\LU?:O&84KJ*;$6O&L0QB>&,
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M*4Q:1 P%CZ [S("GA+BZS@DPDRM72;FZ$[6FHV=]7$7M.RJ@W9"*C)85[2Y
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MX/C^%ZQ_F>'V>L>N1^>Z2$_S&=SJOR^2^!#_ .8*>3DW_P#I\UXW@>+_ /\
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M-9,M )FRDZQ@,.A=*)A!Y>\)9X68,L>&494.6=:[K476(Y79)2J(P5BL>8'
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MG1.R);P:!_#1>;:H[.T8\VMK+J;8B](I&V<:_-3;)H_\50E&X]NM@U8;:C1
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M<I!7$[M]AMJ5J,D?Y5@7V)%^ZMI@HAAF:TFG3.FXMQ</%@.++M79"V1 O^8
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;]JY,3$_"<NQRN3CC&.,8XQCC&.,8XQCC&?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g260304g29d49.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g260304g29d49.jpg
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M(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
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MLAOBJ6L&&#.K>]N$K&QC7@5J0MZ2/K4P#74 -3?M+(B(\]NXSRW99YY^3QB
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MPM.=WND.$49H(5&E19YENWY&1Y<^1GEY1V=?=*QP2M&X(_2<)NHUUD\SECY
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M00AV(6^K>^K0=;WO?5KKWOJUK^[6M[_\, -:E$]+WT??(^8U]!*NNUZ.?[9
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M-2!,K/2C""49%L(MV6>TCRV]HR+/;O,C,;6,"D, & # !@ P 8 , & # !@
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MT(7.T;<D 0C5%JP,BZ0M/?2,H:[2LMG7)@&K>^-#/U=PKB6PQ+@XK=N+&;Q
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M'(VR#/\ +F!$H7NL?9I2L1$H5RPA,D5B)/+#IN7;3C[P7*@B)$;VPC2'0*Q
MSAU;5S'D2K&74PI\JFGQZ>;9PFEO2842R=:2R\ZA#;FHLB)AXT'P#SA*0:NC
M7-%.*$86D8L0_AZ5$A54&]L*N'B&KEX@KJ:Q?;C1+*=4,/KD1V''7F26VHSE
M1R=2<B.UDLDP=IYKU5(8NNFL:B=VR:*-RDI*I?H]3DV=VSNG4^]_F$JT;>82
MI1L8H^L)?W%.,QO9E)Z%*N5%*58"=<1%TMX;GUSUO7UF+["M8<2VY-@X4MY4
M?6RF<,I#K+"D.-0SA.HFOH-3$5Q;+;SB7'4I'/S-!.+ZRVC45K<X"JKB4TIU
MJNLL;T,*7JYU_%TN,OR4+:?GE9,+KHSA)DSFD2'H[2VF5+'16'R[*6T'$K.H
M-D%*9=;4X9ZZIYAFS.Z-"202%<\GI%RQP0Z7-2_3"A:VM\6"<R5Z9)HQ,G$<
MK+(&(68=[I/2[@JLQ%@J(=E9XFN(E#A:%;Q9,5J=.>EK:>=>9X:,_P 39CQY
MCIR$OMM$IM!K=2@S,<AAK0PMC2)<X4TBSRJ*;!M!.Q-C6QH9T2:]6UL>"V]'
M8C2#CS(WPC(ES*]@HCD=U\TNN$AE3B2(2-OY4,Y_$$SDXL2)B%2*!JG%RCNM
M'EE$V,@-''%,-T4:;M:5HZ>EZ84H3S-*Q)STYP]]HS0MYS.DB*O1<K2&ZTVA
MUFE<?D03):4(OF5' 75:JE&\@EW9%";):N%-"VUF>:LQQDG1%-;TTIT4L/.N
M,R,0LQHEG^+4MS#$A";-J[-2$$PLT8=4=B\;:>!)UMULBR29%%JQY!758=!6
MBXBAD6;>3M5OKW$'JO@ML@4QH^3D')'&-A(;"'PY]"U2&/N2(M.O.D!2$MQ+
M7."MQ0LZ52)+QV'<;XMO<%8C?.IK6-(>&YDRKET91YSE>NQ0IM^O)$=N8N9Q
M:="D,I0^J<EDGTO/N/LQ6W#;Y?%>CC N&M(N$HQ7MO*T48OKZ^Z@XD.37-6C
M=2XAZ-:&Y*<@-P#F5MC%?4Y&16JD*C+CQF8TB:\T3UE*V>+'=U%A L%I9&Q*
MTS]>T0-0S(7=!X:AB=D8%!+HX%/*Q4><N _JG]I&N3$-[<X%-92QL2G-QZ5R
M<-_H)5])7>%=QH;#<:Z>BTSD1F4QQNI1$A+3(?3+=<6MXIKDV,;S:&([Z8Z7
M8[:V%MOO=6XHA88AM8:5AN9/E.S,.1YN(6ITB%)XA>N3[%I<2,N"PTVB.JN9
MKIJ8[KDF5&7+6Q+=;E-O18^3LV$:H& # !@ P 8 5@YFB"#C/:0QB"  $$?$
M,8MZ"$(0R^/;$(0M[UH(0ZUO>][WK6M:WO>^K)(R2>LHR2E)&:E&9$1$1&9F
M9GL(B+:9GL(MX@R-1:J2,U&9$1$1F9F9D1$1%M,S/81%M,QE3QT4[^UBM/KW
M%OQ7--ZXFC_PZP=^T])[\-JZAL;>!^*?V?MO= \=%._M8K3Z]Q;\5QUQ-'_A
MU@[]IZ3WX.H;&W@?BG]G[;W0/'13O[6*T^O<6_%<=<31_P"'6#OVGI/?@ZAL
M;>!^*?V?MO= \=%._M8K3Z]Q;\5QUQ-'_AU@[]IZ3WX.H;&W@?BG]G[;W0/'
M13O[6*T^O<6_%<=<31_X=8._:>D]^#J&QMX'XI_9^V]T#QT4[^UBM/KW%OQ7
M'7$T?^'6#OVGI/?@ZAL;>!^*?V?MO=!U+_<M0&L+V45:M;&&&-#D6667.8P,
M9@QHS@@   738A#$+>@A"'6]BWO6M:WO>26D31_F7^?6#MY?[3TG;_KP@\#8
MVR/_ #/Q3N/_ &?MO=!QXM<E0DQB.$G6I6Y1Q3"T%&E&SB,%F%&%MZ<(RS "
M=-" , M;", M:$$6MZWK6];U@](FC_,_\^L';S_VGI.W_7@+ V-LB_S/Q3N+
M_9^V]T'?>.BG?VL5I]>XM^*Y'7$T?^'6#OVGI/?A/4-C;P/Q3^S]M[H'CHIW
M]K%:?7N+?BN.N)H_\.L'?M/2>_!U#8V\#\4_L_;>Z!XZ*=_:Q6GU[BWXKCKB
M:/\ PZP=^T])[\'4-C;P/Q3^S]M[H'CHIW]K%:?7N+?BN.N)H_\ #K!W[3TG
MOP=0V-O _%/[/VWN@>.BG?VL5I]>XM^*XZXFC_PZP=^T])[\'4-C;P/Q3^S]
MM[H'CHIW]K%:?7N+?BN.N)H_\.L'?M/2>_!U#8V\#\4_L_;>Z"&1"X*D(43/
M9]I5T3I1,W!01LV;QDO1Y VMF $\G8W/6C"1#+, $P':!L0!AT+>PBUJ3TB:
M/]G^?6#MWA/2=L_]^%*<#8V+6SP=BDNR,_\ N];;MFW^:"9^.BG?VL5I]>XM
M^*Y'7$T?^'6#OVGI/?A5U#8V\#\4_L_;>Z!XZ*=_:Q6GU[BWXKCKB:/_  ZP
M=^T])[\'4-C;P/Q3^S]M[H'CHIW]K%:?7N+?BN.N)H_\.L'?M/2>_!U#8V\#
M\4_L_;>Z!XZ*=_:Q6GU[BWXKCKB:/_#K!W[3TGOP=0V-O _%/[/VWN@>.BG?
MVL5I]>XM^*XZXFC_ ,.L'?M/2>_!U#8V\#\4_L_;>Z!XZ*=_:Q6GU[BWXKCK
MB:/_  ZP=^T])[\'4-C;P/Q3^S]M[H(6;<%2;L1O5:M&NMI0PMW3B4ZFT9VG
M"H,?&0P! CO"?<]'#++,, 5L6AB 6,>@[" 6]3UQ-'^1_P"?6#MY?[3TGC_W
MX1U#8VS+_,[%.X_]G[;Q?[IXC\PFGCHIW]K%:?7N+?BN1UQ-'_AU@[]IZ3WX
M3U#8V\#\4_L_;>Z!XZ*=_:Q6GU[BWXKCKB:/_#K!W[3TGOP=0V-O _%/[/VW
MN@>.BG?VL5I]>XM^*XZXFC_PZP=^T])[\'4-C;P/Q3^S]M[H'CHIW]K%:?7N
M+?BN.N)H_P##K!W[3TGOP=0V-O _%/[/VWN@>.BG?VL5I]>XM^*XZXFC_P .
ML'?M/2>_!U#8V\#\4_L_;>Z!XZ*=_:Q6GU[BWXKCKB:/_#K!W[3TGOP=0V-O
M _%/[/VWN@A<YN"I%*!C"GM&NCQ%S2%J# DS:,FB+3IY&WG'GCT!S%L))!0!
M&G&BUH!181#&((=;WJ2TB:/\_P#OU@[<?^T])VC_ -^$'@;&W@?BG>7^S]MV
MR_W033QT4[^UBM/KW%OQ7(ZXFC_PZP=^T])[\)ZAL;>!^*?V?MO=!*H]+8I+
M25"F*2>/29.D-"0K/CSTVO1*4X8.Z )4&MJE2 DT8/[82S!!&(']K6MZ^/.;
MJKZCOFWG:.YJ;EJ.M+;[M58P[%MEQ2=9+;RX;SR6UJ3V24K-*C3M(C+:.(LJ
M:XIEM-6]5953CR#<9;LH,J"MU"3U5+:1*::4XA*NQ-2",B/89YB0YRPXT, &
M # #C+?D:OZ,?_"'@0K<?,?0-1&9 L"N'-__ !CO_P#]^M_LW'<^3?X2G_B$
ML_\ F8/_ ,)J1]+M ?\ 0A6_\O%'^*68]!^?5P?-D4;NOC%;MF+K*96BZ&#=
M8VPG()<XI95?F6(X5R<)J"T.BRJG%1)&U,QB<"P]_ITQZ+86=V_]O;3R5/8-
M+Z>Q=H\Q/B!Z_B1<60CP[B5M")%9B"D5>OT2SC%&D/8;?<GL-PS?27#-MK:R
MB23-^.M+FJI'?V!-*V"\*Q\+3YN!;$L68.=<<B7&%L1IPU&Q,@I9S(C&+XS=
M7*=GE'4?%G76W\YL/^32FUM:R%=?+>(4Y9%PGKCU<ZBLW=YJR#51,AO[*J?Q
MOJ&N4)+9#YDB=6IY8G)HF+2W%"1'#ZUK0ZICC"5B )9BH"NQ9Z+KB&\<O V+
M',/RI6'*?#5J<V&Y-.:S0L(C55JS)C2H<B+:QF$FTL\WHLEM1H=8))N$[D4V
MFC#\]@H.DG S6*H4'%U_C"D373FJXJ]_$\A<N[HWX<R%819M',DK)]"?Y/-A
MNH2XS)4M+2F<K<5:6F5&PZ:QV=2%DF<BD]HRVP'"<M1*Y$OF:R5A;E"M^D;.
MJ!WFQ/0CTXFX34S*5[44A;T2@I6(Y4>21LNC?"5K@ZJMX%Q.B6LZQQ%9W;]Q
M&2\T];.V1,+=FSXKA<%#EFM!L'&B./QDLL-.)=-;CB$:AI>QU28_O**SP_6S
MZ.LJ<)4V&XU!+7'?CT;-.<IMFNK)K2N&L(!-N%)3+G-1Y:I$E]I;)-M-N.59
M9.C@);!URI4V,F4J8/4=EUTM**C:@AO?WR8#M$,7EJA)M[&$!\136D[E )-V
MH4J1)2=IUR( Q%ZZXB:!$1SHEN7S;CE/AC$%"\E->M#$V9:GB(JZS6UQPR)=
M6C$<I)(5PCCAMHU'FB49%VY._"?7*+$[;>&'6FK_ !GA;$\=:[1MR375]*6$
ME6U,V_Q!)J;N7<(PE*6C@FFB><X2.^I)*/EV%P$ETXC;1#CK6C:U@;Z*KJI4
MH)7"'J0F0]YK]G*;CY57;>5-FQC8U,P/()->E3DV/#PA(!LEM<-#V4:1<O-"
MEI<5\6J7B6 ]!8P;0X9:*RJ)<Y55+HXJ(Z[*B83;QX<-=JM"52W)$>5*906K
M'?UC2INSAS\(NEH;6;>(P?:,6,G2#B?&3RJ>_@UJ;N#B2<N4W48FDKH95A8-
M4C;BT0&8LN#"D.&2Y4;5):7,_I>.\Z83N23W#;-11B87JW5PC8Y 1&C50X&I
MA$$;X2L7%%&.P-N:A:6G6+VLP(T(FD]00(7?9B?8S-W;P+<0EX^F5.(6:^UQ
MDQ0M0YR*]3ATSE13,5#KR4*E%QA;J4.O1E$;)QEK09\(IO-77#NDK#]@WHO@
M7F%7[:DT?RL4/V%:Y:(:+$+5_B*3?,QUK3#/BK;"G6(\Q)I?*8AMPBX%+FJG
M!J/@M-C:8::@?K'KQ8B@\VBMEP-4W5D\(RETV9#GCP\NLW:F>KG.9ES)$\*D
MCHH3.;*O1C&$]&?W!,D0E:<UH<MUX3BX6FWU$ZU36];B"E<8P]*90];PURN.
MO8AU[IZ1;)MF9;K4E;<B(^T:B6TO4;:93V _^$#0MXYF8UKL,XF9?OZ&WPMB
M)J5BN$^Y'H9Z(/P='PIP6'6(E&NC?@M/1&W8LZ,^E)MOM\(\](7T,LXPV;!R
MN/J"!G1G<P#R2>+*DDFB%:*4T"B!2F"N[8W >(^%_/>7".IP)D#"K=WF5!D*
M\E9U:=TZHM(,K#LM'F(:9&"&*5=<=J6/I5_/L*O#SB*6K2Y32H[!2H)3E2WX
M"";9A.RI=D4YY+O\Y;<)K5Y"GTKX4OUZ2)&(46I4AZ+H6%JNJNL5-.XBNEM8
M@ARI*H5D=<W!C6;BG9%@S"@U!UL=;&V$ZTI\EY)(X=SE"WQR2)+.C9UN)>1[
MOR+DSXMAB_<*<79_CY\76QMICB:2D.K>UMS1M)IM4*7U6K.5$'F+!=2H&DO/
M-Z++EEF!8-8AKU8G;Q[*QW82W:E\ZA^3-@KKGJ^-!;L$268S$4V^+N.3'75N
M(6ITR)PN#U=S39A^1)LZM["EHC!CNC"%HRJJ]B]CE>QH==9-V[%K,LW:IR)(
MERII/<:::KV66VG&TL%FRKANM9N$<I)MJ-V1)K(C4HU%[/F$U+<W"'OAUB22
M.S) ]MXHF_3!;-%J5$@C*5U)1Q]%'F)L:NYI=*%*,)P4P$^/$T0V*,30;^PO
MX%B5=B&TMDR'JN8J]GP+5F8R=9-M7K9YIIFO;DI:A,P84>-J-Z[C1+)M+>5.
MT\U"\&VF%ZK"]I4?"V$Z2B5%C75>WAJLM*.1 D%<U]*Q1,//R+5V(M^QD65A
M+F:[O!-/FA3JW)3 N*%D1V%FTE)+K3NM M\&L6OVF*,<(2,\O?6.?)5Z%*.:
MRE<YO"<U7#$KDH\"FQAI8-N*L)*EWV:G"<@/Y*ET:W\&I5A&PQ<B3@IBGO:.
M-6PZAJ+:38=VV\RT=O8O2)3:G:EJ0OBBZZ-!-]TD.2C4V2V%\1B+3!A>SO4X
M\J\!NP](LG$&&<23+>POWIU+76&''H\AY-%41XD)Q#-X]%:X\BVF6/%6==J%
MJ.FB2W%C^'TU=&%.3;U@);,;*NHBQ:?JR.P"($P=_<&^8Q)/&%[L^.3S)WAL
M62Y:QM3>T-Q --<=3KM%N"K>M;4[-XY>BVVDPD(Q1=MXACX<P9>X6PW I*M%
M1.>8M:M%<_*F2)=C)CO6CL.,Q%CH+BT!#Q)D.99N:W+-Z:Z*)8NKP7AQW"DK
M%FD+#.-<76>([IR_KH\BDN7+:/"@18-3"EL4S%A+DS93A\<LW8YKBM9F36IC
MGBU%;I>KWK23SANL#49JGC^]5T%RG50CJ#O)2H=8TF9&,E*ID<D%+Y <WM2E
M:_2!F6?!H!:1(2A 4<,9J[@='%;BR7C+#]A<,7GP?AK!,NA)^YPNK"Y,N+DU
M[<2&AMR?/.TG+8C..S9T1WX/)+32&22M1J>V?2W;X%@Z/<4U5!*PX=KC#2/!
MQ,J+A_&B<:'(:;AVCL^P<=:JZM-+6HDS&F*ZLG,_"IJ>><D*6A)(CY6Y*<,9
M5?\ *YPXBLB/)XW,8<P,#6V2^(/,L75NYL!RD\YQKP),Q96!J,E)QI(I"XKF
M1Q=RRRC"FU2GV:$PG9,?Z)[+&UE<2#OX*(%K5P84>/:5<NS>H)$%:W%OT1(M
M8D*,JR6I)SGWH;\I*4J3'<1KDI&H:+=.-1HYJ*",6%[)RTI+NQL9<NENH-.Q
MBB)8MMM(C8E-=).L9B:A"5E6QF)\:$I2TKE-.:AI<[^6<07.4%W+VIV@1FVO
M9E(V$#LQY0:6R!J1)&$ZIK%K;N 2W;X./&#3JM;3:;PJ@!,(6;)$(S/L]%\B
MQ3BLCN66E8FQ!A&\+*"M28A88:KFW(YEQI)O<<. HT.%P? $Z1*0[J&:N.I]
M-,2I5@?+#\E]&#L*X]PVK.R:0J>>,GK9QF61\243!5Y622=:,G3DFRHTK9)9
M$F+6)PLE\^M5TGRVRHTN0"M>"VE&S))#GI]F4930]6SGF5TQ/9DR(8V&&JO!
MJA1HQIC)+LH5*PA7J%! #PJN-O-$MI=8DD73V(*]YGJEIL1UZK"JES;6O;JW
M8JU44.8JV1#A53G +61Q:]$EQQTB><6A*R=Y;#6G2EP[A")AUC"UI'D%@_$&
M$K1-5>0:ZCM7;IF:VC$UA 31N3["\9XRTUE,M5PVF65'&:;<4WP.<+YB+X=8
M7&RUF%J<7T57V>X-\A;&M&H<%A,1M2+.=?.S^6C2%G*CR8VO<F5U<=DDCVD9
MBG1R-V%.A.WO;\:5<Q=Y@#$L*,_,/#F(GV)T>,TM]U%7B2ND4<J:EIHE.+1
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MJ7.'_"I<?^1-7VH8LQY?\TE_U63_ '*Q?B_SJ+_68_\ ?('FTSX'C[0A@ P
M8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , )G7D
M!DEGS./P2)(MKGZ1+RT20&^T$A.7U"-5N"TT ![(;VU(6>N7J.P/9*5.:,(!
MBT$ MBPEA:XQKB*JPQ0QCDV=O*3'82>L33*,C7(ER5I2HVHD-A+DF2[JJ-#+
M2U$E2LDGP6)<1U>$J*RQ#<O\7KZR.I]Y19&XZK,D,QHZ#-).293RFX\=O622
MW7$$:DIS47INI2HHW2%=L< C181E-Y7?#NZ"*"4J?WY2 O;F]+-:V+?=%1H
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M&VLBT!^A:",C/SD7E/<*\69T@E(Q$V)F1"5M4Y+=H*&U5C*UQRUG.0R&!/\
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MV&#$N86R&M+I,"D:%<IEK@I)",RRR(N7/;M/H++Q]O9VB%\L" P 8 , & #
M!@ P 8 , *Q<R_\ #3:'T*/?;"/94C\HO+T&*5_DGY.DA9W*14& # !@ P 8
M =-(_P WG[_)G3_D3\E.\N<ND0K<?,?0./$?S4C'J\R_RU-A6\^<^D$[BYBZ
M!(<@2& # !@ P 8 0:%?*9SZ\N7\I8\D]R>;Z3%*?SOTC^@3G(%08 , & #
M!@!!3OTF-WJ*]?:!@R>0^<NA0CE+F/I2)UD"0P 8 , & # ""S_\GQ_UZ@WV
MG;<DM_D5T&(/=Y4])"=9 D, & # !@ P XRWY&K^C'_PAX$*W'S'T#41F0+
MKGS>,,#S&?\ 03!AUH^M^K6A"UK7_P .1W?Q:UOJ_O\ CSY._A)K67X0=F1*
M41<)A#82C(O^R:KD(Q]+= :4GH1KC-*3/@\4;3(C/_M2S'H,SZM#YM#K#'MF
M*4;2FN[86J"9HH28Q>D HT;O>M:+V2(W1FC-[WK6@;#VM[WK6M=>]8 <SOI+
MWOI9WRG[T$6$T*KNQ?>XBAZUL!FC^UW+98]"#L(]"[(M;UO6]]>L /XVN0Z#
MVMK$N@]A49VMJ"=![FA'HI:9U]OJ[",S>BU0^OLIQ[T [8!;UK  D7(EX!&H
M5B5:6$78$8D4$J !'U=?9$,D8PZ%U;UOL[WU]6^OJP XJM[94",UQ7.[6C;R
M% TAZ]6X)$Z,E66H$D,3&JCC@$%J"U8!I1DC'HP"@(B1!T8'8= '/T<3L99>
MCBMC.+&:2#1@-C-*+V7HPTL/7UC+!LXK0QAUL(=FE]>]=L/6 ?7 !@ P 8 ,
M & '&3K4:L1H4JM*I$2,PLX*=04<(HPE2H1G -T6,6RQE+$:M*8$?4("E*H(
M%K1I!H @'U*-*/ $TDPLXL77V3"AA, +LBV$79&#>P[[(@[#OJW\0M;UOX];
MU@!], /@:J3$B[!R@@H?9T/LFFEEB[&S $Z'V1BUOL[.,+*T+JZMF& !U]H8
M=; /H6:4<#MDF%F@[0P=LL81@[90Q%F![0=[UVBS #+&'KZP#"( M:$'>M '
M]X , /B>H(2DC4*CR4Q!>M;,//, 227K>]!UL9A@@@!K8MZ#K8A:UO>]:_OW
MK #B)'=I7F[)0NC<M."#9FRDBU,H-T6'80B'LLDT8M T(00[%O79UL0=;WU[
MUU@'V5KT+> !B]:D1%C%V #5J24P!CZMB[ !'# $0NSK>^SK>]]6M[ZNK6 '
M) ,!@ &%C"86,(1@& 6A & 6M;"( @[V$01:WK81:WO6];UO6^K #^L & #
M!@ P 8 , & # !@ P 8 , *L<V3AIN+=NJ"^SW1.SLQP.UKK#VRI6PC#VM:W
MK>P]H.NO6MZZ]?\ '66GW%,L/NIRUFF'G$YEF6LAM2BS(C(S+,BS+,MG*+C+
M:77F6E9ZKCS3:LMAZJW$I/(\CR/(SRV'MY!JW\Y=R'_5E:?5MY]Z,^7GQR=+
M/>6#?0]C]]CZ(?%6T:=]XJ]*0?ND/.7<A_U96GU;>?>C'QR=+/>6#?0]C]]A
M\5;1IWWBKTI!^Z0\Y=R'_5E:?5MY]Z,?')TL]Y8-]#V/WV'Q5M&G?>*O2D'[
MI#SEW(?]65I]6WGWHQ\<G2SWE@WT/8_?8?%6T:=]XJ]*0?ND/.7<A_U96GU;
M>?>C'QR=+/>6#?0]C]]A\5;1IWWBKTI!^Z0\Y=R'_5E:?5MY]Z,?')TL]Y8-
M]#V/WV'Q5M&G?>*O2D'[I'&6=)+R#7)%2(YMK;1*Q,>E-V"./(1Z*4%"*,V
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M/,(+Q?*9U.R0O\!I>QR1DN*-,N$>$Y_G%VLN8S+(_*99JV;C,A2F;?H)>O\
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M5%(DA9Y!@$Q.@ '7L\!@L>);T[!"XFQD-(4@&LAGCC.V$MH$&W?: #>6B1D
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MVCWX?CXDV"_#'%'ZBI]U#XV^+/!;#OZVR]Y'!=.C"K) V.*XNQYV,:) L5@
M--'^P,:9.8<$(NRWZWV1;!K0NK>M]6]]6^O!?@2X+,R+JQQ1M/+_ $%3[J(/
M\+?%I$9]2V'=A'_YMG[R/DR=&-6;HS-#F;8TZ+-<6Q N,++31_8"QJTI2@8
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M4B=9 D, & # !@ P @L__)\?]>H-]IVW)+?Y%=!B#W>5/20G60)# !@ P 8
M, .,M^1J_HQ_\(>!"MQ\Q] U$9D"P-P&8XR P 8 , & # !@ P 8 , & # !
M@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P K%S+
M_P --H?0H]]L(]E2/RB\O08I7^2?DZ2%G<I%08 , & # !@!TTC_ #>?O\F=
M/^1/R4[RYRZ1"MQ\Q] X\1_-2,>KS+_+4V%;SYSZ03N+F+H$AR!(8 , & #
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M )KE^C^/)_!@HLB41%L)9EV]F[?YBW])CU@X%L, & # !@ P 8 , & # !@
MP 8 , & # !@ P 8 , & # !@ P 8 , & # "L7,O_#3:'T*/?;"/94C\HO+
MT&*5_DGY.DA9W*14& # !@ P 8 =-(_S>?O\F=/^1/R4[RYRZ1"MQ\Q] X\1
M_-2,>KS+_+4V%;SYSZ03N+F+H$AR!(8 , & # !@!!H5\IG/KRY?RECR3W)Y
MOI,4I_._2/Z!.<@5!@ P 8 , & $%._28W>HKU]H&#)Y#YRZ%".4N8^E(G60
M)# !@ P 8 , (+/_ ,GQ_P!>H-]IVW)+?Y%=!B#W>5/20G60)# !@ P 8 ,
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M7)EXS2:S0LC0G5VYUS@!S@^9II1!1AYYA9)))8S3CC1A+***+#L9AAA@]Z
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MO21>DFK]EU)_]-L=8_1;X+(]+W_WJ'7KTG>%"_1-%]UAYXWI(O235^RZD_\
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MS3N,?>)<DN$E#[AM'5N\,D6BJD%?*V0595S.'JEXN._WGOBK=2NU87$W:I8
MMMUX>DRF&$S68L2J4&OS*H;P'E2%C&X+2ULKJ:[8VTZ38SWR;)Z7+=4\^X33
M:&6B4M9F9DAI"$)+<24D1":RJKZ:$U754*/7P6#<-J+%;2RRV;KBGG32VG(L
MUN+6M1[S4HS,6S@-?0BJXFU0.N(LRPN&L8G$;1&H\A*;6=N$[.JY[<Q)$9&@
ME$[7.[DO<5.PZUW56K/.%UB,%O*;*RL+B:]8VDR1/G2":)^7*<4Z^Z3++<=K
M7<49J5P;#3;2,SV(0E);""NK8%1#9KZN(Q @QS=-B+&;2TPT;SSDAW4;3D2>
M$>=<=7EO6M2CVF*XI*<X9\PD-?<F%%15C;89&QM3["[!E-?%A=W5B!O8V<;B
MDDC2A=E:9)L&]HFZ3-YFT.NT$I*1H>]"Y>LQCBNE@.UE3B&WKJ]XUFN)$G/L
MLDIS_2*:2A9< MS_ ,Q;)MJ7^<9Y#BK/!^%KF>U96V'ZFPGLDA*)4N$P\Z:6
MS_%I=4M)D^AO_P M#Q.)1M))$1GG,[-XA\8+GDP9G:]$5G8,J VHF<#]*HLW
M.[D%J;A'"0M^E"DH8N]$HE!^R"/_ )8.ZCZM?VMY74XUQ;11#@4V(;:MAFZX
M^<:',=9:X9W5X1S509=FO53K*WGD68HM<&84O)93KC#]793":0P4B7%;>=)E
MO6-MO641]@C65JIW%F8R>15E;HZY.J%#!HLW5:?'%\0-KYL9$#9$=Q=U3*$;
MFPA8D!*= 6UN"96K)6I"R0E*0J5'=M#$<9L7$*M[1=HF[<L)CMNF4W-*R=D.
M.S>-LK2MJ0<AQ2G#=;6A"D+-1FDT)U<B267*IJ*M%8JE;KXC50J*Y".M:8;:
MA\4>0I#L<H[:4MDTXA:TK022)1*5GF:CSKBIHSA3P\B5BW2EJ"M:DCC=!75E
ML.4Q>#FB6'0-T6-ACNSK4<=;USNY-BY:B:S5+>D1J1FF)2#-E;T3V@\O:8VQ
M;=M1V+;$5K8LQ9;4^,W+EN/(9F,)<0S);2HS)+S:774H66TB6HBWCB:O!>%*
M9U]ZIP_5U[TJ*[!D.18K;2WHCZFUNQG#(NR:<6TVI:#V&:$F>X9\<Z4J-YJT
MJDG>N(<Z5&G9&Z.)ZZ<&)"LB:=D:.X;:&].SGDF)2"FH:5*<V#*  Y I3)U2
M0PE004:#C6KZZ8MU7[%I.9NE2'92K1J0XB:J0_K<.XI]*B6HWB6M+I&9I<0M
M2%DI"C(^1=HJ9^I30O5D)ZF2PU&36.1VUPTL,:O MI94DT))DT(4T9$2FUH2
MM"DK22BPS)>'O#1MJ]'%)10E1)ZIK@4CFJ9F<(HW"8(^I4H"SI/*#BMDC$<Y
M*&UL)TXNRK:E><C0D$".$4066'F$8]QHW82K5O$UPBQF,LQY,Q,UTGG8\<UJ
M88-1'DEAI2UJ;9026TJ6I1)UE&9\2O >#78$:J7AJH77Q'GI$:(J&V;+<B02
M$O/DG+-3SJ6T)6ZLU.*2A*35DDB*4\45%%.5&0U_XV0937U.2@I9)8>QJZUE
M52F*T+NJ,4:D)4)FC%&Y$A020/8>6M<M9TH'EL5HW5)LU(K(.'P=K<6EY,78
M7$^393G$-MKE2W5//J0TG4;2I:LS,D)(DI(]Q%D.;JZBLHX:*^H@QJZ$VMQQ
M$6(VEIE*W5:[BB0G9K+4>:CY3&7('7T(J^,HX97<798;%&]2Z+$,?CZ(IN:T
MJI[=%CV[J"$A.@E@-<7=P7.*L>M=9RM4<<+K$/>\MV-E/MY;D^SEOSICJ&4.
M29+BG7EHCLMQV4J6K,S)IAIMI!?FH0E);"%ROK8%3$1!K8C$&&TMY;<:.@FV
M4+?=6^\I*$["-QYQQU>6]:U*WF-2S=(^B%LVP"G1=1K84\3ZVGJ&H;=L#A_?
M4(JN97$;/'2*+V9OO^;5(Q4^[RA\L=&Y1YH"3.QF2>5AVTL(G-T/)3&;*QI%
MQU&BLPH^*[MF)'CMQ68[<YU+34=ILF6V4((\DMH;23:4EL))$7(-<?T=8(D2
M7IK^%:5V4^^Y*>?7#:4ZX^ZX;KCSA_E&M;BC6I1EM49F8V(VKQ)XR7C)$$PM
MVBJRL*5-I)"5-()-%&QP=C$:40A)4"]:,D)[JW)A#,VG;G0:Q"1W4W12<&C3
M-"PJ?&>*\/Q7(5+B&VK(;JE+7&B3'FF2<61$MQMLE:K+JR(M9UDD.*R3FH]4
MLLNWP=A6^E-S;G#]592VDI0F3*B-./&V@\T-N.&DE/-(,SU6GC6VG65JI+65
MGDQ_>Z]I&M'Z3.XV*OJMJF%O$D>3D: EKCD.A$-9E+N[*B6UK3!)1-3(RMZE
M1WJ@2=12=/LM.1O>@@WKS\A^4\[)E/.R9#ZU.O/ON+>>><6>LMQUUQ2EN+49
MF:EK4:E&>9F9C8&&&(S+4:,RU'CLH2TRPPVAIEIM!$E#;33:4H;0DB(DH0DD
MI(B(B(A@:0<Y^+<5J"D;ZD-G@:JIY$3N"5G54I512;@T[3FQC7,B-1]_9]1O
M;]!%)2IE>$<F.G;7&TD)6M3BCF*AB4HU!1=H7LCV^(L_(.XN'F1QQH6;CKBU
M+$+C<U*I.S^11["3&Y<_J4U.4X@,<I_,51L<879*F*:TA"L3<TGGEOLE-0.*
M>,MCNH;UI1 "29Y9%O,D^4]Q#K*FYL<?[EF;-7D:<[,BTWD[ XRF'1NY^/\
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M)D8<FMH88VAE)B5,H#LQ4O/)V\[F]BFOPQB3$S\J^PBWAB# F0Z"AI(5>5[
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M?/FU%.Y22:U%A)<EO13L8:Y$AM#SAFK@U*6A.J>P^"2O+A%NJ7N-SI0=QA@
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MJ$'0P:ZP[_OUUZR2_"$TCF9?RJIWE_JIG[8@] .CLB,^*VNPC_UH]]@?&/\
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MV2Z+FNR-69'Y.W)'%P2H7]I$D=4B=<L(3JRRE1X1@$LP 8 , & # !@ P 8
M, & # !@ P 8 , & # !@ P 8 , & # "K7-944AXO6TM4;%HA&U,JH[80[$
M+12>6,!IFPAU\8A:  74'7Q[W\6764*<=;;3EK+62$YGD6LH]4LSY"S,MHM/
M+2VTXXK/50A2U9%F>JDM8\BY3R(]@HMY]?@%\Y+.]FCK]ZSNOXO6D?O6I]*L
M_8'3/7_T=]]6OHM[[8>?7X!?.2SO9HZ_>L?%ZTC]ZU/I5G[ =?\ T=]]6OHM
M[[8>?7X!?.2SO9HZ_>L?%ZTC]ZU/I5G[ =?_ $=]]6OHM[[8>?7X!?.2SO9H
MZ_>L?%ZTC]ZU/I5G[ =?_1WWU:^BWOMAY]?@%\Y+.]FCK]ZQ\7K2/WK4^E6?
ML!U_]'??5KZ+>^V'GU^ 7SDL[V:.OWK'Q>M(_>M3Z59^P'7_ -'??5KZ+>^V
M.N>.G.X#K6AU1D2.S=GJVY<F)T*MG0(=FGIC2B]"%M5U!UL8]:V+?Q:U\>\D
MOP>](Y&7\EJ=Y?ZU9^P(/3]H[,C_ )5:[C_U6[]L?&/].7P(;F%D;U,CLP*E
M"T-J-0$%;.@PZ/2HR2#=!'I5U"#HP M!%KXA:ZMZ_OP?X/>D<S/^2U.\_P#6
MK/V +3]H[(B_E5KN+_5;OVQV_GU^ 7SDL[V:.OWK(^+UI'[UJ?2K/V!/7_T=
M]]6OHM[[8SKQTZ4CBYRILYOJ2F!69(9:N;W)X.[ZK]P;6=G9FDG1BYW?'90J
M[U:V\LTQ*A*//WUJ7->WMR8!JQ:F),U[$^B/%V#ZEVYO2J8T)MUIA.I9-NOO
MOO*R;9CLI1KO.F1+<-*?R&FW75FE#:E%S^&M+&$\6VK5-1_"LF8XVZ\K7K7&
MF6&&4YN/R'E+U&6B,T-DI7Y3KC32"4XXA)[&<ZP'9@8 , & $&A7RF<^O+E_
M*6/)/<GF^DQ2G\[](_H$YR!4& # !@ P 8 04[])C=ZBO7V@8,GD/G+H4(Y2
MYCZ4B=9 D, & # !@ P @L__ "?'_7J#?:=MR2W^1708@]WE3TD)UD"0P 8
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MZVM^M>5MGPR:.3#7B6R5L JNO6]J<Y!#*JB#,T*"+"FK<M-4,<45R- ^*9"
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M2([CS$"BB.+3AZI4['J&3UDE(,S)+]F\@\CX68:$\"E1)-F*AELT)=4^;GT
MT3:/6\"T!*EH0K$%JEJ1;.EJJ..1$:F*QI:<RX*(2E<,I)J)Z4MU9+4TE@F]
MG>=3#M4, & # "#0KY3.?7ER_E+'DGN3S?28I3^=^D?T"<Y J# !@ P 8 ,
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MK=.@E"XTU2E1FD[C/TJW%U-K9&(JVLQ!$@T"Z%ZOLT.K;E$^3)S;5N2VMN5
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M:856BK95C8,LD*P:MW':;J%TTJ/-) %M;^] $[$IV:$Y["+M9_O&:<" P 8
M, & # !@ P 8 , & # !@ P 8 , *E\ZB35'$NZTY!8C3SXV@))*!K8AF&FR
M1D 66 .OC$(8Q:"'6OCWO>M9DPU)3+C*49)2E]I2E&>1$DED9F9\A$19F8QI
MB5+B24I(U*4PZE)%O-2D&1$7C,SR(>(3S<_.ST4+O^HKO_1SZ2]<[1[X8X?]
M(L?:'SGZVN/_  0O_1TC[(>;GYV>BA=_U%=_Z..N=H]\,</^D6/M!UM<?^"%
M_P"CI'V0\W/SL]%"[_J*[_T<=<[1[X8X?](L?:#K:X_\$+_T=(^R'FY^=GHH
M7?\ 45W_ *..N=H]\,</^D6/M!UM<?\ @A?^CI'V0\W/SL]%"[_J*[_T<=<[
M1[X8X?\ 2+'V@ZVN/_!"_P#1TC[(>;GYV>BA=_U%=_Z..N=H]\,</^D6/M!U
MM<?^"%_Z.D?9'S.Z.WG.G*-/.XJ7:4206,XXT<&=@@+*+#L9@Q[V3U:"  =B
M%O?]VM;WCKG:/?#'#_I%C[0=;7'_ ((7_HZ1]D?RGZ._G*J((5)N*MV')U))
M9Y!Q<'=A%FDG "84: 6B>H0# ""(.]?WAWK>.N=H]\,</^D6/M!UM<?^"%_Z
M.D?9&\GH<.B]F4$G"WDUR>@#I$I!#%QC93U>2YOVE=$[YH@'?]DNS8?K8D_@
MPL_;;#2E(=F^$A.4@T0F-;(^N/Z TX:6X-A7HPGA.R9FQIS:7;NSA.DME4?6
M/@ZIEY.Q7#&DG9QH/+@B:C:RDNR6T]\Z$]%,Z!/<Q5BNN>A2(+AM4M;-;-#R
M9&J7"6CS*RS23)*X*"2]O"F[)U4FS&<5Z;,\H#U0& # !@ P @T*^4SGUY<O
MY2QY)[D\WTF*4_G?I'] G.0*@P 8 , & # ""G?I,;O45Z^T#!D\A\Y="A'*
M7,?2D3K($A@ P 8 , & $%G_ .3X_P"O4&^T[;DEO\BN@Q![O*GI(3K($A@
MP 8 , & '&6_(U?T8_\ A#P(5N/F/H&HC,@6!FJ]KVZ,^&W2OB7($=!ZO,@R
M,A<=36I$\FE_='!M;5$5[M(C(0[C-%X+4-G@[?A4?>2?O<G6T_<>YE]CX>P[
MI6G4+<W#75'U/**7P7$+I42%DTZZF9JQ2L&"(N&2]POXDN$7K*[+6S/KO$&(
M-%D&]<AXCZG?A])Q>%X]2IES<W&FE1-:4<!\S/@5-<%F\?!HU2['5R+8MG6
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M6]&\2&"3B#S6MYH@9' [O9&^ CD[88^XKV4U3L"4;HV$K$:52<F3K#DYRM*
M[/Q!@O$.&8\6;9Q8ZJ^:XMB+8U\^!:0')#2=9<<Y5?(DM-OD@C63+JD.+0E:
MD)4E"S3@4&,L/XDD2H59*?*?";0_)KY\"=63FV'%:B)!1;"/'=<8-623=:2M
M"%*0E:DJ6@E66S51M(8 , ,=VS:D+I&N)=:]BN)[1"(,TC>I(Y)6]<ZJ$;<6
M<2G$<4W-I"E<K%HT\H/<DQ!IF]"V+0>K6]ZY.EIY]_:0J:K:2]/L'B8BM+=;
M92MTTJ623==4AM!:J3/-:B+DS'&7%O!H:R9<6;JF8$!DWY3J&W'E(;)24FHF
MFDK<6>:BV(29^(3I"L3N*)&X)![,2KTJ=8F&((@"&G5$@/)'L ]:&#8BS [V
M$6M"#O?4+6MZWK./<0IIQ;:RR6VM2%EF1Y*0HTJ+,LR/(R,LR/(^0<@VM+K:
M'$'FAQ"5H/(RS2M)*2>1Y&69&1Y&69<HY64"L, & # !@ P 8 , & # !@ P
M 8 , & # !@ P 8 , & # !@ P 8 , *F\Z%!R7B;=*I./91Z:.MZ@@S6M;V
M6<3)60PH>M"UL.]@&$(M:%K>M[U\>MZ^+,B(E*Y4="BS2MYM*BV[4J61&6S(
M]I&9;-HQY:E(BR%I/)2&7%)/9L4E!F1[<RV&1'MV#QA^=DZ0_P!)V7?5^ ^Z
M6?1/K-Z,_!.%\YLO?1\^.N_I(\*IOS>O]S#SLG2'^D[+OJ_ ?=+'6;T9^"<+
MYS9>^AUW])'A5-^;U_N8>=DZ0_TG9=]7X#[I8ZS>C/P3A?.;+WT.N_I(\*IO
MS>O]S#SLG2'^D[+OJ_ ?=+'6;T9^"<+YS9>^AUW])'A5-^;U_N8>=DZ0_P!)
MV7?5^ ^Z6.LWHS\$X7SFR]]#KOZ2/"J;\WK_ ',/.R=(?Z3LN^K\!]TL=9O1
MGX)POG-E[Z'7?TD>%4WYO7^YCF-_2C=(]*EZ*,-7(F<O;G(E2=C;V9!%X,J7
M.RUU-"A2MJ-,GB CU"I:<>!,023K9IAIH0%Z[6]99D:(]%D1AZ7)PQ71XT9I
MR0^^[+L$-,LLH-QUUQ:II)0AM"5+6I1D24D9GL(76-*^D^6^S%C8EL7Y$EUM
MAAAJ+ 6Z\\\LFVFFT)AFI;CBU)0A*2,U*,B(LS'L]X9P:X(%QXKUMOFRW*T;
M5=&=&_REY6E-*="R'.J)(:CA["4SMS:F&TQE$%.W[7G%'*G9R"XNFSBDRQ*A
M1>%,:6%!98AG.X8JFJBB:5Q:OCMF^IR0TRI1<>DG(==<)Z6HS<X(C2EAK@F3
M)2T+<<]PX-K[VNP_":Q+:NV]VZGC$]]PF$ML.NI290HY1VVD&S%21-\(9*4\
M[PKQ&E#B&F[2YJHVD, & # !@ P @T*^4SGUY<OY2QY)[D\WTF*4_G?I'] G
M.0*@P 8 , & # ""G?I,;O45Z^T#!D\A\Y="A'*7,?2D3K($A@ P 8 , & $
M%G_Y/C_KU!OM.VY);_(KH,0>[RIZ2$ZR!(8 , & # !@!QEOR-7]&/\ X0\"
M%;CYCZ!J(S(%@:"^EV_WJ$P^F4+]AH/GO'0K_1#!_0Q%_B%@/#&F7^EJ?^GA
M_P#PZO'MTSP,/=XT]J)3/.'_ "7YKR22\=+MO!CY+K*_G%2R*H:[7V.W/ZR.
M5]N'JZLGQ[6$\<*$W.I>BFE2^DC9U$?5KG )A?<]I#N[4Q*[&V%,!18N**##
M\C"B+*ON8MW9MU;L=N59%.1;UJ7M4IY.,GF\B.HGTR4-M9*SUT]*JEV."\4X
MZE2L,WU_'Q2NNGT\JEK7+-N0N-7'"746"FM8X/!.EJLJD$;*HRG'2RRU%5GZ
M0OCQS/O.F$DQ+H>M2H3%^/T>11KCG#9'+9-.ZOM66/3,;.7J(PZ&UP)AG<I9
MV$!,,9QEN"%MC4=4S-0U$J%"\QR4[9HSQ-@7#UZN">(K0Y\O$DI<K$\Z+#B5
MUO3PX[Z:^/-G3K3C%=#?DFJ<^1MN.RI2(*7E)0V3*=5TDX:QQ?TC<XL/5A0(
MF'(R(N&8,F9+L*FWF2&%3WX<&#6G'L)C$=*8+)I<0U%C+G*92I:S=5%>2-5V
M$\7!S:E%G<<;VD-N6+3?&]NX_2R@6:V7RM6'D4PUHYI5:UCE[.1'234D4EB]
MNVDG$E;DZ5C9$$H:ERAF<'\QI=LO"UQ6L4F 8E3BC#L6EK+W%+F)(>)'Z:/:
MR,,2+5I:&Y$)]4I1+FPFW277Q75+D2'8CS:'VHW#,8F)ZBQ?NL=R[;#&(95S
M94F&&\.3,.Q[F15Q\2QZIQ#CC$UA,9"D0YCC6I/E-)3'CM2V5J8<DFR_L#Y]
MPVW'_@)&V Z*RVS;89GGC2ZS1EK^.N<SD;P]16<09TG;BULL>2K%C@64<WNS
M@88E(V2!. 1PA%DZV/76VCB=2Q](\J2F9"J:9]C%3,!^SE,P8K#$ROL&:YIY
M^4MMMHU)=9:(EJUC49)(C5L'8VD6#<R='4:.J)-M;AA["[LYBNC.SI3[\2=
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M!BR%IC<2?=0J0S*98S=UU\&\II1I&S3.J!VH& # !@ P 8 , & # !@ P 8
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MG?I'] G.0*@P 8 , & # ""G?I,;O45Z^T#!D\A\Y="A'*7,?2D3K($A@ P
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M5ULD:I$1%ZI,\@#UN& # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & #
M!@ P 8 , & # !@ P 8 , & # !@ P 8 , *L\UU12'B];2T_M:(1M+*J.V
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MX39</P!_Z(=<AZ1:RG9QKR7ME QP=!VQS!9^),)FZBUE!4]TXFS-TASI.7R
M@@HV]&RJ3V1Z/8VY-+5+D$YN"E=2DR9P3.0+KFC&J9:LX3N))18CIL$OXSGU
MZ:=*J[@DP69S5?'LCL2<<?0F0PF0ZJ$EK5=-;*EJ:6R=E&DRT==K)C6'(IX=
MN,:L8-@3UW"RL>%5-=ANV#]<5<;2&%FP^IAM,U3I*:U'B2EU#I?6-](!<<BJ
M.RKM.H^IHE7T7G[Y5,1?)YR(0Q)(_P N8;/.@K@[OACE" [:HTG:P&N*=N9
M26:OC\W*8\PQM<%:B<=1*T;T<:ZJJ!.(+F;93*V/<38]=AER:N-"DU)6#3#!
M-6'XZ6IXTM*=?.) CQW429$ILVW&A5&TC7<BGM;TZ"GAUL.RD5$*188E;A(D
MS(]J<!UY\W8'XJ*EDE.H:8*5.D26E1H\5PG&W2C<+Z3*PI]'8"CBM%1%XLN8
M<IY_Q6-;A6?(F2!>'H=72&P4D\;I$\U:GE>HDX(79")4B<X,CD"1$0N/3-ZY
M6)&A.RI^BFMKI5BN9B&:Q50<'UV,"=*IBR+'B\VT<K%USL5BX5#XXVXRYJ.-
M6"XRW%-I4XV@EN)QH.E.RL8M<B'A^$_:3<6V.$3:^%I+%<<B%6MV*;!J2_4H
MF%#<0\C7;>KT24-I<4EMQ9H;5W%0](O:DXD=)$S7CLP16&VS:UIT"<[QZUSI
M3)4-L52WR1<Z*6R-J8*PH5D)=CXVH:6Q8KD2-ZTN$L.5-Q2)&A.>[%UHQIZ^
M+?*@8GDS)U-3T^(TL2:9,2*Y3W+L1ME#LI%C)<1/93+0\\A$5R.;?!I0Z:W'
M"CWJ;29;SY5$4[#,:)!N+>VPZ;T:X5+EMV]0U*<=4U%77QVUP7E15,M+7)0^
M3AN*6V2&VSD2GASTA3IR=M)TK>2P>O:X=R8\]/@H0*QY,&YH4X,SL0B'%I[6
MD^K"NE2M>-O/$YJWVOG*7Q]IV46D6J>M6%01B8XT:,X3IV;2+86=HRJ2Q'*P
M*KB'13VGV5.%,KK6MMK-#;9.I)E$>R:A27]8UMIR0:59>"=)#V*[=ZKE0*VL
M>3&?D'!.SE%=P'6'DMG#L*NQJJQ;CAMJ-U<BM=F1V=5+;BLUZR=G^=2CM<,
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MR/44K74AQ2VLD%(!\ N.AL9>HD>SR8]F?N-T3XJKB3).L[MJJ(0J5+HX40<
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M4B=9 D, & # !@ P @L__)\?]>H-]IVW)+?Y%=!B#W>5/20G60)# !@ P 8
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M)D6MGXC+F'IV_O\ [LD6PP 8 , & # !@ P 8 , & # !@ P 8 , & # !@
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M\F>_+M9\N6_E%Z<" P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8
M, & # !@ P 8 , & %8N9?\ AIM#Z%'OMA'LJ1^47EZ#%*_R3\G20L[E(J#
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M_P#;%*=(.,^R_P X)OY1_P#H>Q$N\VQP8]&V!?ZOWXSD=5^)?EB5_9>S%77
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MQ;4UE"(&4VH"AIE:Y>F$6C3@$G7.8U)CDM($$O6RE;@8L5F+E)>PG*QJE(E
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MV2_+DK)R1(<4Z\X2$-DMQ9YJ5J-)0VG,_P U"$I+D(B$CRR,<, & # !@ P
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M P 8 , & '&6_(U?T8_^$/ A6X^8^@:B,R!8&X#,<9 8 , & # !@ P 8 ,
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M@"=6E7$A,UUZ+5H3P*DB@/QZZC$Z@LLTO?\ P&'6^K?]V RSZ1RL & # !@
MP 8 ?R((1A$ 6M"",.PB#O\ NV$6MZWK?_TWK>];P&\8[\45:?,UE_\ X!_U
0,G,^V?G,4ZB>U^\_K'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g260304g47o32.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g260304g47o32.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1J"4&AO=&]S:&]P(#,N,  X0DE-!"4
M     !                      .$))300Z      #E    $     $
M  MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN
M=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P
M4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $
M0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L
M     BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<
M0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O
M;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP
M $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !
M4D="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M         $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M        0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0'65
M A         *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',
M    4&=00P    !,969T56YT1B-2;'0               !4;W @56YT1B-2
M;'0               !38VP@56YT1B-0<F- 60           !!C<F]P5VAE
M;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC
M<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P
M   +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #P     $  0/
M     0 !.$))300F       .             #^    X0DE-! T       0
M   >.$))3009       $    'CA"24T#\P      "0           0 X0DE-
M)Q        H  0         !.$))30/U      !( "]F9@ ! &QF9@ &
M   ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4    !
M "T    &       !.$))30/X      !P  #_________________________
M____ ^@     _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M #A"24T$"       $     $   )    "0      X0DE-!!X       0
M.$))300:      ,U    !@              J    A$          0
M                   !              (1    J
M   !                         !     !        ;G5L;     (    &
M8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M    3&5F=&QO;F<          $)T;VUL;VYG    J     !29VAT;&]N9P
M A$    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@
M  =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I
M;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP
M965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P   *@     4F=H=&QO;F<   (1     W5R;%1%6%0
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M;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P
M   *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M    "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
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M# P,# P,# P,# P,# S_P  1"  S * # 2(  A$! Q$!_]T !  *_\0!/P
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M+'8]=;7_ -7?38U!R!BW?6O)9D;'8S.E>GE[R-@;;<[V6G\WU*V6)*3-I^N
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M_P QO'_;_P#H_P"ZZ?+_ ,P/Y_:7R_S/_L/]]__9 #A"24T$(0      50
M  $!    #P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D
M &\ 8@!E "  4 !H &\ = !O ', : !O '  ( !# %, -@    $ .$))300B
M      $N34T *@    @ !P$2  ,    !  $   $:  4    !    8@$;  4
M   !    :@$H  ,    !  (   $Q  (    >    <@$R  (    4    D(=I
M  0    !    I    -  -+#*   G$  TL,H  "<0061O8F4@4&AO=&]S:&]P
M($-3-B H5VEN9&]W<RD ,C Q-SHQ,CHQ,2 Q,#HQ.#HQ,    Z !  ,    !
M__\  * "  0    !   "$: #  0    !    J          & 0,  P    $
M!@   1H !0    $   $> 1L !0    $   $F 2@  P    $  @   @$ !
M  $   $N @( !     $              $@    !    2     $X0DE- _T
M      @          /_A 3!-30 J    "  ' 1(  P    $      1H !0
M  $   !B 1L !0    $   !J 2@  P    $  @   3$  @   !X   !R 3(
M @   !0   "0AVD !     $   "D    T    \     !   #P     %!9&]B
M92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$W.C$R.C$Q(#$P.C$X.C$P
M   #H $  P    '__P  H ( !     $   (1H , !     $   "H
M  8! P #     0 &   !&@ %     0   1X!&P %     0   28!*  #
M 0 "   " 0 $     0   2X" @ $     0             #P     $   /
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M 0$! 0$! 0$! 0'_P  1"  O ),# 1$  A$! Q$!_\0 '@   @(" P$!
M        !P@ "08* P0% 0+_Q  S$  !!0$!   & 0($! <    % @,$!@<!
M"  1$A,4%0D6(1<B(R0G,3)"-'%XH;&XP?_$ !T! 0 " @,! 0
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MVM4>/7M_BNP-\9UH9'R^$_?;)855K=D>C-1-6R-!*6W<]1%5V:,JQ.RE82Q
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JTRX=[MC,@Q@75LG(238JKN9=.).;8DQGMBH$ADP(&WQ<%EZ0PC<AW__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g260304g96y01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g260304g96y01.jpg
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M'9'H(P*M$,/HRE;3S<\5'*:<;SAQ"\)4WGQX3S:Z%:+?:SI=HZAXYKZV652
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M9C/?V</G  !^3V?/FBC/?C[?)]L5O7I.<? G&/\ KQ_!Y;P? ^PU5C_.?/\
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MZ\;.E_!'A*)8I](C'7VZK2HE]Q*LA1 3B\^<:2EME4M.%^9*2SS37I#R!!@
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M9'9'5D=<JR,"K*0>892 00<9!P:\[F1XV:.1&C=&*NCJRNK#D596 *L#G(8
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MZVV@KI]ZEJQ4M=1-:+'P-EL^&J,T]"QP+;:VI('U@]+-''LQI\<SS'/\;J?
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M([+M) &9+B4.50X)\CJ!SIQC%8(W\B=S.:B]]@^_Q33UA%\P&3]]YO6476A
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M^U)_DX3W_N$XY>!]H^JII[B^J7Z_VI/\G">_]PG'+P/M'U4I[B^J7Z_VI/\
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M8V<X5DNRV A#L; ,K;[^BLOI(D375-)' 6RM1#;[?;QI6QT7?6N;V$XL>7Q
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MH<GUT^!NM_XNW_2$^JGOMTW],G?<#W[_ !]TSA7_ !]Y^AR?73X&ZW_B[?\
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M.V+/@1FO]>M"VD1N.GX\>FC-)DHY,@F7:BGP<1B5(CL2S:91$8RRT'ZR3@[
M_I?YKSIK33[2]A>:P33KRVD&UYK*XLKJW9<[MIFMY9(MF1NVAMN?.QDYJ@ZX
M[M&3?SEXB6CW&<.K;2FX*RARQ7*;B"Q7S<XY5/FK=-SK@**WI741D1!D&.EY
M/(@R*/2!224M-DR#Y\H*(LY6$-,Y>9A I(QY#:4H;[Y3GEN>XT;1XSY9?V5L
M!EO([-X[N\<Y^*L%LSI&SXP'N)(D!'G'EBLV"UUK69%-K8WEPS +Y7>)):6B
M+S(9I[A5:15R25@25R.07F*ZCZ+TP%IVNG,/GIG;=926)*W6!+&1F3"AF5,
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M0IZ/3N.MC"+6[1;=&('E]D7EMD)QSN+=\W$"#OD1KE5_#*J"U=> S!) 04\
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M3>FE;MM'84-+@VN/T]NFB4Q^#JRYD,HDN(L<C:(M,U:ZPMM38EA@IC7[]WK
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MLI;9*8(<-2MAQ..<)9ZTUI9Q6J]NO9KK@8QRE%9M5T^WLXF(!'.%H2[9R2I
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M+A$F 4#)9A;O*54#FS, JCF2!6'9:[HVHEEL-3LKLJ<-V$\<F"3@ E20"3R
MZD],UTDYRU;6M2L-[J%5=0/.SP01;B<+; 3YQDDMO/P.)C0&BCLM*_L7/1_
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M!<,N">SDC1WP0)=U7>JEIA+K7XRSUTS!T1+,9?&>\"VG4*0XMD@4IAS"71C
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M*UQYQC,FMO&$-F1QX*3!WB@4L99--C\/L@\FP1T](]1[L=W=D^)H,CF,CO\
MD_77:S4NQ!MGT"$N*!T1Q139(DW'>9XDQ4Y%$.@RX>'%9\66&RF''1''.RW
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M%JE7V;U.;BLULOM[%MVYKO&778>QMJ[%DB&&<Q]*J<S=[*O! H)[L'5J]7(
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M^E'J('8:;988T?LEEEEI"6VFFFJ=*H;:;0G&$H;;0E*4(3C"4IQC&,8QCEU
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MZE1D[8#6A=@/ J"5(7Z #CQ #SYDYY1>$1:4,(4]M1;;@S=M!L5D0N6D"EI
MY51F/.<(V20 /&M@(\@G>FT%5).[!+!B!S7P4Y) 'IJ6--[$KX)VOMCZYD?2
M=6[@*A I2-0,7&A9*M7@&KMG;ACV!"J]/BR[@L+9H\L,$W&'WQI@)F4C,^5K
M;1WX=UBU: =E8ZE?1:?J5DI @6YNF$5GJ$*#S(I1<&.&X:/"3PRAV!>-7K!A
M)TF_@>(=G:WMREI>6XY1+-.>S@NXU'FH_:[(Y2OFRQR!B"5#5B*O9)(^A^];
M%&DQHL]O#K"L=S."><%.76 >K';L>-!"%,J2\-BQ21#C1S["VGTQD>8.VYCT
MI7;=<6WD\UQ9Z#;RO!'=V\M[J<L3&.4V$31PQVD;J0R>63R%970AQ!#*@.)#
MC.UJ>666WTN)VB2=)KB]>-BLAM8W$:P(PYKY1(Y$C*0PCC=0?/J*L]25(JL5
MLDH'66R1==Z7;V2BWW:,@*FU3H_.J(65F;6R"Q[KV;&<[VB'XX!3==['RKXR
M5N-C..FM85OIT=O'!;VXMH%81"&WC!3 E("<ECV G(9B6SC).3UMQ6T<*1Q0
MK%&I"!(D4J '("\E7:,Y!))SCF>=;56+]#;6G)V+CX&[ZNVSKN-K%G%3:HJ.
MC;+#Q5P?LHM4G13H*7L$),5V=/I]IBSHG$N2I>(@\>6C1$O@/$8>H:9VBQ74
M,R0WL+,;'4;8D36\\8!VDE59X6WJ)H'#0S1NRD$G*X]W9B01S1N(KJ/<UK=Q
M9$D4BXRI) 9HSN421."DB,00>HZ*:JN;NP*!7+24.V)(G#$"3(C6<Y:%G8<X
MJ&FV&?%G*L,(E0"_1L+SE?H^6LJ4K.?%GN- U-M7TBSOY$$4TJ/'<Q+\6.[M
MI9+:Z1<DG8+B&39DD[-N>>:Z'2[PW]C;W3J$D=629%.56>%VAF5>_:)8WVYY
M[<9J0N;BL^G%*<4IQ2G%*<4IQ2G%*<4KY[_D[_Z%?]?#]R#ER/O^3]=*[#='
M_P Z7TN_:ZZ2_%I6>4-U/K/TU"]!ZA]%6*Y%33BE.*4XI3BE.*4XI3BE.*4X
MI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI5"NLS8%4HBH,[>.NIP7
M038H*'^I*F2K4E,Z9O$Q,*AQV[A36HU4V-19EIZ&&]T\0JT@+E2,1MAKD<TB
M,EG-%JNNMH<J37MI(-&=$6;5(7[7R.X>4HJWEHJ"5;9\QA+F$S;96V21("KG
MV#W./<F'NK6%YI?"?$=FWNG07%W/I?N>ZE;'3SQ5HMI8+>3S<-<1RW#:;/KU
MJ8KU[CA_4X],,UC"MW8:A>2K/:0Q+[P%[DX2-MFK[%1]U4>=#:D:Y8ZQ/ 1A
M$Q&OXRM@MA3Q!58.:<1\RDD"PH:<6E?=ACMX,;Z"ZM[J&.XMY8Y8)5#QS1.)
M8I$(\UHY$+!E)SS!(]>#7E6KZ+JV@ZE>Z-K>FWVDZMIT[VM_IFI6LUC?V5S&
M</!=6ERD<\$JY&4D16P0<8()TLK66V G/"7J6]8>1XD94'&@2J,=^WBPV1%R
M1C:D*SC'M2OLKMC/;V8Y?ROXR_+D'Y>7=6MPW@?8:]H'5&Y)1:6H_5%MPM6<
M8PN75"0 Z<9^-QZ6EQE)QCX<X2TM7;OX4J5VQF-R][#Y.9IM8]Q^CZ:FBG](
MMXFGF7]A6&.JD3E25/PM4>7+6$IO^R'>G2AAXV)RKV^)T .5<\/L:?:7G#B(
M,@'09/+&>GIY=3X=U5!#W\OI^JIOL>NJ',.L:AUXXW3KUJ&M5R]U]W !)$4-
M#[ D[E!,"S!"E^;,"V@VA6!-@Q@A4JR0+'S*GG"%,I>YKB#1#K,,$L,XM=2L
M9'EL+IEWQAG0)-;W$:D%[6Y0*DJJ5=66.5"6B"G7ZGIWET<1BD$%W:L9+68J
M64%QMDBE4$%H9U 60 AE(1U\Y #!%WB_.A)6F[OU>6Y 2HR@9ELJO.7S7DX-
MXT+3G)P ,@PAAQQM!+#$Z!&EBN-MN90EYG#B>(>\O],<#5M.O=/DC/*\MHIK
M[3W(!P\5W:1NT0?!(2ZB@D4'#+U-:!KJXLV O[.YM74_Q\,;W-HQ_&2>!6*
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MD!=MTKB6:1I BI;PA54N[N,1QC<SR/@ <\V+N[B@@,LA?;'N.6;?(Y8 +%&
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M">E7,DR!*\]_S-M:NZ @V\9\L:/#2R&*RE#336$I[YN]P & .@^W4^)JSUJ
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MG(R3U.:G '08K(\4IQ2G%*K=LW4$Z58BK]KEV-Q-R; K-JJTP^Z%%6?T!K#
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M<CS^%;/+/?RN/OTFIW_:YZ@QW#PQID\]J0QQA!^+@CK48]31UMC=(W0VF/6
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MG/>Q$0+9(B1< ?+6L?W-I>Z>31-?,-J[DK;WMJ+AXE)SA9TGMRRKG"J\3/M
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MA#G?RQQ16EOD/+\.,Y\#33:W%=L9SX4Y[8SGV<I=E16=R%5%+,QZ!5!))]
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M<:5#Q6++-SHXBK8MV:.29601QL58,^64Y&Q3A<,9,D(5\T[')VA2:I"$JSC
M53@^<"0>6T=,G=DX(&#M8G %:30^IY^TC4 62U1>QK/L78VYJ9&0T0313V(2
M#T]LD^CS-RLDF7> 0QHH,%L22DAHMZ6FWS&),&OPLRYF%3+UO:A3(5ECV1QP
MN6;M 6,T8=44"/)).0,@#!!8J=P6IHL;B'4A51B3N&2Z;@H&W.3W9P,8)QSQ
MBC.K^LUZM0LW+5"^6AHFFWS8]CEJC!5B/BZC0=?7--2L=EG [+L1@Y;42X2,
M4N+K;]HL4H$R:=%0CJVG(X>?(V9F4/&A#QQJKLQ9WD3>JJ5CQYV",MM4' )Q
MSH(B21E5P549).692P484\SC&3A<D GGFI#'ZC:69NRR:&8CIMJXUF/]/-,*
M+IC(+S2JO%6QHD"O.7%O8QT(L"6;!3;FJ.FD+L(,I64V?$Z \#BV;9Q"DY*[
M'.  ')'G%.;;.S#97.S?OVD-MP<U24(0/RP?0WB1@G&W/+.W=NP0<8(K#47J
M1CKBQK<2*IM[MQMLUOI[8-IL%7K\&)7J1'[F9+;J9=BB9.\$V0=DXN*ER9 &
MJLWY5.AQ<2EJE!8A3,R5+VQ3M"7C0))-&JNQ+.8<;@I"!3@$ %NSWL<*N?-$
MM'C=YR@!G4 DY.S!."%QT(QG;N)PH)R!:_4?]?*0_O4.?Z7A<M:!_P *I?\
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MZB_,KK,5,FTM\FODF1\4/ET8L\K*/64@<:3 GD$?9#:%( .$0,RAQ(%9P-Q
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M^#/;'V>V>WT,\87\;_5-1D^!^;ZZ_,;+W_G&,YZ9UIS]#.Y*/WQ_Q^$3./\
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MNRHZVP2,=?G]?4]PS]7HJ? %?EQS(]7>?3\V:G_I[GY6VZ.UI-6,\B;F3JB
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M1<Q+%V>%>-F1B\4A!9")&52?-4X90&&5'7(RI%8CJ%(Y$9&2K?&4[F&#R7J
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M(QOH^&I"3EGA86TI0X$#&!N(+CS9!)SP49&QSZ\.DC1H(GE"LS^"0>?FG/K
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M*U0'01E0!GS@<KEF)/F'D54;1SY_%(RJMDBNC^H_Z^4A_>H<_P!+PN86@?\
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M$_CN1Y5;?E$'\]'_ %JJ[>#_ !T7\XGUT]>0OZL1?[("?QW'E5M^40?ST?\
M6IV\'^.B_G$^NGKR%_5B+_9 3^.X\JMORB#^>C_K4[>#_'1?SB?73UY"_JQ%
M_L@)_'<>56WY1!_/1_UJ=O!_CHOYQ/KIZ\A?U8B_V0$_CN/*K;\H@_GH_P"M
M3MX/\=%_.)]=/7D+^K$7^R G\=QY5;?E$'\]'_6IV\'^.B_G$^NGKR%_5B+_
M &0$_CN/*K;\H@_GH_ZU.W@_QT7\XGUUSEZI;R_<-AIH[!B'JG208HXD)AY+
MHDM:9@=1[9A?EJ4T2U#Q3@;8++GBPP68:]GNOR_+RX61D$B,K!B<.C!@0#@@
M$$CJ"#Z1CJ"*@N'YJP9>XJ00?'!'+ET]&#7+*"ZN$S] SL0*A@.Q)2M?C1,:
M)LVGG3JY'9-^JU!KH=AC!?&[5$-F6=!TF3)J4@)F/*'\#I&48Y6"".7HY<N7
MLZ4(\3SY^/=G/,CY/6:F_56XI&U2=GF(2*)I>Q=.V@2,(RS,1%CC\R!5;A[4
M,.).0)3HDG%2<-.#@3<2<V":PMPEDN.]%=CS3)ZY!Z9P1G'@<\L^@],\NZHZ
M8(/I!'U'T\O5[*[TTZQL6^I5BUC-Y9'LM?AYYEC*O$IA$M'CGI84KMCNMGS_
M "EY[8^:1GV8Y8(P2/ XJ\#D ^-;'R*FG%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<
M4IQ2G%*<4IQ2G%*<4KY[_D[_ .A7_7P_<@Y<C[_D_72NPW1_\Z7TN_:ZZ2_%
MI6>4-U/K/TU"]!ZA]%6*Y%354=L_U9E_W&!_FZ>?-ONE_P#"NZ_T6R_[A:]@
MX/\ \!P?\]<_]ZU1KS@:ZBJ5W'6&SI*S;F<@F[/"QM^WITXR>)>J6U54F9+6
MM?B]<1&SE"S4-,QL]$#IBXJPQ9R0RHZ<(%2^J$RI]T-_/1V][9)!IPE,,CVN
MFZPG9SV_;QI>3/=R66Z.2-XI#O>)UW*\0;':\@PK52V]PTEV4[1%GN[%MT<O
M9NT$:P+<8=75T&U74X*N1G8<X-1<%J;J3@Z3=(Z)L&W'YVQZKV)#LFS&W9.P
MR8%KC-OO#:N)KQEAMDDS79K&I",^DS45Z"Y.9&'-NIDI:TK)<S6O]'EN;=WB
ML!%#?6LA5-/CB1H'T\&\$RQ6Z&:,WXY12;A%DK;+'!YHQEM;Z..94DNBSVTZ
M O=-(PE6Z(MBA>1A&_DQYNNW?@&<M)S.U06H=WUNVSCL'8MIO1)<SO:O1"[9
MN.U6Z,!I4K3(8S5I21+-;IQ[!XE^Q*JCK*\*3=HT1UZ+,DVJVV  S9EU#3)H
M(A+#8B18]+FD$&GP6[O<I<2+?*6@MXQL:UV!X05MG8!U0S%W-Q+:\CE<H]P5
M+WD:]K=2RJ(6A5K<XEED(83[MLF#,JDJ2(\*/4#A.HZ^5N2#EX;;=$;++Z/8
M5]@K8$+#V1^-K5\8<ZC9.+F*5>9(N':DZRLP.8D0I>.GK$"QZ1"*)><CGU29
M-(M9E9)+"Z*IQ!("MK))"))K5O>A'CN+5%D*3!6C1HWBA8[90HWK0)?3Q,'2
MZ@).EH09T20B.<&^9'AF?:&C+*[*RO(H\S)VFM4V+K[JJ32*+!5R6V2Y'0%B
MZJ(\Y$3:).?V 2,1M8U/2Y+R-C3OK3TQ-QH&K&"AB"[;?;0/F2E:Z3L:HS)
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MQ(9$<T8C6.:)I%1VD39((SEP@96S&^5.Q3RVL/.P>?*M67:%=2P#%AAMIY@
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M]<1&VLP)8+2XFC)6$!@'CC925/(@'(/(UZOPG>V<.BPQS7=M%()K@E)9XHW
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M_5F-_P 45_ X^Y+JGYUL/YJX_JT^'=E^0W7\N+^M7](TK+I4E69F-^95C/\
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MC'S2UYBLI0G&<J5CMG'*H^-HHR!J.D:QIZ?A7"QP:A;H.]I&T^>XG0#O)M\
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MYL,&'B7'2) 2-9E#3S"I37;&ZC(BO[%HRH39'- NT!]^"FX.KEQEMX#G&#R
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MCD]H^,$\O4._GX4VKX?.?KJ;J[4JM41,@56N0=<"SX?&-"1846RYE.,XPMU
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M<Z9,Y)P%2+4DM'=B>055+'N%8ESP?Q/:(9)=%OFC7):2VC%Y&H',EGLVG50
M0<D@8YYK?$+0XE*T*2M"TX4A:%84E258[I4E6,YPI.<9QG&<9SC.,]\9YVBL
MKJKHRNC ,K*0RLI&0RL"001S!!((YBN<(*DJP*LI(92"""#@@@\P0>1!Y@U_
M7*JBG%*UV6ME>@R4!RTFR$2ME)"&G&R%J4RM;C:7,9:9<3VRMIQ/;*N_=.>^
M.W;OH]2XDT/1YUM=2U"*TG>)9UC=)F)B9WC5P8XW7!>-UP3G*GEC&=E9Z/J6
MH1--9VCSQ*YC9U:, .JJQ7#NIR%=3TQSZUC/?%I?ZO#?XDS^3<U_PYX3_/5O
M_-77]A67\&==_-TO\N#^UI[XM+_5X;_$F?R;CX<\)_GJW_FKK^PI\&==_-TO
M\N#^UI[XM+_5X;_$F?R;CX<\)_GJW_FKK^PI\&==_-TO\N#^UI[XM+_5X;_$
MF?R;CX<\)_GJW_FKK^PI\&==_-TO\N#^UI[XM+_5X;_$F?R;CX<\)_GJW_FK
MK^PI\&==_-TO\N#^UI[XM+_5X;_$F?R;CX<\)_GJW_FKK^PI\&==_-TO\N#^
MUI[XM+_5X;_$F?R;CX<\)_GJW_FKK^PI\&==_-TO\N#^UI[XM+_5X;_$F?R;
MCX<\)_GJW_FKK^PI\&==_-TO\N#^UK:0#PY01D\!])(A"5*9?1A:4N)0M3:L
MXPM*%X[+0I/S2<>W'T.V>=%97MKJ-K%>V4RW%K.&,4RA@KA':-B ZJPPZ,O-
M1S'+E@UJ+BWFM)I+>XC,4T1 DC8@E25# $J2.:L#R)ZU[G,JK-?/?\G?_0K_
M *^'[D'+D??\GZZ5V&Z/_G2^EW[7727XM*SRANI]9^FH7H/4/HJQ7(J:<4IQ
M2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*
MU*7H%$L#ZB9ZE5*;)7G.5D2];AY)]6<_#E3I@3SBLY^/.59SS7W&DZ5>,7N]
M,T^Z<\R]Q96T[$^):6)B?;6++8V,[%I[.UF8\RTMO#(Q/B2Z,:]Z&JE7KF%8
MKU;@('"\>%6(:'CHO"D^SYE6 1F.^/9CV9[X]F.7;:PL++(L[*TM >1%M;0P
M9'@>R1,U7#:VMO\ WO;00?\ ,PQQ?]A5K/\ ,NK].*4XI5-]5SNQ2^L/J<B9
MS6+U?I8=+TTB$O[E@66%:,B(M[L9B)C5P 7F*(;EYQB<2F2=]SLC7FPU9DVI
MH4P>HXVCGSR>7L^KY<U'X1]0_7^_V>FKD<IJ:<4K6;G;(JBU2?M\TM:8RO1A
M,D2EK&,OO^2C\Q$&2K.$K*-(4T(*A64X60^TG*DXSG.) )( [Z@G R>ZN,.Y
M^H&,EC193>VSZM28^=<,<K5,LETBZG61A@LC*?%!#DY&-;LDA'MF!XE90I)C
MR72VL)0(,Z,SR^,)TP.9\XX)/,XQW =.GA5HDL?'T#/*M%K^S]4Q]M#A:/MB
MF0>P7$"O1T94-@085K>04$U*AK;A8Z5],D1BXQYF0;9?!*%,CGT$>6Z*]A:F
M0>7(^CD?E^?K4<QSYCP/2NM73AN21V9#2T':LC^[:H*#1)%"LI%&GXB02]B+
MGV14]FQB'EBE"2H@^,C#G#X=8PR.:P,S:==N".A^8CJ/JSSQ[3<5L]>H^>K*
M<HJNG%*<4IQ2G%*].1>)&CSB A_3#& RGA!/%X?2B6F%K8'\7]CY[J4->+XO
M%W^+E2@%E#'"E@"? $\S\@YU!Z''A7^7K0IF6NC85OMI3\M:[_8I*YWF2.\?
MI\M<+A82YNV&R*G,^<HTF:/.P1YJO-0K'E9RG#>$I_3WA*UM;#A328+$*D,>
MG(R;,8#%"3S'([&\P>"H%'( 5^<?NC7=W?<><0R7I=I$U-[9%?.%MH-L5N%4
M_%5X567E@,TC/S9R3UBW!5-)%=0&]=95.O:[>A-<0760\'%5S7U@ITC5Y#6=
M+O"Z0/(3TC9)3%L<B)"+:(:,99%:<-ATEE-/-')93QFAWFOIPWP_JU[<ZF+C
M5)^!U>:ZU*VOHKN/5KZP&H-';Q6D/D8FCF*E&9V$<Y1&5HRQWFM6>A/Q'KVE
MV5MIQ@TR#C8I#;:=<V4EK)I=A?FP62XENYO+##+"&5PJ O"'<,)-HI/TDSLU
M5^L_I#F*X64#*R&]JW13W W5M.&4G8@,I4]@Q9/EYQYT:149"3,-9<PIK'J]
MHE6,*&0M/%?W6.FZ9J/N'\8IJ<@@B2R.V8-V;Y)#]@'!#!;AXHXY%!Q(IV,"
M&(/=_P!RMJ&HV?NL:;%8H94GM97GA*EXPUO)%V-RR=.TMVE<1.?XLS,1AL$?
M7IOM6TI_J-U]K^C$W!VN9TO<;5+PE4VP[J5#<B#>J3"A3!)XM;L#TPH0&2-$
M8C/"(TC!"WO,RM*<8_+6Q6VAT^61TA0K<PPQEK59PL?8S-V:(718URJ\P#R
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MT^*2V+VFJV6H7]AJ-O,ZI<1226]Q:-"S12/&3&2CNI!/H^C7?Z\.T?V5K_\
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MH\VQD0SP1RR[Y))"ZM&;C;\9.Q*E5#'< SX"L0&**H8*&=:K1T4ON9VRK*7
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M?AQD;MGX^_,NW]RK@:%UEN-(DU652#NUO4]4UA"5Z;K;4+R>T//F?X/S[\@
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M:!F9V"J.F69F/B236LGGFN97GGD:6:0@O(YRS$ *"3WX4 >H5[/,BK5?/?\
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MN?AESZ'J[&5Q,9?Y*MV"0OT/&4N:L,3 O2A3S$ GQST'CGF0<?(,Y[\=/"2
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MO'@;2K.<9SE..DT/2AHNFPZ?Y0UT8I+J5YVC6(R/=W<]VY[-694 :<J &/(
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M;;=<<;;QA"$XYZ_[GFMWO$'"NFW^I,DFH1RW^G7EQ&H2*\GTK4+G36O8U4!
M+L6HN'5 (TEDDCC 1%KSOBW3;;2M;O;6S#):M';7<$+L6>WCOK2&\6V<GSB;
M?M^R4L2[(J,Q+,:N+SLZYZG%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*U:8
MI=:GR\'2T;Z45AE#&'?2SF/S)O*U(3X!R6F_9E:L^+P>+/?VYSVQVYS5>$]
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M\-,->-QSRV\9SG"?&ZM;BNV<Y]JUJS]GG5V5E;:=:P65G'V-M;((X8]\DFQ
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MA(D<2O.>Z<)59&E9#$:AKI" %C[^ZMR!8*"?X9TW,!ZR*H\@4Y_A6I<AD_\
MI.^Y#('/[_XD"O.Q$ DR$C&-6S:>"HI 3ABGK[LT<+*3TOJ'P))$2S4;(K3@
M=W!3<<64X ORVSDC+?92X.E@ 'WPUS!SC_T]JV>77(\LR!SY$@ ]V<&GD"?E
M6I?TG?9^4>49'R]>ZDM$ PL;(2QULVHH2,#?/+3'WW9LP?D<=M;KGHD5$2QT
MK(/Y2A6&0X\(HLA>,-#L.NY2C)=+#$ :AKF2<#.O:J!GTL;P*/220 .9Y4%@
MA('E6I9/CJ=\/G-Q@#Q)Y#OK(>Y1&<YQBV[(SG';OCWSKYWQW^#OCW0>SO\
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M1QI%%%9F7M4"H996:4O* T20] ]K<SHRW$\9S/92K''$1&@M+J.Y?FSM([W
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M" 98F W Y $<97 Z#"CETH[4X8Y<.<X.>8RR, #NR  I7&<#D/BU$;?0[O%
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M*$?JTO'VRUW27]]R@JL\@;!RA&OX9]"P6@IERTP+)<<S,4K([$#S<F/<059
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MG2W;@K-.K,E*MO%0%K&+KCWI"$J/]:19U.LB$"@3IE>&N16<4B\BZF4HL9D
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M(.TRRH_6[L[9QJZ[6JJN\289,56!K1+0Y,Q+M^J@F79%;8RX&D:@8IINP4)
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MT_#3RF6:945$CS)(TO9K&H)W,,D#>PHK-(=JJML<*))'W71*Q((XXRS,SX1
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ME[H6I%T35H-*L&/WM[FUMHM6DB/,=K%8/>0VSL"-P@U!)4(P&4Y ]+2YX7M
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MQ5@(:)C8R,CLMA.A%(9;RG-N-=NKB:6=XH@\SZ4[>=/(<Z3 ((,O+-)*YD0
MSO)([N^6#*2:QH=-A@C2)7?:BWJKRB48OI>VE\V.-$4(W*-4555>14XKSO\
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MWU[I^GQOV/#_ (KC[I/%GY9;_H5K_9T^!^A?D\OZ3/\ UZ>^O=/T^-^QX?\
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M6)]MWW 7HD)4A!K-!EF;%57I)G! 31),1, QZ9VNOGQKTP$.^T$:VT<@IKH
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M6!)([CN7.<<Q@@8!!_R0#<AMNR,)!W%8A%(&9F&0H&Z+<3LR1AE 564C(!0
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MGX"OS0]O*U[,,QS$I#P]4>$I53\6HWIN2/+M)>JI**LL5G8(K\:S.A;VKUE
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M(R*AQ?;MEU_+24K(?5C\^^^IQY>>^5K5G/?F%)++,V^61Y&\78L<> ST'H&
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M[._A\?\ S:_^_/\ J%//_P GYZ=NKSZ;IO\ \'9W\/C_ .;7_P!^?]0IY_\
MD_/7]]-6.J#%0D?EHU:QS:/6Q/N>][O$E@KU#YY'D>ZW+W:$]<>#R<-XKF,
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M)[M=ES- [,6M9)T\V1K8Q%@J9YQQE;(U_A=1"JSRJL$<,4:K'?JIB@;=#'(
M )EB;F@F$F,N.CN&VB(Z1P8*4'F(VI.-'!7^W[/C\OW.7.%C+K?HR3B;A*1D
M>=8"8^.%G!YN:)*@@Q6:^W+S$G.BQ8\T<0>Y9DX)XYE0QO9P%6M+>R?%SI:L
M]M:NDENCNKAW:(QQJLK,93'&D3.8U5!<3B3AM&#+<R9$TMPN8;U@LLRLLK*K
M(54.'<E  @=V<*'8FL"KHAJJ:[,5<*A)AXJ<V65N$]R NDW RZ=EF2K4P];
M+!$6,.=BC<%L,L,"QDB)&"Q+2($8%F#2F.Q=^!_'IFCG:VAD>*S73U$MQI<L
M?D2H8Q \4CM%(NTDEG1G,A[4N9?/JCX0<+]F\8GD57N#=-LAOD?R@N',JR*H
M=3N  "L%"@(%">;7FA.BJOUQNI-PU.-$Q25;-5 N+V):3"<IW'+$S^RF9PPZ
MUDEVH:TSY/KXD:TOS# ,T)&2D4V ;%1KPL2\'<>3&<R6ENWE/D7:CMM)5?\
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M?/I$9E(Z<J^+*Q<I4(K'?VJREE#BO;^:8^''-:MP!PWJN]Q:>]]PV3V^GE8
M6\7MRK6S GFQ$22-D_? 3D;"PXJU>QVJ9_*XAR[.[!D./\F;(F!QR&791^)W
M57"X5K-4F%1>2\&IR.T4V]Y.6%>6\IQ*4+;\QS&%I\O/?*5Y2KOC.,)^#'@_
M%'#YX;U0Z<;D7:F".X2;LC"=DK2*%=-\@#*8SDAR#D$ =!Z?HNJ#6+(78A,!
M[1XFCW]H-R!22K;5)4[A@%01S'/J89NM>IQ!E6V!<#F8EK49T_<P)H^59B(6
M&]+IMBJLU)3A)2V@TQ@M;L$PX\Z8\R,&K"#7'4X'[\TUM+<!9[2W4R&_6*W:
M-4,DDFVXAGC2)5!;>TT48 4$MDJ!DUL)HXB8IY2%\E9YE=FVHF89(G9R<#:(
MY')+$ ?&SRJ#R*QTW;CI5R>@]C5FP5K8&XJC;)*RU6]5>= :VY7VJ #5(X%Y
MQ4U7'Y/*J?3_ "*A+@2P\H0^C+T25ZQ93G9K/K&G7-N)+.:&:TT^X@2&>UGB
M<V$QNGG=@.SF"?PBXS<1O&4 ($B[#6&8["ZAFV3QR1SW44K21312*+J/L!$J
MGSXRV8H<1,K!B<%3NQ4B4C0M"H#5-;A,3KZZ--[-L4(3+3)$D4N7V]/2EFO!
M4@\ZC"C/6$U,R)8K*O S')(P,&VT*RPRWAW.J75T;@R]D/*HK*&41QA!V=A%
M'#;*@!\W9'$BL>K[<L222;\-E! (M@?[R]PZ%F+'==2-+,6/X6YV)&?B]!@
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MUJ3GT:)WA>.2%FB>)E>)XR4:-D(*,A7!4H0"I7!4@$8Q7(L P8-YP8$,#SW
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M5USW>LT#I;VM-VP]^,BB(D*&2:U%R\HVW(2TL")'-E)B #W F"2E-BI.,0P
M@E\<=TE#Q+"')4<QZP:ANA]1^BK0P<U'V.$A[#$N/O14]%Q\S&.E GQA+L?*
M",G!.$1LH,%)Q[ZQGVU.@R(8APCF5,%C,$-N-)BIJ.MA7F4 DX:@T0>/G-AV
M%Z/++CEST1%D4S7[DCD&P[*DASFI I\&+PAV,KX@T)+9F[>5%1I K<,B>E(G
M8V5HCQRWEV7ALH0ZK((99%NKT)OAL(V0HH>3(DF9I8^RMEDD#&4PQRP?#O\
MH'C]N^MJH5-!U_4H:I@24Y-(BQUX*G;-*$35CGY(IYPR4G)R4)SXRY.5D'R3
M2?*0P$.I[ D:(#'#B!L8]Y=/>W,MRZ0Q&0C;#;QK#!#&H"QQ0QKR6.-%55SE
MFQND9Y&9VD<OWUM_,:E.*4XI44[>U>SLZNB, RKM5O%5DVK3K:]!CH)D*9<@
M6'V Y)(ZEM)DH:0%)+@[77WW6P[+5Y.6A"EM(,20SL=-U V$[,\8N+2XC-O?
M6;L52ZM7(+1EAS25&59K:8 M!<1Q2J#LVF",^CP/@:QVH=M(OT<;"6D,.H[8
MJ$BJM;$H2C<.N1E@'$0:B2KRR,,E3=+LT8IJQT^>;8Q@^"*0T<V%-1\S&1]>
MI:=Y'(DMNSW.G7*=O97FS DA+%"DVW*Q75O(#!=0EO,F7*EHGB=P.?6.1]?U
M>%3/S5U-.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*5\]_R=_P#0
MK_KX?N0<N1]_R?KI78;H_P#G2^EW[7727XM*SRANI]9^FH7H/4/HJQ7(J:<4
MIQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*U&^N.-5"><:6MMQ >,I6VI
M2%ISYS6.Z5)SA6,]O9WQG'.7XT=X^%M9>-VC=;52KHQ5E/;1#(92"#CER-;K
MAY5?6M/5U5E,Y!5@&4CLWY$'((]=5#]9R7ZHG?=9'\9SYB\OOORV[_29OZ]>
MS>26GY-;_P S'_5J/*9N2#NNM-?[7%L!D'4]E5RA62MNV>19ARLM;+'A7*?$
MFI7(/"-3TL98(F&%C!C2UESAH\9'N&$/CX=R[EM6MKR[L6N[N2>SFNH9A#<7
M$BYLS(+B1<$,8HUBDD9RJA8E+N% .+$*6$UO!="WMTBN(X)(S)#"AQ<!#$K<
MB [&1$"@G+D*I)(SY)C=>OZ\]&#3^VJ?"$34V?6H=B7O<+&O2MCBCAHN4@(Y
MHR596;-1LF:'''Q8R7#0SRQ0R&&R2&6UQ&=<E#F(ZK*(XTFD,9O'$<,BLZ2N
M5R%C=%9T=L*RJS D FI9=,0J'6Q0N[1H&%NI:16"LBY W.K$*RC+!B 1D@5Z
MDMO*EUH6PR-SV#"4:)K=K13#)BWWBM0L6].N5Z.L[8;1;MA6@,M<5(^D)BIG
M$7.Y'$*D?57J=84D94GOU,T*6\NI7,DT!N%CMS>R.(A,\!8J%RRB1,=I'OBR
MRKVG:;D6'73HP[2QV<*QR=D7E6V1=YC63&2>1VMG:^U\ MMV%6,BL31A3#)(
MTL20,0TV^.0P>Z\P^P\C#C3S+K;JFW6G6U)6VXA2D+0K"DYRG.,\Q#?:@I*M
M>7@8$@@W$P((."""^00>1!Y@U?%K:$ BVMB",@B&(@@]"#MY@UJKNU:HQ<1M
M>/['K[-_-"S(B4=VWQS=O*C\,%$Y.'K:Y#$R^)@8(TCTAL)3/D!EO>/RQWE(
MOB36#;M=B34S:JVQKH/=&W5\A=C3 ]F&W,HVELY8#&2,VC'IPE$!CLA,1N$)
M6#M2N"=PCQO(PI.0,84^!K3S^HS7C%<GK/";$C+O'U>P5NL6%JB6F)M)D+-6
MFRQU4C I1F/F%(CWDRDDWDEDQUA]L88UQMEYT?+*KZQZX9HH))-1MGGBFFB\
MJDNX%DCAA>=V0OC>"B':5!4DJ"0#FK;'3 CR+'9RK')'')V*02%'ED6)0P7.
MT[FY@X. < D8K;Z=LIF[MV-V&-G&TU>X6&D27ISJV,KF*R7@.1<%PT6_AT%;
MJL9%?7EIUU'M6PUGYGEBXFU.V,(DO;G[_;Q7*;;J<_>YEW)NRPPV!YPY@'H3
M5R**RF$A2U@^]RR0MF"(>?&VUL>:<C/0]X[A5@M1&F$6EY#Y9+Z,0Y:L(>?=
M=3A6" L85A*UJQXL8SG&,]N^,9SCX\\[WW,+JYFXCF2:XGE3WKN6VRS22+N$
M]H =K,1D D XSS/C7,<9P01Z0C1PQ1MY9"-R1HC8,<V1E5!P<#E5F.?0%>5U
M7CJ?NMLH>K_7-+F50$X3;:C"HE$ 1DDX,),3+ 9F6A)<,\!;BV%J2E3PKF4=
M^Z/"KLK'4<(Z?9:EJY@OX/*;=+&^N#"99H0[P0-)'EX)(Y0 P!(5QGOR.1YC
MBZ_O=.T<W%A.;:X:\LX!,(XI2J33JCX29)(R2IQS4X[L'G5&O?IZ@OKS2W[2
M];?S1YZ![P\,_F"'^D=6_;J\Y^$/$_Y]E_0-,_9*>_3U!?7FEOVEZV_FCQ[P
M\,_F"'^D=6_;J?"'B?\ /LOZ!IG[)3WZ>H+Z\TM^TO6W\T>/>'AG\P0_TCJW
M[=3X0\3_ )]E_0-,_9*>_3U!?7FEOVEZV_FCQ[P\,_F"'^D=6_;J?"'B?\^R
M_H&F?LE?TQO;?@$G7W2=L'R8K]IJD<8 34-?L,EA2MDBXPQAQX.K#E-8<&+=
MQAP=]IY&>RFW$*QA6!X=X:ECN5318X7%G>R)*M_JC-')#:33(P62\9&(=%.'
M5E/>".52G$G$L<UL7UF25&O+.)XVL=.572:ZAB=2R6JN 4=AE65@>8(-=:N>
M+U[93BE.*4^#X>*5!-NZD].T\IZ-*M;<W+CJ4AV(J89=F,:=1GLMDEV*:(CP
MGD9QV6R><*XG/?&4XSC/:L1N>>,#Q/+KZ_IJDNH[\^K[8J*R.M&H>/.(_7FQ
MBV\9SC#I+%5C<+QC^R2V]9W'L)S\.,.(;7V[>)"<^S$]F1WCY#G]7MJGM!W
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M>Z?'F!V&[@2\^?2=A1%\H$T=(1)DQ5R%5]H<^J'7H8KJ_D:S:>VN)H#;VSO
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M*5"[H$;<C,K8;_[0_H:_MJ](_M[A_P"/Y1\,.%OS_I?Z7%_6K._^3)_="?\
MU.>Z!_\ LY?_ -G3_P"T/Z&O[:O2/[>X?^/X^&'"WY_TO]+B_K4_^3)_="?_
M %.>Z!_^SE__ &=0'N+J;K6\W&X'3.PXBT:K'!:78+'29A!8MIF"7B6UP"I4
M!SQ8B8L<=.9(5AUO)I961B\*8&PA>^T^]LM1MUO+&YAN[=V9$G@=9(BT9VN
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M]#3THA^#>EZ)>).GN6:C3+YT*7)18,/-A3]0GVTL',L$1L]&.K0AYWT"40<
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M-=1HDUPL%RA>&YBC$222/$EQ%*L3E?.C"LQ!)KS'4]!GM->OM$M3Y4]O</'
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MJ5H"++J>(--BCI68=UZ:=:/HT]TL0D>+35NVNQ= -'>G6(+)K1K7=\1;617
M*=H6D6?M>R>.,9+W<ZZA% 9"BR79@6 P':]N+"2Y$PF(YL9T*9#; JF+9VBN
M]?G25N/=VS9V98VHQ#B?_P EQ%@GJT-'3 TIK&_&S,@)):]((]QD)%LCQP;*
MAU1$[8;#<FR(G-A2>?6[+%K!:]I^FV44;6+2-_"9(HIR\92]M5C1DNPOE$CE
MG8AC)%%%;XD['8DT+AFF75Y<,PN0BGLE>2,*X:WF+L&@SV*+A0,%7DDE!3M
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M >+\0;*2%%'#:')CW'*;9QSQRG9R-C4%A#HR[C0;&&:V5H=0B@>_U6V[5[B
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MEHKU)Q>7'U&*L/BDLE>LE03567-(8R#D)NP.59EFKNV%L5,V[6FT0#AZHA.
M^99]S;BXVPLSJND^3 ;>Q\JOMNP2F<1Y][=QB$Y,XB+=F)B90O:>=5CX8:")
MO*/(K[MB=V_L;;.[9V>_'EF!(8_O9D WF,",ML %2%[S%H_3\%]TG_DWF)]R
MCB+\MT7])OO]G5?^'.D_D^H_S-M^UT]YBT?I^"^Z3_R;Q]RCB+\MT7])OO\
M9U/ASI/Y/J/\S;?M=;M0=>356FW)*0)C'F%Q[XN$!O%..^8Z\,XE64O!L(\&
M,,JQG/C\6,Y3V3G&<YQUW!? VK<.:O)?WUQITL+64UL%M9KEY=\DL#J2LUI
MFP")@3O)R1A2"2-%Q%Q+8:O8+:VT5VD@N(YBT\<*IM1)%(S'/*V[+C VXQG)
M'+,R\]4KAZAK>VL9+;5"55(B8"@Y%N?K\Z*=(A/GA>9!231^&"!QB17U(?\
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C.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*5__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g260304g99a99.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g260304g99a99.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  V *P# 1$  A$! Q$!_\0
M'0   00# 0$             !P &" D$!0H" __$ #00  $% 0 ! P,# P($
M!P    0! @,%!@<( !$2$Q05"18A%R(C&#$D)3*!.%)Q<G>AL__$ !T!  (#
M 0$! 0$            ! @@)!P,%! ;_Q  [$0 ! @0$ @8(!@,  P$    !
M @, ! 41!A(A,4%1!Q-A<8'!"!0B,I&AL>$60G*"T? 5(_$7)5*2_]H # ,!
M  (1 Q$ /P#OX]$$+T00O1!"]$$+T00O1!"]$$+T00O1!"]$$+T00O1!"]$$
M+T00O1!'P))'"&(,+FC'%%AE()(F>D<4$$+'2332O<J-9''&USWN541K455_
MA/7C,3#$HP_-3+K;$M+,N/S#[J@AIEEE"G'77%J(2AMM"5+6HD!*02381Z--
M.ONML,MJ=>><0TTV@%2W''%!"$(2-5*4HA*0-22!%9'8>ED]&TTL\#Y8\[5N
MD%H1'_)B.A^7M+8SQ+[>Q9[FMD<CD1T [8!E]W1/?)GETI]($QCW$+C[*W&Z
M%3BY+4:545)!:S6=GWFS8"9GBD+4"D*982Q+DJ+2EKMC@C"C6%Z4EMQ*%5.;
M"7JB^FRK.6]B5;6-V98$I!!LXZ7'= M*4UP>:.ZV>&R68SM=5V]-7=&@M)DU
M;HI!A;&LIB(!;*GIRVN:]Y"SDCI;2-^"1!30C-65I\OT.75N1JDA3Z;.S$C,
MRTA61,JI\ZX@H9G423B69H2ZK^WU+JT(<-@/: &8&XL[T'4&AU^L5:I3,Y)S
MTWAAR4;51PI+KLK,S[3CLK.SS)24I;+;3IDDFY6^VXZ<AET9SK^C_P!]FBL]
MEX\:&RED'.@EW//HBIW/8.6(D8^NI DE<Y6H8*X&^&#@2.&-:_0&N8LQ4KW6
M5]%S&BT3%6P-/3"BV\A58H:7%DA#K65%3DV0HFW6M%F=;:;"4)ZB>>(*G%$\
MZ]-3H[0N5H?25395"7)=Q.'\2+9:"5.,O9G:-/S!0 %%EX3%.=?<S.*$S39<
M$(:0D7T>KGQGE"]$$+T01"Z;R6ZATC3:RC\8>+5'2LWA-!99'2=7Z)T5W,N>
M':^CF4>^SF&_&Y#=:79OI#$?66M]#35>;'M8"0P[.R6![O4K6W-K\+7/CL(C
M<GW0#VDZ7[MS#YXSY#&[W9Z?D'3.=V/'.W9"E#U1V(-O0=91:;%6!KJT7<<]
MV=<+7#ZG-LLVMJK5Q%32V]%;2PU]M5#2S1.D1&EP;CYW[1#!N;$6._\ PQJ?
M+7RFK?%?(932SY"QWMCIM3)7.S=.:H=D#C<[07&SZ3NU1M?9/(K<%BZ"RNC1
MT@B:5,H(3S D+0F, O?A_/ >,)2K=I\AO!1Z3JNK 4-#;</P.)ZF1:S,G+BU
M'32>=UL%(0']R%:5EJ!AMXELXI[XFM'^T"C0>1"6%R>R1.-.-QX?<0S<VRV\
M;Q$W/^3GEQI>H]$Y'7^+/(V:OF-'@]!I7D^3UQ'4NK^C,TK\]^-,CX!+,5.U
M,K:)81R"CH,JC?!\Z3.6-V%@;G7LY>,1NJY'LZ=_&)$;7L^EY)XZZKL_7,33
MT.MR.=NK0WG^2UY.OKK"\2T)JL5F*;6DY7-DFG;(R?.@12/RP_X^VNU!;!8,
M#:46@+FPX_WGYQ(D@7.XY0Y> ]<'[IR/'=-CIILR?>B&B:3)DEM.+R&RSUH=
MG-GDRS$'#4J?.:BIMJA2W!AN,8(PO[0=L[8FA%C;> &XO&!@^R/VO:.]\C=G
MF5K.)KRWZ=\EHXMVD3I&3+TSE?6K7C)4_AW"_9-1I]C]\C_N%^T5OT5"+ 'G
M?Y0 W)'*WSC&W?:Y.=]GY#SC19MD&-[+!I:'/=$;;.2*OZE1BLO*K!6]3)6M
M'';KLR->FYRV;=.F+MZ$FD2I60D8EP!<$\N'9S\.,!-B!SX]O+QX1]/(7M+N
M(XNJMZK.?O?<[/:Y3F_-<&VT6D?K]KKK-@H@,ENE?:_BJVJJHK;2WMH^N+CK
MZ.DL271.<QC7 %SRTN3R$!-AVW '; RL_(+K&WW6WP/CER7+[B/F%Q'E.@]*
MZ5T,_GW.Z_=,K@[6RQ.9;0XK>:C66]('8 MORF4U154YA48,AI122Q1EK $F
MU]A:Y[^'WA7)) &W$[7\^W:'CA^G=ZM_WOF-UX_C8[>Y[*E7N1MZWH@VGXOO
M[%6$#U=,/NV9NKUF9/GM(XF6H5QSF0JKJ95M1$N$2,>8L--?EJ/#;YP[G:W\
M?&WE !Z/Y*^7O+C^8UVD\:^)RD=9Z75<IRZU?DEIRHXM/<4.DT8DMLZ;@(JB
M525^6LVS%0-+G82X6-HCV2ODB8 -]3H+[?>(E1&Z=S;<;Q*3E6A[_='6T79.
M7\WP%= (/)2EX;J]ST4JP-=,YI(YX=IS/!LK8(8$9)$3$58/FD<Z)P\*-21R
M-N%_$6\S$@2=Q;QO!L]*'$,/)/J?S5_.Z(G^UJQR:@J%_P#U.16R#TK7M7_9
MB_ BQ1/?W=]N*KD^)<*U,Z?^D?,58$HTQ[*2AS$<PTK12A9QBD)4D[((1,3P
M'YNHEBH99IH]VZ+,(6"<3U%K4YDTAEP;)U0Y/J21NKVFI6]K#K'@DA3#D CD
MO."^CZ>(!4EBHZ_Z9=^<SW;]$3Y+],2%ZHK4,/>QT,"?RL<;9ROB]HSF.XQT
M8X!F<?8A;DB'&J/(]7-5N<1H6I4J.25:4183<\I"FF-RVA+TSE6F74A71,9X
MH9PO25S(*5U"9SL4UA6N=^PS/+3OU$LE0<<V"E%MFZ2Z""1^H?X_B=8\7;T;
M.U<2:'DL+-SD!A(?\GV%"'+#H:4=K$65\9F9<;+ )&CW%VM=5-5KGL:J6JZ;
M<!RU>Z-9B4I4FVU,X39;JE&EY=&4(E:>P6IR1:2D%10NF]:6VD@ER9EY8&Y
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MBYDTFAS&ERO0"J*LTCZRY*.;2W5+J'E&57V<1@,92.9"&Q UL0 -1H?$?Q"
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-AR892VXZRTZ5IC__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
